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Abstract 
 
Intrahepatic cholangiocarcinoma (iCCA) is a rare and universally lethal 
malignancy arising in the liver. Incidence has steadily been increasing globally yet 
effective therapeutics are lacking. Currently, gold standard treatment is complete 
resection for which a minority of patients are suitable and recurrence rates post-
resection are high. For the majority of patients unsuitable for surgery, standard 
chemotherapeutic options extend life by only 3-6 months on average. As such there 
is a pressing need to elucidate the genetic and molecular features of this 
malignancy so as to inform the development of more effective therapies. To date, a 
small but robust set of driver genes have been discovered and for some targeted 
therapies in development, with mixed results in clinical trials. 
This work aimed to extend the set of known driver genes by exploring the long tail 
of infrequently mutated genes in patient sequencing data. Through computational 
prediction and in vivo screening, a set of driver genes were uncovered which 
cooperate with the more commonly encountered oncogenic RASG 2 isoforms of 
KRAS and NRAS. Validation studies in vivo confirmed that the membrane-
cytoskeleton adaptor protein Merlin, encoded by NF2, and the canonical 
transmembrane semaphorin receptor PLXNB2 encoded by PLXNB2 are tumour 
suppressors occurring at low frequency in the patient population. Mutation of 
these genes significantly accelerated disease progression and propagated 
aggressive, invasive tumour phenotypes.   
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Lay Summary 
 
Intrahepatic cholangiocarcinoma (iCCA) is a rare form of cancer which occurs in 
the liver. For rare cancers such as iCCA the discovery of causative genes is 
particularly difficult. In this research the aim was to discover new causative genes 
in iCCA using methods that overcome this problem. In order to do this, DNA from 
several hundred patient tumours was analysed using a computational approach 
which predicts the genes which are likely to be causative based on what they do 
and how often they are mutated. This list of predicted genes was then used as the 
starting point for experimental work which tested whether these could initiate 
cancer by introducing these mutations in an animal system. 
A single causative gene is rarely enough to cause cancer, and this is particularly 
true for two previously confirmed iCCA genes called KRAS and NRAS. These 2 
related genes are common across many different cancer types, but in the liver they 
are not enough to cause cancer on their own. It was therefore valuable to 
determine which predicted genes can interact with these known genes to initiate 
cancer, and this was also investigated here 
This work used patient data combined with an innovative experimental approach 
to uncover a set of confirmed novel driver genes in iCCA. Specifically, this included 
a core subset of 28 genes which cooperates with both K/NRAS mutants to cause 
cancer. This opens the door to the development of therapeutic approaches capable 
of targeting K/NRAS-mutant iCCA by targeting its co-operating driver mutations.   
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Chapter 1 Introduction 
Intrahepatic cholangiocarcinoma (iCCA) presents myriad clinical challenges and is 
associated with significant mortality. Tumours are asymptomatic and late-
presenting and this is further complicated by marked chemotherapeutic 
resistance  rendering most interventions ineffective. As such, the only chance for 
cure is complete resection or liver transplantation. This is not an option for the vast 
majority of patients who are unsuitable due to advanced disease featuring local 
invasion2. Of those patients who do undergo curative resection, recurrence rate is 
high due to primary disease commonly involving the vasculature3 and/or lymph 
nodes4 6; indeed, even in transplant patients recurrence rates as high as 51% within 
the first 2 years have been reported7. As such there is a pressing need for novel 
non-surgical interventions and there is a focus in the field on molecularly targeted 
therapies. This has been motivated by the recent identification of recurrent 
targetable genomic alterations and exciting progress is continually being made in 
this direction8,9. However, the realisation of effective targeted therapies is 
complicated by the significant molecular and genetic heterogeneity which 
characterises this malignancy 0, . In this study I aim to explore the long tail of 
infrequently mutated genes in iCCA in an attempt to reveal novel drivers and their 
modulation of common drivers. The goal of this is to expand our basic 
understanding of this malignancy to aid in the discovery of therapeutic targets.   
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1.1 Classification and Incidence of Biliary Malignancies 
Cholangiocarcinomas (CCA) represent a genetically and molecularly diverse set of 
bile duct malignancies 2, which after hepatocellular carcinoma (HCC), constitute 
the second most frequent class of primary liver cancer 3. CCAs typically arise from 
the ductular epithelium and can occur at any point along the length of the biliary 
tree. CCA is most commonly classified anatomically based on its position along the 
biliary tree (fig 1.1.1). As such, intrahepatic cholangiocarcinoma (iCCA) arises in the 
second-order bile ducts within the liver parenchyma, perihilar CCAs (pCCA)  
sometimes called Klatskin tumours  are found around the confluence of the left 
and right hepatic ducts and within the common hepatic duct, and distal 
extrahepatic CCA (dCCA) is found within the common bile duct below the junction 
of the cystic and common hepatic ducts and above the Ampulla of Vater 4 (Fig. 
1.1.1).  
The focus of this investigation is iCCA as this is the anatomical subtype with the 
highest mortality despite accounting for as few as 5-10% of all CCA cases 5. This is 
evidenced by the observation that in the UK iCCA has overtaken HCC is the primary 
cause of death from liver cancer 6. ICCA is classified according to gross morphology 
as Mass-Forming (MF), Periductal Infiltrating (PI), and Intraductal Growing (IG) 
subtypes. Histologically there have been a number of proposed classification 
systems 7, but broadly speaking iCCAs are grouped into two histological subtypes 





Figure 1.1.1 Anatomical classification of cholangiocarcinoma: A, Anatomical 
classification of cholangiocarcinoma subtypes. Intrahepatic cholangiocarcinoma 
arises above the second-order bile ducts, i.e. above the second bifurcation of the 
biliary tree. Perihilar arises within the common hepatic duct up to the second 
bifurcation, and extrahepatic occurs in the common duct, below where the 
common hepatic and cystic ducts meet, and above the ampulla of Vater. B-D, 
Cartoon depictions of iCCA growth types with photographs showing gross 
morphology. B, the intraductal growing (IG) subtype describes iCCA contained 
within the bile ducts and spreading along the epithelial surface. As can be seen in 
the photograph, the bile duct wall is increased in thickness, but the tumour is 
contained within. C, mass-forming (MF) describes large solid masses which occlude 
the bile duct and spread into the parenchyma. D, periductal infiltrating (PI) subtype 
tumours grow around the outside of the bile ducts and track along them with 
moderate infiltration into the parenchyma, but without intraductal growth. 
Arrows indicate tumour delineated by purple dashed lines, with bile duct 
delineated by green dashed lines. Photographs adapted from Jae Hoon Lim, AJR 




in the small peripheral ducts falls into the ‘bile ductular/mixed’ subtype, whilst 
iCCA arising in the large ducts are typically of the ‘bile duct/mucinous’ type 9 2 .  
ICCA arises in 7 h decade of life in the general population, although this is modified 
by risk factors as discussed below22. The age-standardised incidence rates (ASIR) 
for iCCA differ from country to country but show an overall trend towards an 
increasing incidence globally. The rise in incidence has been deemed genuine after 
correcting for confounding factors such as erroneous inflation by classification 
artefacts. Such artefacts are attributed to differences in coding between, and time 
of adoption of, different editions of the International Classification of Diseases for 
Oncology (ICD-O). The ICD-O variably switches from classifying perihilar tumours 
as intrahepatic or extrahepatic between editions 23,24. Additionally, it is not 
uncommon for metastasis from cancers of unknown primary (CUP) to be 
wrongfully diagnosed as iCCA which may further exaggerate what is, nonetheless, 







1.2 Epidemiology and Risk Factors 
CCA has an intriguing epidemiology. Incidence shows strong geographical 
variation due to a combination of incompletely understood genetic risk modifiers 
and variable exposure to risk factors often driven by local environment25.  
ASIR per 100,000 for CCA is low in Europe (UK, 2.2; Italy, 3,4)  and the American 
Continent (US, 1.6; Canada, 0.4), with relatively higher rates in Southeast Asia 
(Shanghai, China, 7.6; Busan, South Korea, 8.8), but dramatically peaks at 85.0 in 
North East Thailand26. This is worth exploring in more detail. On the surface this 
peak is attributable to widespread exposure to the carcinogenic liver fluke 
Opisthorchis viverrini. Liver fluke infection represents an established risk factor 
for iCCA with food-borne trematodes estimated to affect 40-50 million people 
worldwide, disproportionately focused in Southeast Asia27. In China and Korea the 
predominant carcinogenic fluke is Clonorchis sinensis, and O felineus is prevalent 
in Eastern Europe 28. Returning to North East Thailand, iCCA due to O viverrini is 
exacerbated by the interplay of cultural practices and socioeconomic factors. 
Primary infection is often through ingestion of a traditional raw fish dish and can 
be treated easily with praziquantel. However, CCA incidence is more prevalent in 
rural regions  particularly around the Mekong River Basin in the North East where 
the fish vector of the fluke is found 29,30. In rural regions chronic or repeat cycles of 
infection are more common, contingent on factors such as lack of access to medical 
care and lower levels of education 3 . Work in a hamster model of O viverrini 
infestation suggests that fluke infection alone is not sufficient to induce overt iCCA 
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but can do so in conjunction with other tumour-promoting exposures32,33. How well 
this experimental observation translates to humans is difficult to resolve. It has 
been suggested that in rural Thailand increased globalisation and a shift from 
agriculture to industry has exacerbated economic disparities leading to greater 
levels of poverty34 36. Some effects of poverty which increase cancer risk include 
higher likelihood of alcohol abuse, higher incidence of smoking, and chronic stress 
and these are all thought to contribute alongside fluke exposure to the increased 
incidence of iCCA seen in these poorer regions 37. Subsequently CCA generally and 
iCCA specifically are sometimes considered diseases of poverty in Thailand38.  
In Europe, North America, and Canada the aetiology is less clear. In many cases 
iCCA is thought to arise sporadically with no known underlying risk factor, indeed 
50% of iCCA cases are of unknown aetiology. The common pathology between 
known (non-genetic) risk factors is a degree of chronic hepatic and/or biliary 
inflammation. Inflammation subsequent to choledochal cysts, primary sclerosing 
cholangitis, Caroli’s disease, cholelithiasis, and cirrhosis are all strongly or very 
strongly associated with iCCA. Hepatitis B and C viral infections are moderately or 
strongly associated, and more classical risk factors for cancer such as alcohol 
consumption, obesity, and cigarette smoking are weakly or moderately associated. 
This points to a prominent role of chronic inflammation as an iCCA risk modifier. 
In addition to inflammation, bile stasis and locally high bile acid concentrations 
subsequent to ductal dilation seen in cysts, Caroli’s disease, and lithiasis results 
may have direct or indirect transformative effects on the biliary epithelium39 43.  
Whilst the above cystic diseases have a strong association with iCCA, they have 
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higher odds ratios for extrahepatic biliary malignancy. The clearest risk factor for 
iCCA is primary sclerosing cholangitis (PSC), an autoimmune disease manifesting 
in the biliary tree: individuals with PSC have a 400-fold higher risk of iCCA than the 
general population.  
In the West, the exposures linked to iCCA development are still to be fully 
elucidated and causal mechanisms remain incompletely understood. Whether or 
not there is a link between heterogeneity in mutational spectra and risk exposure 
remains an unanswered question. It is conceivable that where a very strong risk 
modifier such as PSC or O viverrini underpins iCCA development the mutational 
spectra may be more uniform, whereas in ‘spontaneous’ disease where malignancy 
may arise on the background of multiple exposure to low-risk sources such as 
cigarette smoking, alcohol consumption, transient hepatic inflammation, etc. this 
heterogeneity in risk exposure may be reflected in heterogeneity of the mutational 
spectrum. 
Germline genetic risk factors are less understood due to a paucity of genome wide 
association studies (GWAS) in CCA. To date only one such study is underway and it 
is still in its early stages. Most GWAS focus on PSC and PSC-derived CCA for which 
some risk alleles are known but these do not translate to non-PSC CCA. This is 
exemplified by the finding that two single nucleotide variants in the natural killer 
cell receptor G2D (NKG2D) gene are associated with an increased risk of CCA 
development in patients with PSC 44, but this did not translate on independent 
validation to sporadic CCA 45.  
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Overall, risk factors for iCCA are many and varied and this is reflected in a 
geographically heterogeneous epidemiology and a genetically heterogeneous 















1.3 Cellular, Molecular, and Genetic Pathogenesis of iCCA   
1.3.1 Cell of Origin in iCCA 
Primary liver malignancies are increasingly thought of as a continuum where the 
tumour phenotype is a product of the cell of origin, the mutational landscape, the 
microenvironment, and exogenous exposures46. This is supported by shared 
molecular features between HCC and iCCA47 49, the existence of rare mixed HCC-
iCCA tumours, and the observation that iCCA can arise from mature hepatocytes, 
mature cholangiocytes50 and bi-potent progenitor cells. The possibility of multiple 
cell-types of origin for iCCA can be better understood by first considering liver cell 
plasticity more generally. The liver has a remarkable regenerative capacity 
facilitated primarily by the plasticity of both the hepatocyte and cholangiocyte 
lineages which can trans-differentiate into each other, as well as facultative bi-
potent progenitor cells  the oval cells. Liver regeneration partly involves the 
redeployment of developmental programs resulting in the transient acquisition of 
stem-like phenotypes, de/trans-differentiation, and increased proliferation. 
However, unlike in organogenesis, this occurs in the context of a pro-inflammatory 
milieu and involves cells which may have many decades of accumulated 
mutations. Repeated or chronic activation of regenerative programs increases the 
risk of primary liver cancers, which may be more likely to arise from different cells 
of origin dependant on the type and duration of injury. At early stages, damage of 
the parenchyma results in regeneration from hepatocytes in early disease, but 
from mature cholangiocytes or progenitor cells in late-stage cirrhotic disease5 . 
Generally speaking, injury that targets the parenchyma preferentially induces 
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hyperplasia/regeneration of mature hepatocyte origin. Only when damage is 
extensive, and hepatocytes enter senescence or otherwise exhaust their 
replicative/regenerative potential is hepatocyte replacement from progenitor cells 
or mature cholangiocytes possible. Chronic bile duct injury through fluke 
infestation, cholestasis, or primary sclerosing cholangitis on the other hand 
exposes the mature cholangiocyte to prolonged inflammation and carcinogenic 
agents (e.g. reactive oxygen species, high concentrations of bile acids). Biliary 
damage also induces periportal proliferation of the ducts  termed a ductular 
reaction  which has also been shown to derive from bi-potent stem cells, mature 
cholangiocytes and mature hepatocytes. A plethora of observations support the 
plasticity of the main cell types of the liver which in turn lends credence to multiple 
cell-types of origin in primary liver cancers. ICCA as a product of the aberrant 
activation of developmental programs in the context of tissue injury is further 
supported by the molecular mechanism driving iCCA tumourigenesis. Indeed, 
many of the pathways involved in development, regeneration, disease, and 
malignancy are shared amongst these processes. 
Whilst many molecular pathways are implicated in iCCA pathogenesis, here I focus 
on a limited set: Notch, Hippo, Wnt, p53, and the RAS/RAF/MEK/ERK cascade. Whilst 
this skips over other iCCA-relevant pathways (TGFβ52 55, PI3K/Akt/mTOR56 59, 
Hedgehog signalling60 62, Jak/STAT63 66), this representative subset serves to 
illustrate pathway crosstalk and pleiotropy in the liver during development, 
regeneration, and malignancy. As such they provide a general molecular 
framework within which the results of the present study may be contextualised.  
  
 12 
1.3.2 Hippo Signalling 
The Hippo pathway is best characterised as a regulator of organ size during 
organogenesis where it balances cell proliferation with apoptosis through the 
integration of myriad developmental queues. As such, its core components are 
highly conserved across metazoan lineages67, with upstream regulators showing 
species-specific differences68. At its core, the Hippo pathway is a kinase cascade 
involving the activation of firstly Ste20-like serine/threonine kinases MST1/269,70, 
which in turn activate the large tumour suppressors LATS1/2 through 
phosphorylation of 2 highly conserved regulatory motifs in their c-terminal 
catalytic domain7 . Activated LATS1/2 serves to phosphorylate the transcriptional 
co-activators yes-associated protein (YAP) and transcriptional co-activator with 
PDZ binding motif (TAZ) which prevents their translocation to the nucleus and 
ultimately mediates their destruction by the proteasome72. In the absence of an 
upstream activator, the kinase pathway is inactive and YAP/TAZ translocates to the 
nucleus. There it binds to one of several partners73 (RUNX1/2, TBX5, SMAD, p73, 
ERBB-4), but archetypically one of the TEA DNA-binding proteins (TEAD1-4) to 
induce pro-proliferative and anti-apoptotic transcriptional programmes74,75. 
Upstream activators of the pathway include G-protein coupled receptors76, TAO 
kinases77, FAT cadherins78, MAP4K79, and FERM-domain containing proteins80.  
Notable in the liver is the FERM-domain containing protein Merlin8 ,82, encoded by 
neurofibromin 2 (NF2), a tumour suppressor linked with the familial cancer 
syndrome Neurofibromatosis Type 283. During liver development and regeneration  














Figure 1.3.2.1 Hippo Pathway. The core Hippo pathway consists of a kinase 
cascade whereby, upon activation, MST1/2 and LATS1/2 are phosphorylated. This 
results in phosphorylation of YAP/TAZ which leads to its destruction by the 
proteasome. In the absence of activation YAP/TAZ remains unphosphorylated and 
is able to translocate into the nucleus where it induces transcription of target genes. 




YAP or loss of NF2 causing extrahepatic choledochal cysts87, hepatomegaly and 
tumour formation88. In the adult liver, nuclear YAP is restricted to the biliary 
lineage and Hippo pathway activation maintains mature hepatocyte identity by 
excluding YAP from the nucleus. Subsequently, nuclear translocation of YAP in 
hepatocytes through loss of NF2 causes dedifferentiation of hepatocytes into a 
progenitor state and subsequent reprogramming into a ductal-like state mediated 
by TEAD4 induced transcription of the cholangiocyte lineage genes NOTCH2 and 
SOX989. Although experimental evidence exists for a role of Nf2 loss in human iCCA, 
the literature is sparse. In one study of human iCCA tissue sections, low expression 
of Merlin was correlated with poorer differentiation90. Loss of NF2 in mature 
cholangiocytes results in moderate ductal hyperplasia, but not acquisition of a 
progenitor cell fate or a ductular reaction.  
1.3.3 Notch Signalling 
The Notch pathway functions through cell-cell contact between ligand and 
receptor-expressing cells to elicit highly context-dependent responses. Despite the 
pleiotropic nature of Notch signalling, its core components are comparatively 
simple9 . The core signalling module begins when a member of the single-pass 
transmembrane Notch receptor family (NOTCH1-4)  expressed on the surface of 
one cell  is activated through binding of any of its five Delta-Serrate-Lag (DSL) 
family ligands (JAG1, JAG2, DLL1, DLL3, DLL4), expressed on the surface of an 
adjacent cell. Binding induces a conformational change in the Notch receptor that 
exposes an extracellular cleavage site which is cleaved by ADAM10/17 
metalloproteinases and disintegrin. A subsequent proteolytic cleavage of the 
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intramembrane domain mediated by γ-secretase releases the intracellular 
component of the receptor  the Notch intracellular domain (NICD)  that 
translocates to the nucleus. In the nucleus NICD binds the RBPJ transcription factor 
through displacement of co-repressors; successive binding of co-activators results 
in formation of the RBPJ transcriptional complex that activates Notch target genes. 
The most prominent Notch target genes are the transcriptional repressors 
hairy/enhancer of split (HES) and HES-related with YRPW motif (HEY). HES and 
HEY predominantly inhibit transcription of numerous target genes.  
Notch signalling is pervasive in development with roles in effectively all major 
organ systems. One prominent role of Notch with relevance here is in the control 
of cell fate decisions and the establishment of tissue boundaries through lateral 
inhibition or induction. During liver organogenesis, Notch signalling first specifies 
the ductal plate  the layer of cells which goes on to form the biliary tree - through 
interaction of Notch-expressing hepatoblasts and adjacent Jag-1-expressing portal 
mesenchyme; Jag-1 expression subsequently shifts to the parenchymal side and 
induces ductular morphogenesis in concert with other signalling pathways92  
notably TGBβ93, which itself has been shown capable of mediating complete 
reconstitution of a biliary tree in the mature mouse liver94. Attesting to the 
fundamental importance of Notch in biliary cell fate decisions, germline loss of 
NOTCH2 or JAG1 genes results in Alagille syndrome which is characterised by the 
complete absence or a paucity of the biliary tree95. Out-with development, Notch1 
and Jag1 are both expressed during liver regeneration following partial 

























Figure 1.3.3.1 Notch Pathway. The Notch pathway is a contact-dependent pathway 
whereby a ligand-receptor pair is formed between 2 adjacent cells. In the receiving 
cell this leads to successive proteolytic cleavage of Notch receptor peri-membrane 
domains liberating the intracellular domain, NICD. This translocates to the nucleus 
where it displaces TEAD co-repressors and initiates formation of a co-activation 




conditional loss of NOTCH1 induces nodular regenerative hyperplasia through the 
continuous proliferation of hepatocytes97 with concomitant vascular remodelling 
and without fibrosis98. 
In line with its role in specifying cell fate in the liver, Notch-mediated 
transdifferentiation of mature hepatocytes into iCCA has been shown in two 
complementary mouse models. Forced activation of downstream effectors through 
expression of NICD in mature hepatocytes causes the formation of cystic 
cholagiocellular lesions99. When this is combined with overexpression of Akt the 
result is differentiated, ductular lesions with numerous characteristics of human 
iCCA99. This was also observed in a second model which used the TAA liver damage 
diet as a pro-oncogenic stimulus in place of Akt, and further showed that loss of the 
Notch effector Hes1 abrogated this phenotype 00. In early HCC the transcription 
factor RUNX3 acts to limit HCC progression by directly interacting with NICD to 
suppress Notch signalling 0 . When not suppressed in HCC,  Notch2 signalling 
produces poorly differentiated tumours and correlates with immature 
morphology, aggressiveness and advanced clinical stage in human samples 02. This 
observation further supports the role of aberrant Notch signalling in hepatocyte 
lineage plasticity. Finally, O’Rourke et al. 03 comprehensively profiled the role of 
NOTCH signalling in human iCCA, and delineated a transcriptomic signature for 
prospective stratification of iCCA patients into groups likely to respond favourably 
to pan-γ-secretase inhibitors. Importantly, they demonstrated a pivotal role for 
stromal-epithelial NOTCH signalling as an important modality in human iCCA. They 
further showed the simultaneous upregulation of multiple Notch receptors and 
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ligands thus necessitating the requirement of an inhibitor targeting universal 
components of the pathway (i.e. γ-secretase) as opposed to those targeting 
individual ligands/receptors. This study supports and elaborates on a previous 
study by Guest et al. 04 demonstrating differential overexpression of NOTCH3 in 
human sections, as well as in transgenic and chemical-induced models of iCCA in 
mice and rats, respectively. In this study the authors showed that tumour survival 
was mediated by activation of the PI3k/Akt pathway, which represents a druggable 
target in iCCA56, 05, 06.  
1.3.4 The Wnt pathway 
The canonical and non-canonical Wnt signalling pathways constitute a complex 
network with numerous ligands and extensive crosstalk with each other 07 09 and 
many other pathways 0, . 
Canonical Wnt signalling is fundamental as a regulator of proliferation and 
stemness in both the adult and the embryo. The core components of the canonical 
pathway revolve around the multi-function protein β-catenin 2. In one capacity it 
acts as a plasma membrane-associated linker, bridging the interaction of 
transmembrane E-cadherin to cytoskeletal actin filaments to mediate cell-adhesion 
and mechanotransduction 3. This function is critical in gastrulation and is 
conserved in multicellular organisms, preceding the divergence of Cnidaria and 
Bilateria 4, 5.  In another capacity, β-catenin acts as a transcriptional regulator 
through regulated 6 interaction with the T-cell factor (TCF)/lymphoid enhancer 
binding factor (LEF) family of transcription factors 7, 8. In the absence of pathway 
  
 21 
activation β-catenin not involved in cell-adhesion is turned over by the destruction 
complex  a dynamic assemblage with core components consisting of the 
adenomatous polyposis coli (APC) protein, casein kinase-1⍺	 (CK1⍺), glycogen 
synthase kinase3β (GSK3β), and the scaffold protein Axin 9. Additionally, protein 
phosphatase A2 (PPA2) is also associated with the complex although its function is 
not definitively resolved 20. Phosphorylation of β-catenin allows its recognition and 
binding by the E3-ubiquitin ligase β-TRCP-SCF complex 8, 9, 2  which ultimately 
results in its destruction by the proteasome. Pathway activation is initiated when 
any of the family of canonical ligands  secreted, lipid-modified, glycoproteins 22  
binds to the seven-pass transmembrane co-receptor Fzd. This induces 
heterodimerization of activated Fzd with either of its binding partners, the LRP5/6 
co-receptors, and produces the active Fzd-LRP5/6 receptor complex. GSK3β-
mediated phosphorylation of the active LRP5/6 results in sequestration of Axin to 
the membrane through interaction with the scaffold protein, Dishevelled. This 
ultimately sequesters the destruction complex to the plasma membrane, allowing 
β-catenin to accumulate in the cytoplasm and translocate to the nucleus where it 
activates target genes through interactions with its binding partners  primarily 
through a conserved armadillo repeat domain, crucial for many of β-catenin’s 
protein interactions, and a therapeutic target 8.  
Non-canonical forms of Wnt signalling are β-catenin-TCF/LEF-independent but are 
still mediated by the cognate Fzd receptor in complex with numerous co-receptors. 
The best characterised of these alternative pathways are the Wnt/planar-cell 
























































Figure 1.3.4.1 Wnt Pathways.  A, b-catenin associates with alpha and gamma 
catenins to bridge the interaction of E-cadherin and the actin cytoskeleton at cell-
cell junctions. B, in the absence of ligand, inactive canonical Wnt signalling 
involves the constant turnover of b-catenin by the destruction complex. Upon 
ligand binding and heterotypic receptor dimerisation the destruction complex is 
sequestered to the membrane. This inhibits the destruction of b-catenin, allowing 
it to accumulate and translocate into the nucleus where it induces transcription of 
target genes. C, The Wnt-PCP pathway is b-catenin-independent and is activated 
when Frizzled and Vangl2 form a receptor dimer upon binding of a non-canonical 
Wnt ligand. This can result in both transcription of targets via Jnk/Jun/Fos cascade 
or through cell polarisation through rearrangement of the cytoskeleton mediated 
by RhoA/ROCK. D, The Wnt-Ca2+ pathway involves the production of second 
messengers (DAG, IP3) by phospholipase C upon activation of the ROR receptor. 
This induces intracellular Ca2+ release from the endoplasmic reticulum and 
subsequent calcium-dependent activation of CamKII and PKC. This leads to 




via the Fzd/Vangl2 receptor complex resulting in recruitment and activation of 
Dishevelled which subsequently releases inhibition of DAAM1. This initiates a 
RAC1/RHOA/ROCK/JNK cascade that results in actin cytoskeletal rearrangements 
and c-Jun/c-Fos transcription factor activation in the nucleus. This core pathway 
establishes cell polarity in mesenchyme and epithelial sheets, and is therefore 
indispensable in embryogenesis and organogenesis where it mediates convergent 
extension during gastrulation and neurulation 23, 24, and establishes tissue 
polarity 25 and left-right asymmetry 26. In Wnt-Ca2+ signalling, Fzd/Ror1/2 binding 
initiates phospholipase C (PLC) activation which catalyses the production of 
inositol-1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG) from membrane-
bound phosphatidylinositol-4,5-bisphosphate. IP3 induces Ca2+ release from the 
endoplasmic reticulum which, in combination with calmodulin, activates calcium-
calmodulin-dependent protein kinase II (CaMKII). Meanwhile, DAG, in concert with 
the efflux of Ca2+ from the endoplasmic reticulum, activates protein kinase C (PKC). 
The resultant activation of PKC and CaMKII signals to activate transcription factors 
such as NFκB, CREB, and NFAT 27. 
Wnt signalling in virtually all of its incarnations plays a prominent role in 
development, and this is no less true in liver organogenesis 28. Following 
gastrulation, Wnt signalling induces the foregut 29, 30 and subsequently induces 
expansion of bi-potent hepatoblasts in the liver bud 30. Importantly, Wnt acts as a 
key factor in the specification of biliary fate in coordination with Notch. Decaens et 
al. 3  demonstrated that forced activation of β-catenin through APC loss in the 
mouse embryo resulted in failure of hepatocyte specification from hepatoblasts 
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and the concomitant differentiation of ductular structures of biliary identity. 
Lineage tracing further showed that APC-null hepatoblasts formed mature bile 
ducts when transplanted into the adult liver but did not contribute hepatocytes. 
Beside from a clear role of canonical Wnt signalling in biliary specification, Cui et 
al 32. showed the importance of Wnt-PCP signalling in biliary fate specification and 
ductular morphogenesis in the zebrafish, with its loss resulting in reduced 
development/branching of the biliary tree and absence or incorrect sidedness of 
the gall bladder.   
Mutations in the regulatory domain of β-catenin, required for its phosphorylation 
by GSK3β, are found in >50% of paediatric hepatoblastoma, as are loss-of-function 
mutations in APC and AXIN. To a lesser extent, mutations in these and others in the 
Wnt pathway are also found in HCC where they promote cell proliferation, 
metastasis, and aggressiveness 33. As is the case in hepatoblasts and earlier 
progenitors, Wnt-signalling was shown to target putative HCC stem-like cells and 
promote their stemness and proliferation 34: suppression of Wnt signalling by 
endogenous micro-RNAs results in loss of stemness 35. Somewhat paradoxically 
given its role in biliary fate specification in the embryo, in one study Wnt signalling 
in early HCC was correlated with better hepatocytic differentiation that was 
subsequently lost through a gradual increase in hedgehog signalling with 
concomitant Wnt loss during the temporal progression of HCC development 36.   
In human iCCA, our lab 37 previously demonstrated that WNT7B and WNT10A are 
expressed in human samples and that Wnt signalling can drive iCCA. This is at odds 
with the sparsity of Wnt pathway mutations in iCCA. The authors subsequently 
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resolved this disparity through discovery that inflammatory (CD68+CD163 ) 
macrophages in the tumour stroma induce Wnt expression in iCCA epithelium 
through secretion of WNT7B. Subsequent loss of macrophages or pharmacological 
inhibition of ligand secretion by Porcupine inhibition abrogated tumour growth 
and caused partial regression. In addition to macrophage-derived Wnt activation, 
iCCA may also show increased Wnt activity as the result of decreased expression of 
negative Wnt regulators, such as SRC-like adaptor protein (SLAP) 38. Although the 
mechanism of SLAP expression loss was not explored in the corresponding study, 
others have shown that iCCA frequently features epigenetic promoter silencing of 
other regulators of Wnt 39. Notably, Merino-Azpitare et al. identified SOX17 as a 
novel tumour suppressor in iCCA. They showed that its loss induced Wnt-
dependant proliferation (amongst other changes) through the canonical pathway. 
They subsequently showed that in human samples the SOX17 promoter was 
frequently hypermethylated, which, through decreased expression, correlated 
with decreased overall survival following resection.  
1.3.5 The p53 tumour suppressor 
The tumour suppressor p53 has been dubbed the “guardian of the genome”; 
compromised p53 function through mutation or dysregulation of its numerous 
regulatory pathways is a pervasive pan-cancer hallmark. The diversity of signals 
p53 can receive and transduce is a product of a highly modular domain structure 
rich in intrinsically disordered domains 40 43 and posttranslational modification 
(PTM) sites 44. The former provides flexible binding surfaces through which a 
plethora of proteins can interact, and the latter provides residues which can be 
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dynamically modified to modulate p53 function. Further diversity in function is 
attributable to the fact that p53 is expressed in multiple isoforms with often 
antagonistic functions 45, and because the active p53 protein is a homotetramer. 
This adds additional opportunities for fine-tuning. For example, in unstressed cells 
p53 monomers, dimers, and tetramers exist at low levels, and tetramerisation upon 
DNA damage is reliant on co-factors and PTMs which themselves are subject to 
numerous layers of control 46. Consequently, p53 functions as a network hub 47, 
integrating myriad intracellular and extracellular signals which in turn control cell 
cycle and transcriptional programs. As a tumour suppressor it initiates reparative 
programs and induces cell-cycle arrest upon DNA damage sensing 48, transduced 
by ATM, amongst others. If DNA damage is irreparable, p53 initiates apoptotic 
programs 49.  At its very core p53 is regulated by interactions with the MDM2 and 
MDMX proteins; these homologues perform non-redundant roles in modulating 
p53 individually, and most effectively inhibit p53 when acting in concert 50, 5 .  The 
E3 ubiquitin ligase MDM2 is itself a transcriptional target of p53 and the resulting 
feedback loop 52  whereby active p53 induces MDM2 expression which 
subsequently ubiquitinates p53 causing its nuclear export and proteasomal 
degradation  produces clock-like pulses of p53 activity which continue until DNA 
damage is resolved or the cell dies 53, 54. 
Whilst the role of p53 in development is comparatively understudied, there is 
increasing evidence to suggest it plays a role in embryonic stem cell maintenance 55 
and differentiation in a highly context-dependent manor 56 59. Whilst a role for p53 






















Figure 1.3.5.1 p53 regulation. In unstressed cells, p53 is maintained at a low level 
through a feedback look involving its regulators MDM2 and MDMX. MDM2 is a 
transcriptional target of p53 so as p53 becomes active it upregulates MDM2 which 
in turn inhibits p53, maintaining its activity within a tight range. MDM2 and MDMX 
co-regulate each other as well as both inhibiting p53 through different 
mechanisms, thus leading to a fine-tuned control of resting p53 levels which can be 
modified through regulation of both MDM2 and MDMX. Upon cell stress the 
MDM2/MDMX proteins are inhibited through myriad stress-specific mechanisms 
and p53 is stabilised through phosphorylation. It then translocates into the nucleus 
to initiate cell-survival, cell-cycle arrest, or apoptotic transcriptional programmes. 




emerging role for p53 in various liver pathologies and regeneration 60 62. For 
example, Borude et al. 63 demonstrated significantly greater levels of 
acetaminophen-induced damage in Trp53-null mice. Nonetheless, despite this 
increased damage and delayed the onset of regeneration, Trp53-null mice resolved 
injury in a time comparable with WT mice due to increased levels of regeneration 
attributable to faster cell-cycle progression.  
TP53 occupies a place amongst the handful of frequently mutated genes in iCCA 64
66. A study by Ong et al. 67 and its follow-up by Chan-on et al. 68 indicate that TP53 
mutations are enriched in fluke-related iCCA. The causal mechanisms which might 
favour TP53 mutation in fluke-related iCCA remains to be elucidated. One potential 
causal link may be the relationship between mutational processes active on 
tumour genomes and selection for driver mutations. Temko et al. 69 demonstrated 
that different mutations arise in driver genes as a result of mutational processes 
active on the genome, and that in some cases these are differentially selected. As 
such, the mutational processes active as a result of fluke infestation and chronic 
inflammatory processes warrant further investigation in iCCA; particularly in light 
of the observation that TP53 in the liver preferentially harboured TP53R249S 
mutations as a consequence of aflatoxin exposure 69 (accounting for 16% of p53 
mutations in the cohort used in this study). Several studies also report a statistical 
relationship between PSC and TP53 mutations in iCCA whereby TP53 mutation is 
not detected in PSC samples but is present in iCCA which has developed on a 
background of PSC 70 72, suggesting that TP53 loss is a precipitating event 
mediating the transformation of PSC into iCCA. Loss of cell identity and lineage 
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plasticity is proven to be one consequence of p53 loss. Experimental evidence 
shows that TP53 loss in combination with KRAS gain-of-function mutations 73, 74 or 
NICD expression 75 drives iCCA of both cholangiocyte and hepatocyte origin; the 
former progressing through a pre-malignant biliary intraepithelial neoplastic 
(BilIN) sequence prior to iCCA formation, and the latter emerging directly from 
hepatocytes with concomitant lineage switching to iCCA. In line with these 
observations, Tschaharganeh et al. 76 demonstrated that wild-type p53 acts as a 
gatekeeper of cellular plasticity in mature hepatocytes, and that its loss caused 
aggressive, dedifferentiated tumours, formation of which was accelerated in 
conjunction with Yap expression.  The authors showed that the stem cell marker 
Nestin functionally participated in the acquisition of stemness and tumour 
progression, and that it is ordinarily repressed by wild-type p53 indirectly through 
binding with the Sp1 transcription factor. Poorly differentiated tumours which 
arose from p53 loss and Yap expression could subsequently be directed towards an 
HCC or iCCA lineage through expression of Wnt or Notch pathways, respectively.  
1.3.6 The RAS/RAF/MEK/ERK kinase axis 
 
The final discussion of pathways centres around the small GTPase superfamily 
members KRAS and NRAS. The small GTPases catalyse the hydrolysis of guanosine 
triphosphate (GTP) to guanosine diphosphate (GDP) and make up a family of more 
than 150 members, of which KRAS, NRAS, and HRAS are the archetypal founders 77. 
The RAS proteins act downstream of receptor tyrosine kinases to transduce 
extracellular signals, and in this capacity they function as a binary switch. In their 
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GDP-bound state they are ‘off’ and do not engage their effectors, but upon binding 
of GTP they shift to an active ‘on’ conformation. The cycle of GTP binding, GTP 
hydrolysis, GDP release, and GTP re-binding occurs at too slow a pace to be 
physiologically relevant. Therefore, despite their intrinsic GTPase activity, GTP 
catalysis is aided by interaction with GTPase activating proteins (GAPs). Relatedly, 
the release of GDP to allow recharging is mediated by guanine nucleotide exchange 
factors (GEFs) 78. Upon RTK activation (e.g. EGF binding EGFR), a receptor complex 
forms involving the adaptor protein growth factor receptor bound 2 (GRB2) which 
is constitutively bound to Son of Sevenless (SOS), a GEF 77. SOS and RAS-GDP/GTP 
reciprocally regulate each other 79, 80, and SOS mediates the release of GDP allowing 
RAS activation through binding of GTP, mediated by GAPs such as p120-RasGAP 8  
or NF1 82. 
In its active conformation, RAS initiates a kinase cascade whereby sequential 
kinases are activated through phosphorylation. Activated RAS phosphorylates RAF 
 a serine/threonine kinase  which results in its dimerisation and activation. 
Activated RAF subsequently activates MEK which activates the terminal effector, 
ERK. Through translocation to the nucleus ERK engages transcription factors to 
induce a diverse range of cell-physiological changes including proliferation, 
differentiation, and survival. Activated ERK can also be retained in the cytosol 
where it potentiates the activation of pro-apoptotic proteins 83. Aside from the 
RAF/MEK/ERK axis, Active RAS can also signal through the PI3K/AKT pathway, the 

























Figure 1.3.6.1 RAS/RAF/MEK/ERK Cascade. Upon receptor tyrosine kinase 
activation, RAS is switched from its inactive (GDP-bound) state and into its active 
(GTP-bound) state, mediated by SOS, a GEF. In the active conformation, a cascade 
is initiated involving successive phosphorylation of RAF, MEK, and ERK, ultimately 
leading to the induction of proliferative and pro-survival programmes. Figure 




Oncogenic substitutions at the G12, G13, and Q61 amino acid residues abrogate 
GTP->GDP catalysis by preventing in trans insertion of the catalytic arginine finger 
provided by GAPs 86. This results in a constitutively ‘on’ RAS protein which 
perpetuates downstream kinase pathway activation leading to pro-proliferative 
oncogenic phenotypes.  
Oncogenic K-, N- and HRAS are found in a broad spectrum of cancers, although they 
do show cancer specificity. For example, oncogenic KRAS occurs in almost 100% of 
pancreatic ductal adenocarcinoma 87, 88, whilst oncogenic HRAS is the predominant 
RAS oncogene in head and neck cancer 89, 90. The reason for cancer specificity has 
been extensively investigated. Notable contributions include work by Haigis et 
al. 9  who showed that oncogenic KRAS and NRAS confer different phenotypes in 
the colon. In their study, KRAS caused expansion of stem cells, whilst NRAS did not 
effect growth but did confer resistance to apoptosis. This may explain preferential 
selection for KRAS mutants which in turn may explain the relatively increased 
frequency of oncogenic KRAS compared to NRAS in colorectal cancer. In an elegant 
study by To et al. 92 the authors showed that despite the predominance of oncogenic 
KRAS in lung cancer, oncogenic HRAS could fulfil its role when expressed from the 
endogenous KRAS locus but not from the endogenous HRAS locus. This suggested 
that in the lung at least, the gene-regulatory landscape is a prevailing factor in RAS 
isoform preference.  
Both oncogenic KRAS and NRAS are found in iCCA but have different frequencies 
and different oncogenicities 93, with KRASG 2 mutations occurring more frequently 
and causing more aggressive phenotypes. In iCCA, codon changes targeting the G12, 
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G13, and Q61 residues are found at various frequencies. A study by Chung et al. 93 
assessing the differential oncogenicity of oncogenic RAS isoforms in the liver found 
that the main modifier of oncogenicity was residue. KRASG 2 expression in the liver 
produced tumours with much higher penetrance than NRASG 2, but both HRASQ6  
and NRASQ6  mutations were comparable with KRASG 2. The reasons for different 
potencies at different oncogenic residues is incompletely understood 94, 95 but are 
thought to be cell-specific.  
1.3.7 Molecular Pathway Crosstalk 
Reconciling the vast  and occasionally contradictory  evidence in the literature 
on pathway dysregulation in iCCA to produce a unified model is a formidable 
challenge, and further complexity is added due to the fact that the pathways above 
do not exist in isolation. Pathway crosstalk is a common feature of malignancies 
and here select examples will be used to illustrate the importance of considering 
this.  
Osteopontin, a multifunctional bone sialoprotein, is a critical inflammatory 
regulator in liver disease 96 98 and regeneration 99, with promiscuous roles in 
cancer through interaction with a versatile complement of receptors200. Recently, 
Zheng et al.20  demonstrated that osteopontin was elevated in iCCA and correlated 
strongly with poor survival and recurrence due to metastasis. They went on to 
show that osteopontin recruits ERK2 which phosphorylates β-catenin at S657 and 
increases its stability, thus allowing it to accumulate in the cytoplasm and 
translocate to the nucleus. Here then we see the interaction of kinase signalling 
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through MEK-ERK with the canonical Wnt effector, resulting in its activity even in 
the presence of a functional destruction complex/the absence of Wnt signalling. 
Staying with Wnt, Wnt-Hippo crosstalk is seen vertically at multiple points along 
the respective pathways. At the ‘top’ the Hippo inducer Merlin (NF2) interacts with 
the canonical Wnt co-receptor LRP6 to limit its sensitivity. When Wnt signalling is 
below a certain threshold Merlin binds LRP6 and inhibits Wnt signalling. Frizzled 
binding by Wnt3a results in an increase of intracellular phosphatidylinositol-4,5-
bisphosphate which indirectly induces phosphorylation of Merlin. This causes its 
release from LRP6, thus activating canonical Wnt signalling only above a certain 
threshold of Wnt ligand binding. Subsequently, loss of NF2 in cancer increases the 
sensitivity of Wnt signalling by lowering its threshold for activation202. At the 
‘bottom’, the β-catenin/LCF4 transcriptional factor complex binds to an enhancer 
in the first intron of the Hippo effector YAP, driving its expression and resulting in 
increased downstream Hippo signalling203. Additionally, nuclear translocation of 
YAP and β-catenin are jointly inhibited by STK11  itself recently predicted as a CC 
driver204  the expression of which is correlated with increased survival in gastric 
cancer205.  
Finally, as discussed, Notch activity causes de-differentiation of hepatocytes and is 
a pervasive and druggable feature in iCCA. Several different mechanisms have 
been described whereby activation of Notch signalling represses p53206 208. In one 
proposed mechanism Notch signalling indirectly targets the ARF-mdm2-p53 
tumour surveillance axis, resulting in mdm2 activation and subsequent p53 
repression. In this system inhibiting the mdm2-p53 interaction restored p53 
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activity and allowed for tumour regression. Considering the substantial, but 
incomplete penetrance of TP53 mutations in iCCA and the pervasive activation of 
Notch in certain patient subgroups, this may represent a synergistic therapeutic 
approach alongside γ-secretase inhibitors where patients harbour wild-type TP53.  
1.3.8 Genetics 
The mutagenic processes acting on cells over a lifetime are many and varied, and 
this is reflected by at least some degree of genetic heterogeneity observed across 
all cancer types. However, such heterogeneity is pronounced in iCCA where it is 
amongst its most defining features. As such, iCCA shows extensive low-penetrance 
drivers distributed across diverse signalling pathways209, and complete resolution 
of this set remains a challenge. The root cause of this heterogeneity is incompletely 
resolved but is likely, at least in part, due to the varied exposure of the liver to toxic 
insult throughout life. There is ample opportunity for diverse mutagenic exposure 
due to its role in xenobiotic metabolism2 0 2 4, as well as its targeting by oncogenic 
organisms (HBV/HCV2 5 2 7, flukes28,2 8 22 ) and exposure to inflammation in chronic 
disease resulting in repeat damage/regeneration cycles.  
In iCCA, exome and targeted sequencing studies 64, 67, 68,209,2 7,222,223 have uncovered 
a set of recurrently mutated genes that are consistent across cohorts: TP53, KRAS, 
IDH1/2, PIK3CA, and FGFR2-fusions feature most prominently. A propensity 
towards drivers affecting chromatin metabolism  ARID1A, ARID2, BAP1, PBRM1  
are also observed, and others have shown recurrent deletion or putative loss-of-
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function mutations in the cell cycle regulator phosphatase and tensin homologue 
(PTEN) and the related cell-cycle regulators CDKN2A/B. 
The largest study to date by Nakamura et al. 65 contributed substantially to this 
effort by delineating targetable alterations which segregate by anatomical location 
 previous studies largely grouped anatomical subtypes under the umbrella of  
‘cholangiocarcinoma’. This study showed that IDH1/2, BAP1, and FGFR1/2/3 
mutations/fusions were preferentially found in iCCA. Amongst those alterations 
which are targetable IDH1/2 and FGFR amplifications/fusions are of particular 
note.  
Fibroblast growth factor receptors (FGFRs) are a family of 5 receptor tyrosine 
kinases which interact with a family of 18 ligands. Activation of FGFR induces 
signalling primarily through the RAS/MAPK and the PI3K/Akt pathways, and in 
some cases activates PKC through a mechanism similar to that seen in Wnt/Ca2+ 
signalling224. In iCCA, amplifications of FGFR genes are observed, but more common 
are FGFR2 fusions.  Various fusion partners have been found (BICC1 and 
AHCYL1225, PPHLN1222, CCDC6226, KCTD1 and TXLNA 65) and these universally 
preserve the FGFR2 kinase domain. Experimental validation in Nakamura et al. 65 
and Arai et al.225 showed ligand-independent autophosphorylation of the kinase 
domain activation loop, resulting in increased MAPK signalling and oncogenic 
phenotypes. FGFR2 fusions show mutual exclusivity with oncogenic RAS mutations 
demonstrating that activation of the downstream MAPK pathway is the likely target 
of selection and duel aberrations confer no further selective advantage. Sia et al. 
suggests that these fusion events are potentially caused by downregulation of the 
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DNA-damage response genes ATM and ATR which were found to be differentially 
downregulated in FGFR2-fusion tumours. These proteins are responsible for 
regulating the stability of fragile sites  chromosomal regions prone to breakage 
during replication stress, such as that found in cancer  relevant here as FGFR2 is 
found within such a site on chromosome 10 (FRA10F).  
IDH1 and IDH2 are isocitrate dehydrogenase enzymes which function as 
homodimers to bi-directionally catalyse the interconversion of isocitrate and ⍺-
ketogluatarate (⍺-KG) during the Krebs cycle (with the forward direction strongly 
favoured under physiological conditions). They play central roles in several 
metabolic processes including modulation of redox status, glutamine metabolism 
and lipogenesis227. Point mutations affecting the R132 residue in IDH1 or the R172 
and R140 residues in IDH2 map to arginine residues in the binding pocket, 
abrogating the ability of IDH1/2 to bind its canonical substrate. Dang et al.228 
showed that these mutations resulted in neomorphic activity whereby mutant IDH 
catalysed the conversion of ⍺-ketoglutarate to 2-hydroxyglutarate  a potent 
oncometabolite.	This is consistent with the finding that IDHR 23/R 40/R 72 mutations 
are monoallelic, due to the requirement of the WT product ⍺-ketoglutarate as the 
substrate for the mutant IDH. 2-HG has been shown to competitively inhibit 
enzymes that use ⍺-KG as co-factors. Such enzymes include epigenetic modulators 
responsible for DNA and histone demethylation, and in glioma this mutation alone 
is sufficient to extensively remodel the methylome (and by extension, the 
transcriptome)229. A critical consequence of this was reported first by Lu et al.230 
who showed that 2-HG produced by mutant IDH prevents histone demethylation 
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required for lineage specification, thus locking cells in a progenitor state. Saha et 
al.23  extended this observation to iCCA where they showed that neomorphic IDH 
blocks hepatocyte differentiation and leads to an expanded pool of bi-potent 
progenitors primed for oncogenic transformation. This was reinforced by the 
identification of a hepatic progenitor transcriptional signature in IDH mutant iCCA. 
Analysis performed on TCGA RNA-seq data by Farshidfar and colleagues209 
identified a subset of transcriptionally segregating tumours all of which carried 
IDH1/2 hotspot mutations, and this was validated in an independent cohort. This 
group was enriched for expression of genes active in mitochondrial biosynthesis, 
oxidative phosphorylation, Krebs cycle, and chromatin modification. 	
Despite substantial progress in delineating the (targetable) driver landscape in 
iCCA, several key hurdles remain to be overcome. clinical trials of targeted 
therapies are difficult to implement due to rarity of disease and general molecular 
and genetic heterogeneity which hinders precise stratification. Increasingly 
sophisticated patient stratification frameworks 84, 85 and efforts to group patients 
based on key classifier mutations 66 are undoubtedly at the forefront of advancing 
strategies for patient-tailored therapy. With this in mind, it is frustrating to observe 
how often targeted therapies with tolerable toxicity show inconsistency in patient 
response. For example, 2 trials targeting the frequently dysregulated MAPK 
signalling pathway with the MEK inhibitors binimetinib234 or selumetinib235 
showed mixed response across patients. Patients harbouring KRAS mutations that 
would be expected to benefit from such targeted therapy experiencing no or 
unsustained response, whilst some patients with unknown alterations showed 
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benefit. This is at odds with efficacious preclinical models of selumetinib in 
oncogenic KRAS-driven murine iCCA236. Similarly, in a phase-1 trial for the mutant 
IDH1 inhibitor Ivosidenib, of 73 mutant IDH1 patients only 4 showed a partial 
response (however data for 48 patients was censored)237.  So far, the most successful 
targeted therapies are those against constitutively active FGFR2. The pan-FGFR 
inhibitor BGJ398 is currently in phase III trials238 following an 82% disease control 
rate in phase II239. This demonstrates the utility of targeted therapy in certain cases 
and suggests that a deeper understanding of variability in response in other 












1.4 The Importance of Biological Context for Driver 
Function 
Whether or not a particular mutation can induce transformation or contribute to 
oncogenic phenotypes is dependent on the cell of origin, its differentiation state, 
mutational landscape, and the functions, organisation and output of its signalling 
networks240. 
In the liver, where lineage plasticity is pronounced, the cell of origin cannot be 
identified in human iCCA samples. However, the cell of origin demonstrably 
modifies the output of oncogenic signalling. As discussed above, an example of this 
is the aberrant activation of the Hippo pathway.  In cholangiocytes Hippo 
dysregulation serves to induce moderate proliferation without alteration of cell 
lineage but in hepatocytes induces dedifferentiation and malignancy due to 
expansion of the resultant progenitor pool89. Such dedifferentiated lesions can then 
acquire iCCA or HCC identity dependant on subsequent activation of different 
pathways 76. 
Intrinsic barriers to transformation in response to different oncogenes can 
necessitate additional mutations, and this is also cell-type specific. For example, in 
the pancreas KRASG 2D mutations are pervasive and alone can induce the acinar-to-
ductular metaplasia which is the first step in pancreatic ductal 
adenocarcinoma240,24 . By contrast, in hepatocytes oncogenic K/NRAS mutations 
result in oncogene-induced senescence (OIS)242 which must be overcome by, for 
example, loss of p53243,244. Experimentally, this OIS can be overcome by Trp53 
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mutations in the mouse. In human iCCA, KRAS and NRAS show a degree of mutual 
exclusivity with TP53, each other, and other common drivers. This suggests that in 
human iCCA arising from hepatocytes there may be undiscovered drivers which 
allow escape from OIS. Alternatively, oncogenic RAS mutations arising in 
cholangiocytes may be sufficient to induce iCCA on their own. N-Ras (but not K-Ras) 
expression is increased in senescent cholangiocytes in PSC245 and has been shown 
to induce interleukin 6 (IL6) secretion246. IL6 functions through the JAK/STAT 
pathway in normal cholangiocytes and is regulated through a feedback loop 
involving the transcription factor SOCS3 which is epigenetically silenced in 
iCCA247,248. This leads to inhibition of apoptosis through enhanced expression of the 
negative apoptosis regulator Mcl-6247. IL6 signalling also results in increased 
expression of DNMT1 causing hypermethylation which may target additional 
tumour suppressors248,249. Lastly, IL6 has been shown to act through the MAPK 
pathway to downregulate p21  a mediator of senescence  and increase Akt 
pathway activation through increased production of progranulin248,250 (a 
homologue of which is also secreted by O. viverrini to induce cholangiocyte 
proliferation25 ,252). Therefore, oncogenic RAS mutations may have different 
consequences in iCCA contingent on the cell of origin. 
This is relevant therapeutically when considering that RAS mutational status did 
not predict response to MEK inhibition in the above-mentioned CCA clinical 
trials234,235. This can also be seen in other cancer types: MEK inhibition in KRAS-
mutant lung and pancreatic tumours induced a cell-autonomous survival pathway 
and abrogated the effects of inhibition240,253. This phenomenon was not seen in 
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KRAS mutant colorectal cancer240, in which different cells types differentially 
phosphorylate ERK in response to oncogenic KRAS254. The extent of this 
heterogeneity in phenotypic output was elegantly delineated in Yuan et al.255 where 
the authors knocked down 41 KRAS effector nodes in 92 cell lines and 
demonstrated that each cell line had its own profile of KRAS effector dependencies. 
Interestingly, they then showed that despite this heterogeneity, pancreatic, lung, 
and colorectal cancers that all harboured oncogenic KRAS could be stratified into 
a limited number of groups based on differential effector engagement and this 
caused differential response to targeted therapies. In this model, differential 
effector engagement was a product of both lineage and secondary mutations. This 
study provides strong proof of concept that common drivers act in cell-specific 
manor and this is linked to drug response. The above observations reinforce the 
importance of delineating cell-type specific actions of drivers in the different cells 
of origin in iCCA256. Different arrangements of oncogenic signalling pathways 
inherent to the cell type may influence patient response to targeted therapy, 
making stratification based on the presence of absence of a single driver 
suboptimal. Identifying the cell of origin in human iCCA is not currently possible, 
and this prevents the integration of cell-type-specific knowledge of driver function 
into patient stratification frameworks. However, novel methods leveraging the 
mutational distribution, epigenomic and passenger landscapes of tumours to infer 
cell of origin may aid in this endeavour257 259. The application of these methods to 
experimental systems with known cell-of-origin  as well as the whole-genome 
sequencing of iCCA which is noticeably lacking  may help to identify molecular 
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signatures of originating cell type in human iCCA. integration of this knowledge 
with known driver mutations would aid in more granular stratification.  
As well as cell-type-specific organisation of oncogenic signalling networks, such 
signalling networks are likely modulated by low-frequency or undiscovered 
drivers. The classification of cancer genes as drivers or passengers provides a 
theoretical framework in which to study cancer genetics, with the caveat that it is 
largely based on extremes. Whilst there are a defined set of powerful tumour 
suppressors and oncogenes, and an even larger set of genes with no biologically 
conceivable role in cancer, the middle-ground is likely rich in genes which 
influence tumour phenotypes only in particular contexts. Mutational epistasis and 
acquisition order influence the effect of mutations260 265. Epistatic interactions 
between driver and passenger mutations are challenging to resolve in cancer264, 
but have been hypothesised in two independent mathematical models to enhance 
tumour fitness. In one study266, the fitness advantage conferred on the cell by a 
single tumour suppressor was strongly contingent on the number of passenger 
mutations. By introducing epistasis into the model, the authors demonstrated that 
through interaction with the predominant driver, passenger mutations 
incrementally increased the fitness of the clone, which eventually underwent rapid 
expansion after a passenger threshold was reached. The authors conclude that 
mutations deemed to be neutral in one context cannot be regarded as neutral in all 
contexts  i.e. in the presence of a known driver. A second study267 demonstrated 
the relevance of the proposed ‘middle ground’ mutations which are neither known 
strong drivers but may not be completely neutral passengers either. In their model 
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they showed that deleterious passengers reduced the overall fitness of the cell, but 
this allowed the emergence of weak tumour suppressors which had a relatively 
higher fitness in that context.  
The above models, whilst not based on any particular cancer type, may have 
relevance in iCCA. The genetic heterogeneity inherent to iCCA may facilitate the 
emergence of mutations which in other contexts are neutral, but through epistatic 
interactions with a stronger driver and/or the truly deleterious passenger 
repertoire may confer these mutations with weak driver status. Such weak drivers 
may function to modulate the oncogenic signalling networks utilised by known 
drivers. Elucidation of such genes and the contexts in which they gain driver status 
is challenging but crucial for a deeper understanding of lateral dependencies 








1.5 Contemporary Approaches for Driver Discovery from 
Large-Scale Sequencing Data 
The proliferation of exome and genome scale sequencing in large cancer cohorts 
has inundated the cancer genetics community with rich datasets for analysis. A 
central challenge inherent in this is the filtering of signal from noise and the 
identification and prioritisation of biologically relevant observations. Mirroring 
this, there is a corresponding proliferation of computational strategies which aim 
to aid in this endeavour268.  
Driver prediction tools employ numerous creative approaches for the detection of 
driver genes or mutations. These broadly fall into three categories: functional 
impact prediction, recurrence, and pathway or network analysis269.  Examples of 
the former acting at the mutational level include PolyPhen2270, SIFT27 , and 
MutationAssessor272 which aim to predict deleterious mutations based on 
violations of evolutionarily conserved nucleotides/residues. At the gene level, tools 
such as ActiveDriver273,274 identify genes with enrichment for mutations at post-
translational modification residues in the protein, whilst others look for biased 
accumulation of functionally deleterious mutations275 or mutational clustering in 
the gene276 or protein277. Frequency based approaches aim to identify genes which 
are mutated in a cohort more often than would be expected by chance alone. The 
most utilised of this class of tools is the MutSigCV algorithm. This tool takes into 
consideration that different samples have different background mutation rates 
(BMR), and that different regions of the genome have different BMRs. BMR in 
samples may differ due to variables such as the rate of cellular proliferation, and 
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the integrity of the DNA repair machinery. Across a genome BMRs covary with 
replication timing, chromatin state, transcriptional activity, and protein-DNA 
binding. MutSigCV takes these considerations into account and allows the user to 
provide their own data to aid in accurate modelling of the BMR. This allows 
mutation frequencies that deviate from the BMR to be more accurately predicted278. 
The last category, pathway and network-based prediction, tests for enrichment of 
genes in one set (i.e. cancer mutations in a cohort) in another set (i.e. a database of 
genes known to be involved in a pathway or process)279. Other approaches utilise 
databases of known protein-protein interactions to construct networks de novo 
from the set of mutated genes269,280 282.   
The above examples are far from a comprehensive survey but do serve to 
demonstrate that different, logically sound strategies can be used to mine the 
extensive data for biologically relevant signals. The fact that there is no agreed 
upon gold standard tool for driver prediction is sometimes reported as a 
criticism283. However, the assumption that there can be a perfect method which can 
capture the complexity of biological systems to comprehensively detect drivers is 
highly unlikely, as discussed below. On the contrary, the different methods for 
driver prediction described above can actually be an advantage as different models 
and methods have complementary strengths and weaknesses. This allows the 
selection of a method or methods which best address the question being asked and 
the biological data available to answer it. This is caveated by the requirement that 
the results of a driver prediction analysis should ideally serve as a starting point, 
where predictions are rigorously validated in biological systems. This is imperative 
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given the importance of biological context in determining driver status and driver 
function, as discussed above.  
There is an increasingly pervasive impression across many academic disciplines 
that the combination of exponentially larger datasets with more sophisticated 
modelling and machine learning approaches will gradually solve most problems 
involving complex, non-linear systems284. This is unlikely due to the inherent 
limitation that the biological and statistical models upon which prediction tools are 
built cannot recapitulate the complexity of biological systems  which are 
themselves incompletely understood. Despite the impressive range and 
sophistication of driver prediction algorithms269, trade-offs, biases, and 
inaccuracies are always present; even with machine learning, the output of such 
tools are still correlative an independent of mechanistic biology284,285. This is 
evident in the diversity of biologically rational strategies found in driver prediction 
algorithms and mirrored in the divergent results each produce. This is not a 
criticism of big-data-centric biology, which has resulted in unprecedented rates of 
progress in understanding biological systems. However, this is an 
acknowledgement that a deep mechanistic understanding of biological processes 
and complexity through classical reductionist approaches must continue to be 
thoroughly embraced so as to best reap the rewards of this exciting golden age of 
data-driven cancer genetics.  
In the present study, a combination of big data analysis and in vivo experimental 
screening is used to identify novel drivers of iCCA. These are subsequently shown 





The long tail of infrequently mutated genes in iCCA contains drivers which may act 
alone to induce cholangiocarcinogenesis or may act with more common drivers to 
modify the tumour phenotype. Combining computational driver prediction and in 
vivo screening will allow the identification of such rare drivers, and the contexts 
they operate in.  
1.7 Aims 
 
• Define a set of predicted drivers through computational driver prediction 
using currently existing tumour sequencing cohorts. 
• Develop a method for simultaneously screening predicted drivers in vivo to 
identify novel high-confidence drivers.  
• Validate high-confidence drivers, the contexts they operate in, and their 









Chapter 2 Materials and Methods 
2.1 Cloning of single sgRNAs 
 
Single sgRNAs used in Chapter 4 were cloned into either the LentiGuide-Puro or SB-
CRISPR plasmids. LentiGuide-Puro was bought from Addgene (plasmid number 
#52963) and SB-CRISPR was acquired from our collaborator, Professor Roland Rad 
(Technical University of Munich, Germany), who’s lab originally generated and 
published the plasmid286. Oligos encoding sgRNAs against loxP, Apc, Plxnb2, Trp53, 
Plk1, Fh1, Rnf31, Nf2 or non-targeting controls (‘0007’) were cloned into the 
backbones as follows.  
sgRNA Mouse GeCKOv2 Library ID 5'->3' Sequence  
loxP N/A CGAAGTTATATTAAGGGTTC 
0007 MGLibA_66412 ATTGTTCGACCGTCTACGGG 
Apc_1 MGLibA_04599 GGATCTGTATCCAGCCGTTC 
Apc_2 MGLibA_04600 GACTTACTAGAGCGTCTTAA 
Apc_3 MGLibA_04601 AGATCCTTCCCGACTTCCGT 
Trp53_1 MGLibA_56033 AGTGAAGCCCTCCGAGTGTC 
Trp53_2 MGLibA_56034 AACAGATCGTCCATGCAGTG 
Trp53_3 MGLibA_56035 TGAGGGCTTACCATCACCAT 
Fh1_1 MGLibA_18403 AATTGGGCGAACTCACACGC 
Fh1_2 MGLibA_18404 CGTGTAGAGTTCGACACCTT 
Fh1_3 MGLibA_18405 AAAATCCAAAGAGTTTGCGC 
Plxnb2_1 MGLibA_41608 CTCAGATGGCCGGATCCTTA 
Plxnb2_2 MGLibA_41609 TACTCTGCAGAAGTGCCGTC 
Plxnb2_3 MGLibA_41610 GGAGTCACGACACTGAGCGC 
Nf2_1 MGLibA_33838 GATCCGCACCGTGAATGTCT 
Nf2_2 MGLibA_33839 GAAGCTCATGCGAGAAGCGA 
Nf2_3 MGLibA_33840 CTTGGCGTCATATGCTGTCC 
Rnf31_1 MGLibA_45954 CATACAACCGTAGTACATCC 
Rnf31_2 MGLibA_45955 AGGGTGGCCGGGATGTACTA 
Rnf31_3 MGLibA_45956 TAACCCCGTCTTTCGCAGCA 
Plk2_1 MGLibA_41524 CAGAAGTCCGATACTACCTC 
Plk2_2 MGLibA_41525 AAAACTGCACGACATGCTTA 
Plk2_3 MGLibA_41526 ACGAACAAGAAATCTTGCAC 
Table 2.3.1 sgRNA sequences for single-guide cloning  
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The LentiGuide-Puro or SB-CRIPSR backbone was digested with Esp3I (New 
England Biolabs; R0734S) or BbsI (New England Biolabs; R3539S), respectively, to 
produce staggered ends, with simultaneous dephosphorylation using FastAP 
Thermosensitive Alkaline Phosphatase (ThermoFisher Scientific; EF0654) to 
prevent backbone re-closure during ligation. Plasmid digestion products were size 
separated by gel electrophoresis in 2% agarose gel for 45-60 minutes at 120V 
(constant), and extracted/purified (Zymoclean Gel Recovery Kit, Zymo Research; 
D4008). sgRNA oligos were annealed and simultaneously phosphorylated with T4 
Polynucleotide Kinase (New England Biolabs; M0201S) for 30 minutes at 37oc. 
Ligation of plasmid backbone and insert was carried out at 16oc overnight with T4 
ligase (New England Biosciences; M0202S). Ligation reactions were heat-
inactivated and transformed into Stbl3 cells as per the manufacturer’s instructions 
(One Shot Stbl3 Chemically Competent E.coli; ThermoFisher Scientific; C737303) 
and grown on Luria Broth agar at 37oc overnight. Sanger sequencing of colonies 
(MRC Human Genetics Unit Technical Services) identified those with correctly 
ligated plasmids which were subsequently picked, cultured and extracted as maxi-
prep’s as per the manufacturer’s instructions (QIAfilter Plasmid Maxi Kit, QIAGEN; 
#12263). Plasmid yield was assessed on the NanoDrop ND-1000 Spectrophotometer 
(ThermoFisher Scientific). 
2.2 CRISPR/Cas9 Screening Library Generation 
 
Oligonucleotides encoding sgRNAs targeting the set of predicted drivers were 
designed using spacer sequences from the mouse GeCKo V2 library287 with the 
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Python script supplied in the corresponding paper288 (see Appendix 1 for all sgRNA 
sequences). Library-specific PCR retrieval arms were derived from the protocol for 
parallel oligonucleotide retrieval published by the Luo lab289.  Table 2.3.1 and 2.3.2 
show the general schematic for both libraries, and the primers for specific library 
amplification, respectively.  
 
Table 2.3.1 Oligo schematic for library pool synthesis 
 
Table 2.3.2 Primers for amplifying individual libraries from starter pool 
Complete sgRNA oligos for all target genes and control sequences were custom 
synthesised by Twist Biosciences. Library-A and library-B oligos were amplified 
from the custom oligo pool  separately with 22 cycles on a thermocycler with PCR 
reagents (NEBNext HF PCR MasterMix, New England Biosciences; M0541S). 
Products were purified using the QIAquick Nucleotide Removal Kit (QIAGEN; 
#28304). Purified oligos were then digested with Esp3I and phosphorylated as per 
the single sgRNA cloning procedure above. Digested inserts were purified from the 
reaction by isopropanol precipitation. For each library, this process was repeated 
for 3 technical replicates, which were then pooled together per-library before 
ligation into the SB-CRISPR plasmid backbone. This was to ensure that all oligos 
were present in excess to limit biasing the library downstream. Ligation of inserts 
into digested SB-CRISPR was carried out in 3 technical replicates which were ligated 
Lib Forward Primer-Binding Arm 5' Esp3I cut site 5'->3' Sequence 3' Esp3I cut site Reverse Primer-Binding Arm
A GCACAGTTTCACGATCGCTTTAGC CGTCTCACACCG N(20) GTTTTGAGACG CTGTCGTGGAATCGCTAAAGCAAG
B ACGTGGATGCTAGTGCGGAGTTTA CGTCTCACACCG N(20) GTTTTGAGACG TAGCGTATGACGGCGTTCTGCTAT





overnight at 16oc with T4 ligase as above and then pooled together. Transformation 
of ligated products into Stbl3 was carried out for 10 technical replicates, once again 
to ensure unbiased and complete library representation. Transformants were 
grown overnight at 37oc on Luria Broth agar in 500cm2 square plates 
(ThermoScientific Nunc Square Culture Dish; #UY-01929-00).  All colonies were 
scraped into flasks and cultured for a further 6 hours in LB at 37oc before being 
pelleted and maxi-prep’d. Resultant libraries underwent amplicon sequencing to 
determine the representation and evenness in sgRNA sequences. sgRNA inserts 
were PCR amplified with primers targeting the sequence before and after the insert 
site. This step also served at add MiSeq (Illumina) flow-cell adaptors, variable 
length random sequences to increase sequencing library complexity, and index 
sequences for multiplexed sequencing. Sequencing quality control, sgRNA 
quantification, read coverage and Gini coefficients were generated from 
unprocessed FASTQ files using the MAGeCK-VISPR software290.  
2.3 Lentivirus Generation 
 
Lentiviruses for delivery of LentiCas9-Blast (Addgene #52962), dCas9, or 
LentiGuide-Puro-sgloxP and -sg0007 (non-targeting control) to biliary organoids 
were made as follows. Lentiviral vector mix was made by combining 7.5µg of PAX2 
helper vector (Addgene #12260), 2.5g of pCMV-VSV-G envelope plasmid (Addgene 
#8454), and 10µg of lentiviral vector in 500µl Advanced Dulbecco’s Modified Eagle 
Medium (ThermoFisher Scientific; #12491015).  This was added to a mix of 425µl 
DMEM and 75µl 1mg/ml polyethylenimine (PEI linear, 25K molecular weight, 
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Polysciences Inc.; 23966-1). This combined mixture was added to HEK293 cells 
which were cultured overnight. The following day media were collected and 
lentivirus was concentrated using the Lenti-X lentiviral concentrator (Takara; 
#631232) and titrated to determine concentration using the Lenti-X qRT-PCR 
Lentivirus Titration Kit (Takara; #631235).  
2.4 DNA and RNA extraction from tissue 
 
Both DNA and RNA extraction protocols begin with 50-100mg of snap frozen tissue. 
DNA was extracted from tissue using the DNeasy Blood and Tissue Kit (QIAGEN; 
#69504) as per the manufacturer’s instructions. RNA was extracted by placing the 
tissue into 500µl TRIzol RNA Isolation Reagent (Invitrogen; #15596026), which was 
then homogenized for 3-10 minutes with a steel bead in the Qiagen TissueLyser LT 
(QIAGEN; #69980) depending on the toughness of the tissue (tumours were very 
stromal and solid compared to control liver, for example). To this, 100µl chloroform 
was added and the sample was centrifuged at 12,000 RPM at 4oc for 15 minutes. The 
clear upper fraction was decanted into a fresh tube and an equal volume of 
isopropanol was added. This was then processed using the RNeasy Mini Kit 
(QIAGEN; #74104) as per the manufacturer’s instructions from step 5 of the protocol 
onwards. For downstream sequencing applications DNA and RNA quality (RIN 
score) was quantified using the Agilent 2100 Bioanalyzer with either the DNA 1000 
chip, or RNA 6000 chip (MRC Human Genetics Unit Technical Services).  A minimum 
RIN threshold of 8 was used for RNA-seq.  
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2.5 Real-Time Quantitative PCR   
 
1µg of RNA was reverse transcribed into cDNA using the QuantiTect Reverse 
Transcription Kit (QIAGEN; #205311). RT-qPCR was subsequently performed using 
the LightCycler 480 SYBR Green-1 Master Mix (Roche; #04707516001) on the 
LightCycler 480 machine (Roche). Primers against Cas9 were designed and 
validated using NCBI Primer Blast by Nerea Galdona Yeregui, a Master’s student I 
co-supervised in the lab. Primers targeting housekeeping genes peptidylprolyl 
isomerase A (PPIA) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were 
from the QIAGEN QuanitiTect Primer Assay Library. Each sample was assayed in 
triplicate for each gene to be quantified, and DNase/RNase-free water was used as 
a control. Quantification and calculation of expression fold change was carried out 
using the double delta Ct method29 .  
Gene Forward Primer Reverse Primer 
Cas9 AAAGACCGAGGTGCAGACAG ACCACCAGCACAGAATAGGC 
PPIA Mm_Ppia_1_SG QuantiTect Primer Assay (#QT00247709) 
GAPDH Mm_Gapdh_1_SG QuantiTect Primer Assay (#QT00199388) 
Table 2.6.1 sequences and assays for qPCR 
2.6 Exome Sequencing of Mouse Tumours 
 
DNA was extracted from tumours and one normal liver as described above and 




2.7 Transcriptome Sequencing of Mouse Tumours 
 
RNA was extracted from tumours and one normal liver as described above. Total 
RNA sequencing with ribonucleotide depletion, but without PolyA enrichment, was 
carried out by the Wellcome Trust Clinical Research Facility. This modality was 
chosen over polyA enrichment so as to capture non-coding RNA species. 
2.8 Generation of R26mT/mG (d)Cas9-expressing Bile Duct 
Organoid lines and Lentiviral Transduction.   
 
Livers were perfused with phosphate buffered saline and dissected out of R26mT/mG 
mice. The livers were minced into ~1mm2 chunks which were then digested in 
digestion media (100ml organoid base media with 12.5mg collagenase XI (Sigma; 
#C9407) and 12.5mg dispase II (Gibco; #17105-041)) for 4-6 hours with frequent 
agitation. Bile duct fragments were picked and washed in PBS before being 
suspended in Growth Factor-Reduced Matrigel (Corning; #356252) and plated in 12-
well sterile culture plates (Cellstar, Greiner Bio-One; #665-180) and immersed in 
organoid media. After several days, organoids were passaged and subsequently 
expanded for 2-3 further passages before being scraped from the plates and 
incubated in ice cold versene for 30 minutes at 4oc. This served to dissolve the 
Matrigel. The organoids were washed 3 times in ice cold PBS and fragmented with 
a pipette. A layer of Matrigel was spread to cover the bottom of the wells in a pre-
warmed 6-well culture plate and left to polymerise. 500µl of organoid growth factor 
media was mixed with either 0.2µl, 0.5µl or 1µl of Cas9 or dCas9 lentivirus and 2.5µl 
TransDux transduction reagent (System Biosciences; #LV850A-1). Organoid 
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fragments were pelleted and the supernatant was removed before pellets were 
resuspended in the lentiviral mixture and plated on the Matrigel lawn. After 
overnight incubation the lentivirus/media mix was removed and the surface was 
washed with PBS to remove dead cells before a layer of Matrigel was overlain to 
allow the organoid fragments to re-form organoids. Passaging with puromycin 
selection produced a Cas9 or dCas9-expressing organoid line, as confirmed by 
qPCR. Transduction of organoids with sgRNAs for mT/mG locus editing was 
performed as above with LentiGuide-Puro-sgloxP/-sg0007 lentiviral particles.  
Component Volume  
Advanced DMEM/F12 500ml 
Penicillin/Streptomycin  5ml 
HEPES (1M) 5ml 
Glutamax (100x) 5ml 
Supplement  Concentration 







B27 (without Vitamin A) 20ul/ml 
ROCK inhibitor (Y-27632) 2ul/ml 
Forskolin 1ul/ml 
TGFβ inhibitor (A83-01) 0.5ul/ml 
Gsk3β inhibitor 
(Chir99021) 0.3ul/ml 
Recombinant Wnt3a 1ul/ml 
Table 2.9.1 Organoid Growth Media 
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2.9 Mouse Hydrodynamic Tail Vein Injections 
 
Animal work was carried out primarily by Dr Luke Boulter as I do not hold an 
animal licence. 20ug NICD plasmids, RASG 2 plasmids, and SB-CRISPR-library/single-
sgRNA plasmids were injected per mouse. 6ug SB13 transposase plasmid was 
injected per mouse. Plasmids were delivered over the course of 7-10 seconds 
through the tail vein. 
2.10 Tissue Collection and Processing 
 
After culling, livers were perfused with PBS through the inferior vena cava with 
drainage through the hepatic portal vein, and subsequently dissected out of mice. 
Livers were photographed. When present, tumours were dissected out of livers 
and, if large enough, were cut into 3 equal sections for histology, DNA, and RNA 
extraction. DNA and RNA extraction were prioritised over histology when tumours 
were small. Tissue for DNA was snap frozen in 2-methylbutane chilled on dry ice 
and subsequently stored at -80oc. Tissue for RNA was perfused overnight in 
RNAlater (ThermoFisher Scientific; #AM7020) at 4oc before being stored at -80oc. 
Tissue for histology was fixed in 4% formaldehyde (VWR Chemicals; #9713.5000) 
for 24 hours before being transferred to 70% ethanol for a minimum of 24 hours. 
Tissue was then perfused (Tissue-Tek VIP 5 Jr.) and mounted in paraffin (Tissue-






Sections were dewaxed in 100% xylene for 5x2 minutes and rehydrated through a 
series of solutions of decreasing ethanol concentrations (100%, 75%, 50%, 25%) for 
5 minutes each before being placed in water for 15-20 minutes. Following antigen 
retrieval samples were cooled in gently running cold water for 10 minutes and 
washed in 3x5 minute PBS washes.  Samples were then incubated at room 
temperature for 15 minutes in 3% hydrogen peroxide and washed for 3x5 minutes 
in PBS before being mounted on coverplates (Thermo Scientific Shandon Plastic 
Coverplates; #72110017) and placed in Sequenza racks (VWR; #10129-584). 
Endogenous avidin binding sites, biotin, and biotin receptors were blocked with an 
avadin/biotin blocking kit sequentially for 15 minutes at room temperature 
(Avadin/Biotin Blocking Kit, Vector Laboratories; SP-2001). Non-specific staining 
was decrease by protein blocking for 30 minutes at room temperature with a pan-
species protein block (Agilent-Dako; X090930-2). Primary antibodies were diluted 
in antibody diluent (Antibody diluent, Life Technologies, ThermoFisher Scientific; 
#00-3218) and incubated overnight. Following 3x5 minute PBS washes, biotinylated 
secondary antibody was diluted in antibody diluent and incubated with the 
sections for 30 minutes. Horseradish peroxidase was conjugated to the secondary 
using the VECTASTAIN ABC HRP system (Vector Laboratories; #PK-4010) and DAB 
detection was performed by incubating the slides for 3-5 minutes with DAB 
chromogen (DAB Quanto Chromogen and Substrate, ThermoFisher Scientific; TA-
060-QHDX). Slides were counterstained with Harris haematoxylin and developed 
with Scott’s tap water before being dehydrated through increasing alcohols (as 
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above, in reverse) and cleared for 10 minutes in xylene. Slides were mounted with 
DPX (CellPath; SEA-1304-00A). 
 
Table 2.11.1 Antibodies and their antigen retrieval conditions. 
 
Computational Methods 
Unless otherwise stated, analyses were conducted using the Eddie Mark 3 High-
Performance Compute Cluster running Scientific Linux 7 (‘Eddie3’) at the 
University of Edinburgh or a MacBook Pro with 2.2 GHz Intel Core i7 processor and 
16 GB memory running macOS versions 10.xx.xx (‘desktop’).  
2.12 Statistical Analysis  
 
All statistical analyses were conducted using either R versions 3.0  3.6, or 
GraphPad Prism 7 on a desktop. 
Antigen Antigen Retrieval Primary Antibody Secondary Antibody 
Pan-Cytokeratin Sodium Citrate DAKO (Z0622); 1:300 Biotinylated anti-rabbit
Cytokeratin 19 Sodium Citrate DSBH (AB2133570); 1:200 Biotinylated anti-rat
Collagen I Sodium Citrate Southern Biotech (1310-01); 1:1000 Biotinylated anti-goat
Collagen VI Sodium Citrate Merck (HPA045239-100UL); 1:100 Biotinylated anti-rabbit
Pan-Fibronectin Sodium Citrate AbCam (Ab2413); 1:200 Biotinylated anti-rabbit
⍺-Smooth Muscle Actin Sodium Citrate Sigma (A5228); 1:2000 Biotinylated anti-mouse
F4/80 Proteinase K AbCam (Ab6640); 1:400 Biotinylated anti-rat
Foxp3 Sodium Citrate Invitrogen (FJK-16s); 1:500 Biotinylated anti-rat
MPO Sodium Citrate AbCam (Ab9535); 1:100 Biotinylated anti-rabbit
GFP Tris-EDTA Santa Cruz (sc-8334); 1:500 Biotinylated anti-chicken
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2.13 Published Exome-seq Data Acquisition 
 
Exome-seq FASTQ files from Chan-on et al. 68 were downloaded from the European 
Nucleotide Archive with accession PRJEB4445. Exome-seq FASTQ files from Sia et 
al.222 were downloaded from the Gene Expression Omnibus Database with 
accession GSE63420.  TCGA BAM files were downloaded from the Genomic Data 
Commons after receiving access to individual patient BAM files.  
2.14 Mutation Calling 
 
For the TCGA, Chan-On, and Sia datasets, mutations were called as follows. Input 
FASTQ files were aligned to the Hg19 reference genome using Burrows-Wheeler 
Aligner292 version 0.7.15. PCR and optical duplicates were marked using Picard 
MarkDuplicates version 2.5.0, base quality score recalibration was carried out 
using BaseRecalibrator and local indel realignment was performed with 
IndelRealigner (both from the Genome Analysis Toolkit293 version 3.6 (GATK3)). 
Ensemble variant calling was performed with Mutect278 (1.1.5), Mutect2 (2.1), 
Freebayes294 (1.0.2.29), Vardict-java295 (1.4.6), and Varscan296 (2.4.2) and all passing 
somatic variants which were identified by 2 or more algorithms were taken 
forward. The above analysis was batched and implemented within the Blue Collar 
Bioinformatics pipeline (bcbio-nextgen 1.0.0a0-af4730e). TCGA data were input as 
reads which were aligned to the Hg38 reference so, following mutation calling, 
variants were re-mapped using Picard LiftoverVCF (2.5.0) using the Hg38toHg19 
chain file provided by UCSC. Variant annotation was performed with the Ensembl 
Variant Effect Predictor297 (v88) using the ‘--pick’, ‘--tab’, and ‘--symbol’ options.  
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2.15 Driver Prediction with IntOgen-Mutations 
 
IntOgen-mutations275,276,298,299 was installed on Eddie3 by creating a virtual 
environment with Anaconda (4.3.1). The Anaconda environment was created with 
the following packages to run IntOgen-mutations: 
 






































Additionally, MutSigCV300 (1.3.01) was installed with its Matlab Runtime/Compiler 
dependency (Matlab MCR 9.0.1v901) and integrated into the IntOgen-mutations 
pipeline as per the IntOgen documentation (bitbucket.org/intogen/intogen-
pipeline/scr/master/). IntOgen was run on each published/TCGA cohort 
individually, and then all combined. Significance thresholds for OncoDriveFM and 
OncoDriveCLUST were q=0.05, and q=0.1 for MutSigCV as per the default 
recommendations. The minimum frequency of occurrence for a gene to be 
considered for analysis was n=2 for OncoDriveFM and n=5 for OncoDriveCLUST.  
2.16 Assigning Mutational Signatures 
 
The DeconstructSigs30  package was used in R to infer mutational processes active 
in samples which had a number of mutations out-with the 3rd quartile for that 
cohort’s mutation distribution. Samples in this set with predominant mutational 
signatures302 linked to hypermutator processes were removed.  
2.17 Functional Interaction Inference  
 
Cytoscape28  (3.7.1) with the ReactomeFIVis303 app was used to build a network of 
known and inferred functional interactions between the set of predicted drivers so 
as to explore the relationship between them in a cellular context. This network was 
clustered into modules by connection density and each module was annotated with 




2.18 CRISPR/Cas9-editing validation and Structural Variant 
Analysis 
 
DNA was extracted from FASTQ files from exome-sequencing of tumours arising 
from the RASG 2-library screens were aligned to the FVB mouse reference genome; 
subsequently, indels within 50bp upstream or downstream of sgRNA target sites 
called. This was done by the IGMM Bioinformatics Core (Dr Alison Meynert). The 
following was done by me. 
To determine if indels were likely due to Cas9 activity or were spurious mutations, 
the interval of each indel was observed on the FVB genome using Integrative 
Genomics Viewer304, and overlain with sgRNA library-A/B binding sites. Indels with 
start or end sites out-with sgRNA targets were removed, although this was only the 
case for 5 indels across all samples.  
To determine if editing had induced structural rearrangements, structural variants 
(SVs) were called using Delly2305 (v0.7.9) as follows: all reads which had a minimum 
mapping quality of 20 were used to call germline and somatic SVs, SVs with a PASS 
flag for somatic status, had a minimum variant allele fraction of 0.15, had zero read 
support in the normal, and had precisely mapped breakpoints were then visually 




2.19 Transcriptome Sequencing Analysis  
 
Analysis of RNA-seq data from tumours was done by the IGMM Bioinformatics Core 
(Dr Graeme Grimes) to produce PCA plots and differentially expressed gene sets. 
Volcano plots were made by me.  
2.20 Functional Enrichment Analysis, Clustering, and 
Heatmaps 
 
Driver gene and differentially expressed gene functional enrichment was done 
using g:Profiler306. For differentially expressed genes the set was analysed as an 
ordered query ordered by q-value. Enrichment for Gene Ontology279,307 Molecular 
Function, Biological Process, and Cellular Component terms was carried out, along 
with KEGG308 and Reactome282 pathway enrichment, enrichment for transcription 
factor binding sites using TRANSFAC309 and enrichment for miRNA interactions 
using miRTarBase3 0.  
Dendrograms and heatmaps were generated in R using the Pheatmaps package 
(https://cran.r-project.org/web/packages/pheatmap/index.html) with base R hclust 
‘complete’ clustering on row and column Euclidean distance matrices. 
2.21 Figures 
 
Individual figures were largely made using the R packages ggplot23 , Pheatmap, 
and EnhancedVolcano (DOI:10.18129/B9.bioc.EnhancedVolcano), or GraphPad 
Prism 7 or Affinity Designer. All figure layouts were assembled in Affinity Designer. 
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Where possible, the colour-blind optimised Viridis palette (https://cran.r-


















Chapter 3 Re-analysis of existing sequencing 
data uncovers a novel set of 
candidate driver genes 
3.1 Introduction 
 
The proliferation of exome sequencing (exome-seq) studies in iCCA has provided a 
rich source of data which can be mined for biologically relevant signals. In this 
chapter the set of published exome-seq resources are curated and harmonised into 
a unified set which is subsequently used for driver prediction. A literature search 
identified three driver prediction tools which had complementary strengths and 
weaknesses and were well suited for the data and question being asked. Using these 
on the combined input set identified common, known iCCA drivers, as well as a 
large set which are found at low frequency in the patient population. 
3.2 Hypothesis 
 
Candidate low-frequency iCCA driver genes can be identified from published 
exome-sequencing cohorts using complementary driver prediction methods. 
3.3 Aims 
 
• Identify and characterise suitable sources of iCCA exome-sequencing data 
from published studies and data repositories.  
• Identify and apply suitable methods for identifying candidate driver 
mutations which do not rely on mutation frequency alone. 
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3.4 Existing data sources capture key epidemiological 
trends  
 
Published exome-seq studies have used cohorts of various sizes (range:8-239) to 
explore questions in biliary tract cancer genetics 64, 65, 68,209,222. To best utilise the 
existing data, datasets from the sources listed in table 3.4.1 were reviewed to 
characterise the demographic and clinical characteristics of the samples. This 
made use of both individual published cohorts and data generated as part of the 
agglomerative project The Cancer Genome Atlas (TCGA) and identified a set 
suitable for inclusion in subsequent driver prediction analysis. 
 
 
Table 3.4.1 The five sources of exome-seq data used in the present study. TCGA 
data are accessed from the repository. Filtering for correct subtype, fluke, HBV/HCV 
integration, and PSC status, and hypermutation status reduces the total input to 
277.  
 
The Nakamura 65, TCGA, and Chan-On 68 data contained a mix of iCCA, extrahepatic 
cholangiocarcinoma (eCCA) and gall bladder carcinoma (GCA), and samples of the 
latter subtypes were excluded. As discussed in the Introduction, the risk factors 
associated with iCCA are varied and incompletely understood. Because the link 
between fluke infection and iCCA development is the best characterised out of 
known risk factors, the decision was made to remove samples with reported fluke 
involvement. This was deemed appropriate as the aim of this study was the 
Study PubMed ID Sample Size Subtype Samples After Filtering
Nakamura 26258846 239 iCCA, eCCA, GBC 125
Zou 25526346 103 iCCA 96
TCGA N/A* 51 iCCA, eCCA, GBC 39
Chan-on 24185513 15 iCCA, eCCA 9
Sia 25608663 8 iCCA 8
*see Farshidfar et al.  for analysis on a TCGA subset 416 277
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identification of novel drivers in ‘spontaneous’ disease: those cases without a clear 
and established predisposing risk factor. As such, a single sample with reported 
PSC was also removed as this is another well-defined risk factor. 
Samples with less strongly associated risk factors such as alcohol consumption, 
tabaco exposure, and anti-HBV/HCV antibody reactivity were not excluded except 
in one case where HCV tumour genome integration was confirmed in the 
respective study.   
Generally, across studies there were incomplete clinical and demographic 
metadata associated with each patient, and the types of metadata which were 
reported varied between sources (Fig 3.1). In some instances, basic variables such 
as sex, age, and ethnicity were not reported. This may be the result of stipulations 
made by ethics boards regarding patient anonymity and/or due to the irrelevance 
of reporting such clinical or demographic data to the goals of the respective studies.  
The combined sample set had a preponderance towards male patients without any 
reported known risk factors. The age-at-diagnosis frequency distribution is centred 
around a mean whole-number age of 57 years (range: 29-86), which differs 
significantly from the peak incidence of the 7 h decade reported in recent 
epidemiological studies26 (P<0.0001, one-sample t-test). HCV and HBV are present 
in a proportion of the patients as would be expected due to their association with 
iCCA: a greater percentage of samples have HBV than HCV and this likely reflects 
the endemic status of this virus in parts of Asia 26, where most of the studies were 
carried out. Smoking and alcohol consumption are not recognised as strong risk 
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factors and this is reflected in their low incidence here: 6.12% and 3.60%, 
respectively. Overall, the combination of samples currently available from already 
published studies constitutes a set that closely captures key epidemiological trends 
regarding age, ethnicity, sex, and risk factors.  
One key consideration which should be highlighted is that in contrast to other 
cancer types  such as oesophageal, colorectal, leukaemia and lymphoma  iCCA 
and liver malignancies generally are not easily accessible without surgical 
procedures. As such, all of the samples included here were collected in their 
respective studies as a by-product of surgery with curative intent. No samples were 
reported to have been taken post-mortem or otherwise out-with the context of 
surgical resection. A consequence of this is that all current sequencing data for iCCA 
is representative of only the small minority of iCCA patients who meet the criteria 
for resection. Subsequently they may be unintentionally enriched for less 
aggressive tumours without extensive vascular or lymph node involvement, or that 
were detected early (a possible explanation for the lower than expected average 
age in the cohort). This is a challenging problem to overcome and has yet to be 





Figure 3.4.1 Demographic and clinical attributes of the combined cohort: A-G 
shows the proportion of each clinical attribute in the combined cohort; notably 
there is a lot of missing data which are not reported in the respective publications. 
H, distribution of ages of patients in the pooled cohort, the average is centred 
around 57 years  younger than the average age at diagnosis in larger 




3.5 Data harmonisation produces a unified mutation set 
for driver prediction 
 
Sequencing data from each source were available in various formats and at various 
stages of processing. Ideally, data would be acquired as raw sequencing reads with 
little to no processing. This would aid in data harmonisation between the different 
sources by allow maximum control over bioinformatic processing thus limiting 
factors affecting the number of mutations called to library preparation and 
sequencing variables (DNA quality, exome capture probes used, depth of coverage, 
sequencing platform, etc.). In reality however, this was not possible as raw reads 
were not readily available for all samples. Sequencing reads from the Zou 64 dataset 
were accessible on the Short Reads Archive (SRA) however the correspondence 
between files and biological samples, and between tumour and matching normal 
reads was not self-evident, nor was it explained in the publication or its 
supplementary data. Repeated attempts to gain clarification from the authors 
through personal communication proved fruitless. Sequencing reads from the 
Nakamura dataset were available through the International Cancer Genome 
Consortium (ICGC), however, at the time of the present analysis the complete set of 
raw reads corresponding to the iCCA samples reported in the paper were not 
accessible (at the time of writing the complete data are now available). To expedite 
the analysis in light of the above issues the decision was made to derive mutations 
from the publications’ supplementary data.  
The mutations reported for the above studies had undergone stringent filtering and 
only high-confidence single nucleotide variants (SNVs) or small insertions or 
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deletions (indels) were reported. For each set, single nucleotide polymorphisms 
found in dbSNP were removed if present and the remaining mutations were 
converted into a format suitable for downstream analysis using Python 
programming. 
For the Sia222, Chan-On, and TCGA samples, data were available as either unaligned 
sequencing reads (FASTA format) or aligned reads (BAM format) and in those cases 
mutations were called using an in-house pipeline (Materials and Methods).  
 
Table 3.5.1 Data format and statistics of mutations in exome-seq sources 
 
The average number of mutations differed between sources and the reason for this 
is not entirely resolvable but is likely explained in part by the in-house mutation 
calling strategy. The in-house analysis employed a pipeline with an ensemble 
mutation calling step wherein mutations were called using 5 different algorithms. 
Mutations which were independently called by 2 or more methods whilst passing 
their internal filters for somatic mutations were carried forward for driver 
prediction. In contrast with the Nakamura and Zou mutations, there was no hard 
filtering to minimise false-positives after initial calling. The goal of this 
computational analysis was not to derive a list of very high-confidence mutations, 
but to provide input for a pipeline which ultimately undergoes experimental 
validation. The expectation with this strategy is that false-positive calls present at  
Study Data Format Mean muts/sample Min-Max
Nakamura Supplementary 330 10 - 6119
Zou Supplementary 70 1 - 1268
TCGA BAM 977 416 - 7868
Chan-On FASTA 400 272 - 549




Figure 3.5.1 Data processing pipeline. The data were batch processed such that 
FASTQ files were aligned to Hg19 reference genome before undergoing pre-
processing to correct for artefacts and systemic effects. Mutations were then 
called by 5 algorithms and those mutations which were identified by 2 or more 
algorithms were taken forward for driver prediction. See Materials and Methods 
for details.   
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this stage  and which may be propagated through the driver prediction steps  will 
be lost during functional screening if they are not relevant to tumour initiation or 
progression. The advantage of this approach is that mutations which recurrently 
arise later in tumour evolution and are present subclonally will be retained 
whereas they may normally be lost due to hard filtering on read depth or variant 
allele frequency. The identification of subclonal mutations relies on very high 
depth sequencing3 2 which has not been reported in iCCA, however this more 
relaxed approach to mutation filtering may retain genuine subclonal drivers 
lacking traditionally adequate read support and allow them to emerge during 
experimental screening.   
Whilst this may account for the discrepancy between the in-house sets and the 
supplemental sets it does not explain the large difference in average between the 
Sia/Chan-On sets and the TCGA set. These 3 sets were processed with the same 
pipeline with the exception of an additional step for TCGA samples. The original 
aligned reads from TCGA were aligned to the GRCh38 reference genome but 
mutation coordinates were converted to the GRCh37 release to aid in data 
harmonisation with the other sources and compatibility with downstream 
analyses. This step produced no error or unexpected outcome, and visual 
inspection of 50 randomly selected mutations using UCSC Genome Browser 
confirmed that this had been successful. The only other variable which may 
explain the discrepancy is read depth and coverage being substantially greater in 
TCGA samples compared to the Sia and Chan-On samples. Explicit sequencing 
metrics were not reported in the latter studies and given their small size it may be 
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reasonable to assume that sequencing depth was lower than in TCGA samples 
although this cannot be confirmed. 
The above bioinformatics workflow harmonised data for input to subsequent 
analyses by calling mutations using a common framework where possible, and by 
recording mutations for each sample in a common format and with coordinates 













3.6 Identification of a suitable driver prediction strategy 
 
In each of the publications from which the data were derived, attempts were made 
to identify genes with potential relevance to disease initiation or progression. This 
problem was approached using different strategies: identification of significantly 
mutated genes with 65 and without 68 correction for sample or gene-specific 
mutation rates; integrative multi-omics analysis209; and functional effect 
prediction222. As discussed in the Introduction different methods have their 
strengths and weaknesses and there is no gold standard: disease relevance 
suggested by any method should ideally be a starting point for hypothesis 
generation and experimental investigation. In the absence of a gold standard tool 
a literature survey of published methods was carried out. Three complementary 
methods were chosen which were best suited to the characteristics of the dataset, 
the biological question being explored, and the experimental approach being 
employed.  
To identify significantly mutated genes the widely used MutSigCV300 tool was 
chosen. This method was developed specifically to reduce the false-positive rate 
when deriving SMGs from large cancer sequencing cohorts, so was appropriate for 
the sample size of 277 used here. It corrects for sample-specific mutation rates, as 
well as mutation rates varying across different regions of the genome. Because it 
assesses mutational frequency at the sample level as opposed to the gene level (i.e. 
x number of samples carry a mutation in gene y, as opposed to gene x carries y 
number of mutations), its power to detect SMGs scales strongly with cohort size.  
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To compliment this approach, two gene level prediction algorithms were also 
selected: OncodriveFM275 and OncodriveCLUST276. These tools were created to 
address problems with frequency-based approaches so are therefore less depended 
on sample size. They analyse any gene with at least 2 or 5 mutations, respectively, 
regardless of how many samples those mutations are distributed across.  
OncodriveFM was developed to identify lowly recurrent drivers so is particularly 
suited for the question at hand. It operates on the assumption that if a gene shows 
a bias towards harbouring functionally detrimental mutations this indicates that 
loss of function is being selected for during tumour evolution  a pattern indicative 
of a tumour suppressor gene. 
Lastly, OncodriveCLUST was developed to overcome limitations of both frequency-
based and functionality-based methods; it focuses instead on spatial clustering of 
non-synonymous mutations around specific residues along the amino acid 
sequence. It is therefore best suited for predicting putative neomorphic mutations 
which often show this pattern of distribution.    
Whilst the power and accuracy of the latter methods inevitably increases with 
cohort size, the metric being assessed for each is not frequency of occurrence as is 
seen in MutSigCV. For OncodriveFM the relevant derived metric is the ratio of 
functionally detrimental mutations to functionally benign mutations in a given 
gene; for OncodriveCLUST the spatial distribution of non-synonymous mutations 
is compared against a null model of the distribution of synonymous mutations 
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derived from each gene in the input. With this in mind these three methods were 
chosen for driver prediction as their strengths complement each other. 
The three algorithms can be implemented individually or together within the 
IntOgen-mutations298 pipeline. This pipeline provides a wrapper for OncodriveFM 
and OncodriveCLUST and was developed by the same group; MutSigCV can be 
integrated into the pipeline as it was here. IntOgen-mutations performs a pre-
processing step for OncodriveFM whereby a functional impact score for each 
mutation is predicted using PolyPhen2270, but is then corrected using the TransFIC 
(Transformed Functional Impact Scores in Cancer) algorithm299. Briefly, PolyPhen2 
and similar functional impact tools are not optimised for cancer and instead infer 
the impact of a nucleotide change in an evolutionary context by determining its 
propensity to vary across multiple species alignments. TransFIC attempts to 
recontextualise mutations into the setting of human cells. It does this firstly by 
calculating a baseline tolerance to change for each gene family using the 
distribution of human germline SNPs as a proxy for tolerance to change in the 
human lineage. If a gene family harbours many naturally occurring SNPs then it is 
scored as being more tolerant to nucleotide change. Secondly, if a gene has a high 
degree of paralogy in the human lineage then it is assumed that loss of the gene 
through somatic mutation is less impactful to the cell as its paralogs may 
compensate through functional redundancy. These transformed scores serve as 




3.7 IntOgen-mutations uncovers novel candidate drivers 
in iCCA 
 
As mentioned above, some of the samples have large numbers of mutations and 
initially these samples were included in the driver prediction analysis; however, 
upon reviewing the results there were a substantial number of uncharacterised 
genes (Open Reading Frames, KIAA genes3 3), and those which have previously 
been identified as known false positives due to their length or numeracy in the 
genome (mucins [MUC4, MUC21]; olfactory receptors [OR10Z1, OR9G1]; ZNF family 
members [ZNF181, ZNF443, ZNF696, ZNF823], PCLO)300. As such the identification 
and removal of hypermutated samples was carried out. This involved the removal 
of samples which met 2 criteria: firstly, they harbour a total number of mutations 
out-with the 3rd quartile of their respective cohorts’ mutation count distribution; 
and secondly, they exhibit a predominant mutational signature associated with a 
mutator phenotype or exposure to a prominent mutagen.  
This resulted in the identification of 27 statistical outliers and the subsequent 
removal of 19 samples with predominant Alexandrov signatures302 linked with 
tabaco exposure, mismatch repair deficiency, activation induced cytidine 
deaminase (AID) overactivity, or defective polymerase epsilon. These 19 samples 
represented only 6.4% of total samples yet contributed 43.9% of all mutations and 






Figure 3.7.1 Identification and Removal of Outliers. A, identification of statistical 
outliers (red) on a source-by-source basis. The range of mutation count per sample 
varied between studies and may be attributable to depth of coverage or mutation 
filtering methods. B, prior to removal 6.4% of samples (inner, red) identified as both 
statistical outliers and harbouring genomes with Alexandrov signatures 4, 6, 9, or 
10 accounted for 43.9% of all mutations (outer, red; segments represent individual 
samples, size proportional to % contribution of mutations to whole).  
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Following the removal of hypermutated samples, IntOgen-mutations was run on 
each constituent cohort (Sia and Chan-On were combined) as well as the pooled    
cohort. Genes identified in at least one of the analyses were taken forward as 
candidates, resulting in 96 candidate drivers for experimental screening.  
To substantiate the legitimacy of the prediction process, the genes were searched 
in the COSMIC Cancer Gene Census3 4,3 5  a curated database of genes for which 
there is substantial evidence for a functional role in cancer  and 32 (33%) were 
found to overlap. To determine if a similar number of COSMIC genes is likely to be 
found in a given set of 96 genes by chance alone, 96 genes were randomly sampled 
from the total set of input genes and the overlap with COSMIC was determined. 
100,000 permutations of this resampling were plotted, and it was found that on 
average a given random set of 96 genes contains only 6 COSMIC genes and that an 
upper bound of 14 was rarely observed. In a further attempt to quantify this the 
simulated data from the permutation analysis was used to model the probability of 
observing at least 32 mutations by random chance in the data as follows: 𝑁(𝜇, 𝜎) is 
the normal distribution with mean(𝜇)= 6.26, and standard deviation(𝜎)=2.32; using 
this model 𝑃(≥ 32) = 0.01. It should be noted that this is a rough estimate as it is 
modelled on a normal distribution which did not accurately fit the simulated 
distribution (D’Agostino-Pearson, P<0.0001), but more accurate model fitting was 
out-with the scope of the current analysis and this served only as an 
approximation. Nevertheless, the above simulations strongly suggest that the 





















N(6.26, 2.32), P<0.0001, D'Agostino-Pearson
P(≥32 COSMIC genes) = 0.01
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Figure 3.7.2 Permutation analysis and statistical modelling of driver 
prediction. Black bars  simulated frequency distribution of 100,000 iterations of 
the intersect of 96 randomly sampled genes from the input set of genes intersected 
with the COSMIC database; Blue curve  a model of the normal distribution 
parameterised using the simulated frequency distribution showing the probability 
of randomly picking 96 genes from the input harbouring at least 32 COSMIC genes 




and not due to random chance; this is supported also by the observation that the 
highest scoring genes are known drivers of iCCA.  
Amongst the input of 277 patient samples 55% carried ³ 2 predicted drivers, and 
18% carried none. Regarding the number of samples a predicted driver was found 
in, it was seen that on average 11 samples harboured a given COSMIC mutation, 
although this average is skewed by the presence of TP53, KRAS, and ARID1A in this 
set, which are found at high frequency (n=62, 48, and 33, respectively). Of the 
predicted drivers which are ‘novel’  not found in COSMIC  they are found on 
average in 3-4 patients (corresponding to ~1.5% of the sample population) and this 
result supports the hypothesis that low-frequency drivers may exist in the long tail 
of infrequently mutated genes found in ICC. Comparing the different driver 
prediction methods, OncodriveFM predicted significantly more drivers than 
MutSigCV, however the relative accuracy of each method will be seen during 
functional validation of this gene set.  
Amongst the predicted drivers there are a number of cancer-associated genes that 
are only predicted by one of the methods. Key examples include NF2, only 
identified by MutSigCV and only when all samples were combined; known PIK3CA 
hotspot mutations with clinical relevance (E545 and H1047) 06,3 6 only identified by 
OncoDriveCLUST; and the tumour suppressor SETD2, a histone lysine 
methyltransferase identified by OncodriveFM. Interestingly, whilst NF1 mutations 
have been reported in iCCA209, the related NF2 have not, despite being shown in 
models to induce iCCA. Loss of NF2 activates the Hippo pathway, activation of 
which through other methods have been used to initiate iCCA in murine models of 
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the disease 76. Similarly, SETD2 loss has not been explored in iCCA yet given its role 
in modulating the epigenome3 7 it fits in amongst the other epigenetic modulators 
mutated in iCCA: ARID1A, IDH1/2, BAP1 and PBRM1  indeed the association 
between mutations in BAP1, PBRM1, and SETD2 have been explored in clear cell 




Figure 3.7.3 IntOgen predicts known and novel drivers. A, OncodriveFM 
predicts significantly more drivers than MutSigCV. B, the number of samples each 
driver is found in segregated into COSMIC and novel genes; the average is higher 
for COSMIC genes, with established iCCA drivers found at high frequency in the 
cohort. In line with the hypothesis, on average a given novel driver is found in only 
3-4 samples. C, the percentage of samples with a given number of drivers, the 
majority harbour 2-3 drivers, with only a tiny fraction harbouring 7-8. D, the 
complete set of predicted drivers, whether they are known, found in COSMIC or 
novel, the analyses they are found in and the prediction algorithm that identifies 
them in the pooled cohort analysis. A complete set of the mutations in genes 




3.8 Pathway and Functional Interaction Analysis  
 
To explore the functional significance of predicted drivers, networks were 
constructed based on known and predicted physical interactions28 ,303 and 
clustered into modules based on connection density3 9. This produced a network 
with 6 modules containing a mix of known, COSMIC, and novel genes. The use of 
filler genes (those connecting predicted driver genes but not found in the 
prediction analysis) were not used to construct this network, as direct interactions 
between components was preferable for biological relevance and clarity. Gene 
ontology analysis was performed on the modules to ascertain the biological 
processes each module may participate in. Processes featuring novel drivers, or 
novel drivers in combination with better known cancer genes include negative 
regulation of cell growth (APBB1, STK11), negative regulation of cell proliferation 
and migration (NF2), and regulation of angiogenesis (EPHA2), amongst others. 
Importantly, the connectivity between novel and known genes in shared processes 
suggests that  although mutated at low frequency in the patient population  these 
novel drivers may contribute to cancer phenotypes by disrupting the same 
processes as more established cancer genes. Finally, to determine whether or not 
any of the predicted drivers represent potential new drug targets, known cancer 
drug-gene interactions were projected onto the network. This revealed ABL as a 
network hub, however the drugs associated with this gene are largely for the 
targeting of ABL fusions seen in leukaemia and therefore may be of limited utility 




Figure 3.7.4 Functional interaction network. A, Network constructed from 
predicted drivers for which evidence of a functional interaction (solid lines, arrow 
- positive interaction, blunt - negative interaction) is known, or predicted (dashed). 
The network is clustered into a community of subnetworks termed modules based 
on density of connectedness. Numbers link a given module to its biological process 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.7.5 Drug target identification. A, The interaction network from 3.7.4 
with cancer drugs (red diamonds) projected onto it and their gene targets 




3.9 Discussion  
 
The above analysis supports the hypothesis that the long tail of infrequently 
mutated genes in iCCA contains putative driver genes, and that such genes with 
disease relevance can be mined from existing data using a rational selection of 
prediction tools. Existing publications provides a rich source of under-utilised data 
which can be pooled together to provide the statistical power to detect rare patterns 
of occurrence that are not visible when considering the component studies in 
isolation. The union of different prediction tools with complementary strengths 
and weaknesses, acting on a combined sample set of a size not yet seen in iCCA, 
revealed a promising set of predicted drivers for experimental screening. 
Furthermore, genes previously unexplored in iCCA exist in interaction networks 
alongside known iCCA drivers and established cancer genes generally, and such 
network participate in disease-relevant processes. The identification of high-
confidence novel drivers through the use of functional genomic screening will 















The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-
Associated 9 (Cas9) system has been adapted from the bacterial immune system for 
molecular biology applications, namely precision genome editing320,32 . Cas9 
encodes an endonuclease capable of cleaving dsDNA to produce a blunt-ended 
double strand break (DSB). In its endogenous bacterial setting Cas9 is directed to 
its target cleavage site by dual RNAs constituting a homing CRISPR RNA (crRNA), 
and a trans-activating crRNA (tracrRNA) that is required for maturation of the 
holoenzyme322. In this setting, the crRNA directs the Cas9 enzyme to a target site 
where Cas9 mediates localised melting of the dsDNA and the crRNA subsequently 
hybridises with its complementary genomic sequence. Cas9 then cleaves within 
this genomic target to generate a DSB. Target suitability is constrained by the 
requirement for a 3-nucleotide conserved protospacer adjacent motif (PAM) next 
to the target site. In this way Cas9 is programmed by the crRNA and can be directed 
to almost any region of the genome provided the presence of a proximal PAM 
site323. 
This programmability has made CRISPR/Cas9 highly effective in experimental 
systems for precision editing of loci in a variety of genomes. For ease in 
experimental applications the dual RNA guidance system found in nature has been 
simplified into a single RNA called a short guide RNA (sgRNA)322. Repair of the DSB 
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follows either the non-homologous end joining (NHEJ) pathway which repairs the 
blunt-ended DSB with the frequent introduction of frameshifting insertion or 
deletion (indel) mutations. Alternatively, if an exogenously supplied homologous 
repair template is provided the DSB can be repaired  albeit at low frequency  by 
homology directed repair (HDR). These two repair pathways allow for the targeted 
knockout of gene expression through frameshifting mutation, or the modification 
of a locus with carefully designed single or dual sgRNAs and repair templates.  
This system is tractable and amenable to multiplexing286. These properties make it 
suitable for high-throughput targeted mutagenesis screening and therefore 
appropriate for the screening of candidate driver genes. Targeted gene disruption 
through DSB-NHEJ can identify genes which normally function as tumour 
suppressors.  Alternatively, the inclusion of a template carrying a specific point 
mutation allows investigation of putative oncogenes through DSB-HDR; however, 
this is not easily multiplexed and present approaches suffer from low efficiency324, 
therefore screening of putative oncogenes was not pursued here and the decision 
was made to focus on identifying novel tumour suppressors.  
A primary obstacle is delivery of CRISPR/Cas9 in vivo to a specific target tissue. The 
delivery of genetic constructs to tissues of interest has been primarily achieved 
through packaging of DNA constructs in viral (retro-/lenti-, adeno-(associated))325 
or non-viral vectors (lipoplexes/polyplexes)326 with modification to the packaging 
to achieve tissue-specific tropism.  
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For targeting the liver in mice, it is possible to deliver naked DNA in solution due 
to the anatomy of the liver vasculature327. The capillaries of the liver, known as 
liver sinusoids, have a discontinuous fenestrated endothelium lacking tight 
junctions and basement membrane which allows facile materials exchange 
between the vasculature and the parenchyma. The rapid and high-pressure 
(hydrodynamic) injection of a large volume of DNA solution into the circulation via 
the tail vein results in cardiac congestion and causes retrograde flow back out of 
the atrium, through the vena cava and into the liver through the hepatic vein. In 
the liver, the hydrodynamic force causes enlargement of fenestrae and passage of 
plasmid solution into the space of Disse surrounding the hepatocytes328. The 
pressure causes deformation of the hepatocyte membrane and the formation of 
pores through which the plasmid solution enters the cytoplasm - a process termed 
hydroporation329. The pores subsequently close within 10 minutes post-injection 
and heart rate returns to normal ~1 minute post-injection; mice that have 
undergone hydrodynamic tail vein injection (HDTVI) experience a life span 
comparable to uninjected mice.  
In this chapter the efficiency of editing in vivo by a CRISPR/Cas9 plasmid in the liver 
following hydrodynamic tail vein injection was investigated. Through the use of an 
mT/mG reporter mouse it was found that this was an efficient method for delivery 
and target disruption in the adult murine liver, achieving sufficient editing 





Targeted genome editing in the adult murine liver is achievable by CRISPR/Cas9 
plasmid delivery via hydrodynamic tail vein injection; furthermore, multiple 
plasmids can be delivered to a single cell.   
4.3 Aims 
 
• Validate the mT/mG reporter system in vitro as a readout of CRISPR/Cas9-
induced DSB-NHEJ at a target locus.  
• Confirm CRISPR plasmid delivery and editing of the mT/mG locus and the 
endogenous Apc locus in the adult murine liver. 
• Determine the feasibility of delivering multiple plasmids simultaneously to 













4.4 The mT/mG reporter can be used as a visual readout 
of CRISPR/Cas9 editing 
 
The duel colour genetic mT/mG reporter allele encodes a floxed membrane-tagged 
tandem dimer Tomato (tdTomato: ‘mT’) and polyadenylation signal, followed by a 
membrane-tagged Enhanced Green Fluorescent Protein (EGFP: ‘mG’) and 
polyadenylation signal (fig 4.4.1; A). Expression at the locus is driven by a 
cytomegalovirus enhancer-chicken beta-actin promoter (pCA) and results in 
expression of the tdTomato fluorescent protein330. Upon Cre-mediated 
recombination, the tdTomato cassette  including its stop codon  are excised and 
the EGFP fluorescent protein is instead expressed from the pCA promoter following 
DSB repair. This system has classically been used to investigate questions regarding 
tissue-specific expression by, for example, expressing Cre from a suspected tissue-
specific promoter in R26mT/mG mice and assessing the tissue for a red-green colour 
change33 ,332. Here instead the system was used to report the efficiency of 
CRISPR/Cas9 editing in vivo by targeting sgRNAs to loxP sites in the absence of Cre333. 
The loxP-targeting sgRNA (sgloxP) guides Cas9 to the loxP sites resulting in the 
introduction of DSBs and excision of the tdTomato and stop codon. Subsequent 
repair by NHEJ results either in EGFP expression, or loss of fluorescence if the 
repair shifts the EGFP expression cassette out of reading frame (fig 4.4.1; C). If 
generation and delivery of a plasmid carrying Cas9 and sgRNA expression cassettes 
was successful, then liver cells which have received and expressed the plasmid 





Figure 4.4.1 mTmG reporter locus and SB-CRISPR plasmid structure. A, 
schematic of the mT/mG reported allele: the mT element is flanked by loxP sites 
and followed by the mG element. Whist the mT element is present, EGFP is not 
expressed from the CMV enhancer-chicken beta-actin promoter (pCA). B, schematic 
of the SB-CRISPR plasmid: a sgRNA spacer-scaffold sequence is driven by the U6 
promoter, the gRNA spacer is flanked by restriction enzyme sites (not shown) to 
enable facile cloning of 20bp sgRNA spacer sequences targeting desirable genomic 
loci. FLAG-tagged Cas9 is flanked by nuclear localisation signals (NLS) and driven 
by the same pCA promoter as is found in the mT/mG reporter. Sleeping Beauty LTRs 
facilitate integration of the CRISPR construct into the host genome. C, Editing 
schematic for sgloxP in mT/mG reporter cells. Upon expression of sgloxP and Cas9 
from the SB-CRISPR plasmid, sgloxP and Cas9 form the catalytically active Cas9 
holoenzyme which is directed to the mT/mG loxP sites. Editing and subsequent 
double-strand break repair by non-homologous end joining (NHEJ) results in 
excision of the mT element and either EGFP expression from the pCA promoter, or 




To confirm the utility of both the reporter and the sgloxP guide before testing in 
vivo, an in vitro editing experiment was first performed in murine bile duct 
organoids derived from the R26mT/mG mouse, homozygous for the reporter allele. 
Two lines were used: one stably expressing human codon-optimised Streptococcus 
pyogenes Cas9 (referred to as Cas9 from now onwards) and a second stably 
expressing a catalytically inactive Cas9 (‘dead Cas9’: dCas9). Either A 20bp spacer 
targeting the loxP locus (sgloxP), or a random 20bp sequence with no known 
genomic target (sg0007), was cloned into the sgRNA expression cassette of the 
LentiGuide-Puro (LGP) plasmid287. This was subsequently packaged as a lentivirus 
with broad tissue tropism through pseudotyping with the vesicular stomatitis virus 
envelope glycoprotein (VSV-G)334. 36 hours following transduction of Cas9 and 
dCas9 organoid fragments with either LGP-sgloxP or LGP-sg0007, the resulting 
organoids surviving puromycin selection were imaged either on a confocal 
microscope (Cas9), or a fluorescence light microscope (dCas9) (fig 4.4.2; A, B, 
respectively).  
In Cas9 organoids that received sgloxP there were several types of colour change 
observed: where cells were homozygously edited, both red-to-green and red-to-
colourless is observed (fig 4.4.2; A, middle panel). When only one copy of the locus 
was edited there was expression of both EGFP and tdTomato resulting in yellow 
upon merging channels (fig 4.4.2; A, right panel). There may also be heterozygous 
editing in cells which appear red due to loss of EGFP reading frame in a single 
successfully edited mT/mG locus, but this outcome cannot be resolved through 
imaging alone and sequencing of the locus in the different organoid populations 
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was not carried out. Mosaicism is seen in some organoids which have successfully 
been edited because lentiviral transduction was carried out on organoid 
fragments, not single cells (fig 4.4.2; A, middle panel). If not all cells in the fragment 
were transduced, then the resultant organoids were mosaic; this mosaicism is lost 
with longer selection time and multiple passages (data not shown). 
dCas9-sgloxP (fig 4.4.2, A, left panel), as well as Cas9-sg0007 and dCas9-sg0007 
organoids showed no sign of red-to-green colour change, indicative of unsuccessful 
editing at the mT/mG loci (fig 4.4.2; B). These observations are in agreement with 
what is known about Cas9’s mechanism of editing. Cas9 requires a sgRNA for its 
endonuclease function: in its unbound state it is catalytically inactive, only 
acquiring its DNA recognition and cleavage activities upon sgRNA binding through 
conformational change323. This suggests that in Cas9-sg0007 organoids the lack of a 
colour change is not attributable to lack of Cas9 endonuclease activity, but to 
incorrect targeting by the sg0007 guide. In the case of dCas9-sgloxP the lack of 
editing is likely due to the catalytic inactivity of dCas9 despite binding of an 
accurately targeting sgRNA. Cas9 cleavage is performed by 2 distinct nuclease 
domains: an HNH-like nuclease domain (aa1-56) responsible for cleavage of the 
strand which hybridises to the sgRNA, and a RuvC-like nuclease domain (aa780-
906) which cleaves the opposite strand. The dual mutations D10A and H840A found 
in dCas9 inactivate both of the nuclease domains rendering the enzyme 
‘catalytically dead’ but still able to interrogate and bind target loci. In the case of 
dCas9-sg0007 the lack of colour change is a product of both a non-targeting sgRNA 




Figure 4.4.2 Editing of the mT/mG reporter allele in R26mT/mG biliary 
organoids. A, in Cas9 expressing organoids transduction of the LentiGuide-Puro 
plasmid expressing sg0007 results in no colour change, when Cas9 organoids are 
transduced with sgloxP different colour changes can be seen: homozygous editing 
(middle panel) results in loss of fluorescence (asterisk) or EGFP expression (arrow), 
mosaicism is a result of patchy transduction in the organoid fragment producing 
regions with no editing (arrowhead). Homozygous editing (right panel) is seen 
when only one locus is edited to produce EGFP expression. B, organoids expressing 




The above results establish that the mT/mG reporter system can be used as a visual 
readout of successful CRISPR/Cas9 targeting, cleavage, and repair by NJEH, and that 
the components of the system and the protocols to generate them were viable (see 















4.5 Tissue-specific CRISPR/Cas9 delivery to the adult 
murine liver: mT/mG editing 
 
To determine the efficiency of CRISPR/Cas9 construct delivery to, and editing in, 
cells in the adult mouse liver via hydrodynamic tail vain injection (HDTVI), the 
sgRNAs from above were cloned into a Sleeping Beauty transposon-CRISPR/Cas9 
plasmid (SB-CRISPR)286 (fig 4.4.1, B). An HDTVI dose titration of SB-CRISPR-sgloxP 
was carried out in the R26mT/mG mouse to determine the optimal dose for delivery 
and editing. Mice were culled 7 days post-injection and slides were 
immunohistochemically stained for GFP. This showed that in the presence of 
transposase (SB13) the number of editing events increased with the concentration 
of SB-CRISPR-sgloxP over a range of 0.2-20µg when injection volume remained 
constant. Further, when SB13 was not included with the highest sgloxP 
concentration, the number of editing events was significantly decreased (fig 4.5.1; 
A, B). This suggests that with co-delivery of SB13, the SB-CRISPR transposon is 
integrated and expressed stably as opposed to the CRISPR/Cas9 expression cassettes 
being expressed transiently from the plasmid without long-term integration, as 
previously suggested286.  
Focusing on the 20µg + SB13 group there is a range of 0.14-0.67% edited cells, which 
represents 630-3089 cells in a section of the left lobe of the mouse liver. To arrive 
at a rough approximation of the number of edited cells in a whole liver; consider 
that Sohlenius-Sternbeck335 calculated a mean of 135 ± 10 million (mean ± SEM) 
hepatocytes per gram of murine liver, and Nascimento-Sales and colleagues336 
notes that the mean liver weight of the FVB strain (the genetic background of the 
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R26mT/mG used here) on a conventional chow diet is 1.4g ± 0.04 (mean ± SEM). This 
gives us a rough hepatocellularity number of 189 million cells per FVB liver. If a 
given section shows 0.14-0.67% editing, then it can be estimated that between 
264,600 and 1,266,300 cells (0.14-0.67% of 189 million) may be edited across the 
whole liver in a given HDTVI with 20µg SB-CRISPR co-delivered with SB13 
transposase.  
The main factor influencing hepatocellular uptake of the plasmid, other than 
plasmid concentration, is the hydrodynamic force applied during injection. 
Optimal delivery is achieved when a solution 10% of the mouse’s circulating blood 
volume is delivered over a 7-second period. This is difficult to keep constant from 
mouse-to-mouse; total volume delivered, the period over which it is delivered, and 
the exact proportion of the mouse’s circulating blood volume that the injection 
volume represents will vary slightly between replicates. This may explain the 
numerical range of editing events seen in each group. However, even at the lower 
end observed in the 20µg+SB13 group, enough cells are edited to correctly power 
even a whole-genome screen. For example, there are 129,211 unique sgRNA 
sequences in the commonly used whole-genome GeCKOv2 library288.  If we assume 
that at least one sgRNA sequence is present in every transfected cell, then every 
unique sgRNA would be represented in at least 2 cells. At the upper range observed 
in this experiment this number increases to 9 cells per sgRNA. 
Although these are approximations which rely on certain assumptions  e.g. each 
lobe and liver region experiencing the same delivery and uptake dynamics  this 
experiment provides evidence that a 20µg HDTVI with SB-CRIPSR in the presence 
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of SB13 transposase is sufficient to power a sub-genome-scale screening 









Figure 4.5.1 Dose titration of SB-CRISPR-sgloxP. A, the percentage of edited cells 
at each concentration of SB-CRISPR-sgloxP with and without the presence of SB13. 
B, the same data as in A, but expressed as number of edited cells. C-E. 
immunohistochemistry (IHC) for GFP in a liver section from a mouse that received 
20µg + SB13. Editing can be seen in small clusters (D), and GFP expression was 
confirmed by native fluorescence (E). F-G, IHC for GFP in a liver section from a 
mouse that received 20µg without SB13: editing still occurs but is rarely observed 
and is presumably the result of transient expression from the SB-CRISPR-sgloxP 




4.6 Tissue-specific CRISPR/Cas9 delivery to the adult 
murine liver: Apc editing 
 
The above experiment demonstrates the relationship between SB-CRISPR 
concentration and number of editing events using a convenient genetic reporter. 
However, an effective screening experiment requires the targeted disruption of 
endogenous genes resulting in a cell-physiological change. To assess the functional 
impact of editing an endogenous gene, the Apc gene was knocked down using a 
sgRNA targeting its 1s  exon. Apc is a component of the canonical Wnt-b-catenin 
signalling pathway where it functions as a scaffold for the destruction complex. In 
the absence of Wnt ligand the constitutively produced Wnt effector protein b-
catenin is sequentially phosphorylated by components of the destruction complex 
and subsequently ubiquitinated and degraded by the proteasome. Upon activation 
by a Wnt ligand, the destruction complex is sequestered to the cell membrane 
allowing cytosolic b-catenin to evade destruction and translocate to the nucleus. 
Here it recruits co-activators and transcription factors and initiates a range of 
transcriptional programs involved in processes such as proliferation, stemness, 
and epithelial-mesenchymal transition 28,337. The targeted knockdown of Apc 
causes loss of the destruction complex and allows constitutive activation of Wnt-b-
catenin downstream effector signalling: the phenotypic readout of this is increased 
nuclear b-catenin and increased expression of target genes. Processing of b-catenin 
by the destruction complex requires an intact N-terminus; the absence of the N-
terminus in the ΔN90-b-catenin mutant results in stabilisation of the protein and 
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increased translocation to the nucleus338. In this way ΔN90-b-catenin phenocopies 
Apc loss and provides a suitable positive control.  
20µg of either SB-CRISPR-sgApc, SB-CRISPR-sg0007, or pT3-N90-beta-catenin was 
delivered via HDTVI alongside SB13, and livers were examined 7 days later. 
Immunohistochemically, there is no increase in nuclear b-catenin in the SB-CRISPR-
sgApc group compared to the negative control, whilst the ΔN90-b-catenin positive 
control group showed a significant increase in nuclear b-catenin (fig 4.6.1; A, B). 
The lack of nuclear b-catenin in the sgApc group was unexpected, so Wnt pathway 
activation was checked at the transcriptional level. Via RT-qPCR, it can be seen that 
b-catenin transcriptional targets are upregulated relative to the non-targeting 
control, but not to the extent seen in the ΔN90-b-catenin group (fig 4.6.1; C). These 
data suggest that Apc is being knocked down in the sgApc group, but the loss of Apc 
does not produce as strong a phenotype as stabilisation of b-catenin. A possible 
biological explanation is that the stabilised b-catenin remains in the nucleus for 
longer and accumulates, resulting in stronger activation of target genes. 
Conversely, a methodological explanation is that there is simply more b-catenin in 
the cell in the ΔN90-b-catenin group; the ΔN90-b-catenin protein is surplus to the 
endogenous copies of wild-type b-catenin and there may be many copies of the 
expression vector in each cell. The strong nuclear b-catenin staining seen in the 
ΔN90-b-catenin group supports the hypotheses that there is more cellular b-catenin 
overall, and/or it is remaining in the nucleus for longer. However, the RT-qPCR data 
support the successful targeted loss of Apc in vivo through CRISPR/Cas9-mediated 




Figure 4.6.1 APC editing in vivo. A, percentage of cells with nuclear b-catenin 
positivity by IHC; mice receiving SB-CRISPR-sg0007/sgApc showed no positivity, 
whilst mice receiving ΔN90-b-catenin had significantly more cells with nuclear 
positivity (P<0.0001, one-way ANOVA). B, representative images of b-catenin IHC 
quantified in A. C, RT-qPCR results showing expression of b-catenin transcriptional 
targets relative to GAPDH; mice receiving the SB-CRISPR-sgApc plasmid showed 
expression intermediate between the negative and positive controls suggestive of 




Together with the mT/mG editing experiments above, this shows that it is possible 
to generate and deliver the SB-CRISPR plasmid into an experimentally useful 
number of cells, that the plasmid integrates and is functional, and this results in 
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4.7 Delivery of multiple plasmids to individual 
hepatocytes in a tumour model of intrahepatic 
cholangiocarcinoma 
 
The induction of tumourigenesis commonly requires more than one genetic 
alteration339 34 . It follows that for effective screening, delivery of multiple SB-
CRISPR plasmids is required to induce a number of different editing events; 
alternatively, delivery of SB-CRISPR screening plasmids alongside oncogene 
expression vectors is required. In either case multiple distinct plasmids need to be 
delivered to individual cells. Here an established experimental mouse model of 
intrahepatic cholangioncarcinoma99 is used to demonstrate that up to 4 plasmids 
can be delivered simultaneously to single cells.  
The expression of the NOTCH1 receptor intracellular domain (NICD) and 
constitutively active myristoylated Akt (myrAKT) has been shown to induce iCCA 
in the murine liver from a hepatocyte origin. The exact mechanism is incompletely 
understood, however evidence suggests that NICD first induces trans-
differentiation of mature hepatocytes into biliary-like cells, and subsequently 
induces the formation of invasive cystadenocarcinomas when expressed 
alone99,342,343. AKT, when expressed alone gives rise to mainly hepatocellular 
carcinomas with occasional benign cholangiocellular lesions. When expressed 
together in mature hepatocytes, lineage switching and subsequent or concurrent 
transformation is thought to be primarily driven by NICD and accelerated by 
myrAKT which provides metabolic support to drive proliferation99.  
  
 124 
Using this model alongside the R26mT/mG/SB-CRISPR-sgloxP system described above, 
separate plasmids expressing NICD, myrAKT and SB13 were delivered alongside 
SB-CRISPR-sgloxP to the liver via HDTVI. This resulted in tumour formation after 6 
weeks. As observed in the biliary organoid experiments, numerous colour changes 
were observed reflecting the various zygosity of editing. Predominantly the 
tumours observed were of a single colour, indicative of tumours of a clonal origin 
with homozygous editing (fig 4.7.1). There was, however, a single mass with 







Figure 4.7.1 clonal editing in mice. R26mT/mG mice injected with plasmids carrying 
NICD, myrAKT, SB-CRISPR-sgloxP and SB13 expression vectors develop tumours 
with colour change, suggesting the uptake of all 4 plasmids. Homozygous editing is 
seen here with two different outcomes as shown in preceding sections. Both loss of 
fluorescence (arrowhead) and EGFP expression (arrow) is seen in tumours with 
close proximity. This suggests a clonal origin of these tumours where the respective 





Figure 4.7.2 A, Polyclonal editing in mice. A, an example of a tumour with 
different mT/mG editing outcomes indicative of a polyclonal and/or polyphyletic 
tumour. The predominant bulk of the tumour expresses both tdTomato and EGFP, 
with patches of only EGFP (asterisks) and patches with no fluorescence (arrows). B, 
detail of an EGFP expressing region which has lost tdTomato expression but is 
surrounded by tissue expressing both tdTomato and EGFP (merge, right panel). C, 
detail of two regions with loss of fluorescent, surrounded by tdTomato and EGFP 
expressing tissue. C, far right panel shows surrounding normal liver with tdTomato 
expression, and tumour expressing EGFP (asterisk), no fluorescence (arrows), and 




The majority of cells in this tumour express both EFGP and tdTomato as evidenced 
by comparison with the surrounding tdTomato-expressing unedited liver 
parenchyma; this is indicative of heterozygous editing of the mT/mG reporter. The 
tumour has regions where only EGFP is expressed, suggesting homozygous editing 
and in-frame DSB repair; but also has regions which appear to have lost any 
expression of fluorescent protein suggesting homozygous out-of-frame DSB repair. 
The different colour changes observed raises the question of whether this tumour 
arose from a single heterozygously edited cell and underwent clonal diversification 
with some clones losing the second copy of tdTomato through subsequent editing 
to produce green clones. This may be possible, however this explanation wouldn’t 
account for the regions without fluorescent protein expression. The locus can only 
be edited once as excision of the mT locus removes the loxP target. If the locus were 
heterozygously edited in the founder cell to produce a clone with both EGFP and 
tdTomato expression, there could not be a subsequent editing event that results in 
loss of fluorescence, only an editing event on the unedited locus which would 
produce a clone with EGFP only. It is therefore more likely that this tumour is 
polyphyletic  arising from multiple individual cells which have different editing 
outcomes at the mT/mG locus. This is further supported by the observation that at 
this concentration of SB-CRISPR, cells are frequently edited in close proximity (fig 
4.5.1; D,E, and fig 4.7.1).   
The presence of tumours with colour change suggests that all 4 plasmids were 
delivered to cells. This supports the proposed mechanism of uptake being non-
selective whereby injection of an admixture of plasmids in solution results in 
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uptake of a random mixture of plasmids in a given cell. When injecting a mixture 
with a small number of different components it is presumed that in the majority of 
cells all of the components will be taken up  this is observed here as there were no 
tumours without a colour change, and no normal cells with a colour change. Almost 
all tumours were either completely EGFP-expressing, or completely colourless 
demonstrating that in the majority of founder cells homozygous editing was the 
predominant editing outcome. The tumour in figure 4.7.2 was the only tumour seen 
with homozygous editing and serves as an important example showing that this 
mode of editing is a possible  if rare  outcome, and further shows that tumours 
arising from HDTVI may represent distinct tumours which have merged. Both of 
these observations are important when analysing and interpreting any tumours 
which have arisen from in vivo driver screening.   
This experiment shows that the delivery and expression of multiple distinct 
plasmids is possible. What is not known is the relative copy number of each 
plasmid, or the absolute number of plasmids which are taken up by each cell. It 
shows that for small plasmid admixtures if a cell receives one plasmid, it likely 
receives all the different plasmids in the admixture. Although not explored here, 
there presumably exists a threshold of plasmid uptake above which the uptake is 
toxic. However, knowledge of the upper limit of plasmids which can be received by 
a cell is not as important here as knowing that a small number can be delivered. It 
is thought that between 2-8 driver genes are needed to initiate tumorigenesis 
depending on the cancer type, and various models of ICC demonstrate that 2 
mutations are frequently sufficient. The above experiment shows that at least 4 
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distinct plasmids can be delivered, therefore a sufficient number of different SB-
CRISPR plasmids carrying sgRNAs targeting different candidate genes could be 
delivered to induce tumourigenesis.  
4.8 Discussion 
 
The targeted knockdown of candidate driver genes in vivo necessitates tissue-
specific delivery of CRISPR/Cas9 at high enough efficiencies to enable 
representation of the screening library. The above experiments demonstrate that 
targeted mutagenesis at reporter and endogenous loci is possible through 
hydrodynamic tail vein injection of CRISPR/Cas9 plasmids, and that delivery of 
multiple plasmids is achievable in this context.  Editing efficiencies were high 
enough to enable theoretical representation of a whole-genome screening library 
 multiple orders of magnitude greater in size than the screening library utilised in 








Chapter 5 In vivo screening identifies novel 




A primary challenge in cancer biology is the discovery of drivers which exist at low 
frequency in the patient population. The previous chapters have computationally 
delineated candidate driver genes which occur at low frequency in the input 
population, and validated a system for delivery of CRISPR/Cas9 editing plasmids 
into the adult murine liver. In this chapter, the set of predicted drivers is screened 
in vivo alone and in the presence of the Notch Intracellular Domain (NICD) which 
induces hepatocyte transdifferentiation, or oncogenic RASG 2 isoforms, which 
potentiate the RAS/RAF/MEK/ERK kinase cascade. Both Notch and RAS signalling 
are dysregulated in iCCA, and how the set of low-frequency predicted drivers may 




Novel low-frequency drivers occur in iCCA and may operate alone or interact with 
more common molecular aberrations. This question can be explored through in 





• The generation of a fully and equally represented SB-CRIPSR plasmid 
library suitable for unbiased screening in vivo.  
• To identify driver genes capable of initiating iCCA of hepatocyte origin. 
• To identify driver genes cooperating with RAS oncogenes to initiate iCCA of 
hepatocyte origin.  












5.4 Generation of a CRISPR/Cas9 screening library  
 
To produce a sgRNA library targeting the candidate driver genes generated in 
Chapter 3, genes were first searched in the Mouse Genome Informatics database to 
determine their mouse homologues. This resulted in the dropout of 5 genes for 
which no mouse homologue exists: KRTAP12-1, encoding a keratin associated 
protein with putative involvement in hair colour not expressed in the liver344; 
RBMXL1, a primate-specific retrotransposed pseudogene of RBMX  also predicted 
as a driver  with 96% sequence conservation and liver expression, but with 
indeterminate function345; SPANXD, a spermatogenesis gene with loss of expression 
in testicular embryonal carcinoma346; ZNF181, a member of the expansive KRAB-
ZNF protein family with roles in the suppression of transposable element 
transcription347,348; and C2orf76, a putative protein coding gene with unknown 
function and limited annotation. This dropout reduced the number of genes for 
screening to 91.  
Two screening libraries targeting the same genes were designed: one for discovery 
(Lib-A) and the other for validation (Lib-B). Each library contained 473 sgRNAs 
composed of 273 gene-targeting (3 sgRNAs per gene for 91 drivers), and 200 non-
targeting control sgRNAs. Between the libraries the control sequences were the 
same, but the gene-targeting sequences were different. This was to ensure that 
genes enriched in Lib-A screening were the result of target gene knockout and not 
off-target effects: there should be near-perfect concordance between enriched 
genes in screens performed with Lib-A and Lib-B. sgRNA sequences were obtained 
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from the Mouse GeCKOv2 library which is designed to limit off-target effects and 
knock out genes reliably by targeting constitutively expressed exons287.   
To generate plasmid libraries for hydrodynamic tail vain injection, an initial 
protocol was developed based on those published by the Luo289 and Zhang349 labs. 
This protocol was sequentially optimised to increase yield and library 
representation (fig 5.4.1; Materials and Methods). sgRNA insert sequences from the 
resulting libraries were amplified and sequenced on the Illumina MiSeq prior to 
injection to determine sgRNA representation. The resulting amplicon sequencing 
validated a pair of libraries with complete (Lib-A) and near-complete (Lib-B) 
representation, and near-perfect equality as measured by the Gini coefficient of the 
read count distribution. The Gini index is a metric borrowed from economics 
where it traditionally measures levels of income inequality - Gini coefficients range 
from 0 (perfect equality) to 1 (perfect inequality) - but has been used in biology for 
applications in molecular biology290, transcriptome analysis350, and ecology35 . Here 
it is used such that a coefficient of 0 would mean that every sgRNA sequence had 
an identical number of sequencing reads covering it, indicating perfectly equal 
representation in the plasmid library; whilst a coefficient of 1 would mean every 
read covered 1 sgRNA sequence, indicative of only one sgRNA sequence present in 
the library. Here SB-CRISPR-Lib-A had a Gini coefficient of 0.07 and no 
unrepresented sgRNAs, and SB-CRISPR-Lib-B had a Gini coefficient of 0.09 with 6 
unrepresented sgRNAs. The sgRNAs missing from Lib-B were a mix of non-targeting 
controls (3) and sgRNAs targeting genes (3), however those genes still had 2 sgRNAs 
covering them.  
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The design and optimisation of a library generation protocol resulted in a pair of 
libraries which could be confidently taken forward for in vivo screening without 


















Figure 5.4.1 Screening library generation and sgRNA sequence representation. 
A, schematic of how the library is made; libraries are amplified from a pool and 
cloned into the SB-CRISPR backbone. B, MiSeq amplicon sequencing showed a low 




5.5 In vivo driver screening generates tumours of hepatic 
origin 
 
To initially identify combinations of cooperating tumourigenic drivers within the 
candidate set, the screening library was screened alongside a notch intracellular 
domain (NICD) expression vector. Notch signalling is a critical determinant of 
hepatocyte-cholangiocyte/cholangiocarcinoma transdifferentiation in several 
established models46,342,352. However, NICD alone produces no histological change 
after 10 weeks, and produces cystic cholangiocellular tumours after 20 weeks99. 
Because HDTVI targets hepatocytes and not cholangiocytes, the inclusion of NICD 
as a transdifferentiation factor was necessary to preferentially screen for drivers 
involved in iCCA induction, and not HCC induction. NICD, transposase (SB13) and 
either SB-CRISPR-LibA or SB-CRISPR-LibB were injected into 4-5 week old FVB mice 
that were subsequently culled 10 weeks post-injection. Mice which received either 
of the libraries alongside SB13 and NICD developed macroscopically cystic lesions 
with low penetrance (here defined as the percentage of mice harbouring at least 1 
lesion). Whilst those mice that received SB13+library or SB13+NICD did not develop 
any identifiable lesions after 10 weeks. Due to the cystic nature of the lesions, 
histology was not possible as tissue collection for DNA and RNA extraction 
destroyed the structure. This result showed that there are drivers within the 
screening set which can accelerate the formation of cystic lesions previously 
described at 20 weeks with NICD alone99. Because screening the library without 




Figure 5.5.1 Experimental design for in vivo driver screening and results of 
NICD/SB-CRISPR-Lib-A A screening. A, mice are injected via hydrodynamic tail 
vein injection and culled at 10 weeks. B, C, NICD or the screening libraries alone 
did not produce any tumours, but together resulted in cystic lesion formation at 10 




targeted genes could not initiate iCCA of hepatocyte origin without the inclusion 
of an oncogene.  
As discussed in the Introduction, both oncogenic KRAS and oncogenic NRAS are 
found in iCCA at different frequencies. Whether both RAS oncogenes cooperate 
with the same or a different set of drivers may reveal underlying common co-
dependencies or important differences that could aid in more granular patient 
stratification. To explore this question, in vivo screening of predicted drivers was 
carried out in the presence of either human KRASG 2D or NRASG 2V expression 
plasmids.   
Following injection of screening libraries, mice injected with either KRASG 2D or 
NRASG 2V expression plasmids plus either SB-CRISPR-Lib-A or -B harboured large 
macroscopic tumours consistent with a mass forming (MF) subtype, with 
phenotypic penetrance comparable between RAS oncogenes. In contrast, mice 
injected with either of the oncogenic RAS plasmids alone developed neither 
macroscopic nor microscopic lesions. Whilst differences in tumour burden 
(number/mouse) between KRASG 2D-library and NRASG 2V-library mice was not 
significantly different (P=0.9, Kolmogorov-Smirnov), several KRASG 2D-library mice 
harboured comparatively large numbers of tumours (12, 7, 6) when compared with 
the NRASG 2V-library group (max=3). Additionally, the duration of the experiment 
was 10 weeks, however all mice in the KRASG 2D-library group had to be culled at 8 
weeks due to sickness, with several showing ascites. Although not significant at this 
sample size, it is in support of previous observations regarding the differential 




Figure 5.5.2 Driver prediction libraries synergise with RASG12 oncogenes.  A, 
both library A and B generate tumours when injected alongside oncogenic RASG 2 
isoforms, resulting in large, solid macroscopic lesions. Oncogenic RASG 2 plasmids 
do not produce tumours alone. B, Both RASG 2 oncogenes generated tumours 
alongside screening libraries at similar frequencies.  
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As with the SB-CRISPR plasmid, both oncogenic RAS plasmids have expression 
cassettes flanked by Sleeping Beauty LTRs to allow stable genome integration in the  
presence of SB13 transposase. Both RASG 2 expression cassettes are driven from the 
CAGGS promoter and are transcriptionally linked to GFP via an internal ribosomal 
entry site. Immunohistochemistry for GFP showed that both RASG 2 plasmids had 
stable tumour integration without expression in the stroma (fig 5.5.3; A). In the 
livers of mice that had received only the RASG 2 plasmid without the screening 
library, GFP-positive cells were found only very rarely. This is in line with what is 
known about immune-mediated senescence surveillance and clearance of 
oncogenic RAS-expressing hepatocytes243.  
 
Previous studies have reported not to have detected stable integration of the SB-
CRISPR plasmid following hydrodynamic delivery to the liver286. However, In light 
of the significantly greater number of editing events seen in Chapter 4 when SB-
CRISPR is delivered with SB13 compared to when it is delivered without 
transposase (fig 4.5.1), whether or not the plasmid was stably integrating in this 
instance was unclear. To address this, RT-qPCR for Cas9 was carried out using RNA 
extracted from NRASG 2D-library and KRASG 2V-library tumours and NICD-library 
lesions, and compared against mTmG-Cas9 organoids described in Chapter 4 
(positive control), and both freshly isolated murine bile duct, and tumours initiated 
with KRASG 2V and a short hairpin RNA against Trp53 (negative controls). This 
showed that Cas9 was expressed in NICD-library lesions and in a subset of 
NRASG 2V-library tumours  but not all  and not in any of the KRASG 2D-library 




Figure 5.5.3 KRAS and NRAS oncogenes are expressed in tumour cells, but Cas9 
expression is significantly decreased. A, in library tumours GFP is localised to 
the tumour epithelium indicative of oncogenic RAS expression in this 
compartment. GFP positive cells are rarely seen in the livers of mice that did not 
receive the screening library. B, Cas9 expression was reduced or undetectable in 






The reason for this heterogeneity is unclear: the integration and expression of the 
RASG 2 expression plasmids demonstrates that the SB13 is delivered and expressed 
in these cohorts, and the results reported in Chapter 4 further supports this for SB-
CRISPR. Possible explanations include the large stromal component of these 
tumours (discussed below) which may limit the collection of RNA from tumour cells 
and dilute a Cas9 signal below the limit of detection. Alternatively, cells which have 
transcriptionally silenced Cas9 could be adaptively selected for during the early 
stages of tumour evolution. As Cas9 is a foreign entity which elicits an immune 
response353 355, its transcriptional silencing may be advantageous in immune 
evasion. The problem of an anti-Cas9 immune response has been addressed in 2 
relevant mouse studies. In one such study356 the investigators used an adenoviral 
CRISPR/Cas9 system to edit Pten in the murine liver to model non-alcoholic 
steatohepatis (NASH). They found anti-Cas9 IgG1/2a antibodies at 14 days post-
injection and produced some evidence for a cellular immune response. 
Nonetheless, they detected CRISPR-mediated Pten mutations and were able to 
successfully model NASH. In another study, the authors reported T-cell mediated 
rejection of Cas9-expressing tumour cells in murine cell-line xenograft models. 
They discovered that following tumour remission several weeks after grafting, 
there was recurrence of tumours composed of cells with reduced Cas9 
expression357. This supports the hypothesis that there is an immune-mediated 
selective pressure for the emergence of Cas9 lowly-expressing cells. Although not 
explored further here, this is an important consideration when interpreting the 
output of screening experiments here and elsewhere.  
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5.6 RASG12-library tumours recapitulate histological 
aspects of advanced human iCCA 
 
Human iCCA shows a spectrum of morphological features which has led to multiple 
histological classification systems20,358. Prominent features in classical human iCCA 
are well-to-moderately differentiated glandular structures surrounded by 
extensive desmoplastic stroma, whilst more advanced malignancy often presents 
as poorly differentiated carcinoma lacking well-defined glandular structures 7,359. 
In both KRASG 2D-library and NRASG 2V-library cohorts the tumours showed 
morphologic heterogeneity within and between tumours. Examination by a clinical 
histopathologist (Dr Timothy Kendall, Division of Pathology, University of 
Edinburgh) confirmed that these tumours are iCCA and that they show classical 
aspects described above, as well as regions of high-grade malignancy and regions 
of the less commonly observed sarcomatoid morphology. Some tumours also had 
dense necrotic areas and all showed some degree of immune infiltration as will be 
discussed. Interestingly, GFP staining (indicative of RASG 2 plasmid expression) is 
seen localised to ductular structures with cuboidal epithelium indicative of the 
cholangiocyte lineage (fig 5.5.3; A). Because HDTVI targets hepatocytes and not 
cholangiocytes and these tumours were formed in the absence of NICD, this 
indicates that RASG 2 mutations in combination with targets in the screening library 







Figure 5.6.1 RASG12 screen tumours show variable morphologies. A-B, KRASG 2D 
library tumours. Arrowheads highlight cuboidal epithelium with loss of definitive 
ductular structures; asterisk denoted desmoplastic stroma, and double-dagger 
denotes necrotic region. C-D, arrowheads denote cuboidal epithelium organised 
into ductular structures. Asterisk indicates regions classified as ‘sarcomatoid’ and 




To further investigate the identity of tumour cells, sections were stained with a 
broad-spectrum cytokeratin antibody (PanCK) and the cholangiocyte marker 
cytokeratin 19 (CK19) which has value in differentiating iCCA from HCC360,36 . All 
tumours showed pervasive cytokeratin expression indicative of carcinoma and this 
also served to highlight necrotic and stromal regions  for example necrotic cores 
can be seen in figure 5.6.2 A (densely packed cells, blue regions in macro images, 
and on the right of insets).  The cholangiocyte marker CK19 has tightly restricted 
expression in normal liver where it is confined to the bile duct epithelium and not 
expressed in any other cell type. Both KRASG 2D and NRASG 2V tumours showed 
extensive CK19 expression in cells of variable morphologies. Well-differentiated 
ductular structures with CK19+ cuboidal epithelium were readily observed in all 
tumours, with a subset also showing CK19+ cuboidal epithelium not arranged in 
glands. Remarkably, both RASG 2 tumour cohorts also had cases with CK19+ spindle 
cells recapitulating the morphology of rare intrahepatic sarcomatous 
tumours362,363.   
A predominant feature of iCCA is its fibro-desmoplastic stroma, consisting of dense 
extracellular matrix (ECM) composed of ECM molecules not present in normal 
liver364. Cellular contributions to the stroma include a dynamic repertoire of 
immune cells, and cancer associated fibroblasts (CAFs) which are largely 







Figure 5.6.2 Lineage identity of RASG12 screen tumours. A, PanCK stains 
cytokeratin, a marker for tumour epithelium and CK19 highlights the cholangiocyte 
identity of much of the epithelial compartment. Comparison of both images 
demonstrates that some regions lose CK19 indicating loss of biliary cell identity. B, 
in normal liver CK19 is tightly restricted to the bile duct epithelium, but in RASG 2 
tumours CK19 staining cells are found in several morphologies; ductular, cuboidal, 
and spindle-like.  
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To explore the acellular composition of the stroma, staining for collagen 1, collagen 
6A6, and pan-fibronectin was carried out. Collagens, generally speaking, are 
important stromal components which modulate cancer cell biology and 
prognosis366. The choice of Col1 and Col6A6 here is based on the formers previous 
association with cholangiocarcinoma as a biomarker for fibrosis367 due to its 
secretion by cancer associated fibroblasts (CAFs); and the latter due to its strong 
differential expression between normal and NRASG 2V tumours in this study (data 
not shown). Similar to Col1, fibronectin is also secreted by reactive CAFs which 
have subsequently been shown to align fibronectin to orchestrate directional 
cancer cell migration368.  
Col1 was extensively present in the stroma of all KRASG 2D and NRASG 2V tumours. 
When compared to the NICD/myrAKT model, Col1 staining serves to highlight the 
comparatively dense stroma seen in screen tumours and suggests that this model 
may be a useful tool for studying stroma in iCCA. Col6A6 was present in normal 
liver with peri-portal staining which is extracellular and localised to the basement 
membrane surrounding the ducts. Curiously, in both RASG 2 and NICD/myrAKT 
tumours, staining was seen in both the intracellular and extracellular 
compartments. Col6A6 is one of 6 Col6 chains which make up the Col6 protein369. 
Col6 has a been shown to activate canonical Wnt signalling370, as well as promote 
epithelial-mesenchymal transition and tumour inflammation37 373  all important 
processes linked to iCCA. Importantly, in vitro and in vivo evidence suggests that 
Col6 expression is increased in response to cisplatin and that this mediates cisplatin 
resistance in ovary and breast cancer374,375. Whist these studies focused on subtypes 
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of Col6 other than Col6A6, this is still a relevant finding for iCCA which is treated 
with cisplatin as standard and often develops resistance; further study of Col6A6 
in iCCA is warranted. Fibronectin was found to be weakly expressed in the 
cytoplasm of normal hepatocytes, but not biliary cells, and this is in line with 
previous studies assessing fibronectin expression in the normal liver376. 
NICD/myrAKT, and NRASG 2V tumours had strong stromal staining likely as a 
product of CAFs. Unexpectedly, KRASG 2D tumours did not have strong stromal 
fibronectin staining, but occasionally had intracellular staining in the cytoplasm of 
ductular structures. Whilst cytoplasmic accumulation of fibronectin has been 
shown in CCA377 and in thyroid carcinoma378, further validation of this finding is 
necessary to rule out non-specific staining. In line with Col1 and fibronectin being 
prominent acellular components of the stroma, ⍺-smooth-muscle actin (⍺SMA) 
positive CAFs were also a pervasive feature in both screen tumours and the 
NICD/myrAKT control tumours. ⍺SMA expressing cells were not present in the 
normal liver: hepatic fibroblasts and CAFs transdifferentiate from quiescent 
hepatic stellate cells in response to injury and acquire ⍺SMA expression only when 
activated379,380. Infiltrating macrophages and neutrophils were observed in both 
RASG 2 tumours and NICD/myrAKT tumours, however regulatory T-cells were seen 








Figure 5.6.3 Extracellular matrix components. All tumours stained positive for 
collagen 1 (A), B, Collagen 6A6 showed basement membrane localisation in normal 
liver but expression in the cellular and stromal compartments in tumours. C, 
fibronectin showed the expected localisation in all groups except the KRASG 2D 





Figure 5.6.4 Immune infiltrate in tumours. All tumours showed infiltration of 
cancer associated fibroblasts (A), tumour associated macrophages (B), and 
neutrophils (D), however only RASG 2 screen tumours showed regulatory T-cell 
infiltration (C). Spleen was used as a positive control.   
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5.7 Exome sequencing of RASG12-library tumours 
identifies novel drivers of intrahepatic 
cholangiocarcinoma 
 
Exome sequencing was used to determine which CRISPR-mediated mutations 
generated iCCA in conjunction with KRAS and NRAS oncogenes. 16 KRASG 2D-library 
tumours (including 2 pancreatic lesions, thought to be invasions from the liver), 
and 10 NRASG 2V-library tumours were sequenced alongside one normal liver 
control from an uninjected mouse. All indels within 50bp of a sgRNA binding site 
were visually inspected to determine overlap with sgRNA target sites. Virtually all 
indels had start or end positions approximately 3bp upstream of the Cas9 
protospacer adjacent motif (PAM) sequence which strongly indicates that they are 
the consequence of CRISPR/Cas9 editing and not spurious.  
A potential risk of inducing so many CRISPR/Cas9 DSBs simultaneously in 
individual cells is that they may induce larger structural rearrangements through 
repair of discordant breakpoints, or excision of intervening sequence between 
sgRNAs as demonstrated in the mTmG model in Chapter 4. Previous studies that 
used the SB-CRISPR plasmid for screening a smaller number of genes in the liver 
reported no such rearrangements, however, due to the comparatively larger set of 
sgRNAs used this was checked here. Structural variant analysis on the NRASG 2V-
library tumour exomes confirmed that, whilst not extensive, 4 high-confidence 
structural rearrangements mapping to CRISPR/Cas9-induced breakpoints were 
observed in 3 samples. In 2 such cases, inversion of a segment between a Trp53 
sgRNA binding site and either a Nf2 or Rnf43 sgRNA binding site was observed 
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leading to the disruption of target exons in both cases. In another tumour, a small 
intragenic deletion between 2 Plk2 sgRNA binding sites was seen which served to 
disrupt only this gene. And lastly, one case harboured a 32kb duplication of a 
segment spanning part of Nf2 exon 7, with the end of the duplicated sequence 
mapping to a Nf2 sgRNA target site. Although uncommon, duplications due to 
CRISPR/Cas9 have been described, and these tended to segregate with deletions or 
inversions38 ; this seems to be the case here where the Trp53-Nf2 inversion 
described above was found in the same tumour as the Nf2 exon 7 duplication.  
A minimum of 2 drivers were observed per tumour across groups, with a whole-
number median of 5 drivers pre tumour seen in the NRASG 2V group, and 6 (actual 
5.5) in the KRASG 2D group.  Interestingly, tumours from the same mouse did not 
cluster together except in the 2 mice with pancreatic invasions. In these mice, 
pancreatic tumours clustered with 2-3 other samples from the same mouse. As 
library uptake is random, this suggests that these tumour clusters may be 
descendants of a common clone/tumour. Nuclear Corepressor 1 (Ncor1) was edited 
in the pancreatic metastasis of mouse 986418 and was not present in any of the 
other 986418 tumours that it clustered with. Additionally, Ncor1 was detected in a 
tumour of the NRAS group which uniquely showed diaphragmatic invasion. Ncor1 
expression is downregulated in HCC and breast cancer and its loss in experimental 
systems causes invasion and metastasis382, which supports a role for it here as a 





Figure 5.7.1 CRISPR/Cas9 editing outcomes. A, indels within 50bp of sgRNA 
spacer target sites localise 2-4bp proximal to PAM sequences indicative of 
CRISPR/Cas9 mediated editing. B, Tumours in NRAS and KRAS oncogene screens 
harboured on average the same number of CRISPR/Cas9-induced mutations (~5). C, 
schematic of structural variations likely caused by Cas9 editing, with breakpoints 
localising to sgRNA target sequences (black bars).   
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Across both RASG 2-library screens a total of 66 of the 91 predicted drivers targeted 
by the screening library were mutated, and 27 of these were shared between both 
screens. Notably, Trp53 was mutated in all but 2 samples which reinforces the 
importance of Trp53 loss in the escape of Ras-induced senescence in hepatocytes. 
Despite TP53 not significantly co-occurring with RAS mutations in the human data 
this result shows that other genes capable of escaping RAS-induced senescence  at 
least in hepatocytes  were not present amongst predicted drivers. This disparity is 
perhaps explainable by the fact that in this study iCCA is of hepatocyte origin so 
necessarily requires Trp53 loss to escape senescence.  
Broad functional profiling of shared drivers uncovered significantly enriched 
biological processes including numerous developmental and neurodevelopmental 
processes, morphogenetic processes, and cell mobility and motility. The overlap 
between neurodevelopmental and cancer genes is not novel: genes with canonical 
involvement in neurodevelopment due to their role in cell signalling (Nf2, K/Nras, 
Cacna1c), cell motility (Plxnb2, Fn1, Thbs1, Ablim1), and cell cycle (Rb1, Plk2) were 
found mutated in this screen. Some of these have known roles in cancer but some 
have not previously been described.   
At a regulatory level, 19 of the 27 shared drivers had predicted binding sites for the 
Zic1 transcription factor. Zic1 is significantly decreased in gastric and colorectal 
cancer through promoter hypermethylation, and associated with decreased overall 
survival383 386. Additionally, Trp53 and Nf2 were both found to interact with miR-
138-5p which has tumour suppressive roles in cancer387, and has previously been 




Figure 5.7.2 Common and unique drivers between KRASG12D and NRASG12V 
screens. A, Exome-seq results for a subset of tumours showing which driver genes 
were mutated and with which sgRNA. Trp53 is only rarely targeted by sgRNA-1 
which was underrepresented in the screening library when compared to sgRNAs 2 
and 3. Notably NRAS tumour 718-A harboured a large number of mutations and 
this is possibly a result of 718-A being having multiple cells of origin as discussed 
above. 27 drivers were shared between screens, with Trp53 present in all samples 
except one across all screens. B, Based on driver gene profiles, KRASG 2D and 
NRASG 2V screen tumours do not cluster together, nor do tumours from the same 
liver, with the exception of tumours from mouse 986418 and 986420, these mice 
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Figure 5.7.3 Biological process enrichment in shared drivers and proposed 
Survivin regulatory module. A, Gene Ontology Biological Process terms enriched 
amongst the shared driver set mainly involved developmental processes and 
regulation of cell migration. B, the transcription factor Zic1 and microRNA miR-
138-5p had proposed binding sites for/interactions with p53. As both also regulate 
Survivin, which is upregulated in iCCA, a proposed mechanism of whereby 
Survivin may be upregulated in response to mutational loss of p53 or promoter 
hypermethylation of Zic1. This depends on whether or not Zic1 ordinarily acts to 
induce p53 expression.   
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somewhat tangential, it’s interesting to note that Zic1 and miR-138-5p both interact 
with Trp53, and both are negative regulators of Survivin389,390. Survivin  a negative 
regulator of apoptosis  is expressed in human cholangiocarcinoma in response to 
the chemotherapeutic agent doxorubicin39  and is correlated with poor 
prognosis392. Survivin is also differentially upregulated in all tumours in this study 
as assessed by transcriptome analysis (see below). A 2016 study found that 
regulation of p53 and miR-138 was unidirectional in human lung cancer cells, with 
p53 loss resulting in miR-138 downregulation. This hints at a potential mechanism 
whereby p53 loss may lead to Survivin expression via downregulation of miR-138-
5p, priming cells for doxorubicin resistance. If Zic1 expression is similarly 
decreased in iCCA as it is in gastric and colorectal cancer, this may be an additional 
route to Survivin expression without mutation of TP53, contingent on Zic1 acting 
as a positive regulator of TP53 expression. 
To further characterise the screen tumours, RNA sequencing (RNA-seq) was used 
to determine differentially expressed genes when compared to normal bile duct or 
KRASG 2D-shTrp53 tumours. As expected, normal bile duct and KRASG 2D-shTrp53 
tumours clustered together on principal component analysis, whilst KRASG 2D-
library tumours did not cluster together, and instead were distributed across the 
plot. A loose cluster could be seen in the top right of the plot and these 3 samples 
all had Nf2 mutations. Nf2 was the most frequently mutated gene across both 
RASG 2 screens and splitting the samples based on Nf2 mutation status separated 
the KRASG 2D-library group into 3. Nf2-A consisted of screen tumours harbouring 
Nf2 mutations which clustered together in the top right corner, Nf2-B consisted of 
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screen tumours with Nf2 mutations which did not cluster together, and the 
remaining group consisted of screen tumours without Nf2 mutation. Nf2-A samples 
were all from different mice and uniquely shared Brca2 mutations when compared 
to Nf2-B. The 2 samples that clustered closest in the top right additionally shared 
Plk2 mutations. Indeed, one such tumour harboured only 4 CRISPR-mutated genes: 
Trp53, Nf2, Brca2, and Plk2. 
 Differential gene expression analysis between the Nf2-A screen tumours and those 
without Nf2 mutations identified a large set of differentially downregulated genes, 
but few upregulated genes (Appendix 2). Enrichment analysis for biological 
processes showed only weak enrichment for cAMP signalling amongst the 229 
upregulated genes, however the 1312 differentially downregulated genes 
segregated into 741 process annotations. A complete list of enriched processes, 
cellular compartments, molecular functions, KEGG and REACTOME pathways, and 
transcription factor binding sites can be found in Appendix 3. As a means of 
highlighting disease-relevant biological processes, the set of enriched biological 
processes was filtered based on the following terms (‘*’ denotes any combination 
of letters): “cancer”, “liver”, “bile”, “apopto*”, “cycle”, “signal*”, “matrix”, 
“development”, “immun*”, and “*abol*”. Enriched terms (limited to a maximum of 
30) are displayed in Fig 5.7.3, A.. Most striking is the strong statistical enrichment 
of terms related to metabolism, suggesting extensive metabolic rearrangements in 
these tumours. Processes linked to regulation of apoptosis, immune response, and 





Figure 5.7.4 Principal component analysis of all samples and differential gene 
expression of Nf2-A compared to the Nf2-negative KRASG12D screen tumours. A, 
PCA based on differential gene expression identifies a cluster of samples 
harbouring Nf2 mutations (Nf2-A, purple ellipse), this group segregates from other 
samples harbouring Nf2 mutations (Nf2-B). Nf2-A also share Brca2 mutations, and 
the pair clustering most closely harbour Plk2 mutations. B, differential gene 
expression between Nf2-A tumours and screen tumours without Nf2 mutations 




Figure 5.7.5 Curated biological process enrichment terms in differentially 
downregulated genes in the Nf2-A group compared to Nf2-negative screen 
tumours. Marked enrichment for metabolic processes (top) characterises this set 
of downregulated genes. Also notable is downregulation of physiological processes 
involved in bile acid homeostasis (bottom). Downregulation of genes involved in 





and extensive stroma in these tumours. Interestingly, terms linked to both liver, 
biliary, and tube development as well as bile acid biosynthesis and secretion 
strongly suggest a differential loss of biliary cell identity in this group of Nf2 
tumours compared to the rest of the screen. This is further supported by 
enrichment of transcription factor binding motifs for HNF1b, and HNF4a 
(responsible for maintaining cholangiocyte and hepatocyte lineage identity, 
respectively) in the set of differentially downregulated genes. Therefore, it might 














5.8 In vivo validation confirms Plxnb2 and Nf2 as novel 
drivers cooperating with oncogenic RASG12 isoforms. 
 
Ascribing any definitive driver signal to a particular mutation is hampered by the 
noise of genetic heterogeneity intrinsic to this screening process. Therefore, 
following a literature search of all mutations and in light of biological process 
enrichment and transcriptome sequencing, 5 proposed drivers were chosen for in 
vivo validation: Nf2, Plxnb2, Plk2, Rnf31, and Fh1.   
As discussed in the Introduction, Nf2 is an upstream regulator of the Hippo 
pathway which itself has known roles in iCCA. It has also been shown to have 
decreased expression histologically in human samples90. Plxnb2 and Plk2 shared 
overlapping biological process annotations and clustered closely to Trp53 (fig. 5.7.3; 
A). Plk2 mutation is also likely to be the causative mutation explaining the close 
clustering of samples in the top right of the PCA plot (fig 5.7.4; A). Plk2 is a mitotic 
kinase and direct transcriptional target of p53, playing a role in cell-cycle 
progression and centrosome maturation.  There is conflicting evidence for its role 
in cancer. In some studies, including those regarding iCCA, Plk2 expression is anti-
apoptotic and pro-proliferative393,394. Other studies have shown that Plk2 loss can 
confer resistance to platinum and taxane-based chemotherapies395, and it has been 
implicated as tumour suppressors in gastric396 398 and hepatocellular carcinomas399. 
Due to its recurrent mutation here, it was appropriate to investigate its potential 
involvement further. Plxnb2 is a transmembrane semaphorin receptor with roles 
in neural and cardiac development400, and immune homeostasis40 . Interestingly, it 
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contains an intracellular domain with RasGAP homology and protein structure 
resembling that of NF1 and RASA1402 (also mutated in the screen, fig 5.7.2; A, top 
bar chart). Plxnb2 loss due to epigenetic silencing has been implicated as marker 
for poor prognosis in lung adenocarcinoma403, where oncogenic KRAS also plays a 
crucial role404. Rnf31 is the catalytic component of the linear ubiquitin chain 
assembly complex (LUBAC)405 which is indispensable for the ubiquitination of 
NFκB signalling  its loss inhibiting the induction of TNF-⍺ induced apoptosis406. 
Indeed, it has been implicated as a tumour suppressor in HCC407. Lastly, Fh1 
encodes fumarate hydratase, a Krebs cycle enzyme which catalyses the conversion 
of fumarate to malate. Fh1 is a well-defined tumour suppressor in other cancer 
types, loss of which leads to metabolome and epigenome remodelling408. In a 
multistep progression, Fh1 loss initially results in senescence but also mediates its 
escape through indirect hypermethylation of p16408. Given the central role of 
IDH1/2 neomorphic mutations in metabolome/epigenome remodelling in iCCA, it 
was plausible that Fh1 loss may also act as a tumour suppressor through related 
mechanisms. 	
To validate the driver status of these genes in vivo, mice were injected via HDTVI 
such that for each proposed driver, 3 sgRNAs targeting the gene were injected 
alongside NRASG 2V alone, or NRASG 2V plus 3 sgRNAs targeting Trp53 (sgTrp53). 
NRASG 2V plus sgTrp53 guides were used as a positive control. For this initial 
experiment, 3 mice were used per group.  
Mice with NRASG 2V/driver guides alone did not form tumours within the 10 weeks 




Figure 5.7.6 Nf2 and Plxnb2 in vivo validation results. A-B, Kaplan-Meier 
survival curves show significantly decreased time to death mice which received 
sgPlxnb2 or sgNf2 alongside sgTrp53 and NRASG 2V, but not with NRASG 2V, or alone. 
C, Macroscopic images of two different livers from NRASG 2V/sgTrp53/sgPlxnb2 mice 
or NRASG 2V/sgTrp53/sgNf2 mice (D). E, H&E staining of a 
NRASG 2V/sgTrp53/sgPlxnb2 liver showing extensive tumour spread across the lobe, 
which is more pronounced in NRASG 2V/sgTrp53/sgNf2 mice (F) where almost the 
entire lobe is consumed by tumour. G-H, H&E, 20x magnification of section 
enclosed in box in the above overview image. I-J, corresponding GFP staining in the 
above section, indicative of NRASG 2V expression. GFP can be seen staining spindle-
like cells which have lost epithelial morphology.   
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solid lesions at 10 weeks. One mouse which receiving NRASG 2V/sgTrp53/sgFh1 did 
harbour one tumour at 10 weeks. However, mice that had received 
NRASG 2V/sgTrp53/sgPlxnb2 or NRASG 2V/sgTrp53/sgNf2 showed substantial tumour 
burden with a significant decrease in survival time (P=0.015, 
NRASG 2V/sgTrp53/sgPlxnb2; P=0.031, NRASG 2V/sgTrp53/sgNf2) requiring early 
culling. Macroscopically and histologically, the NRASG 2V/sgTrp53/sgPlxnb2 
tumours had better defined borders than the NRASG 2V/sgTrp53/sgNf2 group, which 
were very invasive: tumours having taken over almost the entirety of the lobe, with 
no clear boundaries where one tumour stops and another begins (fig 5.7.6; C-F) 
Both showed marked loss of cuboidal epithelial morphology and exhibited spindle 
cell morphology. GFP staining for NRASG 2V-expressing tumour cells showed 
invasive fronts with spindle cells intercalating with morphologically normal 
surrounding hepatocytes in NRASG 2V/sgTrp53/sgNf2 tumours.  
Together these results establish that Nf2 and Plxnb2 are novel drivers of 
intrahepatic cholangiocarcinoma through cooperation with oncogenic RASG 2 





The identification and validation of driver genes requires a flexible platform that 
is genetically tractable. The above work utilised the popular hydrodynamic tail vail 
injection method for delivery of a screening library to the murine liver. This 
approach initially showed that replacement of myrAKT with the screening library 
in the commonly used NICD/myrAKT iCCA model increased the onset of lesions by 
10 weeks compared to the study initially describing the model99.  
Screening alongside oncogenic RASG 2 isoforms uncovered a common set of 27 
genes, a strong biological signal shared between screening experiments. These 
genes showed biological process enrichment for developmental processes and 
those involved in cell motility. Although not significant at this sample size, it is 
interesting to note that common iCCA drivers segregated with NRASG 2V and 
KRASG 2D mutations: ARID1A was lost in three samples exclusively in the NRASG 2V 
screen, whilst BAP1 and PBRM1 were lost in one sample each in the KRASG 2D 
screen. Another puzzling observation is the loss of oncogenes in this screen, which 
preferentially identifies tumour suppressors through loss of function. In the 
KRASG 2D screen, several kinases which are known oncogenes were mutated, 
sometimes recurrently: Kras itself, as well as Braf, Erbb2 and 3, and Pik3ca were 
all mutated preferentially in the KRASG 2D screen. Conversely, Idh1 was lost in the 
NRASG 2V screen. Whether or not this is a genuine signal or these mutations are 
passengers is not clear, and warrants further investigation.  
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Validation of 5 proposed drivers identified Nf2 and Plxnb2 as drivers of iCCA. These 
mutations occur rarely in the human population: in 1.8% and 1.5% of patients, 
respectively (n=409, cBioPortal). Here they are shown to significantly accelerate 
tumourigenesis and mortality through cooperation with both NRAS and KRAS 
when p53 is lost in the hepatocyte compartment. Both RASG 2 oncogenes have been 
shown to induce senescence in the liver, and this is dependent on p53243,244. As such 
Loss of p53 is required for escape of senescence and is also likely responsible for 
hepatocyte-cholangiocyte transdifferentiation due to its role in gatekeeping lineage 
plasticity in the liver.  
The contribution of Plxnb2 and Nf2 to the tumour phenotype is the subject of 
ongoing work. Plxnb2 is a semaphorin receptor, and contains 3 notable binding 
domains: a GTPase activating protein (GAP) domain with homology to RasGAPS, a 
Rho-GTPase binding domain (RBD), and a PSD-95/Discs-large/ZO-1 (PDZ) binding 
domain409. Whether or not the Plxnb family have intrinsic GAP activity has been 
the subject of much research but still remains largely unanswered. Plxnb1 has been 
shown to exhibit GAP activity on R-Ras and Rap1, but whether or not this extends 
to Plxnb2 is not yet known4 0. Through its PZD binding domains it interacts with 
PDZ-RhoGEF, and leukaemia associated RhoGEF (LARG) to transduce signals to 
RhoA and thus mediate cytoskeletal rearrangements in response to semaphorin 
signalling. Through its RBD it interacts with the atypical Rho-GTPase family 
members Rnd1/2/3 which remodel the actin cytoskeletin4 0. Rnd3 plays a crucial 
role in inhibiting tumour cell invasion, its activation causes the loss of actin tension 
and results in cell rounding. Work in melanoma4 , glioma4 2, and various cancer 
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cell lines4 3,4 4 has demonstrated that Rnd3 activity suppresses invasive 
phenotypes/ameboid movement, and that its loss enhances invasiveness. A study 
by McColl et al.4 5 showed that Plxnb2 is the effector of Rnd3 through direct binding. 
They demonstrated that overexpression of Plxnb2 and Rnd3  together, but not 
alone  enhanced inhibition of invasion and cell rounding phenotypes. They finally 
demonstrated that mutation of the Plxnb2 binding site for Rnd3 abrogated the 
rounding phenotype and enhanced invasiveness and migration. In light of this, it 
is possible that loss of Plxnb2 in NRASG 2V/sgTrp53/sgPlxnb2 tumours enhances 
aggressiveness by potentiating invasion and migration, this is supported by the 
spindle cell morphology seen in figure 5.7.6.  
Aside from its previously discussed role in iCCA through dysregulation of the Hippo 
pathway (see section 1.3.2), Nf2 may also influence phenotype through heterotypic 
interactions with the Rho-family GTPase RAC1. RAC1 is negatively regulated by Nf2, 
and Nf2 loss increases activity of RAC14 6. RAC1 has a plethora of roles in cancer, 
notably including invasion and migration, increased proliferation, and 
chemotherapeutic resistance4 7. Overactivation of RAC1 has been shown to 
promote epithelial-mesenchymal transition in colorectal cancer4 8 and is associated 
with aggressiveness and poor prognosis in both breast4 9 and gastric cancer420. 
Myant et al.42  demonstrated a critical role of RAC1 in Wnt-mediated intestinal 
transformation following APC loss. A subsequent study showed that fibronectin-
induced cell migration in breast cancer was dependent on Wnt signalling, and that 
this was mediated through direct interactions between β-catenin and RAC1422. This 
points to RAC1 as an important mediator of proliferation and invasion and this may 
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be potentiated thought loss of Nf2 and overactivation of canonical Wnt signalling 
as is seen in iCCA. Therefore, in addition to dedifferentiation due to loss of Hippo 
signalling, Nf2 loss may synergise with canonical Wnt signalling through release of 
RAC1 inhibition to drive poorly differentiated, invasive tumours.  
Nf2 has previously been explored as a tumour suppressor in the liver. One study 
showed that its loss in embryonic liver resulted in oval cell expansion and eventual 
HCC and iCCA. A second study inspired by this explored NF2 mutation and 
expression in human HCC and iCCA histological sections, finding a low frequency 
of mutations and low expression in a subset of samples. To my knowledge, the 
present study is the first example of Nf2 being unbiasedly identified as a driver of 
iCCA directly from human data. Nf2 was identified through both computational 
screening of patient exome sequencing and then through in vivo screening as part 
of a library, and finally validated in the adult murine liver. This provides strong 
evidence in support of what has previously been an incompletely resolved 








Chapter 6 Discussion and Concluding Remarks 
 
The present study set out to identify novel drivers in iCCA, and in particular, those 
which have not been detected previously due to their low frequency in the patient 
population. Leveraging the combined wealth of readily available exome 
sequencing data served to increase sample size  and therefore statistical power  
to detect uncommon drivers. Indeed, Nf2 was predicted to have driver status by the 
driver prediction tool MutSigCV which assigns driver status based on mutation 
frequency in a cohort. Crucially, it was only identified by MutsigCV when the entire 
pooled cohort was analysed together, not when any one exome-seq study was used 
alone. In addition to increasing sample size, the use of multiple tools with different 
prediction models increased the set of candidate drivers. Plxnb2 was not identified 
by MutSigCV, but by OncoDriveFM, a tool that assigns driver status based on the 
ratio of benign to damaging mutations; whilst accuracy is increased with sample 
size, mutation occurrence above two instances is not required.  
Screening the set of candidate drivers in vivo alongside KRASG 2D and NRASG 2V 
oncogenes identified a common set of overlapping drivers. The validation of Nf2 
and Plxnb2 as cooperating partners with both oncogenic RAS isoforms and p53 loss 
demonstrated the validity of this approach. Further exploration of the contexts in 
which and mechanisms by which these mutations operate will yield deeper insight 
into the biology of iCCA. Indeed, whether or not oncogenic RAS is an essential 
requirement for Nf2/Plxnb2 driver function was not explored here, and a follow-
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up experiment with Nf2/Plxnb2 loss alongside p53 loss alone  or with other 
oncogenes  will shed light on this. Moving forward, it will be interesting to explore 
the other mutations that were found to be shared between RASG 2 screens as well 
as those found independently with NRASG 2V and KRASG 2D. The latter sets are of 
particular interest and it will be exciting to see if any of them function as drivers 
only when co-mutated with the respective RASG 2 isoform they were discovered 
with.  
In vivo screening explored the oncogenic capacity of prospective human iCCA 
drivers using a hepatocyte cell of origin. As iCCA can also arise from cholangiocytes 
a suitable next step will be to develop a parallel screening system which targets 
cholangiocytes. A possible system could use an adenoviral sgRNA delivery 
system423,424 coupled with biliary restricted Cas9 driven from, for example, a CK19 
promoter. Further biliary specificity could be achieved through injection of 
adenovirus into the biliary tree: a recent study described a method for delivery into 
the murine bile duct through injection into the gall bladder with simultaneous 
clamping of the common bile duct425.  
A possible disadvantage of in vivo screening is the potential for selection of Cas9-
low cells biasing the output of the screen. An alternative screening system would 
be human or mouse biliary organoids. Indeed, this was attempted in mouse biliary 
organoids using the same libraries as here but packaged in lentivirus for delivery 
(data not shown). This system offers certain advantages; notably the ability to 
target cholangiocytes specifically, and also the ability to exert a degree of control 
over the dose of viral particles (hence the number of sgRNAs) delivered to each cell. 
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The primary problem is the lack of a clear selection pressure for tumour 
suppressors or a clear phenotypic output. Furthermore, the characteristic 
involvement of the acellular stroma in iCCA further excluded the use of organoids 
as the ECM substrate used to grow them might further bias the results by providing 
an inauthentic ECM. Another potential solution would be to perform the screen in 
immunocompromised mice. This would avoid Cas9-mediated immune biasing of 
the output, but it may also bias the output away from genes involved in immune 
evasion in the context of human cancer. The cellular stroma is also rich in 
infiltrating immune cells; indeed, this was shown to be recapitulated in the screen 
tumours by the presence of regulatory T-cells, neutrophils, and tumour-associated 
macrophages. Ultimately, the most desirable system is one which recapitulates the 
complex environment of human tumourigenesis. This necessitates a model with a 
tissue microenvironment (stroma, blood supply, tissue architecture, mechanical 
forces), and a systemic environment (circadian cycle, hormonal fluctuations, 
microbiome) mirroring the multi-scale physiological interplay inherent to human 
cancer  and this includes an immune system. The effect of anti-Cas9 mediated 
immune selection has not been quantified in the literature, limiting the ability to 
make an accurate decision about the impact of this on experimental design. With 
this in mind it was most appropriate to move forward with the screen in 
immunocompetent adult mice. RASG 2-library tumours showed significantly lower 
Cas9 expression than Cas9-expressing organoids, or NICD/SB-CRISPR-Lib tumours. 
However, the recurrence of a set of drivers found across tumours, and a subset 
shared between RASG 2 oncogenes suggests that the selective advantage of these 
mutations outweighs the selective advantage of low Cas9 expression: that following 
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selection for Cas9-low cells, a genuine biological signal for adaptive driver 
acquisition persists.  
Whilst the primary aim of this study was to identify drivers, the screening model 
described here may have other useful applications. From a histopathological 
perspective, compared to the widely used NICD/myrAKT model, RASG 2-library 
tumours more broadly recapitulate morphological and stromal features of 
advanced human iCCA. NICD/myrAKT tumours are small and well differentiated 
cystadenocarcinomas that lack the extensive desmoplastic stroma found in 
classical human iCCA. They are powerful as a model due to their consistency, ease 
of generation and well-defined molecular/genetic aetiology. The tumours 
generated here show morphology consistent with ductular, high-grade, and 
sarcomatoid subtypes, as well as extensive stroma and a broader repertoire of 
immune infiltrating cell types. As such they represent a complimentary model for 
the study of the cellular and acellular stroma. Additionally, linking CRISPR/Cas9-
induced mutations in this study to different phenotypes will likely yield multiple 
models with known genetic aetiologies linked to desired stromal or morphological 
features. This would facilitate the study of a broader spectrum of iCCA phenotypes 
than is currently possible using existing models. 
The screening library may confer great value as a preclinical model for targeted 
therapeutic response by providing a source of genetic heterogeneity. The inclusion 
of a library containing human predicted drivers, in combination with a therapeutic 
target mutation (oncogenic RAS, neomorphic IDH, constitutively active FGFR2 
fusions), may constitute a powerful model for dissecting the genetic factors which 
  
 190 
contribute to differential treatment response in clinical trials. This represents a 
logical next step in the development of this system. For the purposes of unbiased 
driver screening, hypermutated samples were removed at the computational 
driver prediction stage to decrease false positives. However, when they were 
included, a number of likely candidate drivers were predicted alongside the 
proliferation of high-confidence false positives. Although not appropriate in this 
study due to the risk of biasing the input set for experimental driver screening, 
manual curation of the driver prediction results with and without hypermutated 
samples could yield a set of target genes which more extensively model human 
genetic heterogeneity. This would be advantageous in an experimental model to 
identify mutational (contra)indications for targeted therapy: a beneficial prospect 
for a tumour type which is consistently defined by heterogeneity at all levels.  
The data sources used as the raw input for this study arise from publications which 
have contributed immeasurably to the field through the elucidation of common 
drivers of iCCA. This study aimed to extend this work by using the same data to 
explore the long tail of infrequently mutated genes in iCCA. The primary result of 
this study demonstrates that within the noise of genetic heterogeneity exists 
disease-relevant genes, the mutation of which interacts with more common drivers 
to influence tumour phenotype and disease progression. Building upon the 
methodology and results of this study will hopefully shed further light on the 
genetic aetiology of iCCA and other cancer types more generally.  
This work newly identifies PLXNB2 and confirms NF2 as iCCA tumour suppressors 
which cooperate with common drivers to accelerate disease progression.  
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Appendix 1: sgRNA spacer sequences 
 
Library-A 
Gene  sgRNA ID sgRNA Spacer Sequence 
Abl1 Abl1_1 CCCTTCATACCGCAGCGAGA 
Abl1 Abl1_2 AAGGGAGGGTGTACCACTAC 
Abl1 Abl1_3 CGAGAGCCGCTTCAACACTC 
Ablim1 Ablim1_1 GTCATAGATCGCCTTGACCT 
Ablim1 Ablim1_2 GAAAGTATCTATTCTAGACC 
Ablim1 Ablim1_3 CTTACAGTCGGGATGCCACA 
Acvr1b Acvr1b_1 GTGTCTACCATAACCGCCAG 
Acvr1b Acvr1b_2 GTCTACGACCTCTCCACGTC 
Acvr1b Acvr1b_3 AGGGCCGGTTCGGGGAAGTA 
Akap9 Akap9_1 GATGCCGTCTCGCTGTTTAA 
Akap9 Akap9_2 GCCGCCATTAAACAGCGAGA 
Akap9 Akap9_3 GCGCACCTGCTTCAGCCCTT 
Apbb1 Apbb1_1 CGAGACGGATTCCGATCTAC 
Apbb1 Apbb1_2 GGAATCCGTCTCGAAAGCGT 
Apbb1 Apbb1_3 GAAGGACAATGTCGCCTCCT 
Aqp7 Aqp7_1 ACTCCCCAGGCATTCGTGAC 
Aqp7 Aqp7_2 GGCATCCTTGTTACCGTCCT 
Aqp7 Aqp7_3 CATTCGGCCTAGTGCACAAT 
Arhgap8 Arhgap8_1 GGCCCTCACCGCACTACTTC 
Arhgap8 Arhgap8_2 TCCTCCAGGGGATGACCGCC 
Arhgap8 Arhgap8_3 TATAGTCGTTCTCCACATGC 
Arid1a Arid1a_1 GCCCTGCTGGCCATACGCAC 
Arid1a Arid1a_2 GGTCCCTGTTGTTGCGAGTA 
Arid1a Arid1a_3 TAACCCATACTCGCAACAAC 
Arid2 Arid2_1 TACCAGCAACACAGCGTGTC 
Arid2 Arid2_2 ATAGCGAAGTCCACTTCATT 
Arid2 Arid2_3 CACTTTACTGCTCGCTAATG 
Atf7ip Atf7ip_1 CCGTACGTACTTCTCACAGG 
Atf7ip Atf7ip_2 TCCAAAACGTTTGGTTAACC 
Atf7ip Atf7ip_3 GGCAGTGCTCACCGAGCTGC 
Atp2b1 Atp2b1_1 TTACGTGCATTATCCCCTTC 
Atp2b1 Atp2b1_2 AATTGCAGCCATAGTATCAT 
Atp2b1 Atp2b1_3 CCTGCTCAATTCGACTCTGC 
Atp7a Atp7a_1 AACACGGTATTGGTTAAGAC 
Atp7a Atp7a_2 CAAGGTGTTCAGCGCATTAA 
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Atp7a Atp7a_3 GCAGCCGAAGTACCTCAAAT 
Bap1 Bap1_1 TCAAATGGATCGAAGAGCGC 
Bap1 Bap1_2 CCGCCGCAAGGTTTCTACGT 
Bap1 Bap1_3 GCCCACGCTGAGCCGAATGA 
Bcor Bcor_1 GATGAGGCCGAATCCAACGA 
Bcor Bcor_2 CTTACGGGCTGCATACGAGC 
Bcor Bcor_3 CGACGCTTCAAAAGCCAGGC 
Braf Braf_1 TCATAGGTACCCGCAAGATG 
Braf Braf_2 GAGGCCCTATTGGACAAATT 
Braf Braf_3 GTTGTTCCGTGATGCATCTG 
Brca2 Brca2_1 TAGGACCGATAAGCCTCAAT 
Brca2 Brca2_2 AAAGCTCCTCAAACCAATTG 
Brca2 Brca2_3 GGACTAGCAACATCTACCAC 
Cacna1c Cacna1c_1 CAACCGCCACACGGCCGCCC 
Cacna1c Cacna1c_2 CTCCTCGCAGGTTCCAACTA 
Cacna1c Cacna1c_3 GTTGGAGTCGTCTTCCGGAA 
Camkk1 Camkk1_1 ACAGGCCGTCCTCCCCCCAG 
Camkk1 Camkk1_2 TCTCCTGATACACACGCTCC 
Camkk1 Camkk1_3 TCTGTCTTCACTTTCGTTGT 
Cc2d2a Cc2d2a_1 ACTCACTCCGGGGCCCCCGC 
Cc2d2a Cc2d2a_2 AGGCAGAAAGCGCATTGTTG 
Cc2d2a Cc2d2a_3 CAACAATGCGCTTTCTGCCT 
Ccdc66 Ccdc66_1 TGAATACTGCTTATCCGTAC 
Ccdc66 Ccdc66_2 CACTACCGGTACTTGTCCAG 
Ccdc66 Ccdc66_3 TGCTCATGTTCACTCGTGAC 
Cdk18 Cdk18_1 GCCCTGCACTGCTATTCGAG 
Cdk18 Cdk18_2 GAACCAGCGCCGATTCTCCA 
Cdk18 Cdk18_3 TCCCAGTCAGATATCGGCTT 
Cdkn2a Cdkn2a_1 GTGCGATATTTGCGTTCCGC 
Cdkn2a Cdkn2a_2 CCCAACGCCCCGAACTCTTT 
Cdkn2a Cdkn2a_3 GGGGTACGACCGAAAGAGTT 
Chd4 Chd4_1 GCTTCGGATAAATCCTCGTC 
Chd4 Chd4_2 TCGGACCCTCACCAACTACA 
Chd4 Chd4_3 TCCTGACTTACCTAACAAAT 
Cped1 Cped1_1 TAGTCGACACATGTGCTCCC 
Cped1 Cped1_2 TGGTCTAGGTCCGGAGCTGC 
Cped1 Cped1_3 GTCGACTAAGCCTACATCAA 
Cpt1a Cpt1a_1 GACTATGCGCTACTCGCTGA 
Cpt1a Cpt1a_2 CACTCACGATGTTCTTCGTC 
Cpt1a Cpt1a_3 GGGTTACTCACGTGGTGTCT 
Dbndd2 Dbndd2_1 CATAGGTAGCATCTCGTCTA 
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Dbndd2 Dbndd2_2 GTTTATTGATCTTGCGGATC 
Dbndd2 Dbndd2_3 GATGTGGTCCTGTCAGACGT 
Dchs1 Dchs1_1 TAGGTAGGGCTATCAAATCG 
Dchs1 Dchs1_2 TGTGTGTACCACCCGGACCC 
Dchs1 Dchs1_3 TAGAGCGCGCAGTGTATAGA 
Ece2 Ece2_1 GAACGTCGCGCTGCACGAGT 
Ece2 Ece2_2 CTCGTGCAGCGCGACGTTCA 
Ece2 Ece2_3 GACCATGGATGTTCGAGCAC 
Ehhadh Ehhadh_1 AGCTGCGTTCCTCTTGCACC 
Ehhadh Ehhadh_2 CTATCGGATTGCCAATGCAA 
Ehhadh Ehhadh_3 GCCATCCAAGGCGTGGCTCT 
Elf3 Elf3_1 CGACTTCTCCCGCTGCGACA 
Elf3 Elf3_2 CTAGCGAGCGGCCCCAGTTC 
Elf3 Elf3_3 CAAAGGGGCCCGAGTCGCCT 
Epha2 Epha2_1 CAACGTGGTATCCGGCGACC 
Epha2 Epha2_2 TTCGCTGTCGAAGCACGCAA 
Epha2 Epha2_3 CTGCTGACCGTGATCTCGTC 
Erbb2 Erbb2_1 CTTACAGGCCCGGGAACGAT 
Erbb2 Erbb2_2 GCTAGACAACCGAGACCCTT 
Erbb2 Erbb2_3 ACATGGACACCAATCGTTCC 
Erbb3 Erbb3_1 CCCCTTGCAGACTTCGTGAC 
Erbb3 Erbb3_2 CGGGGAACCCAGGTCTACGA 
Erbb3 Erbb3_3 GCCCTTACCTAACCTCCGAG 
Esrra Esrra_1 TGTACTTCTGCCGTCCGCCG 
Esrra Esrra_2 GTACGTCCTGCTGAAAGCTC 
Esrra Esrra_3 TGCGACACCAGAGCGTTCAC 
Etv6 Etv6_1 GCATGGCGTGCTCTTCCGGT 
Etv6 Etv6_2 GTGAACATGAAGCGGAGTCG 
Etv6 Etv6_3 CTGACAGGGGGTACGTTTCC 
Fam136a Fam136a_1 GCGCCGCTACCTGCATCTTC 
Fam136a Fam136a_2 CGAGCGCTGCCATGCGCCTC 
Fam136a Fam136a_3 CATGGCAGCGCTCGATGCAT 
Fam174b Fam174b_1 CCACGATCACCGTCGCCTTC 
Fam174b Fam174b_2 TCGCAGAGCCGAGTCCGCTT 
Fam174b Fam174b_3 GCCATTTCCACACGTTCCGC 
Fh1 Fh1_1 AATTGGGCGAACTCACACGC 
Fh1 Fh1_2 CGTGTAGAGTTCGACACCTT 
Fh1 Fh1_3 AAAATCCAAAGAGTTTGCGC 
Fn1 Fn1_1 CCAGGTCTCCCCCACGACGT 
Fn1 Fn1_2 GACCTACCTAGGCAACGCCC 
Fn1 Fn1_3 CCTACAAGATTGGCGACAAG 
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Fzd2 Fzd2_1 ATCGACGGCGACCTGCTGAG 
Fzd2 Fzd2_2 GGCGCGGTGGTGAGTAGCGC 
Fzd2 Fzd2_3 TGCGAGCATTTCCCGCGTCA 
Gpr162 Gpr162_1 AGTCCAACGGCTCGGCTATC 
Gpr162 Gpr162_2 TCTCCGGATAGCCGAGCCGT 
Gpr162 Gpr162_3 GTGTGTGGCGATCATGTCCG 
Gstp1 Gstp1_1 GTCAGCCAGCAGCATTCGCA 
Gstp1 Gstp1_2 ATTGTCTACTTCCCAGTTCG 
Gstp1 Gstp1_3 TCACATAGTTGGTGTAGATG 
Heatr3 Heatr3_1 CACTACCAGACTTAGCCCGT 
Heatr3 Heatr3_2 GCCGGCGCACAGCATCCCGA 
Heatr3 Heatr3_3 ATTGACCTGGCTGTCTCCGT 
Helz Helz_1 GCAACGAGTAATGTCCTGTC 
Helz Helz_2 CTTCTACGTGACATCCAGAC 
Helz Helz_3 GCTGATGAAGATTGTAGGCA 
Hrct1 Hrct1_1 GAAACCGAGTCCGACAAGCC 
Hrct1 Hrct1_2 GTGGTGGTGAACGCCCACAC 
Hrct1 Hrct1_3 CGCCGGCCATGGAAGAGTCG 
Idh1 Idh1_1 TGGGCCTGTAAGAATTACGA 
Idh1 Idh1_2 GGCCCAAGCTATGAAGTCCG 
Idh1 Idh1_3 AGTCTTCAATTGACTTATCC 
Idh2 Idh2_1 ATGTTCCGGATCGTTCCGTT 
Idh2 Idh2_2 AGAGCCCTAACGGAACGATC 
Idh2 Idh2_3 TCGAGCTGGCACGTTCAAGT 
Il1r1 Il1r1_1 AGTCCCGGTCCGCTGATATG 
Il1r1 Il1r1_2 GCCGTATGTCCTATACGTTC 
Il1r1 Il1r1_3 TTGCTTCCCCCGGAACGTAT 
Itpr2 Itpr2_1 GGACATCGTGTCCCTGTACG 
Itpr2 Itpr2_2 TGACCGAGCCCTCCGCGTAC 
Itpr2 Itpr2_3 GTTCCCCTGTTTCGCCTGCT 
Itpr3 Itpr3_1 AGCATCCAGCGTCACCCGCA 
Itpr3 Itpr3_2 GCTGGATGCTACGGGCAATG 
Itpr3 Itpr3_3 GGTCTTACCTCGGAACTTCT 
Kras Kras_1 TGAGTATGACCCTACGATAG 
Kras Kras_2 AGCAGCGTTACCTCTATCGT 
Kras Kras_3 TAGAACAGTAGACACGAAAC 
Mme Mme_1 TGCTCGACTGATTCAGAATA 
Mme Mme_2 GGCCAGTAGCATCAGATAAC 
Mme Mme_3 TCCCAGTTATCTGATGCTAC 
Msr1 Msr1_1 GCGTTCCGTGTCTATAAGGT 
Msr1 Msr1_2 TGAACGTGCGTCAAATTTCA 
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Msr1 Msr1_3 TTCCTTGATTTCGTCAGTCC 
Mtch2 Mtch2_1 CTTTGACCGAGTTATCAAAG 
Mtch2 Mtch2_2 GGCACCTACCATAGCAAAAG 
Mtch2 Mtch2_3 AAAATATTTCGTCCTATTGT 
Ncor1 Ncor1_1 GGATATGAACAGTTTCACTC 
Ncor1 Ncor1_2 AATGTATTAGGCCTCAAGAA 
Ncor1 Ncor1_3 TATGCCTTACCTGCTGGTGT 
Nf2 Nf2_1 GATCCGCACCGTGAATGTCT 
Nf2 Nf2_2 GAAGCTCATGCGAGAAGCGA 
Nf2 Nf2_3 CTTGGCGTCATATGCTGTCC 
Notch2 Notch2_1 GTCGTCGATATTCCGCTCAC 
Notch2 Notch2_2 GCCTCCGTTGACGCAGGGCG 
Notch2 Notch2_3 TACGAGTGCACCTGCCAAGT 
Nprl3 Nprl3_1 AGCGGCGCTCCTCATGCTGC 
Nprl3 Nprl3_2 CTGCCAGTACCTCACTCGAG 
Nprl3 Nprl3_3 AAGGTTCTCGGATGTTATTC 
Nras Nras_1 CTAGCATACCTGTCGGGTCT 
Nras Nras_2 GACCTCAGCCAAGACCCGAC 
Nras Nras_3 TTGCAGATATTAACCTCTAC 
Pbrm1 Pbrm1_1 CAAACTCATTTCTTGTTCGA 
Pbrm1 Pbrm1_2 GTTGTAGCCACAAATCCATC 
Pbrm1 Pbrm1_3 ACATCACTTACCACTTTGGA 
Phf20l1 Phf20l1_1 CACGATCCAGCTGGGTCGAT 
Phf20l1 Phf20l1_2 GATATGATGAGTGGATTTAC 
Phf20l1 Phf20l1_3 TGTTGTCCTATCGACCCAGC 
Pik3ca Pik3ca_1 GCGCACTATTTATGACCCAG 
Pik3ca Pik3ca_2 TCACCATGCCGTCATACTCC 
Pik3ca Pik3ca_3 CAGAAGTCCAAGACTTTCGA 
Pik3r1 Pik3r1_1 AGATGCGTCTCGTACCAAAA 
Pik3r1 Pik3r1_2 GGAGTACACCCGTACTTCCC 
Pik3r1 Pik3r1_3 GTGAATTACCTGCTGGTATT 
Plch2 Plch2_1 TAGCCCGTCGCCAGCGTACC 
Plch2 Plch2_2 CCGTAGTCCCCCAAGCCAAA 
Plch2 Plch2_3 GATATTGGTCCCTGGTACGC 
Plk2 Plk2_1 CAGAAGTCCGATACTACCTC 
Plk2 Plk2_2 AAAACTGCACGACATGCTTA 
Plk2 Plk2_3 ACGAACAAGAAATCTTGCAC 
Plxnb2 Plxnb2_1 CTCAGATGGCCGGATCCTTA 
Plxnb2 Plxnb2_2 TACTCTGCAGAAGTGCCGTC 
Plxnb2 Plxnb2_3 GGAGTCACGACACTGAGCGC 
Rasa1 Rasa1_1 ACACGCCTTCTATCTTCTAC 
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Rasa1 Rasa1_2 CTATAGCAGAAGAACGCCTC 
Rasa1 Rasa1_3 CGTGACTGTAATAACCTATT 
Rb1 Rb1_1 AGAAATCGATACCAGTACCA 
Rb1 Rb1_2 TGACATAGCATTATCAACCT 
Rb1 Rb1_3 TTGGGAGAAAGTTTCATCCG 
Rbmx Rbmx_1 CCTTAAGCCCCTGTGTCCCG 
Rbmx Rbmx_2 CTCTTGACTTATTCGTTTCT 
Rbmx Rbmx_3 CGAGAAACGAATAAGTCAAG 
Rev1 Rev1_1 ACGGCGTCTGCAATATTTAG 
Rev1 Rev1_2 TGAAATGAAGTTGCAGTCCG 
Rev1 Rev1_3 TTGGTCGTAGGGCGGGTACA 
Rexo4 Rexo4_1 TGATACTTACTCAGTGGGCG 
Rexo4 Rexo4_2 CCCTAGCTTGACAAAAGCCT 
Rexo4 Rexo4_3 GTGTCGATCGTGAACCAGTA 
Rnf31 Rnf31_1 CATACAACCGTAGTACATCC 
Rnf31 Rnf31_2 AGGGTGGCCGGGATGTACTA 
Rnf31 Rnf31_3 TAACCCCGTCTTTCGCAGCA 
Rnf43 Rnf43_1 GAGACGCTTACCCCGGCGGG 
Rnf43 Rnf43_2 CAGGGGCGAGGAGCTCGTCG 
Rnf43 Rnf43_3 TTTCCACAGGCCCGAATGGC 
Rps29 Rps29_1 CTCACCAAGAGCGGGAACCC 
Rps29 Rps29_2 GAAGGACATAGGCTTCATTA 
Rps29 Rps29_3 TGGGTCACCAGCAGCTCTAC 
Sdk1 Sdk1_1 AGAACTCACGTGCTACGCTC 
Sdk1 Sdk1_2 TCCTGTTCCGCACCACGCAG 
Sdk1 Sdk1_3 CATCACTCGCTGTTGTAGCA 
Setd2 Setd2_1 GATCTCTTTCGGACCGACAT 
Setd2 Setd2_2 GTCGGTCCGAAAGAGATCGA 
Setd2 Setd2_3 ACTGCATTCGCTTAATATCC 
Sf3b1 Sf3b1_1 GTCCTCCAAAGATTGCCGAT 
Sf3b1 Sf3b1_2 GCCTGGATATCATGCCCCCG 
Sf3b1 Sf3b1_3 TATATCATTAAGCAACGCCA 
Smad4 Smad4_1 GCCAAGTAATCGCGCATCAA 
Smad4 Smad4_2 TCCGTTGATGCGCGATTACT 
Smad4 Smad4_3 ACAACCCGCTCATAGTGATA 
Smu1 Smu1_1 TCCAGATGAATATAGCGCTC 
Smu1 Smu1_2 ATTGATAGAGCTTCGTGAAT 
Smu1 Smu1_3 CTTGCCTCGAAACAAATCGA 
Snrpn Snrpn_1 GGAACTCCACCTCCACCTGT 
Snrpn Snrpn_2 TGGGGAATAGGTACACCTGC 
Snrpn Snrpn_3 TTCACAGGTCATGACCCCAC 
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Stk11 Stk11_1 GCGCCCTACGTATATGGTGA 
Stk11 Stk11_2 TGTACAGCACGTCCACAAGC 
Stk11 Stk11_3 ATTCCAGGCCGTCAATCAGC 
Tbc1d8b Tbc1d8b_1 CTAGGGACTAATCGCTGAAG 
Tbc1d8b Tbc1d8b_2 GTCTGGTGTAGGATGCGAAA 
Tbc1d8b Tbc1d8b_3 CCGTCCTCTCCAGTAACTGC 
Tgfbr1 Tgfbr1_1 ATCTATTCAAGTAATCGAAA 
Tgfbr1 Tgfbr1_2 CTTCTAGAGAAGAGCGTTCA 
Tgfbr1 Tgfbr1_3 AGTGATGGATCCTCTTCATT 
Thbs1 Thbs1_1 AAGGGGCCCCGGTCGCCGAC 
Thbs1 Thbs1_2 CCCTTCACCAGTCGGCGACC 
Thbs1 Thbs1_3 GCTATCCGCACCAACTACAT 
Tmtc1 Tmtc1_1 GTAGAATGACATTGACCGCG 
Tmtc1 Tmtc1_2 TTATACTCACCGCCTCAGTG 
Tmtc1 Tmtc1_3 CCATGTCGCCGAGAGCTATG 
Tmtc4 Tmtc4_1 GGCCTTTACCGGTGTACTGT 
Tmtc4 Tmtc4_2 AGGATTAACTACTACCTGTC 
Tmtc4 Tmtc4_3 CCCCAAGGGGCGTGTCTGAC 
Trp53 Trp53_1 AGTGAAGCCCTCCGAGTGTC 
Trp53 Trp53_2 AACAGATCGTCCATGCAGTG 
Trp53 Trp53_3 TGAGGGCTTACCATCACCAT 
Ttc8 Ttc8_1 CGATCTATGCACGCAGATGC 
Ttc8 Ttc8_2 CGACCTATCACTAGCTCATC 
Ttc8 Ttc8_3 CGGCCAGGTACCTGATCATA 
Wdr62 Wdr62_1 ATGACATGGTCCTCAATGTT 
Wdr62 Wdr62_2 GTCACTATGTACTTCCCATC 
Wdr62 Wdr62_3 ATGTGCTTACCCTGCTAAGT 
Zfp317 Zfp317_1 CCATAAATAGGTTATCAGGT 
Zfp317 Zfp317_2 TTATAGCAATCTAAGTTCAC 
Zfp317 Zfp317_3 GAACTACATCTAAAGTCAAA 
Zfp36l2 Zfp36l2_1 CGATATCGACTTCTTGTGCA 
Zfp36l2 Zfp36l2_2 CGCGTGCGCCAAACGCTCGC 








Gene sgRNA ID sgRNA Spacer Sequence 
Abl1 Abl1_1 CGCAACAAGCCCACTATCTA 
Abl1 Abl1_2 TCATCACCGCCGCTTCCTTC 
Abl1 Abl1_3 GTCTCAGCGAAGCAGCTCGA 
Ablim1 Ablim1_1 TCTTTCCAGGTTCTACCGTG 
Ablim1 Ablim1_2 TATGAGCCTTTCTACACATC 
Ablim1 Ablim1_3 TCCAGCATCCCTGGTTCACC 
Acvr1b Acvr1b_1 CACGCCATACTTCCCCGAAC 
Acvr1b Acvr1b_2 CATGGTGCTCCACGCCATCC 
Acvr1b Acvr1b_3 CCGCTACACAGTGACCATTG 
Akap9 Akap9_1 GCCGGGAATCCTGATTGCTC 
Akap9 Akap9_2 TGATATTGAAGAGTTGACTC 
Akap9 Akap9_3 CGAGCTACATTCATCTGCAG 
Apbb1 Apbb1_1 CTCCTTCAGCTCACCTGGAC 
Apbb1 Apbb1_2 CTTGAACAAACCTTGATCCC 
Apbb1 Apbb1_3 CCCAATGGAGTTGGGACTGA 
Aqp7 Aqp7_1 GGTGCCATTAACCACTTTGC 
Aqp7 Aqp7_2 GAAGTTCCCTGTATATGTGC 
Aqp7 Aqp7_3 CAGAGATGCCGCCTGCTACA 
Arhgap8 Arhgap8_1 CTTCCGGTCAAACTCCTTGT 
Arhgap8 Arhgap8_2 GTACAACGTACAGTGCCTTC 
Arhgap8 Arhgap8_3 GCTCAACCACCAGCGCCTGC 
Arid1a Arid1a_1 AGTGTCGCGCAGTCTCGCTC 
Arid1a Arid1a_2 TGAGCGAGACTGCGCGACAC 
Arid1a Arid1a_3 CTGCTGCTGATACGAAGGCT 
Arid2 Arid2_1 TACCTGACACGCTGTGTTGC 
Arid2 Arid2_2 GCCGTTTAAGAAGATCCCTG 
Arid2 Arid2_3 TCCGCCTAAAGTAGTGACTC 
Atf7ip Atf7ip_1 TGCTGTGTTTGATAAGACGT 
Atf7ip Atf7ip_2 ATTCTTCATCCATATATCGC 
Atf7ip Atf7ip_3 AGAGGAGCGAGTTCCAGCCG 
Atp2b1 Atp2b1_1 TGGGCTTACCGTACTTCACT 
Atp2b1 Atp2b1_2 GGAATCATCTTCACCTTACT 
Atp2b1 Atp2b1_3 TGCTATAGGTACTCATGTGA 
Atp7a Atp7a_1 CTTCAGGCGCTCAACATCAA 
Atp7a Atp7a_2 GTTTGCTACACAAGAAGCAC 
Atp7a Atp7a_3 CGCAATTTAAGACGAGAAGA 
Bap1 Bap1_1 ATCCTTCATTCGGCTCAGCG 
Bap1 Bap1_2 CCTGATCGTAGGTGTCAAAG 
Bap1 Bap1_3 TCTTACCGAAATCTTCCACC 
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Bcor Bcor_1 CTGTGAACGTTCCCATACAG 
Bcor Bcor_2 GAAGCGTCGCCATCATTCAC 
Bcor Bcor_3 ACAGCTGGATGAACAGCGAG 
Braf Braf_1 GCAAATGATTAAGTTGACAC 
Braf Braf_2 TCTTCCTGCCCAACAAACAG 
Braf Braf_3 CTTGCTGGTGTACTCTTCAT 
Brca2 Brca2_1 TGTGTGCACCGCAGAGTAAG 
Brca2 Brca2_2 GTACTACAACGAGAAAAGCC 
Brca2 Brca2_3 TCACTGAGACAAGATTTCAG 
Cacna1c Cacna1c_1 CCCAACGCTTACCTCCGCAA 
Cacna1c Cacna1c_2 GCCGCAGTGGACGGAGCACG 
Cacna1c Cacna1c_3 TCCGCGTGCTCCGTCCACTG 
Camkk1 Camkk1_1 TCTGCAGGGTGCCTATGGTG 
Camkk1 Camkk1_2 TACAAGCTGCAGAGTGAGAT 
Camkk1 Camkk1_3 TCTCACTCTGCAGCTTGTAC 
Cc2d2a Cc2d2a_1 CAAGCTCAGGAGGTTGGTCT 
Cc2d2a Cc2d2a_2 CTCCCTCATTCGTTCCCTCA 
Cc2d2a Cc2d2a_3 AAGCCGGTTCTAGAAGCTGA 
Ccdc66 Ccdc66_1 ATATGGGGACAGTATTAACT 
Ccdc66 Ccdc66_2 GAAATGCCTCTTGAGCTCTC 
Ccdc66 Ccdc66_3 AAGTTAATACTGTCCCCATA 
Cdk18 Cdk18_1 ACCCTCTCGAATAGCAGTGC 
Cdk18 Cdk18_2 CGTTGTTGATACTGCATGCC 
Cdk18 Cdk18_3 CATGGACATCCGCCTACCCC 
Cdkn2a Cdkn2a_1 GGCTGGATGTGCGCGATGCC 
Cdkn2a Cdkn2a_2 TCGTGCGATCCCGGAGACCC 
Cdkn2a Cdkn2a_3 CCGCACCGGAATCCTGGACC 
Chd4 Chd4_1 TTGCGGATCGGCACCTCCAC 
Chd4 Chd4_2 TAAGAGCAAGCGCCAAAAAA 
Chd4 Chd4_3 GGCTCTGCGCTCAGACAGTG 
Cped1 Cped1_1 TCCCGAGGTTTCCATACATG 
Cped1 Cped1_2 GCAGAAGGGCCGTCCTCCAC 
Cped1 Cped1_3 AAGATTACCTGGAAATCTTC 
Cpt1a Cpt1a_1 GCAGGCGCGGCAGAGACGTC 
Cpt1a Cpt1a_2 CTGTCAAAGATACCGTGAGC 
Cpt1a Cpt1a_3 GGGGTCCACTTTGGTATGCA 
Dbndd2 Dbndd2_1 ATTTGGACTGCGCAGGTTGG 
Dbndd2 Dbndd2_2 GCCGCAGCTGTTGGCGCTCC 
Dbndd2 Dbndd2_3 AGCGCCAACAGCTGCGGCTC 
Dchs1 Dchs1_1 AGAATTAGCCCGTCTGCCTA 
Dchs1 Dchs1_2 ATTATGCCCACACTGGTGCC 
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Dchs1 Dchs1_3 AAAGTCGCCCATGGGGTCCC 
Ece2 Ece2_1 GTCCAGTGCTCGAACATCCA 
Ece2 Ece2_2 GTAAGCCGGTTGCTAGTTCC 
Ece2 Ece2_3 ATGCTCAATCCCGTTATGAC 
Ehhadh Ehhadh_1 GCTCTTGACTTAATTACCTC 
Ehhadh Ehhadh_2 AACCGTCTGAGCAAATTTGA 
Ehhadh Ehhadh_3 TATGGTCCAAACTAGCTTTC 
Elf3 Elf3_1 ACTCCTGGATGATGGCCGCC 
Elf3 Elf3_2 CCCTACTACTGCAGTACCTA 
Elf3 Elf3_3 CCTGGACCTCACCGAGAGCA 
Epha2 Epha2_1 GTGCCAAAGTAGAACTGCGT 
Epha2 Epha2_2 CTCACGCACCCCTATGGCAA 
Epha2 Epha2_3 TTTACTCACCCCTTTGCCAT 
Erbb2 Erbb2_1 TGACGTTGTCCAAAGGGTCT 
Erbb2 Erbb2_2 CATGCTTCGCCACCTCTACC 
Erbb2 Erbb2_3 AGGGAGTCGCAACTTCATGT 
Erbb3 Erbb3_1 CTCAGCCCGTTTAGAGTCCC 
Erbb3 Erbb3_2 GTCCCGTAAGCACAATCTCC 
Erbb3 Erbb3_3 TTGACTGGAGGGACATCGTG 
Esrra Esrra_1 CCACTATCTCTCGATCAAAA 
Esrra Esrra_2 TACAATTCAAGGTGTGCGTC 
Esrra Esrra_3 GAGCATCGAGTACAGCTGTC 
Etv6 Etv6_1 CAGGTTTGCAGCCGATTTAC 
Etv6 Etv6_2 ACACAGTGCCTCGAGCGCTC 
Etv6 Etv6_3 CGCTACCGATCTCCTCATTC 
Fam136a Fam136a_1 TTGTTGGGATGAGGTGCATG 
Fam136a Fam136a_2 GGTGCAGCAACTCCGAGTGC 
Fam136a Fam136a_3 TGACAAAGCCAAAGACTCAA 
Fam174b Fam174b_1 TCATCGTCCTCCTCATTCAG 
Fam174b Fam174b_2 CTCCAACAGCAGCGTCGACG 
Fam174b Fam174b_3 GTCTGCTGCTGCGCGTCTTC 
Fh1 Fh1_1 ATGCCGAAAGCTTGAATGAC 
Fh1 Fh1_2 GTTCCAACCGATAAGTATTA 
Fh1 Fh1_3 AGCTGCTGCTGAAGTAAACC 
Fn1 Fn1_1 CCTACGTCGTGGGGGAGACC 
Fn1 Fn1_2 GACTGTACCTGCATCGGGGC 
Fn1 Fn1_3 CCACTTACCTATAGGTTTGC 
Fzd2 Fzd2_1 GCCGGACCGGCCCAGTTCCA 
Fzd2 Fzd2_2 CGGTTATCGCACGGTGGTGC 
Fzd2 Fzd2_3 ATCTGCTCCGCGCCGTGACG 
Gpr162 Gpr162_1 CCCGTTGTTGTGCCAGCCGA 
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Gpr162 Gpr162_2 GGGGAGCGCTACTATGCCCG 
Gpr162 Gpr162_3 GCACATGCTCTTCCCACCGC 
Gstp1 Gstp1_1 CATCATTCACCATATCCATC 
Gstp1 Gstp1_2 TCGAACTGGGAAGTAGACAA 
Gstp1 Gstp1_3 GCGAATGCTGCTGGCTGACC 
Heatr3 Heatr3_1 AAAGGACATCATGACGCCCC 
Heatr3 Heatr3_2 TTGTGTTACAGTACTTACGT 
Heatr3 Heatr3_3 TGTAGAGAGCATAGCCAATG 
Helz Helz_1 AGACTCCCCTGACAGTGACT 
Helz Helz_2 CTGTGCTGCATGCAGCTGAA 
Helz Helz_3 GACACTTCTCACAGAAACAG 
Hrct1 Hrct1_1 TCACCCCGGTCACATGGTGA 
Hrct1 Hrct1_2 AGCGGCGGGCTCCATGAGCA 
Hrct1 Hrct1_3 CTTCCAGATGTTAGGCCTTC 
Idh1 Idh1_1 TCGTGATGCCACCAATGACC 
Idh1 Idh1_2 TGGCACCATCCGAAACATTC 
Idh1 Idh1_3 ACTATTCTGAAGAAGTATGA 
Idh2 Idh2_1 GGGGATGTACAACACCGACG 
Idh2 Idh2_2 TGGACGGTGACGAGATGACC 
Idh2 Idh2_3 CAAGGTGGAGAAGCCGGTAG 
Il1r1 Il1r1_1 CAGCAAGACCCCCATATCAG 
Il1r1 Il1r1_2 ACGAAATTACCTTATACCAC 
Il1r1 Il1r1_3 TGAAAATAATGAGTTACCCG 
Itpr2 Itpr2_1 TTGGCAAGGTCTCCCGCCTC 
Itpr2 Itpr2_2 TGGGCAGAGTATCGATTCAT 
Itpr2 Itpr2_3 CTTGTAGCATGCTGCAGAGC 
Itpr3 Itpr3_1 AACCCCCCCAAGAAGTTCCG 
Itpr3 Itpr3_2 CACGGGGACGTGGTGAAGTA 
Itpr3 Itpr3_3 TTTGTCCTGTTTAGTCTGCT 
Kras Kras_1 AATCACACTTATTCCCTACC 
Kras Kras_2 CCTCCCCAGTTCTCATGTAC 
Kras Kras_3 TCTCGACACAGCAGGTCAAG 
Mme Mme_1 ATTTATACACGATCTGTACA 
Mme Mme_2 GACTTCTTCAAGTATGCTTG 
Mme Mme_3 TCATCAGACTGCATAAAATC 
Msr1 Msr1_1 GCAGTACTAATACCTGTTGT 
Msr1 Msr1_2 GGAGAAGTTGAAGTCCTTCA 
Msr1 Msr1_3 TCAGCATCCTCTTGTTCATG 
Mtch2 Mtch2_1 TTGACTCCAAGACTGTGTTC 
Mtch2 Mtch2_2 TTACCTGTAAGACTTTCCCA 
Mtch2 Mtch2_3 CTCTTACCTCTTTGATAACT 
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Ncor1 Ncor1_1 AGTTAATACAGAGTATGGAC 
Ncor1 Ncor1_2 TCCCAGTACCCGACACCAGC 
Ncor1 Ncor1_3 TTCCATTACCTGTCAGAACC 
Nf2 Nf2_1 CACTGGGGCTTCGGGAAACC 
Nf2 Nf2_2 TGGACTGCAGTATACAATCA 
Nf2 Nf2_3 GTTGGATCATGATGTTTCGA 
Notch2 Notch2_1 GCACCCTCGCCCTGCGTCAA 
Notch2 Notch2_2 CATTACCTGTGAAGCCGACT 
Notch2 Notch2_3 ATTGCCGCTGTCCCCCTCAG 
Nprl3 Nprl3_1 TTGACAGCATATCTGCTCCG 
Nprl3 Nprl3_2 GGAGCTTCCCGCTTTGGAGA 
Nprl3 Nprl3_3 TACCACGTTAAAAAGAATCA 
Nras Nras_1 CTTCGCCTGTCCTCATGTAC 
Nras Nras_2 AAGCTCAACAGCAGTGACGA 
Nras Nras_3 CTGGGCCTCACCTCTATGGT 
Pbrm1 Pbrm1_1 TAACACCATCCGAGACTATA 
Pbrm1 Pbrm1_2 TTACAAGCAGCTTTATACTC 
Pbrm1 Pbrm1_3 TCAACCAGACTATTATGAAG 
Phf20l1 Phf20l1_1 GATGACTCCAGCGCTCAAAA 
Phf20l1 Phf20l1_2 TTTGTTAATTGCTTCAATCT 
Phf20l1 Phf20l1_3 GCACATTAAAGCCATGCCTG 
Pik3ca Pik3ca_1 TACTTCTGCTTGTCGTTGTT 
Pik3ca Pik3ca_2 GAATGTTCCTTCGAAAGTCT 
Pik3ca Pik3ca_3 TCTTACCTAGGATTGGAACA 
Pik3r1 Pik3r1_1 TTGAGTTAATAAACCACTAC 
Pik3r1 Pik3r1_2 GACGCATCTACTAAAATGCA 
Pik3r1 Pik3r1_3 GTACCATTCAGCATCCTGCA 
Plch2 Plch2_1 GACTACGGCTTGGATATGCC 
Plch2 Plch2_2 AGCACCGCTCCTGCCTCCGA 
Plch2 Plch2_3 ATTGGTCCGCTTCTACTACC 
Plk2 Plk2_1 GAGTAGCTAAACCTCATCAG 
Plk2 Plk2_2 GAAGGTGGGAGACTTTGGTT 
Plk2 Plk2_3 CACCTCCTTCTGTGTTCCAG 
Plxnb2 Plxnb2_1 TGCCCAGGAACGCAACAGTG 
Plxnb2 Plxnb2_2 GCACCTCTCCTTGGGCCCGC 
Plxnb2 Plxnb2_3 TTCCTCGGCCCGTGAGCACT 
Rasa1 Rasa1_1 TATAGGATTATTGCTATGTG 
Rasa1 Rasa1_2 CCTTATTGTTGAAGACCTAG 
Rasa1 Rasa1_3 TACCTTATTTCATCAGTGTC 
Rb1 Rb1_1 TCTTACCAGGATTCCATCCA 
Rb1 Rb1_2 TGTAGCTCAGTAAAAGTGAA 
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Rb1 Rb1_3 TACAGAAAAGCATAGAAACC 
Rbmx Rbmx_1 CCCCTCCCGGGGAGGACACA 
Rbmx Rbmx_2 CTTTACCCATGTGTCCTCCC 
Rbmx Rbmx_3 GTTACGGAGGCCCGCCACGA 
Rev1 Rev1_1 TCAGCTCTACACCAAGCCGT 
Rev1 Rev1_2 TTTCTCAATTCCTCCGCAGA 
Rev1 Rev1_3 CACCCTGTTGTTGAGCTGTT 
Rexo4 Rexo4_1 ACTAGTATCTTCCTGTCCGT 
Rexo4 Rexo4_2 TGTCTCATAGGGAAGACATC 
Rexo4 Rexo4_3 AATGTTGAAGGGCAGAATCC 
Rnf31 Rnf31_1 ATCCACCGTGCTGCGAAAGA 
Rnf31 Rnf31_2 CAACGCTCTCTCTTAGCAGC 
Rnf31 Rnf31_3 CTAAGAGAGAGCGTTGAAGA 
Rnf43 Rnf43_1 TCCAGGCAAACTATGACGTG 
Rnf43 Rnf43_2 GATGTCAAAGAGTACTGCGT 
Rnf43 Rnf43_3 GTTTGTGTACAAGAATCGGA 
Rps29 Rps29_1 CGCGTCTGCTCCAACCGCCA 
Rps29 Rps29_2 TCACCCACGGAAGTTCGGCC 
Rps29 Rps29_3 GGTGACTCCAGTAGAGCTGC 
Sdk1 Sdk1_1 CGTTGCACCGTATTTCAAAA 
Sdk1 Sdk1_2 TCTCTAAACCACGTCACTTG 
Sdk1 Sdk1_3 GCCCCCAACCTCAAGTGACG 
Setd2 Setd2_1 AGTTCCTCTCGATGTCCAAA 
Setd2 Setd2_2 ATCGTCTCCTCATGATTGAA 
Setd2 Setd2_3 CTGGGGCTTAAGGGCTGCTA 
Sf3b1 Sf3b1_1 TTTGTATTCATCTTCCCGAT 
Sf3b1 Sf3b1_2 TTCTCGCATAACATCCATGT 
Sf3b1 Sf3b1_3 GCGAGAACAACATTTGACTA 
Smad4 Smad4_1 AGACGGGCATAGATCACATG 
Smad4 Smad4_2 CTGCCCGCCAGAATACTGGC 
Smad4 Smad4_3 AGGTCAGCCGGCCAGTATTC 
Smu1 Smu1_1 ATGACCATCGATTTGTTTCG 
Smu1 Smu1_2 GAACAGTTTACATCGGGCAC 
Smu1 Smu1_3 TCAAGTACTGCATGATTAGT 
Snrpn Snrpn_1 ATCTTCCTTACATCTTTAGG 
Snrpn Snrpn_2 GCTGGCAGAGGAGTGCCAGC 
Snrpn Snrpn_3 GAACTTGGTTTCAATGACTG 
Stk11 Stk11_1 GTACTGCGTATGTGGCATGC 
Stk11 Stk11_2 TCGGAATGTGATCCAGCTTG 
Stk11 Stk11_3 TGACACCTGCCGGACAAGCC 
Tbc1d8b Tbc1d8b_1 GTGTACTTGTCAATTGCATG 
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Tbc1d8b Tbc1d8b_2 AGCATTCACGTATGTTCTCA 
Tbc1d8b Tbc1d8b_3 TAATGAGACATACCTTCTTA 
Tgfbr1 Tgfbr1_1 CATACAAATGGCCTGTCTCG 
Tgfbr1 Tgfbr1_2 TTGACCTAATTCCTCGAGAC 
Tgfbr1 Tgfbr1_3 GTTACGCCATGAAAATATCC 
Thbs1 Thbs1_1 CACCATCGTGACCACTCTGC 
Thbs1 Thbs1_2 ACTCCTCGTTGTTCTTGTAC 
Thbs1 Thbs1_3 AGTCCAGTACAAGAACAACG 
Tmtc1 Tmtc1_1 TTTCTAGGTGGCTGGCATCG 
Tmtc1 Tmtc1_2 AAGAAGGGGGAAGCCGTTGT 
Tmtc1 Tmtc1_3 AACCAAGCACACTCCAAACA 
Tmtc4 Tmtc4_1 CTCCAGTCAGACACGCCCCT 
Tmtc4 Tmtc4_2 GATACTCAGCAATACCCAGA 
Tmtc4 Tmtc4_3 TTACTTACCAGCAGGTAACA 
Trp53 Trp53_1 GGCCTTACCAGGATATCTTC 
Trp53 Trp53_2 ATAAGCCTGAAAATGTCTCC 
Trp53 Trp53_3 GTGCTGTGACTTCTTGTAGA 
Ttc8 Ttc8_1 CTTCCAGATGAGCTAGTGAT 
Ttc8 Ttc8_2 CCTCCTGTTTGGTTAGTGCC 
Ttc8 Ttc8_3 GAGGACCGACTCAAGCTGTC 
Wdr62 Wdr62_1 ATTGGGTGAGAAAGCCACAC 
Wdr62 Wdr62_2 TTTCCCTAGGTGCGTGGTGG 
Wdr62 Wdr62_3 GATGGGAAGTACATAGTGAC 
Zfp317 Zfp317_1 TGATTCTTGTCAGCAGAGTT 
Zfp317 Zfp317_2 AGCATCTGATGATGTAAGAT 
Zfp317 Zfp317_3 GACATTTCAAGATATTGCTG 
Zfp36l2 Zfp36l2_1 CAAGAAGTCGATATCGTAGA 
Zfp36l2 Zfp36l2_2 GACCCACAACTTCGCCGCCG 









Non-Targeting Controls (common between both libraries) 





















































































































































































































Appendix 2: Differentially Expressed Genes 
Between Nf2-A and KRASG12D-Library Tumours 
 
Upregulated (ordered by log2 fold change) 
Gene ID Gene Name log2 Fold Change P-value P(adj) 
MGP_FVBNJ_G0017302 Cfd 4.384444214 4.30E-06 0.00017903 
MGP_FVBNJ_G0000052 Ighv7-1 3.531523959 8.97E-05 0.00252514 
MGP_FVBNJ_G0022490 Adipoq 3.441007774 0.00102384 0.01950631 
MGP_FVBNJ_G0033495 Slc5a5 3.01705766 0.00010906 0.00297187 
MGP_FVBNJ_G0028916 Rbp7 3.002657264 1.50E-06 6.89E-05 
MGP_FVBNJ_G0022423 Tbx1 2.999890466 1.17E-05 0.0004379 
MGP_FVBNJ_G0022875 Sim2 2.986600227 0.00151647 0.02665906 
MGP_FVBNJ_G0030971 B4galnt3 2.948664467 0.00023502 0.00573179 
MGP_FVBNJ_G0027812 Penk 2.861201955 0.00094071 0.01820267 
MGP_FVBNJ_G0026033 Mpped2 2.726239209 1.39E-07 7.96E-06 
MGP_FVBNJ_G0029302 Fgfbp1 2.677871058 0.00202403 0.03324805 
MGP_FVBNJ_G0020798 Fam107a 2.622394741 0.00020526 0.00513558 
MGP_FVBNJ_G0033916 Vat1l 2.543625305 0.00316314 0.04672599 
MGP_FVBNJ_G0021464 Cldn10 2.477684012 0.00053777 0.01155983 
MGP_FVBNJ_G0020769 Isl1 2.428196089 0.0018201 0.03078293 
MGP_FVBNJ_G0023563 Adgrf4 2.414631081 0.00131364 0.02380684 
MGP_FVBNJ_G0015259 Gm13429 2.295997381 0.00031079 0.00721642 
MGP_FVBNJ_G0019067 Higd1b 2.287231062 0.00263376 0.04071374 
MGP_FVBNJ_G0019350 Cbr2 2.240790946 2.72E-05 0.00092037 
MGP_FVBNJ_G0016481 Pappa2 2.150865873 0.00240546 0.0382455 
MGP_FVBNJ_G0003801 AI115009 2.062556039 0.00077162 0.01556578 
MGP_FVBNJ_G0025147 Sfmbt2 2.060721612 0.00278649 0.0424563 
MGP_FVBNJ_G0029441 Gnrhr 2.057138989 2.13E-05 0.00074896 
MGP_FVBNJ_G0030245 Wnt2 2.036402468 0.00067847 0.01398462 
MGP_FVBNJ_G0024052 Reep2 2.021313946 5.34E-06 0.00021694 
MGP_FVBNJ_G0024951 Loxl4 2.003282231 0.0001197 0.00320698 
MGP_FVBNJ_G0017158 Zfp365 1.991244019 7.31E-05 0.00213168 
MGP_FVBNJ_G0030085 Papolb 1.969554203 0.00074618 0.01513477 
MGP_FVBNJ_G0030996 Mfap5 1.943287185 0.00088864 0.01739127 
MGP_FVBNJ_G0005388 1700018A04Rik 1.936628277 0.00311443 0.04619149 
MGP_FVBNJ_G0017489 Usp44 1.925937622 0.00141853 0.02529642 
MGP_FVBNJ_G0030084 Radil 1.912447317 0.00094001 0.01820267 
MGP_FVBNJ_G0030963 Lrtm2 1.897101298 0.00052371 0.01133409 
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MGP_FVBNJ_G0027776 Ak5 1.865973689 0.00128694 0.02339901 
MGP_FVBNJ_G0017931 Ccdc85a 1.855631533 6.60E-11 7.60E-09 
MGP_FVBNJ_G0025605 Lrp2 1.835430232 0.00218612 0.03526101 
MGP_FVBNJ_G0022142 Aqp2 1.756186625 0.00103984 0.01971004 
MGP_FVBNJ_G0018124 Sowaha 1.688970804 0.00013522 0.00356299 
MGP_FVBNJ_G0026018 Tcp11l1 1.684517242 0.00014091 0.00369534 
MGP_FVBNJ_G0034571 Slc35f2 1.651483327 0.00252358 0.03946036 
MGP_FVBNJ_G0019625 Trim9 1.648437137 0.00312055 0.04625017 
MGP_FVBNJ_G0016854 Plagl1 1.605543295 0.00238969 0.03803878 
MGP_FVBNJ_G0029605 Ephx4 1.603218216 5.79E-05 0.00174534 
MGP_FVBNJ_G0025567 Pla2r1 1.595036746 6.63E-05 0.00195846 
MGP_FVBNJ_G0002865 Gm12002 1.507153422 0.00187614 0.0314208 
MGP_FVBNJ_G0023941 Greb1l 1.474769316 1.25E-06 5.87E-05 
MGP_FVBNJ_G0018072 NA 1.4175676 0.00088828 0.01739127 
MGP_FVBNJ_G0004509 0610038B21Rik 1.41726054 0.00062948 0.01312668 
MGP_FVBNJ_G0026541 Procr 1.38226708 0.00344848 0.04994811 
MGP_FVBNJ_G0036701 Gm10855 1.356292315 0.00258871 0.04021253 
MGP_FVBNJ_G0025438 Ralgps1 1.349843877 3.11E-05 0.00103608 
MGP_FVBNJ_G0015847 Sdpr 1.315638979 0.00161064 0.0278532 
MGP_FVBNJ_G0025582 Cobll1 1.300943926 0.00196631 0.03251561 
MGP_FVBNJ_G0026153 Jmjd7 1.27181428 1.72E-05 0.00062116 
MGP_FVBNJ_G0008900 Mir5620 1.261654801 0.00328314 0.04802125 
MGP_FVBNJ_G0025930 Agbl2 1.242094136 7.56E-06 0.00029732 
MGP_FVBNJ_G0007022 Lockd 1.24094661 0.00218293 0.03526059 
MGP_FVBNJ_G0033563 Arhgap10 1.226931229 0.00132863 0.02401991 
MGP_FVBNJ_G0023062 Hcfc1r1 1.22689975 0.00022094 0.00544208 
MGP_FVBNJ_G0001956 NA 1.223950897 0.00236728 0.03771908 
MGP_FVBNJ_G0015302 Gm13986 1.212166039 0.00127813 0.02327684 
MGP_FVBNJ_G0025373 Sh3glb2 1.202704656 0.00010798 0.00295331 
MGP_FVBNJ_G0034950 Amotl2 1.197275996 0.00066371 0.01376252 
MGP_FVBNJ_G0035976 Gja6 1.189200704 0.00039444 0.00888132 
MGP_FVBNJ_G0035816 Drp2 1.1644393 0.00210762 0.03439314 
MGP_FVBNJ_G0026143 Oip5 1.163334982 0.00170497 0.02911785 
MGP_FVBNJ_G0017810 Gatsl3 1.149881813 0.00120071 0.02221161 
MGP_FVBNJ_G0027560 Sort1 1.142919002 0.00191276 0.03193802 
MGP_FVBNJ_G0039038 Gm23995 1.100300736 0.00329901 0.04815857 
MGP_FVBNJ_G0001698 NA 1.09479016 0.00184461 0.03107951 
MGP_FVBNJ_G0017312 Abca7 1.080352743 0.00292913 0.04414696 
MGP_FVBNJ_G0027188 NA 1.077752708 0.00176564 0.0299756 
MGP_FVBNJ_G0023905 Ston1 1.071408489 0.00034458 0.00790157 
MGP_FVBNJ_G0023605 Tjap1 1.056027424 0.00156015 0.02727627 
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MGP_FVBNJ_G0026093 Fmn1 1.052513083 9.88E-08 5.81E-06 
MGP_FVBNJ_G0023829 NA 1.022093848 0.00028916 0.00678495 
MGP_FVBNJ_G0035173 Oxsr1 1.008795814 8.49E-06 0.00032989 
MGP_FVBNJ_G0018105 Jade2 0.986703817 5.79E-05 0.00174534 
MGP_FVBNJ_G0024625 Rom1 0.98451075 0.00097129 0.01866466 
MGP_FVBNJ_G0022529 Apod 0.962329671 0.00292914 0.04414696 
MGP_FVBNJ_G0027753 Ssx2ip 0.961047584 0.00219437 0.03531745 
MGP_FVBNJ_G0034889 Plscr2 0.932352376 8.74E-06 0.00033655 
MGP_FVBNJ_G0029611 Glmn 0.919366654 4.08E-05 0.00130435 
MGP_FVBNJ_G0035334 Maoa 0.913216001 0.00087218 0.01717484 
MGP_FVBNJ_G0034031 2310022B05Rik 0.912224779 0.00170459 0.02911785 
MGP_FVBNJ_G0025627 Slc25a12 0.90788819 3.91E-05 0.00126163 
MGP_FVBNJ_G0039251 Gm24299 0.902839194 0.00187604 0.0314208 
MGP_FVBNJ_G0029425 Paics 0.896507534 0.00027679 0.0065222 
MGP_FVBNJ_G0032777 Fam57b 0.896403058 0.00150953 0.02655792 
MGP_FVBNJ_G0023901 Msh6 0.892236189 0.00100998 0.01930838 
MGP_FVBNJ_G0025320 Vav2 0.883717835 2.29E-06 0.00010049 
MGP_FVBNJ_G0016860 Adat2 0.878729829 0.00242678 0.03847459 
MGP_FVBNJ_G0035972 Phka2 0.878709039 0.00091822 0.01784475 
MGP_FVBNJ_G0018106 Cdkn2aipnl 0.874432937 0.00269283 0.04131175 
MGP_FVBNJ_G0034560 Zc3h12c 0.867391051 0.00061858 0.01298345 
MGP_FVBNJ_G0035975 Cdkl5 0.858156769 0.00268451 0.04128349 
MGP_FVBNJ_G0029882 Bri3bp 0.84613653 0.00317342 0.04684689 
MGP_FVBNJ_G0035190 Rpsa 0.833780103 0.00245211 0.03868362 
MGP_FVBNJ_G0029616 Rpl5 0.829440347 0.00218503 0.03526101 
MGP_FVBNJ_G0023202 Ergic1 0.824471715 0.00268186 0.04128349 
MGP_FVBNJ_G0023623 Ppp2r5d 0.824109067 0.00104821 0.01985185 
MGP_FVBNJ_G0034927 Pik3cb 0.820554883 5.53E-09 3.97E-07 
MGP_FVBNJ_G0012059 NA 0.811105878 0.00079407 0.01588927 
MGP_FVBNJ_G0013118 NA 0.796599148 0.00057979 0.01223875 
MGP_FVBNJ_G0025108 Nmt2 0.793064992 0.00027534 0.00649726 
MGP_FVBNJ_G0033659 Zfp791 0.79009974 0.00130963 0.02375343 
MGP_FVBNJ_G0026825 Zfp512b 0.781702475 0.00101593 0.01940536 
MGP_FVBNJ_G0023647 Usp49 0.778210186 0.00299379 0.04479223 
MGP_FVBNJ_G0034691 Rpl4 0.766892801 8.66E-07 4.17E-05 
MGP_FVBNJ_G0025292 Snapc4 0.760445878 0.00126311 0.02307753 
MGP_FVBNJ_G0024654 Ddb1 0.75990353 0.00243538 0.03857548 
MGP_FVBNJ_G0017433 Mterf2 0.756723539 0.0014323 0.02546041 
MGP_FVBNJ_G0026034 Arl14ep 0.755478306 7.36E-05 0.0021428 
MGP_FVBNJ_G0023118 NA 0.752363827 0.00265336 0.04091411 
MGP_FVBNJ_G0025559 Pkp4 0.740499929 0.0007449 0.01513477 
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MGP_FVBNJ_G0033365 Wwc2 0.737010351 0.00091664 0.01782966 
MGP_FVBNJ_G0025639 Ola1 0.73367698 0.00246368 0.03883862 
MGP_FVBNJ_G0029617 Fam69a 0.731711548 0.00032001 0.00739975 
MGP_FVBNJ_G0033072 Arhgef18 0.721482557 0.00096964 0.01865142 
MGP_FVBNJ_G0034122 Taf1d 0.721128546 0.00078669 0.01579737 
MGP_FVBNJ_G0029016 Fam132a 0.719086343 0.00021622 0.00533739 
MGP_FVBNJ_G0010183 NA 0.717074762 0.00062951 0.01312668 
MGP_FVBNJ_G0034559 Rdx 0.716915204 0.0020956 0.03424704 
MGP_FVBNJ_G0029860 Mphosph9 0.71525807 0.00013886 0.00365105 
MGP_FVBNJ_G0030242 Met 0.712943991 0.00055663 0.01185082 
MGP_FVBNJ_G0024591 Rtn3 0.701470375 0.00096263 0.01854625 
MGP_FVBNJ_G0029625 Mfsd7a 0.700534177 0.00206663 0.03382317 
MGP_FVBNJ_G0026271 Anapc1 0.696206296 1.16E-09 9.83E-08 
MGP_FVBNJ_G0030049 Sun1 0.693894902 0.00067058 0.0138922 
MGP_FVBNJ_G0030124 Trrap 0.69102864 0.00067229 0.01390178 
MGP_FVBNJ_G0009909 NA 0.689469188 1.83E-05 0.00065867 
MGP_FVBNJ_G0034564 Kdelc2 0.685701043 0.00020226 0.00508867 
MGP_FVBNJ_G0033012 Ap2a2 0.680958219 4.22E-05 0.00133772 
MGP_FVBNJ_G0030147 Cdk8 0.680325081 0.00047279 0.0103833 
MGP_FVBNJ_G0026823 Dnajc5 0.679334155 0.0027987 0.04255507 
MGP_FVBNJ_G0026546 Uqcc1 0.669294378 0.00102977 0.01958587 
MGP_FVBNJ_G0025306 Rpl7a 0.668802005 0.0019721 0.03258713 
MGP_FVBNJ_G0024882 Ide 0.66616497 0.00164492 0.02837999 
MGP_FVBNJ_G0026366 Ndufaf5 0.653415171 0.0015337 0.02689833 
MGP_FVBNJ_G0026279 Ttl 0.653392607 0.00301409 0.04506014 
MGP_FVBNJ_G0011290 NA 0.653235547 0.00013317 0.00352147 
MGP_FVBNJ_G0030187 Stard13 0.651863109 0.00185085 0.03116112 
MGP_FVBNJ_G0021902 Rpl3 0.647110428 0.00074309 0.01512716 
MGP_FVBNJ_G0025137 Usp6nl 0.644195604 0.00030806 0.00716062 
MGP_FVBNJ_G0029298 Cc2d2a 0.638135443 0.00217295 0.03512492 
MGP_FVBNJ_G0029812 Ppp1cc 0.637435569 6.09E-05 0.00182272 
MGP_FVBNJ_G0025157 Fam188a 0.631150315 0.00045236 0.00998162 
MGP_FVBNJ_G0026040 Lin7c 0.63031777 2.76E-05 0.00093352 
MGP_FVBNJ_G0026024 Eif3m 0.62904358 0.00244477 0.03859511 
MGP_FVBNJ_G0024439 Doc2g 0.62659339 0.00136577 0.02443364 
MGP_FVBNJ_G0025193 Arhgap21 0.623397842 0.00124999 0.02289525 
MGP_FVBNJ_G0027135 Mnd1 0.615260215 0.0017552 0.02984376 
MGP_FVBNJ_G0035203 Sec22c 0.614931941 0.00134296 0.02416136 
MGP_FVBNJ_G0029914 Sbds 0.610638813 0.00067217 0.01390178 
MGP_FVBNJ_G0025052 Smc3 0.609019458 0.0018899 0.03157998 
MGP_FVBNJ_G0024588 Mark2 0.608772467 0.00066089 0.01371684 
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MGP_FVBNJ_G0034567 Npat 0.606336038 0.00282943 0.04293455 
MGP_FVBNJ_G0026149 Rpap1 0.605516184 0.00042763 0.00951332 
MGP_FVBNJ_G0024765 Vps13a 0.603877458 0.00157287 0.02741279 
MGP_FVBNJ_G0024422 Mrpl21 0.598308729 0.00259982 0.04030081 
MGP_FVBNJ_G0022960 Tcp1 0.597753734 1.19E-05 0.00044529 
MGP_FVBNJ_G0023588 Hsp90ab1 0.597048078 0.00027154 0.00641876 
MGP_FVBNJ_G0029646 NA 0.593728207 8.12E-05 0.00233086 
MGP_FVBNJ_G0029827 Anapc5 0.59219497 1.11E-05 0.00042043 
MGP_FVBNJ_G0026126 Rpusd2 0.591733469 0.00126624 0.02307918 
MGP_FVBNJ_G0023903 Foxn2 0.583834283 4.37E-15 1.43E-12 
MGP_FVBNJ_G0026408 Napb 0.581997262 0.00079404 0.01588927 
MGP_FVBNJ_G0024785 Abhd17b 0.581228467 0.00166162 0.02853563 
MGP_FVBNJ_G0023834 NA 0.579682275 0.00165819 0.02853563 
MGP_FVBNJ_G0025222 Dph7 0.575599157 0.00088565 0.01736319 
MGP_FVBNJ_G0025517 Scai 0.574853487 0.00156393 0.02732096 
MGP_FVBNJ_G0026822 Tpd52l2 0.570143962 0.00158348 0.02757598 
MGP_FVBNJ_G0029870 Eif2b1 0.564745181 0.00077868 0.01569397 
MGP_FVBNJ_G0026084 Slc12a6 0.563201026 8.81E-05 0.00248646 
MGP_FVBNJ_G0029198 Zfp512 0.562930006 0.00286992 0.0434307 
MGP_FVBNJ_G0029794 Gm15800 0.554106309 0.00091184 0.0177829 
MGP_FVBNJ_G0023601 Xpo5 0.554004179 0.00230036 0.03678424 
MGP_FVBNJ_G0023741 Gtf2f1 0.553542609 6.54E-05 0.00193781 
MGP_FVBNJ_G0026165 Zfp106 0.552477794 0.00165092 0.02846148 
MGP_FVBNJ_G0026560 Phf20 0.550065753 0.000476 0.01044337 
MGP_FVBNJ_G0025569 Rbms1 0.545716723 0.00309477 0.04602103 
MGP_FVBNJ_G0026101 Dph6 0.544499688 0.00032695 0.00753679 
MGP_FVBNJ_G0029622 Pigg 0.543235974 0.00327354 0.04794379 
MGP_FVBNJ_G0025265 Rabl6 0.530696007 0.00014115 0.00369734 
MGP_FVBNJ_G0029801 Mapkapk5 0.5301103 2.55E-07 1.37E-05 
MGP_FVBNJ_G0026249 Snrnp200 0.529738393 5.24E-05 0.00161017 
MGP_FVBNJ_G0015655 NA 0.521927404 0.00053185 0.01145449 
MGP_FVBNJ_G0036001 Mospd2 0.518860885 0.00244248 0.03858639 
MGP_FVBNJ_G0026384 Polr3f 0.510819105 0.00062284 0.01304861 
MGP_FVBNJ_G0030101 Zdhhc4 0.508874228 0.00262799 0.04065316 
MGP_FVBNJ_G0012583 NA 0.508553191 0.00319556 0.0471003 
MGP_FVBNJ_G0026232 Galk2 0.505728048 0.00062671 0.01311747 
MGP_FVBNJ_G0026021 Qser1 0.49355029 0.00041507 0.00928016 
MGP_FVBNJ_G0029629 Tmem175 0.486061524 0.00174032 0.02963599 
MGP_FVBNJ_G0025622 Tlk1 0.483560653 0.00145218 0.02575228 
MGP_FVBNJ_G0034522 Usp28 0.477528667 5.90E-05 0.0017759 
MGP_FVBNJ_G0027030 Eif2a 0.475539742 0.00113344 0.02114277 
  
 215 
MGP_FVBNJ_G0026303 Ptpra 0.473132197 0.00184328 0.03107951 
MGP_FVBNJ_G0025150 Rbm17 0.470488072 0.00330987 0.04828549 
MGP_FVBNJ_G0035229 Zdhhc3 0.460064002 0.00017589 0.00449638 
MGP_FVBNJ_G0025154 Fbxo18 0.455143407 1.89E-05 0.0006739 
MGP_FVBNJ_G0022906 NA 0.452879015 0.00241962 0.03840706 
MGP_FVBNJ_G0026398 Xrn2 0.451313861 0.00011798 0.0031762 
MGP_FVBNJ_G0023270 Cmtr1 0.447912087 0.00187561 0.0314208 
MGP_FVBNJ_G0026600 Dhx35 0.447836774 0.00083957 0.01661223 
MGP_FVBNJ_G0025295 Inpp5e 0.443147988 0.00050123 0.010911 
MGP_FVBNJ_G0026514 Cbfa2t2 0.440252979 0.00054033 0.01159246 
MGP_FVBNJ_G0022432 Hira 0.435705897 0.00045192 0.00998162 
MGP_FVBNJ_G0023823 Birc6 0.434568175 0.0015929 0.02765368 
MGP_FVBNJ_G0029554 Hnrnpdl 0.426952598 0.00113784 0.02120694 
MGP_FVBNJ_G0029575 Aff1 0.420130652 0.00069263 0.0142429 
MGP_FVBNJ_G0025609 Ppig 0.414584816 0.00326827 0.04792959 
MGP_FVBNJ_G0026538 Trpc4ap 0.411499828 1.82E-05 0.00065404 
MGP_FVBNJ_G0031449 NA 0.407922678 2.83E-05 0.00095127 
MGP_FVBNJ_G0024789 Smc5 0.405854248 0.00256676 0.03995339 
MGP_FVBNJ_G0025499 Rc3h2 0.397804641 0.00100667 0.01927457 
MGP_FVBNJ_G0029892 Stx2 0.382323434 0.00256089 0.03989153 
MGP_FVBNJ_G0024608 Stx5a 0.379879534 0.00126554 0.02307918 
MGP_FVBNJ_G0026826 Prpf6 0.375467124 0.00121409 0.02240472 
MGP_FVBNJ_G0025446 Gapvd1 0.37542879 0.00179021 0.03032337 
MGP_FVBNJ_G0024051 Kdm3b 0.364493354 0.00136382 0.02441845 
MGP_FVBNJ_G0025180 Mllt10 0.356072343 8.37E-05 0.00239088 
MGP_FVBNJ_G0026533 Ncoa6 0.346287513 0.00021251 0.00526914 
MGP_FVBNJ_G0024233 Snx2 0.342697666 0.00319693 0.0471003 
MGP_FVBNJ_G0026491 Asxl1 0.307385519 0.0014512 0.02575228 
MGP_FVBNJ_G0029844 Vps33a 0.281174352 0.00031618 0.00731881 
MGP_FVBNJ_G0022963 NA 0.24321458 0.00149198 0.02631819 








Downregulated (ordered by log2 fold change) 
Gene ID Gene Name log2 Fold Change P-value P(adj) 
MGP_FVBNJ_G0033334 Klkb1 -6.2311663 1.60E-16 8.09E-14 
MGP_FVBNJ_G0033786 Ces3b -6.1677257 2.37E-24 4.31E-20 
MGP_FVBNJ_G0039773 NA -5.8351415 1.75E-18 1.77E-15 
MGP_FVBNJ_G0027127 Fgg -5.6133256 2.08E-21 1.55E-17 
MGP_FVBNJ_G0020918 Itih4 -5.6096541 3.87E-24 4.31E-20 
MGP_FVBNJ_G0030990 A2m -5.5528682 2.67E-20 7.44E-17 
MGP_FVBNJ_G0039590 NA -5.4370853 2.34E-19 4.01E-16 
MGP_FVBNJ_G0027129 Fgb -5.4211464 2.08E-20 6.62E-17 
MGP_FVBNJ_G0027128 Fga -5.4098092 1.64E-19 3.05E-16 
MGP_FVBNJ_G0021006 Mbl1 -5.4071587 8.42E-19 9.88E-16 
MGP_FVBNJ_G0028291 C8b -5.358267 4.10E-20 9.53E-17 
MGP_FVBNJ_G0028292 C8a -5.3397157 4.96E-18 3.95E-15 
MGP_FVBNJ_G0039589 NA -5.3010204 4.16E-18 3.45E-15 
MGP_FVBNJ_G0017676 Hsd17b6 -5.2820894 2.18E-14 5.51E-12 
MGP_FVBNJ_G0019870 Serpina10 -5.2721687 6.98E-21 3.89E-17 
MGP_FVBNJ_G0028146 Orm2 -5.2119906 3.35E-19 5.17E-16 
MGP_FVBNJ_G0020920 Itih1 -5.2027968 7.98E-19 9.88E-16 
MGP_FVBNJ_G0016639 Apcs -5.1702064 1.28E-17 9.82E-15 
MGP_FVBNJ_G0018533 Serpinf2 -5.1688434 4.28E-20 9.53E-17 
MGP_FVBNJ_G0035319 Otc -5.1427099 4.67E-16 2.04E-13 
MGP_FVBNJ_G0024913 Cyp2c70 -5.1406436 3.51E-19 5.17E-16 
MGP_FVBNJ_G0019875 NA -5.0743681 3.71E-19 5.17E-16 
MGP_FVBNJ_G0032049 Saa4 -5.0416173 3.16E-17 2.07E-14 
MGP_FVBNJ_G0025065 Habp2 -5.0114251 1.43E-18 1.52E-15 
MGP_FVBNJ_G0020919 Itih3 -4.9936076 5.09E-16 2.18E-13 
MGP_FVBNJ_G0023309 Cyp4f15 -4.9803253 4.88E-15 1.53E-12 
MGP_FVBNJ_G0031942 Aspdh -4.9798737 1.16E-12 1.95E-10 
MGP_FVBNJ_G0022485 Fetub -4.9638824 1.95E-20 6.62E-17 
MGP_FVBNJ_G0021528 Ugt3a2 -4.9254362 8.79E-17 4.90E-14 
MGP_FVBNJ_G0020185 Slc17a3 -4.925287 1.23E-11 1.66E-09 
MGP_FVBNJ_G0019874 NA -4.9252644 2.25E-15 8.08E-13 
MGP_FVBNJ_G0016401 F13b -4.9144832 7.09E-17 4.16E-14 
MGP_FVBNJ_G0028142 Ambp -4.9122599 4.18E-18 3.45E-15 
MGP_FVBNJ_G0032012 Fgf21 -4.8996402 5.29E-11 6.30E-09 
MGP_FVBNJ_G0018604 Vtn -4.8819821 2.23E-17 1.55E-14 
MGP_FVBNJ_G0032531 Hpx -4.8496338 1.57E-17 1.17E-14 
MGP_FVBNJ_G0024597 Slc22a26 -4.8485013 3.02E-15 1.02E-12 
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MGP_FVBNJ_G0022519 Cpn2 -4.828484 6.19E-17 3.73E-14 
MGP_FVBNJ_G0024601 NA -4.8237556 4.74E-10 4.37E-08 
MGP_FVBNJ_G0016084 2810459M11Rik -4.8198836 5.35E-17 3.36E-14 
MGP_FVBNJ_G0029496 5830473C10Rik -4.8129373 5.08E-11 6.09E-09 
MGP_FVBNJ_G0023422 Apom -4.800059 2.59E-16 1.23E-13 
MGP_FVBNJ_G0024907 NA -4.7783821 5.69E-12 8.19E-10 
MGP_FVBNJ_G0029632 Slc26a1 -4.7735507 9.49E-17 5.16E-14 
MGP_FVBNJ_G0017654 Inhbc -4.7505073 2.16E-14 5.51E-12 
MGP_FVBNJ_G0021962 Cyp2d26 -4.743761 1.21E-16 6.45E-14 
MGP_FVBNJ_G0029495 Afm -4.7301546 5.61E-16 2.36E-13 
MGP_FVBNJ_G0033324 Fgl1 -4.725988 4.38E-15 1.43E-12 
MGP_FVBNJ_G0031097 Pzp -4.7243273 7.11E-15 2.06E-12 
MGP_FVBNJ_G0028061 Plppr1 -4.7213843 2.77E-10 2.71E-08 
MGP_FVBNJ_G0032994 Cdhr5 -4.721059 2.27E-18 2.11E-15 
MGP_FVBNJ_G0031829 Hamp -4.7198636 5.42E-17 3.36E-14 
MGP_FVBNJ_G0022951 Plg -4.7146854 1.46E-15 5.62E-13 
MGP_FVBNJ_G0024964 Cpn1 -4.6847047 7.61E-19 9.88E-16 
MGP_FVBNJ_G0032974 Nlrp6 -4.674676 1.24E-16 6.45E-14 
MGP_FVBNJ_G0030204 Pon1 -4.6676627 3.19E-16 1.48E-13 
MGP_FVBNJ_G0021379 Cpb2 -4.6661794 1.27E-14 3.49E-12 
MGP_FVBNJ_G0022487 Kng2 -4.6506519 3.00E-18 2.67E-15 
MGP_FVBNJ_G0019876 Serpina11 -4.6378938 2.97E-14 7.35E-12 
MGP_FVBNJ_G0027758 Uox -4.6332986 1.86E-15 6.91E-13 
MGP_FVBNJ_G0021511 C9 -4.6291079 4.26E-16 1.90E-13 
MGP_FVBNJ_G0035703 Gjb1 -4.6216713 1.96E-16 9.71E-14 
MGP_FVBNJ_G0016638 Crp -4.6100415 2.78E-15 9.54E-13 
MGP_FVBNJ_G0031225 Slco1b2 -4.5709193 3.26E-16 1.49E-13 
MGP_FVBNJ_G0019886 Serpina3k -4.5678837 4.37E-14 1.04E-11 
MGP_FVBNJ_G0024965 Cyp2c44 -4.5661113 4.76E-15 1.51E-12 
MGP_FVBNJ_G0017675 Sdr9c7 -4.5617367 2.69E-10 2.66E-08 
MGP_FVBNJ_G0022486 Hrg -4.5546041 3.32E-14 8.13E-12 
MGP_FVBNJ_G0035505 F9 -4.5534953 8.34E-17 4.77E-14 
MGP_FVBNJ_G0025226 Entpd8 -4.5443081 1.45E-14 3.93E-12 
MGP_FVBNJ_G0019149 Apoh -4.5361295 1.20E-14 3.34E-12 
MGP_FVBNJ_G0017653 Inhbe -4.5259488 5.71E-16 2.36E-13 
MGP_FVBNJ_G0024841 A1cf -4.5230639 1.13E-14 3.19E-12 
MGP_FVBNJ_G0033703 Ces1b -4.5174264 5.86E-14 1.32E-11 
MGP_FVBNJ_G0030021 Azgp1 -4.5157557 9.81E-14 1.95E-11 
MGP_FVBNJ_G0029836 Hpd -4.5127122 5.26E-15 1.61E-12 
MGP_FVBNJ_G0030139 Cyp3a11 -4.5077488 2.03E-15 7.41E-13 
MGP_FVBNJ_G0027126 Lrat -4.5047112 2.28E-15 8.08E-13 
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MGP_FVBNJ_G0027659 Cfi -4.5019598 1.12E-20 5.00E-17 
MGP_FVBNJ_G0016178 Agxt -4.4983026 5.99E-14 1.33E-11 
MGP_FVBNJ_G0035026 Slc38a3 -4.4980716 7.27E-15 2.08E-12 
MGP_FVBNJ_G0022874 Cldn14 -4.4933211 2.35E-11 3.04E-09 
MGP_FVBNJ_G0022484 Ahsg -4.4900382 4.70E-14 1.09E-11 
MGP_FVBNJ_G0020478 Fbp1 -4.4855256 9.46E-16 3.77E-13 
MGP_FVBNJ_G0030736 Nat8f2 -4.4836671 5.32E-15 1.61E-12 
MGP_FVBNJ_G0027046 Aadac -4.4781837 6.51E-14 1.41E-11 
MGP_FVBNJ_G0031525 Foxa3 -4.4432345 4.26E-14 1.02E-11 
MGP_FVBNJ_G0024600 NA -4.4390621 3.95E-09 2.97E-07 
MGP_FVBNJ_G0033333 F11 -4.4349639 5.17E-13 9.29E-11 
MGP_FVBNJ_G0017687 Apon -4.425947 2.12E-18 2.05E-15 
MGP_FVBNJ_G0029487 Gc -4.4255515 2.53E-17 1.71E-14 
MGP_FVBNJ_G0018915 Krt12 -4.4223068 0.00011239 0.00304881 
MGP_FVBNJ_G0029455 NA -4.4206889 5.15E-09 3.77E-07 
MGP_FVBNJ_G0028062 Acnat1 -4.4172389 2.10E-17 1.51E-14 
MGP_FVBNJ_G0035863 Serpina7 -4.4115252 7.11E-12 1.01E-09 
MGP_FVBNJ_G0033108 Slc10a2 -4.4029384 2.60E-12 4.08E-10 
MGP_FVBNJ_G0017673 BC089597 -4.3969922 6.03E-14 1.33E-11 
MGP_FVBNJ_G0027712 Adh4 -4.3957061 3.50E-13 6.35E-11 
MGP_FVBNJ_G0020020 Akr1c20 -4.3903673 4.73E-12 7.22E-10 
MGP_FVBNJ_G0024716 Gm4952 -4.3880438 1.20E-13 2.35E-11 
MGP_FVBNJ_G0011167 NA -4.3447887 1.38E-06 6.41E-05 
MGP_FVBNJ_G0025950 F2 -4.3325294 5.94E-16 2.41E-13 
MGP_FVBNJ_G0030143 NA -4.3318253 7.65E-08 4.59E-06 
MGP_FVBNJ_G0016490 Serpinc1 -4.330957 1.22E-15 4.78E-13 
MGP_FVBNJ_G0016962 Sult3a1 -4.3299142 5.35E-15 1.61E-12 
MGP_FVBNJ_G0023979 Ttr -4.3207174 1.62E-14 4.34E-12 
MGP_FVBNJ_G0021956 NA -4.3162387 5.60E-11 6.53E-09 
MGP_FVBNJ_G0026288 Pdyn -4.3129267 4.38E-06 0.00018127 
MGP_FVBNJ_G0031228 Slco1a1 -4.3114224 6.33E-14 1.38E-11 
MGP_FVBNJ_G0030707 Clec4f -4.30411 9.13E-13 1.55E-10 
MGP_FVBNJ_G0021629 Dpys -4.3014743 6.79E-14 1.45E-11 
MGP_FVBNJ_G0017688 Apof -4.2997185 1.65E-14 4.36E-12 
MGP_FVBNJ_G0030808 Uroc1 -4.2952491 2.14E-13 4.04E-11 
MGP_FVBNJ_G0024022 Myo7b -4.2895389 1.16E-09 9.83E-08 
MGP_FVBNJ_G0035212 Cyp8b1 -4.2854449 5.51E-12 8.14E-10 
MGP_FVBNJ_G0016961 Sult3a2 -4.2828761 5.59E-12 8.14E-10 
MGP_FVBNJ_G0026753 Pck1 -4.2775119 1.62E-13 3.11E-11 
MGP_FVBNJ_G0032690 Acsm1 -4.271492 2.84E-13 5.23E-11 
MGP_FVBNJ_G0033139 Proz -4.267821 4.23E-14 1.02E-11 
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MGP_FVBNJ_G0021659 Colec10 -4.2647755 8.58E-12 1.19E-09 
MGP_FVBNJ_G0027610 Dpyd -4.2635306 1.02E-12 1.73E-10 
MGP_FVBNJ_G0034897 Paqr9 -4.2564204 1.91E-14 4.96E-12 
MGP_FVBNJ_G0028835 Agmat -4.2543781 1.91E-13 3.64E-11 
MGP_FVBNJ_G0016897 Aldh8a1 -4.2415175 2.32E-14 5.81E-12 
MGP_FVBNJ_G0031201 Art4 -4.2383138 8.79E-14 1.81E-11 
MGP_FVBNJ_G0028582 Tlr12 -4.2357345 2.10E-09 1.69E-07 
MGP_FVBNJ_G0028258 Angptl3 -4.2341292 2.62E-11 3.35E-09 
MGP_FVBNJ_G0030642 Sftpb -4.2114463 0.00025069 0.00602817 
MGP_FVBNJ_G0020184 Slc17a2 -4.206245 1.37E-13 2.66E-11 
MGP_FVBNJ_G0029453 Ugt2b36 -4.2062355 5.52E-14 1.26E-11 
MGP_FVBNJ_G0020635 NA -4.2013658 4.74E-10 4.37E-08 
MGP_FVBNJ_G0025454 NA -4.1994694 1.93E-12 3.12E-10 
MGP_FVBNJ_G0018916 Krt20 -4.178719 6.82E-07 3.35E-05 
MGP_FVBNJ_G0023304 Pglyrp2 -4.1704282 6.24E-15 1.83E-12 
MGP_FVBNJ_G0017674 Rdh7 -4.1577502 2.76E-12 4.27E-10 
MGP_FVBNJ_G0020297 Elovl2 -4.1573164 1.70E-12 2.77E-10 
MGP_FVBNJ_G0027759 Dnase2b -4.1491404 2.80E-09 2.19E-07 
MGP_FVBNJ_G0031069 Ntf3 -4.1435512 5.97E-10 5.39E-08 
MGP_FVBNJ_G0021959 NA -4.1267726 4.88E-12 7.40E-10 
MGP_FVBNJ_G0026693 Slc13a3 -4.11711 5.25E-12 7.85E-10 
MGP_FVBNJ_G0022954 Slc22a1 -4.1133405 1.21E-12 2.01E-10 
MGP_FVBNJ_G0018425 Gltpd2 -4.1090909 6.96E-14 1.48E-11 
MGP_FVBNJ_G0024905 Cyp2c39 -4.1013704 1.28E-12 2.09E-10 
MGP_FVBNJ_G0034029 Agt -4.0996019 1.66E-14 4.36E-12 
MGP_FVBNJ_G0018406 Asgr2 -4.0984656 7.76E-14 1.62E-11 
MGP_FVBNJ_G0033088 Clec4g -4.0861826 9.81E-14 1.95E-11 
MGP_FVBNJ_G0032037 Abcc6 -4.0698209 7.44E-14 1.56E-11 
MGP_FVBNJ_G0016754 Slc30a10 -4.0635858 2.83E-11 3.59E-09 
MGP_FVBNJ_G0029772 Sds -4.0512018 3.54E-10 3.41E-08 
MGP_FVBNJ_G0021759 BC025446 -4.0497874 2.72E-13 5.05E-11 
MGP_FVBNJ_G0027157 Cd5l -4.0495794 1.23E-11 1.66E-09 
MGP_FVBNJ_G0017451 Pah -4.0485615 2.87E-12 4.42E-10 
MGP_FVBNJ_G0024904 Cyp2c38 -4.0449477 8.32E-12 1.17E-09 
MGP_FVBNJ_G0004057 Gm42604 -4.034288 1.68E-07 9.43E-06 
MGP_FVBNJ_G0017484 Amdhd1 -4.0294955 1.61E-11 2.11E-09 
MGP_FVBNJ_G0034503 Apoa1 -4.0234294 2.05E-12 3.26E-10 
MGP_FVBNJ_G0019643 NA -4.015506 2.83E-08 1.82E-06 
MGP_FVBNJ_G0033704 NA -4.0105057 4.55E-14 1.07E-11 
MGP_FVBNJ_G0017864 Igfbp1 -3.999106 6.94E-08 4.21E-06 
MGP_FVBNJ_G0026347 Fermt1 -3.9990361 1.47E-10 1.54E-08 
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MGP_FVBNJ_G0002767 Prox1os -3.9980276 2.06E-06 9.29E-05 
MGP_FVBNJ_G0019019 G6pc -3.9953669 3.98E-09 2.98E-07 
MGP_FVBNJ_G0031562 Apoc4 -3.9938355 1.48E-11 1.96E-09 
MGP_FVBNJ_G0016809 Iyd -3.9932927 8.30E-11 9.35E-09 
MGP_FVBNJ_G0024465 2010003K11Rik -3.9773116 5.10E-12 7.68E-10 
MGP_FVBNJ_G0021322 Adamdec1 -3.9676911 3.65E-09 2.76E-07 
MGP_FVBNJ_G0031563 Apoc1 -3.9540305 7.09E-12 1.01E-09 
MGP_FVBNJ_G0020980 Fam25c -3.9405985 1.32E-10 1.41E-08 
MGP_FVBNJ_G0033866 Hp -3.9392352 2.71E-15 9.44E-13 
MGP_FVBNJ_G0034958 1300017J02Rik -3.9312135 8.13E-12 1.15E-09 
MGP_FVBNJ_G0022002 Ppara -3.9270184 1.10E-11 1.51E-09 
MGP_FVBNJ_G0030158 Pdx1 -3.9116946 3.27E-07 1.72E-05 
MGP_FVBNJ_G0020303 Adtrp -3.9077582 1.15E-13 2.27E-11 
MGP_FVBNJ_G0021534 Agxt2 -3.8977547 3.76E-11 4.60E-09 
MGP_FVBNJ_G0021954 Cyp2d11 -3.8900518 1.33E-10 1.41E-08 
MGP_FVBNJ_G0020019 Akr1c6 -3.8899634 9.49E-14 1.92E-11 
MGP_FVBNJ_G0019331 Gcgr -3.8849517 4.93E-11 5.93E-09 
MGP_FVBNJ_G0025080 Gfra1 -3.8846429 4.60E-15 1.49E-12 
MGP_FVBNJ_G0027119 Tdo2 -3.8789756 2.82E-09 2.20E-07 
MGP_FVBNJ_G0018405 Asgr1 -3.8730799 1.80E-10 1.84E-08 
MGP_FVBNJ_G0017843 Gck -3.8652862 1.43E-11 1.91E-09 
MGP_FVBNJ_G0035346 Rgn -3.8583768 2.67E-12 4.16E-10 
MGP_FVBNJ_G0020634 NA -3.8552538 8.44E-09 5.96E-07 
MGP_FVBNJ_G0027409 Hfe2 -3.8488237 1.63E-09 1.35E-07 
MGP_FVBNJ_G0016118 Ugt1a9 -3.8444069 4.69E-11 5.68E-09 
MGP_FVBNJ_G0024909 NA -3.8415931 6.61E-11 7.60E-09 
MGP_FVBNJ_G0018579 Pipox -3.8397945 1.09E-11 1.51E-09 
MGP_FVBNJ_G0031431 Slc27a5 -3.8315239 2.17E-11 2.82E-09 
MGP_FVBNJ_G0029577 Hsd17b13 -3.8295717 3.30E-09 2.53E-07 
MGP_FVBNJ_G0016746 Mar-01 -3.8223125 1.94E-10 1.96E-08 
MGP_FVBNJ_G0019374 Zfp750 -3.816966 2.69E-11 3.43E-09 
MGP_FVBNJ_G0001201 NA -3.8134218 8.78E-07 4.21E-05 
MGP_FVBNJ_G0036830 Gm44167 -3.8080727 1.04E-05 0.00039372 
MGP_FVBNJ_G0028905 Masp2 -3.8030792 2.77E-10 2.71E-08 
MGP_FVBNJ_G0020636 Bhmt2 -3.798478 9.79E-10 8.46E-08 
MGP_FVBNJ_G0024912 Cyp2c50 -3.7921773 9.41E-11 1.04E-08 
MGP_FVBNJ_G0027181 Rhbg -3.7865628 6.29E-08 3.83E-06 
MGP_FVBNJ_G0027867 Ttpa -3.7834387 3.31E-10 3.22E-08 
MGP_FVBNJ_G0024210 Cdo1 -3.7821915 1.65E-10 1.71E-08 
MGP_FVBNJ_G0021214 Gjb2 -3.7595639 4.36E-10 4.09E-08 
MGP_FVBNJ_G0005179 1810063I02Rik -3.7504759 1.09E-05 0.00041064 
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MGP_FVBNJ_G0028064 Baat -3.7485198 3.77E-10 3.62E-08 
MGP_FVBNJ_G0017217 Ftcd -3.7442946 7.68E-10 6.74E-08 
MGP_FVBNJ_G0018030 Timd2 -3.7422597 3.46E-11 4.28E-09 
MGP_FVBNJ_G0029197 Gckr -3.7336057 5.56E-10 5.04E-08 
MGP_FVBNJ_G0030160 Urad -3.7297987 5.20E-09 3.79E-07 
MGP_FVBNJ_G0031660 Cyp2b9 -3.7291994 1.23E-08 8.40E-07 
MGP_FVBNJ_G0022610 Hgd -3.7197365 2.50E-11 3.22E-09 
MGP_FVBNJ_G0019711 Slc10a1 -3.7141564 1.17E-10 1.28E-08 
MGP_FVBNJ_G0018010 Adra1b -3.7140842 7.91E-11 8.95E-09 
MGP_FVBNJ_G0016589 Apoa2 -3.7090294 8.96E-12 1.24E-09 
MGP_FVBNJ_G0001819 NA -3.7063006 4.10E-05 0.0013074 
MGP_FVBNJ_G0023625 Gnmt -3.6971777 1.88E-07 1.04E-05 
MGP_FVBNJ_G0029454 NA -3.6857988 1.78E-10 1.83E-08 
MGP_FVBNJ_G0026909 Slc2a2 -3.6849137 8.26E-10 7.19E-08 
MGP_FVBNJ_G0016640 Olfr16 -3.6836052 9.72E-05 0.00269577 
MGP_FVBNJ_G0023973 Dsg1c -3.6835835 2.40E-06 0.00010499 
MGP_FVBNJ_G0030141 NA -3.6798598 1.32E-11 1.77E-09 
MGP_FVBNJ_G0003191 Gm16573 -3.6737977 2.49E-06 0.00010744 
MGP_FVBNJ_G0019212 Slc16a5 -3.6735286 4.86E-08 3.01E-06 
MGP_FVBNJ_G0021854 Tmprss6 -3.6576976 4.54E-10 4.22E-08 
MGP_FVBNJ_G0005015 Gm2061 -3.6525562 2.60E-05 0.00088892 
MGP_FVBNJ_G0021300 Gulo -3.6518446 1.94E-09 1.58E-07 
MGP_FVBNJ_G0033933 Hsd17b2 -3.6492048 1.39E-09 1.17E-07 
MGP_FVBNJ_G0035403 Rhox5 -3.6481228 8.73E-07 4.19E-05 
MGP_FVBNJ_G0032963 Cyp2e1 -3.644909 2.56E-10 2.54E-08 
MGP_FVBNJ_G0009927 NA -3.6442557 0.00016225 0.00420116 
MGP_FVBNJ_G0028246 Cyp2j5 -3.6433449 2.07E-12 3.27E-10 
MGP_FVBNJ_G0024903 Cyp2c29 -3.638457 3.05E-11 3.84E-09 
MGP_FVBNJ_G0024962 Abcc2 -3.6278217 3.05E-09 2.37E-07 
MGP_FVBNJ_G0033390 Aadat -3.6240494 8.59E-09 6.04E-07 
MGP_FVBNJ_G0019878 Serpina12 -3.6078861 3.78E-09 2.86E-07 
MGP_FVBNJ_G0016050 Scg2 -3.6065775 0.00010331 0.00283956 
MGP_FVBNJ_G0020200 NA -3.6044292 1.51E-10 1.58E-08 
MGP_FVBNJ_G0020407 F12 -3.6024265 6.16E-09 4.40E-07 
MGP_FVBNJ_G0030626 Fabp1 -3.6022425 3.87E-10 3.70E-08 
MGP_FVBNJ_G0016933 Smlr1 -3.6017333 4.13E-10 3.94E-08 
MGP_FVBNJ_G0016130 Spp2 -3.5916937 4.80E-09 3.53E-07 
MGP_FVBNJ_G0017802 Sec14l4 -3.5863095 1.20E-10 1.29E-08 
MGP_FVBNJ_G0029461 Sult1e1 -3.5856482 3.33E-05 0.00110011 
MGP_FVBNJ_G0024911 Cyp2c54 -3.5837648 1.60E-07 9.05E-06 
MGP_FVBNJ_G0029456 Ugt2a3 -3.5818213 4.21E-10 3.99E-08 
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MGP_FVBNJ_G0028031 Stra6l -3.576419 9.15E-14 1.87E-11 
MGP_FVBNJ_G0024260 Iigp1 -3.573879 7.93E-13 1.38E-10 
MGP_FVBNJ_G0035963 Cnksr2 -3.5712498 1.44E-08 9.76E-07 
MGP_FVBNJ_G0031659 Cyp2b13 -3.5684891 4.67E-08 2.90E-06 
MGP_FVBNJ_G0021996 Smc1b -3.5623747 3.14E-05 0.00104389 
MGP_FVBNJ_G0020908 Il17rb -3.5613787 1.61E-10 1.68E-08 
MGP_FVBNJ_G0023548 Crisp1 -3.548272 0.00020528 0.00513558 
MGP_FVBNJ_G0029493 Alb -3.5481249 3.09E-09 2.39E-07 
MGP_FVBNJ_G0015160 Gm20319 -3.5472644 6.05E-08 3.69E-06 
MGP_FVBNJ_G0022530 Bdh1 -3.5449726 1.95E-10 1.97E-08 
MGP_FVBNJ_G0016768 Prox1 -3.5408393 5.09E-14 1.17E-11 
MGP_FVBNJ_G0026043 Bbox1 -3.5396543 1.39E-09 1.17E-07 
MGP_FVBNJ_G0002341 NA -3.5385673 1.76E-06 8.04E-05 
MGP_FVBNJ_G0030247 Cftr -3.536022 1.43E-07 8.12E-06 
MGP_FVBNJ_G0021501 C6 -3.5347314 2.22E-16 1.08E-13 
MGP_FVBNJ_G0007043 1700049E15Rik -3.5330123 3.92E-05 0.00126163 
MGP_FVBNJ_G0028295 Prkaa2 -3.5228535 6.01E-10 5.40E-08 
MGP_FVBNJ_G0021957 NA -3.5219579 4.45E-06 0.00018331 
MGP_FVBNJ_G0023610 Slc22a7 -3.5201504 1.81E-08 1.20E-06 
MGP_FVBNJ_G0029326 Slc34a2 -3.5183797 2.16E-10 2.16E-08 
MGP_FVBNJ_G0007410 Gm27216 -3.5152865 5.21E-08 3.21E-06 
MGP_FVBNJ_G0034250 Tbx20 -3.5150427 5.49E-11 6.47E-09 
MGP_FVBNJ_G0028145 Orm1 -3.5088794 2.03E-05 0.00072065 
MGP_FVBNJ_G0033782 Ces2e -3.5077732 1.99E-09 1.61E-07 
MGP_FVBNJ_G0031455 Sult2a8 -3.5054655 2.58E-09 2.04E-07 
MGP_FVBNJ_G0019887 Serpina3m -3.4962537 3.46E-09 2.64E-07 
MGP_FVBNJ_G0032688 Acsm5 -3.4924519 1.10E-09 9.43E-08 
MGP_FVBNJ_G0029350 Klb -3.4898162 3.80E-09 2.86E-07 
MGP_FVBNJ_G0035794 Pcdh11x -3.486151 0.00042683 0.00950505 
MGP_FVBNJ_G0018264 Slc47a1 -3.4780505 1.26E-08 8.54E-07 
MGP_FVBNJ_G0028381 NA -3.4743736 1.28E-05 0.00047391 
MGP_FVBNJ_G0021670 Sntb1 -3.4729465 5.55E-12 8.14E-10 
MGP_FVBNJ_G0030159 Cdx2 -3.4691779 0.00020495 0.00513558 
MGP_FVBNJ_G0028067 Aldob -3.4659816 1.73E-07 9.67E-06 
MGP_FVBNJ_G0025312 Adamts13 -3.4646677 5.22E-08 3.21E-06 
MGP_FVBNJ_G0031838 Hpn -3.4613878 1.91E-09 1.56E-07 
MGP_FVBNJ_G0034761 Lipc -3.4609893 4.46E-10 4.16E-08 
MGP_FVBNJ_G0034506 Apoa5 -3.4545073 1.61E-08 1.08E-06 
MGP_FVBNJ_G0008081 Gm44482 -3.4490909 4.75E-05 0.00147669 
MGP_FVBNJ_G0029055 Steap4 -3.4464319 5.33E-09 3.87E-07 
MGP_FVBNJ_G0039850 NA -3.4431929 3.59E-09 2.73E-07 
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MGP_FVBNJ_G0015966 Erbb4 -3.4423363 7.12E-07 3.49E-05 
MGP_FVBNJ_G0024790 Mamdc2 -3.4400909 2.28E-09 1.82E-07 
MGP_FVBNJ_G0030258 Aass -3.4387733 4.89E-08 3.02E-06 
MGP_FVBNJ_G0039683 NA -3.4286183 7.47E-13 1.31E-10 
MGP_FVBNJ_G0025018 Cyp17a1 -3.4247797 0.00014325 0.00374616 
MGP_FVBNJ_G0034470 Treh -3.4236785 3.56E-05 0.0011663 
MGP_FVBNJ_G0026630 Rims4 -3.420939 1.44E-09 1.20E-07 
MGP_FVBNJ_G0021454 Slitrk6 -3.4157757 0.00061915 0.01298345 
MGP_FVBNJ_G0033828 Lcat -3.4035897 3.61E-11 4.44E-09 
MGP_FVBNJ_G0024868 Slc16a12 -3.3948954 1.02E-10 1.13E-08 
MGP_FVBNJ_G0027613 Tmem56 -3.3931953 1.02E-09 8.79E-08 
MGP_FVBNJ_G0021749 Ly6d -3.377645 4.69E-09 3.49E-07 
MGP_FVBNJ_G0017725 Mettl7b -3.3758906 3.07E-11 3.84E-09 
MGP_FVBNJ_G0028383 NA -3.375555 4.54E-05 0.00142244 
MGP_FVBNJ_G0021041 1700011H14Rik -3.3713798 1.95E-05 0.0006942 
MGP_FVBNJ_G0020909 Chdh -3.3689446 3.83E-08 2.42E-06 
MGP_FVBNJ_G0023752 C3 -3.3685162 2.01E-12 3.22E-10 
MGP_FVBNJ_G0028098 NA -3.3676392 6.87E-10 6.07E-08 
MGP_FVBNJ_G0022761 Robo2 -3.3634996 4.78E-09 3.53E-07 
MGP_FVBNJ_G0029065 Abcb4 -3.3625707 6.67E-10 5.93E-08 
MGP_FVBNJ_G0028318 Dio1 -3.361555 8.46E-09 5.96E-07 
MGP_FVBNJ_G0019712 Smoc1 -3.3598391 3.09E-11 3.85E-09 
MGP_FVBNJ_G0021958 Cyp2d12 -3.3585809 1.07E-07 6.27E-06 
MGP_FVBNJ_G0035027 Gnat1 -3.3529914 4.16E-08 2.59E-06 
MGP_FVBNJ_G0026928 Kcnmb2 -3.3484109 9.97E-05 0.00275703 
MGP_FVBNJ_G0030987 Slc6a13 -3.3446011 1.83E-08 1.21E-06 
MGP_FVBNJ_G0029451 Ugt2b1 -3.3418441 2.08E-09 1.68E-07 
MGP_FVBNJ_G0023291 Cbs -3.3394451 5.53E-12 8.14E-10 
MGP_FVBNJ_G0022701 Adgrg7 -3.3359906 4.30E-06 0.00017903 
MGP_FVBNJ_G0017301 Elane -3.3353617 6.75E-05 0.0019871 
MGP_FVBNJ_G0022149 Gpd1 -3.3251233 4.78E-09 3.53E-07 
MGP_FVBNJ_G0015693 Xkr9 -3.3222088 4.01E-08 2.52E-06 
MGP_FVBNJ_G0020637 Dmgdh -3.3182585 3.03E-08 1.93E-06 
MGP_FVBNJ_G0021960 Cyp2d37-ps -3.3157751 9.78E-08 5.78E-06 
MGP_FVBNJ_G0015965 Cps1 -3.3153113 5.80E-09 4.15E-07 
MGP_FVBNJ_G0026237 Slc27a2 -3.3075621 7.25E-08 4.38E-06 
MGP_FVBNJ_G0024717 Glyat -3.3044358 1.89E-10 1.92E-08 
MGP_FVBNJ_G0022617 Nr1i2 -3.3040188 7.79E-07 3.80E-05 
MGP_FVBNJ_G0025258 C8g -3.3021597 7.28E-10 6.42E-08 
MGP_FVBNJ_G0032687 Pdilt -3.2971918 1.37E-05 0.00050803 
MGP_FVBNJ_G0032701 Anks4b -3.2953208 4.94E-09 3.62E-07 
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MGP_FVBNJ_G0030257 Ptprz1 -3.2940515 3.16E-06 0.00013397 
MGP_FVBNJ_G0016348 Adora1 -3.2936297 6.47E-09 4.60E-07 
MGP_FVBNJ_G0029402 Lrrc66 -3.2919097 6.64E-07 3.27E-05 
MGP_FVBNJ_G0021961 Cyp2d40 -3.2910767 1.02E-08 7.08E-07 
MGP_FVBNJ_G0023314 Cyp4f14 -3.290659 1.05E-09 9.04E-08 
MGP_FVBNJ_G0033779 Ces2a -3.2868973 9.92E-09 6.91E-07 
MGP_FVBNJ_G0034630 Cyp1a2 -3.2867336 2.60E-09 2.05E-07 
MGP_FVBNJ_G0002859 Gm11967 -3.286694 0.00010192 0.00281036 
MGP_FVBNJ_G0034981 Glyctk -3.2828341 1.39E-10 1.47E-08 
MGP_FVBNJ_G0023860 Tmem178 -3.2825317 5.61E-13 1.00E-10 
MGP_FVBNJ_G0013269 NA -3.2800689 9.33E-05 0.00260433 
MGP_FVBNJ_G0012262 NA -3.2751473 2.31E-06 0.00010143 
MGP_FVBNJ_G0031115 Clec1b -3.2708348 7.90E-08 4.72E-06 
MGP_FVBNJ_G0021573 Dnah5 -3.2684439 8.80E-05 0.00248535 
MGP_FVBNJ_G0030675 Eva1a -3.2679977 1.06E-10 1.17E-08 
MGP_FVBNJ_G0029215 Slc5a1 -3.2658913 2.43E-07 1.32E-05 
MGP_FVBNJ_G0019654 Tmem30b -3.2642712 3.91E-08 2.46E-06 
MGP_FVBNJ_G0031229 Gm6614 -3.2640094 3.93E-07 2.03E-05 
MGP_FVBNJ_G0026913 Egfem1 -3.2602357 3.80E-06 0.00015883 
MGP_FVBNJ_G0031195 Gucy2c -3.2586621 5.98E-07 2.99E-05 
MGP_FVBNJ_G0033874 Tat -3.2558103 1.68E-07 9.43E-06 
MGP_FVBNJ_G0019044 Nags -3.2514617 2.29E-08 1.49E-06 
MGP_FVBNJ_G0027425 Pdzk1 -3.2510466 1.08E-08 7.44E-07 
MGP_FVBNJ_G0019921 Slc25a47 -3.2496782 3.46E-07 1.82E-05 
MGP_FVBNJ_G0023282 Tff1 -3.2463616 0.00016252 0.00420116 
MGP_FVBNJ_G0027297 Ivl -3.2419803 4.51E-06 0.00018525 
MGP_FVBNJ_G0033911 Cntnap4 -3.2287388 0.00035986 0.00819377 
MGP_FVBNJ_G0007400 Gm28182 -3.2242943 5.75E-05 0.00174066 
MGP_FVBNJ_G0027904 Cnr1 -3.2203041 0.0005504 0.01175187 
MGP_FVBNJ_G0020015 Akr1c18 -3.217043 0.00074564 0.01513477 
MGP_FVBNJ_G0021237 Shisa2 -3.2154143 4.00E-11 4.87E-09 
MGP_FVBNJ_G0027946 Dnaic1 -3.2146207 6.37E-06 0.00025419 
MGP_FVBNJ_G0030140 NA -3.2099454 1.22E-10 1.31E-08 
MGP_FVBNJ_G0031237 Gys2 -3.20643 1.35E-06 6.27E-05 
MGP_FVBNJ_G0015441 5033403H07Rik -3.202546 5.99E-07 2.99E-05 
MGP_FVBNJ_G0039857 NA -3.2011742 1.38E-07 7.92E-06 
MGP_FVBNJ_G0023547 Crisp3 -3.1960234 0.0012305 0.02263124 
MGP_FVBNJ_G0034787 Onecut1 -3.1839161 1.80E-07 1.01E-05 
MGP_FVBNJ_G0021660 Mal2 -3.1791008 1.21E-09 1.02E-07 
MGP_FVBNJ_G0027816 Cyp7a1 -3.1787186 2.23E-08 1.45E-06 
MGP_FVBNJ_G0024466 Pcx -3.1749486 1.88E-09 1.55E-07 
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MGP_FVBNJ_G0024908 NA -3.1711447 1.71E-10 1.76E-08 
MGP_FVBNJ_G0020398 Fgfr4 -3.1690929 1.63E-15 6.14E-13 
MGP_FVBNJ_G0023709 Lrg1 -3.1671682 5.44E-11 6.45E-09 
MGP_FVBNJ_G0029099 Reln -3.163207 2.20E-09 1.76E-07 
MGP_FVBNJ_G0025520 Kynu -3.1614426 1.59E-11 2.10E-09 
MGP_FVBNJ_G0028289 Dab1 -3.1597648 6.27E-06 0.00025038 
MGP_FVBNJ_G0004158 2210019I11Rik -3.1596637 8.79E-05 0.00248535 
MGP_FVBNJ_G0026185 Ckmt1 -3.151456 2.67E-05 0.00090976 
MGP_FVBNJ_G0024837 Mbl2 -3.1489399 5.49E-09 3.96E-07 
MGP_FVBNJ_G0003631 Hnf4aos -3.1485209 0.00010814 0.00295407 
MGP_FVBNJ_G0016306 Pm20d1 -3.1468612 6.47E-10 5.79E-08 
MGP_FVBNJ_G0027710 Adh1 -3.1403217 2.69E-08 1.74E-06 
MGP_FVBNJ_G0018464 Ggt6 -3.1394984 1.30E-07 7.50E-06 
MGP_FVBNJ_G0030592 Gprin3 -3.138731 2.46E-09 1.95E-07 
MGP_FVBNJ_G0029460 Sult1d1 -3.1370362 5.25E-07 2.68E-05 
MGP_FVBNJ_G0016333 Etnk2 -3.1269988 5.39E-07 2.73E-05 
MGP_FVBNJ_G0029448 Tmprss11e -3.122105 0.00204746 0.03360823 
MGP_FVBNJ_G0000128 NA -3.1215958 0.00072314 0.01477504 
MGP_FVBNJ_G0025996 Slc1a2 -3.120714 7.52E-08 4.52E-06 
MGP_FVBNJ_G0032693 Acsm3 -3.1095904 8.64E-08 5.14E-06 
MGP_FVBNJ_G0033382 Hand2 -3.1072173 5.87E-15 1.75E-12 
MGP_FVBNJ_G0030708 Cd207 -3.1067452 1.72E-05 0.00062094 
MGP_FVBNJ_G0028166 Rasef -3.0956926 3.60E-06 0.00015166 
MGP_FVBNJ_G0022747 Epha3 -3.0856953 1.10E-10 1.20E-08 
MGP_FVBNJ_G0034505 Apoa4 -3.0849861 0.000102 0.00281036 
MGP_FVBNJ_G0021319 Nefm -3.0794147 0.00052972 0.01141962 
MGP_FVBNJ_G0030485 Aoc1 -3.0761429 6.65E-05 0.00195978 
MGP_FVBNJ_G0027627 Fabp2 -3.0753203 5.13E-06 0.00020923 
MGP_FVBNJ_G0034801 Bmp5 -3.0708717 1.30E-10 1.40E-08 
MGP_FVBNJ_G0025412 Lcn2 -3.0671256 1.25E-07 7.25E-06 
MGP_FVBNJ_G0018690 Gm11437 -3.0664676 1.07E-05 0.00040569 
MGP_FVBNJ_G0031953 NA -3.0648541 6.52E-10 5.82E-08 
MGP_FVBNJ_G0016405 Kcnt2 -3.0622519 7.42E-11 8.48E-09 
MGP_FVBNJ_G0025455 AI182371 -3.0609766 1.17E-08 7.97E-07 
MGP_FVBNJ_G0016465 Fam163a -3.0598062 6.03E-05 0.0018086 
MGP_FVBNJ_G0016905 Tcf21 -3.058837 9.12E-11 1.02E-08 
MGP_FVBNJ_G0031217 Pik3c2g -3.0571101 1.07E-07 6.27E-06 
MGP_FVBNJ_G0019879 Serpina5 -3.0444655 0.00067332 0.0139101 
MGP_FVBNJ_G0025068 Plekhs1 -3.0437019 1.95E-06 8.81E-05 
MGP_FVBNJ_G0020229 Agtr1a -3.0427372 1.54E-09 1.28E-07 
MGP_FVBNJ_G0030764 Bmp10 -3.0416389 2.54E-06 0.00010914 
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MGP_FVBNJ_G0029077 Hgf -3.0379811 8.75E-13 1.50E-10 
MGP_FVBNJ_G0030496 Npy -3.0344718 9.12E-05 0.00256084 
MGP_FVBNJ_G0019871 Serpina6 -3.0286357 1.50E-08 1.01E-06 
MGP_FVBNJ_G0021529 Capsl -3.0220367 3.91E-05 0.00126163 
MGP_FVBNJ_G0020187 Slc17a4 -3.0105703 2.40E-09 1.91E-07 
MGP_FVBNJ_G0016391 Nr5a2 -3.0063291 9.69E-09 6.77E-07 
MGP_FVBNJ_G0018761 Hlf -3.0026993 2.21E-06 9.80E-05 
MGP_FVBNJ_G0025214 Il1f10 -3.0024147 7.23E-05 0.00211482 
MGP_FVBNJ_G0006518 Gm15611 -2.9946829 3.39E-05 0.00111515 
MGP_FVBNJ_G0016909 Vnn3 -2.9944311 6.49E-08 3.94E-06 
MGP_FVBNJ_G0030812 Aldh1l1 -2.9910843 2.00E-08 1.31E-06 
MGP_FVBNJ_G0040130 NA -2.9897183 1.66E-05 0.00060289 
MGP_FVBNJ_G0023708 Plin5 -2.9815376 2.17E-05 0.00076201 
MGP_FVBNJ_G0025145 Itih2 -2.979824 4.02E-09 3.00E-07 
MGP_FVBNJ_G0003818 Gm11844 -2.9748435 1.54E-05 0.00056353 
MGP_FVBNJ_G0017548 Syt1 -2.9685377 2.43E-06 0.00010598 
MGP_FVBNJ_G0019163 Abca8b -2.9670726 3.14E-09 2.41E-07 
MGP_FVBNJ_G0027726 Gbp2b -2.9634567 3.65E-07 1.90E-05 
MGP_FVBNJ_G0003653 Ctcflos -2.9572027 1.43E-05 0.00052611 
MGP_FVBNJ_G0034081 Mmp10 -2.9531675 0.00159665 0.02769713 
MGP_FVBNJ_G0020968 Gdf2 -2.94748 3.01E-06 0.00012847 
MGP_FVBNJ_G0020616 Acot12 -2.9467399 1.25E-05 0.0004662 
MGP_FVBNJ_G0004152 Gm16035 -2.9457635 0.00014335 0.00374616 
MGP_FVBNJ_G0017370 Creb3l3 -2.9424127 1.67E-07 9.40E-06 
MGP_FVBNJ_G0033234 Ido2 -2.9393847 4.17E-08 2.59E-06 
MGP_FVBNJ_G0023971 Dsc2 -2.9391124 8.81E-09 6.17E-07 
MGP_FVBNJ_G0031271 Pthlh -2.9362211 0.00063317 0.01319066 
MGP_FVBNJ_G0001366 NA -2.9362103 6.50E-07 3.21E-05 
MGP_FVBNJ_G0027447 Hsd3b1 -2.9359246 8.60E-06 0.00033297 
MGP_FVBNJ_G0005720 1700001G01Rik -2.9349011 6.89E-05 0.00202285 
MGP_FVBNJ_G0035202 Vipr1 -2.9327118 2.49E-07 1.35E-05 
MGP_FVBNJ_G0027961 NA -2.926118 8.60E-06 0.00033297 
MGP_FVBNJ_G0018808 Ngfr -2.91696 3.48E-06 0.00014678 
MGP_FVBNJ_G0032350 Plekhb1 -2.9109646 8.39E-08 5.00E-06 
MGP_FVBNJ_G0021977 Scube1 -2.9103017 2.14E-06 9.58E-05 
MGP_FVBNJ_G0011575 NA -2.9077087 1.50E-05 0.00055085 
MGP_FVBNJ_G0023502 Ubd -2.903389 8.91E-05 0.00250986 
MGP_FVBNJ_G0032569 Syt9 -2.9008709 2.91E-07 1.54E-05 
MGP_FVBNJ_G0016546 Gpa33 -2.8995602 0.00312518 0.04628793 
MGP_FVBNJ_G0006798 Gm27033 -2.8986822 0.00080492 0.0160631 
MGP_FVBNJ_G0020791 Dnase1l3 -2.8940036 1.88E-08 1.24E-06 
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MGP_FVBNJ_G0033706 Ces1e -2.8920356 0.00034561 0.00790157 
MGP_FVBNJ_G0006420 0610043K17Rik -2.8908217 2.33E-05 0.00080754 
MGP_FVBNJ_G0015817 Slc9a2 -2.8881227 0.00012727 0.00339326 
MGP_FVBNJ_G0010089 NA -2.8833464 0.00058868 0.01241459 
MGP_FVBNJ_G0012887 NA -2.8803248 0.00040912 0.00917473 
MGP_FVBNJ_G0017122 NA -2.8779934 2.75E-07 1.46E-05 
MGP_FVBNJ_G0028126 NA -2.870418 5.01E-10 4.60E-08 
MGP_FVBNJ_G0021193 Mcpt2 -2.8698979 0.00295647 0.04440881 
MGP_FVBNJ_G0030388 Mgam -2.8695525 1.57E-07 8.89E-06 
MGP_FVBNJ_G0017383 Tjp3 -2.867365 7.80E-10 6.82E-08 
MGP_FVBNJ_G0022896 Dscam -2.8657423 0.00020929 0.00520686 
MGP_FVBNJ_G0024910 Cyp2c37 -2.8389997 5.75E-07 2.90E-05 
MGP_FVBNJ_G0028382 NA -2.834547 0.00055537 0.01183537 
MGP_FVBNJ_G0040280 NA -2.8321092 0.00010668 0.00292125 
MGP_FVBNJ_G0022038 Tymp -2.823468 1.25E-07 7.28E-06 
MGP_FVBNJ_G0020694 Ocln -2.8214638 3.09E-06 0.00013132 
MGP_FVBNJ_G0016248 Sctr -2.8199973 0.000113 0.00306058 
MGP_FVBNJ_G0016992 Mfsd4b1 -2.8164847 4.32E-06 0.00017951 
MGP_FVBNJ_G0003846 NA -2.8144907 8.88E-06 0.00034144 
MGP_FVBNJ_G0034205 Ap1m2 -2.8131716 5.62E-06 0.00022639 
MGP_FVBNJ_G0031317 Eps8l1 -2.8098304 2.12E-05 0.00074896 
MGP_FVBNJ_G0017977 Gabrp -2.8015557 0.00010489 0.00287586 
MGP_FVBNJ_G0027838 Cdh17 -2.8014058 1.22E-05 0.00045618 
MGP_FVBNJ_G0015796 Aff3 -2.7987984 6.43E-07 3.18E-05 
MGP_FVBNJ_G0032985 Ano9 -2.7969105 2.20E-05 0.00076816 
MGP_FVBNJ_G0018118 Leap2 -2.796882 4.41E-05 0.00138604 
MGP_FVBNJ_G0034957 Trf -2.7928708 2.56E-10 2.54E-08 
MGP_FVBNJ_G0022967 Dact2 -2.7917107 5.55E-11 6.51E-09 
MGP_FVBNJ_G0016999 Ddo -2.7904822 4.84E-07 2.48E-05 
MGP_FVBNJ_G0020806 Cadps -2.7885177 0.00219353 0.03531745 
MGP_FVBNJ_G0019641 Lrrc9 -2.7865592 0.00035558 0.00811276 
MGP_FVBNJ_G0022471 Ehhadh -2.7865032 2.53E-05 0.00086756 
MGP_FVBNJ_G0032050 Saa2 -2.7826569 3.12E-09 2.41E-07 
MGP_FVBNJ_G0028361 Slc5a9 -2.7816143 0.00135511 0.02432106 
MGP_FVBNJ_G0028157 Astn2 -2.7806686 4.05E-07 2.09E-05 
MGP_FVBNJ_G0010363 NA -2.779573 0.00273932 0.04179475 
MGP_FVBNJ_G0032075 Csrp3 -2.7752775 4.40E-06 0.00018196 
MGP_FVBNJ_G0019427 Mycn -2.7643635 5.76E-11 6.69E-09 
MGP_FVBNJ_G0016560 Rxrg -2.7617904 5.56E-05 0.00169175 
MGP_FVBNJ_G0015990 Gpbar1 -2.7579464 1.12E-05 0.00042091 
MGP_FVBNJ_G0031568 Cblc -2.754922 7.44E-07 3.64E-05 
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MGP_FVBNJ_G0022794 Cldn8 -2.7511226 0.00020277 0.00509586 
MGP_FVBNJ_G0033785 Ces2h -2.7511061 0.00033957 0.00779545 
MGP_FVBNJ_G0032663 Sox6 -2.7482308 5.48E-09 3.96E-07 
MGP_FVBNJ_G0025393 NA -2.7475569 7.83E-07 3.81E-05 
MGP_FVBNJ_G0019960 Aspg -2.7472239 2.23E-06 9.88E-05 
MGP_FVBNJ_G0025603 Abcb11 -2.7454287 8.44E-07 4.08E-05 
MGP_FVBNJ_G0019466 Colec11 -2.7270294 9.29E-07 4.44E-05 
MGP_FVBNJ_G0007249 2810030D12Rik -2.7236966 0.00015768 0.00410121 
MGP_FVBNJ_G0018258 Kcnj12 -2.721736 0.00249756 0.03917878 
MGP_FVBNJ_G0017805 Sec14l2 -2.7171784 2.15E-07 1.18E-05 
MGP_FVBNJ_G0021532 NA -2.7164939 5.84E-07 2.93E-05 
MGP_FVBNJ_G0025156 Itga8 -2.7146656 1.45E-06 6.71E-05 
MGP_FVBNJ_G0031332 Il11 -2.7135463 0.00096976 0.01865142 
MGP_FVBNJ_G0034047 BC021891 -2.7094717 2.29E-07 1.26E-05 
MGP_FVBNJ_G0027456 Vtcn1 -2.7064708 2.23E-06 9.87E-05 
MGP_FVBNJ_G0021181 Cideb -2.7063088 1.38E-07 7.92E-06 
MGP_FVBNJ_G0016963 Rsph4a -2.7023866 6.42E-06 0.00025554 
MGP_FVBNJ_G0030911 Atp2b2 -2.7018701 1.72E-05 0.00062116 
MGP_FVBNJ_G0018967 Krt14 -2.6963147 0.00121858 0.02244901 
MGP_FVBNJ_G0033045 Slc22a18 -2.6904751 4.02E-08 2.52E-06 
MGP_FVBNJ_G0002815 Gm15343 -2.6897998 4.61E-05 0.00143903 
MGP_FVBNJ_G0028245 Cyp2j9 -2.6891395 7.89E-05 0.00227343 
MGP_FVBNJ_G0028294 1700024P16Rik -2.6867132 9.87E-06 0.00037612 
MGP_FVBNJ_G0034713 Slc51b -2.6822833 0.00055973 0.01188274 
MGP_FVBNJ_G0026356 Snap25 -2.680576 4.88E-05 0.00151466 
MGP_FVBNJ_G0024655 Vwce -2.6751615 2.82E-05 0.00094812 
MGP_FVBNJ_G0022008 Celsr1 -2.6748818 1.10E-18 1.23E-15 
MGP_FVBNJ_G0032685 Gp2 -2.673799 0.00094263 0.01822384 
MGP_FVBNJ_G0029887 Glt1d1 -2.6721405 0.00057077 0.01208263 
MGP_FVBNJ_G0030988 Slc6a12 -2.6698834 2.48E-06 0.0001074 
MGP_FVBNJ_G0024980 Pax2 -2.6682266 0.00044803 0.0099175 
MGP_FVBNJ_G0023681 Kcnh8 -2.6647051 0.00188221 0.03147505 
MGP_FVBNJ_G0005690 Gm19585 -2.6630068 0.00038266 0.00865987 
MGP_FVBNJ_G0033708 Ces1g -2.6576059 5.86E-07 2.94E-05 
MGP_FVBNJ_G0019995 Ptprn2 -2.6551499 0.0001027 0.00282638 
MGP_FVBNJ_G0016402 NA -2.6541398 1.96E-06 8.83E-05 
MGP_FVBNJ_G0030246 Asz1 -2.653149 0.00095377 0.01842322 
MGP_FVBNJ_G0003327 Gm15318 -2.652406 1.62E-05 0.00059021 
MGP_FVBNJ_G0031674 Cyp2f2 -2.648899 1.54E-08 1.03E-06 
MGP_FVBNJ_G0030530 Wipf3 -2.6452988 1.31E-08 8.90E-07 
MGP_FVBNJ_G0003059 Gm11789 -2.636573 3.39E-05 0.00111548 
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MGP_FVBNJ_G0023662 Treml4 -2.6349311 1.24E-05 0.00046369 
MGP_FVBNJ_G0032211 Fsd2 -2.626727 0.0003315 0.00761796 
MGP_FVBNJ_G0027584 NA -2.6258563 2.66E-05 0.00090796 
MGP_FVBNJ_G0027441 Hmgcs2 -2.6247123 2.39E-06 0.00010465 
MGP_FVBNJ_G0016675 Kmo -2.6201989 7.40E-08 4.46E-06 
MGP_FVBNJ_G0028450 2610528J11Rik -2.6195129 9.68E-05 0.00268686 
MGP_FVBNJ_G0003011 Gm11586 -2.6191837 0.00023381 0.00570861 
MGP_FVBNJ_G0030202 NA -2.6010732 3.17E-05 0.00105056 
MGP_FVBNJ_G0027464 Mab21l3 -2.6004439 4.69E-06 0.00019206 
MGP_FVBNJ_G0033932 Sdr42e1 -2.5988944 4.02E-06 0.0001677 
MGP_FVBNJ_G0023869 Haao -2.5944823 1.07E-06 5.11E-05 
MGP_FVBNJ_G0005577 Gm28876 -2.5932614 0.00148733 0.02629196 
MGP_FVBNJ_G0019868 Ifi27l2b -2.5894107 1.16E-06 5.52E-05 
MGP_FVBNJ_G0027963 Gm2564 -2.5870921 5.79E-05 0.00174534 
MGP_FVBNJ_G0018645 Ccl11 -2.5855537 0.00082808 0.01645161 
MGP_FVBNJ_G0018917 Krt23 -2.5842886 4.73E-05 0.00147224 
MGP_FVBNJ_G0017245 Lrrc3 -2.5826501 2.55E-07 1.37E-05 
MGP_FVBNJ_G0024202 Kcnn2 -2.5752267 1.72E-06 7.86E-05 
MGP_FVBNJ_G0021007 Sftpd -2.5702612 0.00054331 0.01163401 
MGP_FVBNJ_G0019186 Gprc5c -2.5658603 5.33E-10 4.85E-08 
MGP_FVBNJ_G0031837 Fxyd3 -2.5644747 1.14E-05 0.00042689 
MGP_FVBNJ_G0007272 NA -2.5635734 2.22E-08 1.45E-06 
MGP_FVBNJ_G0031126 Klrc1 -2.562014 1.29E-05 0.00047705 
MGP_FVBNJ_G0028961 Ajap1 -2.5575979 0.00110213 0.02069715 
MGP_FVBNJ_G0028786 Rnf186 -2.5572878 0.0007252 0.01479343 
MGP_FVBNJ_G0031451 Sult2a3 -2.5545292 0.00083026 0.01648019 
MGP_FVBNJ_G0024435 NA -2.5540964 0.0014997 0.02642665 
MGP_FVBNJ_G0021197 Ctsg -2.5506962 0.00264433 0.04082047 
MGP_FVBNJ_G0018044 NA -2.5505685 2.27E-05 0.00079113 
MGP_FVBNJ_G0008149 Gm27463 -2.5503567 0.0001306 0.00346166 
MGP_FVBNJ_G0032321 Dgat2 -2.5481497 2.14E-06 9.58E-05 
MGP_FVBNJ_G0011350 NA -2.5452556 2.46E-06 0.00010663 
MGP_FVBNJ_G0017927 5730522E02Rik -2.5407601 4.47E-05 0.00140221 
MGP_FVBNJ_G0022647 Cfap44 -2.5405847 0.00223743 0.03595856 
MGP_FVBNJ_G0027531 Prok1 -2.5392372 0.00020365 0.00511201 
MGP_FVBNJ_G0030260 Cadps2 -2.5345071 1.94E-09 1.58E-07 
MGP_FVBNJ_G0030349 Akr1d1 -2.5314 9.90E-05 0.00274182 
MGP_FVBNJ_G0028507 Mfsd2a -2.5267975 0.00092593 0.01797906 
MGP_FVBNJ_G0023150 Prss29 -2.5264717 0.00109899 0.02065556 
MGP_FVBNJ_G0030261 Rnf133 -2.5263621 0.00253889 0.03963191 
MGP_FVBNJ_G0001635 NA -2.5248865 0.00116621 0.02162732 
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MGP_FVBNJ_G0018734 Mpo -2.517544 0.00214213 0.03472739 
MGP_FVBNJ_G0021613 Grhl2 -2.5172514 3.05E-06 0.00013013 
MGP_FVBNJ_G0007037 2010013B24Rik -2.5171767 0.0009927 0.01905972 
MGP_FVBNJ_G0007097 Gm28076 -2.5162152 0.00125987 0.02303837 
MGP_FVBNJ_G0003102 Gm15523 -2.5132184 0.00136104 0.02440775 
MGP_FVBNJ_G0029591 NA -2.5082877 1.87E-05 0.00067004 
MGP_FVBNJ_G0028591 Hpca -2.5079766 7.57E-05 0.00218767 
MGP_FVBNJ_G0018969 Krt17 -2.5078031 0.00271093 0.04150706 
MGP_FVBNJ_G0017670 NA -2.507134 7.53E-06 0.0002966 
MGP_FVBNJ_G0027446 NA -2.5067092 6.09E-05 0.00182272 
MGP_FVBNJ_G0005763 AW112010 -2.5057269 1.43E-07 8.12E-06 
MGP_FVBNJ_G0027947 Enho -2.5027054 5.85E-06 0.00023453 
MGP_FVBNJ_G0016671 Fmn2 -2.5021916 0.00042091 0.00939194 
MGP_FVBNJ_G0027820 Car8 -2.5019778 7.90E-06 0.00030899 
MGP_FVBNJ_G0024258 Gm4951 -2.4971873 2.36E-07 1.29E-05 
MGP_FVBNJ_G0021198 Gzme -2.4949532 0.00336169 0.04891339 
MGP_FVBNJ_G0025333 Cel -2.4918238 0.003016 0.04506014 
MGP_FVBNJ_G0019551 Akap6 -2.4892956 2.14E-07 1.18E-05 
MGP_FVBNJ_G0023277 Glp1r -2.4887538 0.00187456 0.0314208 
MGP_FVBNJ_G0000718 NA -2.4862049 8.57E-05 0.00243685 
MGP_FVBNJ_G0039557 NA -2.4758301 5.42E-05 0.00165705 
MGP_FVBNJ_G0026349 Hao1 -2.4748041 4.09E-05 0.00130468 
MGP_FVBNJ_G0018649 Tmem132e -2.474634 4.42E-05 0.00138659 
MGP_FVBNJ_G0022310 Grin2a -2.4743102 0.00135268 0.02430771 
MGP_FVBNJ_G0022834 Hunk -2.4732162 6.34E-13 1.12E-10 
MGP_FVBNJ_G0039682 NA -2.4717207 4.36E-10 4.09E-08 
MGP_FVBNJ_G0024024 Proc -2.4699726 2.26E-06 9.97E-05 
MGP_FVBNJ_G0001472 NA -2.4657255 0.00151801 0.02666509 
MGP_FVBNJ_G0027122 Gucy1a3 -2.4654909 5.63E-12 8.15E-10 
MGP_FVBNJ_G0020967 Gdf10 -2.4621438 4.92E-05 0.00152567 
MGP_FVBNJ_G0026259 Prom2 -2.4546962 0.00024106 0.00584748 
MGP_FVBNJ_G0039935 NA -2.4530765 0.0027005 0.04140079 
MGP_FVBNJ_G0021538 Ttc23l -2.452616 0.00248631 0.03910878 
MGP_FVBNJ_G0020546 Ube2ql1 -2.4523869 0.00194853 0.03231745 
MGP_FVBNJ_G0036719 Gm43189 -2.4511279 0.00024958 0.00602101 
MGP_FVBNJ_G0029142 En2 -2.450399 0.00037206 0.00844393 
MGP_FVBNJ_G0016635 Slamf8 -2.4491958 0.00025331 0.00605205 
MGP_FVBNJ_G0035909 Il13ra2 -2.4491324 0.0020615 0.03376413 
MGP_FVBNJ_G0029944 Mlxipl -2.4483538 1.41E-05 0.00051881 
MGP_FVBNJ_G0016404 NA -2.4466311 2.07E-10 2.07E-08 
MGP_FVBNJ_G0029590 NA -2.4465439 4.24E-05 0.00134129 
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MGP_FVBNJ_G0016366 Elf3 -2.4462553 1.65E-06 7.60E-05 
MGP_FVBNJ_G0030662 Ctnna2 -2.4420923 0.00039863 0.00896659 
MGP_FVBNJ_G0018238 Pemt -2.4282757 1.32E-06 6.16E-05 
MGP_FVBNJ_G0027819 Tox -2.426531 3.45E-06 0.00014585 
MGP_FVBNJ_G0026256 Gpat2 -2.4264676 0.00018486 0.00469322 
MGP_FVBNJ_G0025507 Lhx2 -2.4248038 3.78E-07 1.96E-05 
MGP_FVBNJ_G0004731 Gm5524 -2.4227589 5.02E-06 0.00020513 
MGP_FVBNJ_G0002060 NA -2.4224582 0.00133038 0.02403208 
MGP_FVBNJ_G0022386 Serpind1 -2.4218509 5.63E-06 0.00022661 
MGP_FVBNJ_G0030262 Rnf148 -2.4182293 0.00173615 0.02958755 
MGP_FVBNJ_G0004143 Gm17112 -2.4137283 7.41E-05 0.00215123 
MGP_FVBNJ_G0019463 Sox11 -2.4117403 0.00224269 0.03599129 
MGP_FVBNJ_G0024720 Keg1 -2.4082599 2.48E-05 0.0008546 
MGP_FVBNJ_G0021652 Aard -2.4057057 5.32E-05 0.00163201 
MGP_FVBNJ_G0018877 Ppp1r1b -2.4050354 0.00065383 0.01358292 
MGP_FVBNJ_G0034947 Ky -2.4049553 0.0012367 0.02270785 
MGP_FVBNJ_G0027125 Rbm46 -2.4041529 1.81E-05 0.00065113 
MGP_FVBNJ_G0002376 NA -2.3967965 0.00060005 0.01263049 
MGP_FVBNJ_G0035782 Pof1b -2.3961468 3.06E-05 0.00102105 
MGP_FVBNJ_G0022472 Map3k13 -2.3935042 5.34E-07 2.71E-05 
MGP_FVBNJ_G0015934 Zdbf2 -2.3927407 0.00345281 0.04997832 
MGP_FVBNJ_G0028331 Zyg11a -2.3923808 0.00011914 0.00319593 
MGP_FVBNJ_G0016525 F5 -2.3902138 2.16E-06 9.63E-05 
MGP_FVBNJ_G0019430 Fam84a -2.3894889 2.10E-06 9.45E-05 
MGP_FVBNJ_G0018032 Timd4 -2.3885068 7.53E-06 0.0002966 
MGP_FVBNJ_G0028046 Gabbr2 -2.3860029 2.43E-05 0.00083779 
MGP_FVBNJ_G0020202 Dcdc2a -2.3787337 0.00017279 0.00442711 
MGP_FVBNJ_G0035111 Pth1r -2.376189 1.21E-06 5.71E-05 
MGP_FVBNJ_G0020003 Macc1 -2.3753137 0.00054012 0.01159246 
MGP_FVBNJ_G0017128 Hkdc1 -2.374404 0.00022152 0.00545025 
MGP_FVBNJ_G0023785 Lama1 -2.3738546 5.34E-07 2.71E-05 
MGP_FVBNJ_G0023398 Slc44a4 -2.3703767 7.76E-06 0.0003041 
MGP_FVBNJ_G0015725 Gsta3 -2.3699459 9.45E-06 0.00036117 
MGP_FVBNJ_G0023123 Meiob -2.3692215 4.22E-05 0.00133654 
MGP_FVBNJ_G0025316 Adamtsl2 -2.3686515 6.22E-05 0.00185035 
MGP_FVBNJ_G0017627 Slc16a7 -2.3673906 5.58E-06 0.00022519 
MGP_FVBNJ_G0033578 Hhip -2.3648426 0.00090868 0.01773677 
MGP_FVBNJ_G0013643 NA -2.361933 0.00043874 0.0097333 
MGP_FVBNJ_G0025995 Pamr1 -2.3600053 3.90E-08 2.46E-06 
MGP_FVBNJ_G0015842 Slc40a1 -2.357568 1.41E-06 6.55E-05 
MGP_FVBNJ_G0029338 0610040J01Rik -2.3573133 1.33E-06 6.20E-05 
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MGP_FVBNJ_G0002056 NA -2.3565805 3.27E-07 1.72E-05 
MGP_FVBNJ_G0016062 Col4a4 -2.3564771 0.00016361 0.00422109 
MGP_FVBNJ_G0017706 Erbb3 -2.3563405 2.34E-07 1.28E-05 
MGP_FVBNJ_G0016126 Ugt1a1 -2.3462721 4.03E-05 0.00129387 
MGP_FVBNJ_G0027433 Fmo5 -2.3462149 9.92E-06 0.00037725 
MGP_FVBNJ_G0028303 Ttc22 -2.3441628 0.0004343 0.00965204 
MGP_FVBNJ_G0002888 Gm12195 -2.3416881 0.00199951 0.03291803 
MGP_FVBNJ_G0006337 Gm12354 -2.3412233 0.00184452 0.03107951 
MGP_FVBNJ_G0025053 Rbm20 -2.3402028 4.12E-05 0.0013125 
MGP_FVBNJ_G0027547 Gstm3 -2.3310813 8.30E-05 0.00237462 
MGP_FVBNJ_G0004549 NA -2.3302738 6.19E-05 0.00184465 
MGP_FVBNJ_G0034220 Angptl8 -2.3276079 3.53E-05 0.00115833 
MGP_FVBNJ_G0029459 Sult1b1 -2.3250465 0.00017319 0.00443236 
MGP_FVBNJ_G0030274 Tmem229a -2.3227021 7.32E-07 3.59E-05 
MGP_FVBNJ_G0019475 Sntg2 -2.3208045 0.00013152 0.0034819 
MGP_FVBNJ_G0002050 NA -2.3199037 0.00159927 0.02769955 
MGP_FVBNJ_G0021005 Sftpa1 -2.3168524 0.00271724 0.04157172 
MGP_FVBNJ_G0021056 Tlr11 -2.3162887 0.0006047 0.01271633 
MGP_FVBNJ_G0022317 Ciita -2.3160876 1.69E-05 0.00061389 
MGP_FVBNJ_G0017011 NA -2.3152021 4.19E-05 0.00133086 
MGP_FVBNJ_G0019918 Degs2 -2.3127426 0.00021321 0.0052808 
MGP_FVBNJ_G0020186 Slc17a1 -2.3122962 0.00011163 0.00303588 
MGP_FVBNJ_G0032966 Urah -2.311243 9.36E-06 0.00035836 
MGP_FVBNJ_G0027121 Gucy1b3 -2.3038416 8.00E-13 1.38E-10 
MGP_FVBNJ_G0033562 Nr3c2 -2.2982586 8.36E-07 4.05E-05 
MGP_FVBNJ_G0004806 Gm8883 -2.2933997 1.45E-06 6.71E-05 
MGP_FVBNJ_G0006035 9430093N23Rik -2.2902823 0.00327339 0.04794379 
MGP_FVBNJ_G0023975 NA -2.2900588 0.00100735 0.01927457 
MGP_FVBNJ_G0035978 Rai2 -2.289746 2.96E-08 1.90E-06 
MGP_FVBNJ_G0007463 9530059O14Rik -2.2876529 0.00327672 0.04795884 
MGP_FVBNJ_G0021491 Itgbl1 -2.283698 0.00159792 0.02769763 
MGP_FVBNJ_G0031952 Myh14 -2.2804216 0.00037236 0.00844393 
MGP_FVBNJ_G0017203 Chchd10 -2.2794085 1.87E-05 0.00066947 
MGP_FVBNJ_G0031212 Mgst1 -2.2771033 1.30E-05 0.00048188 
MGP_FVBNJ_G0024259 F830016B08Rik -2.2748686 6.60E-06 0.00026241 
MGP_FVBNJ_G0020743 Ankrd55 -2.2706141 2.45E-06 0.00010636 
MGP_FVBNJ_G0024443 BC021614 -2.2698358 2.13E-05 0.00074896 
MGP_FVBNJ_G0030539 Crhr2 -2.2686167 0.00242079 0.03840706 
MGP_FVBNJ_G0034475 Ttc36 -2.2683344 2.74E-05 0.0009274 
MGP_FVBNJ_G0030421 Epha1 -2.2676521 3.75E-05 0.00122003 
MGP_FVBNJ_G0030195 Tfpi2 -2.2669771 1.47E-06 6.78E-05 
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MGP_FVBNJ_G0032702 Crym -2.2630528 0.00019713 0.00497635 
MGP_FVBNJ_G0035943 Spin2c -2.2625927 2.74E-07 1.46E-05 
MGP_FVBNJ_G0034913 Clstn2 -2.2609925 5.69E-06 0.00022845 
MGP_FVBNJ_G0019892 Clmn -2.2605605 7.99E-06 0.00031209 
MGP_FVBNJ_G0033702 Ces1a -2.253582 0.00215616 0.0348787 
MGP_FVBNJ_G0023365 H2-Ob -2.2508549 1.54E-05 0.00056352 
MGP_FVBNJ_G0021500 Plcxd3 -2.2472755 0.00115581 0.0214701 
MGP_FVBNJ_G0033784 Ces2g -2.2435216 2.94E-07 1.55E-05 
MGP_FVBNJ_G0006320 Gm20752 -2.242923 2.41E-06 0.00010511 
MGP_FVBNJ_G0002787 Gm29571 -2.2417082 0.00320409 0.04717466 
MGP_FVBNJ_G0014965 Gm16565 -2.2402924 0.00016862 0.00434021 
MGP_FVBNJ_G0016888 Map7 -2.2390764 7.61E-05 0.00219739 
MGP_FVBNJ_G0022053 Kif21a -2.2378074 2.52E-07 1.36E-05 
MGP_FVBNJ_G0028103 D630039A03Rik -2.2369796 6.59E-05 0.0019479 
MGP_FVBNJ_G0024011 Syt4 -2.2326452 0.00269021 0.04130394 
MGP_FVBNJ_G0016267 Tmem163 -2.2312515 0.00018973 0.0048114 
MGP_FVBNJ_G0034843 Elovl4 -2.226562 0.00169327 0.02898969 
MGP_FVBNJ_G0004090 Hnf1aos2 -2.2255129 0.00071666 0.01465598 
MGP_FVBNJ_G0028143 Kif12 -2.2176964 8.49E-06 0.00032989 
MGP_FVBNJ_G0016376 Lad1 -2.2151959 3.38E-05 0.00111515 
MGP_FVBNJ_G0029303 Prom1 -2.2143343 5.25E-07 2.68E-05 
MGP_FVBNJ_G0017196 Gstt1 -2.2096816 2.71E-05 0.00092037 
MGP_FVBNJ_G0028181 Frem1 -2.2087231 1.44E-05 0.00052919 
MGP_FVBNJ_G0029780 Rasal1 -2.2072898 0.0010025 0.01923128 
MGP_FVBNJ_G0031065 Plekhg6 -2.2043613 2.58E-05 0.00088638 
MGP_FVBNJ_G0030699 Slc4a5 -2.197357 0.00141707 0.02529049 
MGP_FVBNJ_G0019785 Esrrb -2.1970576 0.000618 0.01298345 
MGP_FVBNJ_G0026890 Cp -2.1959888 2.23E-07 1.22E-05 
MGP_FVBNJ_G0023427 Ltb -2.1914546 5.53E-05 0.00168483 
MGP_FVBNJ_G0030630 Cd8a -2.1905348 0.00150108 0.0264301 
MGP_FVBNJ_G0025574 Dpp4 -2.1867622 5.21E-06 0.00021192 
MGP_FVBNJ_G0025392 NA -2.1826772 1.29E-07 7.46E-06 
MGP_FVBNJ_G0016948 Rspo3 -2.1815743 5.84E-07 2.93E-05 
MGP_FVBNJ_G0032739 Aqp8 -2.1745892 0.00010883 0.00296928 
MGP_FVBNJ_G0022503 Cldn1 -2.171524 3.82E-05 0.0012383 
MGP_FVBNJ_G0016953 Hey2 -2.1676188 2.17E-06 9.64E-05 
MGP_FVBNJ_G0015780 Vwa3b -2.1622331 0.00197401 0.03259463 
MGP_FVBNJ_G0028765 Alpl -2.1617746 2.73E-08 1.76E-06 
MGP_FVBNJ_G0027211 Pklr -2.1610231 0.00017709 0.00452179 
MGP_FVBNJ_G0035131 Dclk3 -2.1604981 0.00029184 0.00683352 
MGP_FVBNJ_G0033417 Nat1 -2.1496337 0.00214197 0.03472739 
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MGP_FVBNJ_G0017667 Gpr182 -2.147746 2.36E-05 0.00081563 
MGP_FVBNJ_G0016283 C4bp -2.1434028 2.40E-05 0.00083111 
MGP_FVBNJ_G0016990 Mfsd4b3 -2.1429625 5.10E-05 0.00157506 
MGP_FVBNJ_G0029452 Ugt2b35 -2.1391117 2.81E-05 0.00094613 
MGP_FVBNJ_G0021955 NA -2.1358536 0.00014474 0.00377809 
MGP_FVBNJ_G0035630 NA -2.1339257 1.17E-12 1.95E-10 
MGP_FVBNJ_G0029759 Nos1 -2.130963 0.00233314 0.03722832 
MGP_FVBNJ_G0035795 Nap1l3 -2.1290988 0.00012141 0.00324897 
MGP_FVBNJ_G0023368 H2-Eb1 -2.1287768 2.25E-05 0.00078385 
MGP_FVBNJ_G0035257 Nudt11 -2.1272693 0.00268544 0.04128349 
MGP_FVBNJ_G0027833 Esrp1 -2.1245324 0.00113032 0.02110787 
MGP_FVBNJ_G0002077 NA -2.1233241 3.58E-05 0.00117172 
MGP_FVBNJ_G0032889 Lhpp -2.1218667 3.79E-06 0.00015865 
MGP_FVBNJ_G0028244 Cyp2j6 -2.1179155 1.14E-08 7.85E-07 
MGP_FVBNJ_G0025690 Frzb -2.1149322 1.95E-08 1.28E-06 
MGP_FVBNJ_G0039657 NA -2.113589 0.00024265 0.00587914 
MGP_FVBNJ_G0028516 Heyl -2.111149 0.00093703 0.01817868 
MGP_FVBNJ_G0019862 Asb2 -2.1103559 0.00079166 0.01586958 
MGP_FVBNJ_G0015136 Gm15941 -2.108986 0.000199 0.0050123 
MGP_FVBNJ_G0025595 B3galt1 -2.102719 0.00019287 0.00488542 
MGP_FVBNJ_G0017332 Reep6 -2.1007919 4.61E-05 0.00143903 
MGP_FVBNJ_G0029529 Sowahb -2.1006145 1.63E-09 1.35E-07 
MGP_FVBNJ_G0021645 Sybu -2.0981771 6.00E-06 0.00024028 
MGP_FVBNJ_G0027587 Olfm3 -2.0961273 0.00214203 0.03472739 
MGP_FVBNJ_G0015513 NA -2.0957353 0.00017851 0.00454768 
MGP_FVBNJ_G0025942 Nr1h3 -2.0946539 5.36E-06 0.00021734 
MGP_FVBNJ_G0027391 Car14 -2.0928507 0.00261632 0.04052846 
MGP_FVBNJ_G0032848 Itgax -2.0921709 0.00121661 0.02243138 
MGP_FVBNJ_G0028674 Kdf1 -2.0920974 3.92E-05 0.00126163 
MGP_FVBNJ_G0033478 Gdf15 -2.0920512 9.10E-05 0.00255689 
MGP_FVBNJ_G0021667 Col14a1 -2.0889963 1.84E-06 8.37E-05 
MGP_FVBNJ_G0017603 Grip1 -2.0834799 0.00020551 0.00513558 
MGP_FVBNJ_G0019248 Foxj1 -2.0817362 0.00029121 0.00682594 
MGP_FVBNJ_G0022039 Odf3b -2.0760537 0.0014252 0.02537466 
MGP_FVBNJ_G0015891 Aox3 -2.0712958 0.00017804 0.00454093 
MGP_FVBNJ_G0007308 Irx3os -2.0703789 0.00170798 0.02912968 
MGP_FVBNJ_G0026838 Hnf4g -2.0686138 0.00022936 0.00561219 
MGP_FVBNJ_G0025679 Zfp385b -2.0666523 0.00013924 0.00365572 
MGP_FVBNJ_G0033641 Klf1 -2.0656705 0.00269047 0.04130394 
MGP_FVBNJ_G0039901 NA -2.0651041 5.64E-05 0.00171391 
MGP_FVBNJ_G0034531 Plet1 -2.0627302 0.00132099 0.02390118 
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MGP_FVBNJ_G0033339 Pdlim3 -2.0585839 5.54E-06 0.00022423 
MGP_FVBNJ_G0015871 Pgap1 -2.0574839 2.63E-13 4.93E-11 
MGP_FVBNJ_G0027565 5330417C22Rik -2.0574674 1.12E-05 0.00042103 
MGP_FVBNJ_G0024236 Prdm6 -2.055472 0.00026929 0.00637242 
MGP_FVBNJ_G0018459 Slc13a5 -2.054153 0.00030565 0.00711929 
MGP_FVBNJ_G0024305 Atp8b1 -2.0536772 3.09E-08 1.96E-06 
MGP_FVBNJ_G0017690 Il23a -2.0529359 0.00295173 0.04436747 
MGP_FVBNJ_G0016043 Sgpp2 -2.0517214 0.00057961 0.01223875 
MGP_FVBNJ_G0018623 Rab11fip4 -2.0515961 7.88E-07 3.83E-05 
MGP_FVBNJ_G0026000 Ehf -2.0511566 4.25E-05 0.00134263 
MGP_FVBNJ_G0035366 Klhl13 -2.0497264 3.25E-13 5.94E-11 
MGP_FVBNJ_G0023814 Ehd3 -2.0478822 3.73E-06 0.00015678 
MGP_FVBNJ_G0033305 Cldn23 -2.0456246 0.00086227 0.0170247 
MGP_FVBNJ_G0018095 Col23a1 -2.0439988 0.001053 0.01992575 
MGP_FVBNJ_G0032731 Chp2 -2.0436551 2.29E-05 0.00079514 
MGP_FVBNJ_G0023878 Slc3a1 -2.0420112 0.00027544 0.00649726 
MGP_FVBNJ_G0020767 Itga1 -2.0368489 4.37E-10 4.09E-08 
MGP_FVBNJ_G0016586 Pcp4l1 -2.0342822 0.00178309 0.03022571 
MGP_FVBNJ_G0018295 Hs3st3b1 -2.0332242 3.62E-07 1.89E-05 
MGP_FVBNJ_G0033206 Atp7b -2.0329668 5.23E-05 0.00161017 
MGP_FVBNJ_G0027641 Ugt8a -2.0300995 0.00010389 0.00285206 
MGP_FVBNJ_G0019779 Mfsd7c -2.0294421 2.31E-05 0.00080326 
MGP_FVBNJ_G0018999 Hsd17b1 -2.0279983 0.00108136 0.0203415 
MGP_FVBNJ_G0028135 Bspry -2.0277223 5.48E-05 0.00167301 
MGP_FVBNJ_G0032662 Insc -2.0248478 2.06E-05 0.00073143 
MGP_FVBNJ_G0027158 Fcrl1 -2.0169309 0.00011773 0.00317339 
MGP_FVBNJ_G0036226 NA -2.0160306 0.00252436 0.03946036 
MGP_FVBNJ_G0023567 Adgrf1 -2.0156156 0.00025203 0.00605205 
MGP_FVBNJ_G0023370 Btnl2 -2.0142021 0.00069552 0.01428916 
MGP_FVBNJ_G0022661 NA -2.0123362 7.46E-05 0.00216332 
MGP_FVBNJ_G0025319 Sardh -2.0119781 4.73E-05 0.00147224 
MGP_FVBNJ_G0004961 Gm16548 -2.010176 0.00073601 0.01499679 
MGP_FVBNJ_G0032978 Ifitm1 -2.0097362 3.38E-06 0.00014312 
MGP_FVBNJ_G0019179 Sdk2 -2.0054653 5.47E-07 2.77E-05 
MGP_FVBNJ_G0031835 Fxyd1 -2.0048644 5.27E-05 0.00161661 
MGP_FVBNJ_G0030040 Stag3 -2.0034794 0.0021365 0.03472739 
MGP_FVBNJ_G0023393 Cfb -1.9996095 4.15E-05 0.0013209 
MGP_FVBNJ_G0020283 Bmp6 -1.9992909 5.20E-05 0.00160205 
MGP_FVBNJ_G0025127 Ccdc3 -1.9987584 5.77E-05 0.00174436 
MGP_FVBNJ_G0029589 Abcg3 -1.9968378 0.00012751 0.00339326 
MGP_FVBNJ_G0023516 H2-M2 -1.9957678 0.00188009 0.03146325 
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MGP_FVBNJ_G0025451 Cutal -1.9934736 2.96E-05 0.00098908 
MGP_FVBNJ_G0023366 H2-Ab1 -1.993446 8.42E-05 0.00239684 
MGP_FVBNJ_G0021683 Klhl38 -1.9927233 0.00281159 0.04269292 
MGP_FVBNJ_G0031206 Rerg -1.9909375 7.31E-09 5.19E-07 
MGP_FVBNJ_G0027546 Gstm6 -1.9880529 0.00015401 0.00401527 
MGP_FVBNJ_G0018728 Sep-04 -1.9866352 1.15E-08 7.86E-07 
MGP_FVBNJ_G0020568 Tppp -1.9847336 0.00041815 0.0093396 
MGP_FVBNJ_G0031123 Klrk1 -1.9817753 0.00038743 0.00874988 
MGP_FVBNJ_G0035625 Prrg1 -1.9797468 2.15E-06 9.62E-05 
MGP_FVBNJ_G0016623 Casq1 -1.9781275 3.22E-05 0.00106714 
MGP_FVBNJ_G0034729 Dapk2 -1.9767076 0.00019416 0.00491253 
MGP_FVBNJ_G0035124 NA -1.9763203 0.00034529 0.00790157 
MGP_FVBNJ_G0018325 Ntn1 -1.9746079 1.77E-06 8.07E-05 
MGP_FVBNJ_G0021546 Npr3 -1.9741687 7.12E-06 0.0002814 
MGP_FVBNJ_G0027887 Epha7 -1.9713325 9.36E-10 8.12E-08 
MGP_FVBNJ_G0034064 Gucy1a2 -1.9709342 1.90E-06 8.59E-05 
MGP_FVBNJ_G0010634 NA -1.9665926 0.00067881 0.01398462 
MGP_FVBNJ_G0035169 Acaa1b -1.9660484 0.00040995 0.00918406 
MGP_FVBNJ_G0034048 Kcnk1 -1.9630065 0.00043883 0.0097333 
MGP_FVBNJ_G0016800 G0s2 -1.9627022 0.00032995 0.00759017 
MGP_FVBNJ_G0024417 Cd226 -1.9606302 0.00241014 0.03829258 
MGP_FVBNJ_G0023944 Abhd3 -1.9568736 7.72E-05 0.00222665 
MGP_FVBNJ_G0031286 Nlrp12 -1.9557751 4.47E-06 0.00018384 
MGP_FVBNJ_G0020432 Lect2 -1.9553488 0.000262 0.00622634 
MGP_FVBNJ_G0035176 Xylb -1.9532274 3.64E-05 0.0011858 
MGP_FVBNJ_G0019884 NA -1.9515365 0.00053606 0.01153417 
MGP_FVBNJ_G0033058 Shank2 -1.9499807 6.11E-05 0.00182717 
MGP_FVBNJ_G0016735 Susd4 -1.9462219 0.0021502 0.03480768 
MGP_FVBNJ_G0021594 Rida -1.9437862 6.32E-05 0.0018759 
MGP_FVBNJ_G0023126 Igfals -1.941285 0.00013444 0.00354662 
MGP_FVBNJ_G0018298 Hs3st3a1 -1.9401041 2.99E-06 0.0001278 
MGP_FVBNJ_G0001030 NA -1.9388581 2.64E-05 0.00090142 
MGP_FVBNJ_G0016369 Lmod1 -1.9346609 8.08E-06 0.0003148 
MGP_FVBNJ_G0035242 Cxcr6 -1.9343528 0.00147028 0.02603185 
MGP_FVBNJ_G0029258 Ablim2 -1.932653 0.00017123 0.00439216 
MGP_FVBNJ_G0025617 Sp5 -1.9320072 0.00065091 0.0135349 
MGP_FVBNJ_G0027799 Lrrc7 -1.9311831 0.00325268 0.04776389 
MGP_FVBNJ_G0027035 Med12l -1.9297526 8.57E-07 4.13E-05 
MGP_FVBNJ_G0031116 Clec9a -1.9282758 2.80E-05 0.00094375 
MGP_FVBNJ_G0034762 Aqp9 -1.9268172 5.36E-05 0.00164128 
MGP_FVBNJ_G0018441 Scimp -1.9265145 0.00145951 0.02586161 
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MGP_FVBNJ_G0039519 NA -1.9259577 0.00047783 0.01047326 
MGP_FVBNJ_G0026908 Tnik -1.924309 5.66E-08 3.47E-06 
MGP_FVBNJ_G0019432 Lpin1 -1.9230996 0.00274273 0.04181826 
MGP_FVBNJ_G0010316 NA -1.9120494 0.00112292 0.02100861 
MGP_FVBNJ_G0023367 H2-Aa -1.9100757 0.00013375 0.0035324 
MGP_FVBNJ_G0019946 Gm266 -1.9048321 0.00056134 0.01190557 
MGP_FVBNJ_G0033367 Tenm3 -1.9040438 0.00077026 0.01555244 
MGP_FVBNJ_G0032051 Saa1 -1.9010143 1.25E-06 5.87E-05 
MGP_FVBNJ_G0018681 Wfdc18 -1.8951181 0.00194319 0.03225287 
MGP_FVBNJ_G0016704 Coq8a -1.8923196 0.0002248 0.00552489 
MGP_FVBNJ_G0019164 Abca8a -1.8922948 0.0002104 0.00522848 
MGP_FVBNJ_G0028841 Fhad1 -1.8922822 0.00031564 0.00731378 
MGP_FVBNJ_G0016776 Batf3 -1.8853198 3.86E-05 0.00125118 
MGP_FVBNJ_G0023687 Sult1c2 -1.8853063 0.00166093 0.02853563 
MGP_FVBNJ_G0015887 Spats2l -1.8841294 2.71E-07 1.44E-05 
MGP_FVBNJ_G0030323 Plxna4 -1.8830905 1.76E-08 1.17E-06 
MGP_FVBNJ_G0015695 Msc -1.8820653 8.18E-05 0.00234263 
MGP_FVBNJ_G0018781 Epn3 -1.8768068 0.0019509 0.03233267 
MGP_FVBNJ_G0019882 Serpina3c -1.8760459 0.00019696 0.00497635 
MGP_FVBNJ_G0040332 NA -1.8757365 0.00193948 0.03223938 
MGP_FVBNJ_G0038056 Gm25047 -1.8745484 0.00310024 0.04604089 
MGP_FVBNJ_G0028830 Tmem82 -1.8729031 5.72E-05 0.00173463 
MGP_FVBNJ_G0015935 Adam23 -1.8623444 0.00078283 0.01574906 
MGP_FVBNJ_G0035465 Gpc4 -1.8615487 2.44E-07 1.32E-05 
MGP_FVBNJ_G0018454 Pitpnm3 -1.8609846 0.00211075 0.0343957 
MGP_FVBNJ_G0022202 Krt79 -1.8590362 0.00253474 0.03959483 
MGP_FVBNJ_G0026588 Tgm2 -1.8577002 2.71E-06 0.00011604 
MGP_FVBNJ_G0033449 Tm6sf2 -1.8534067 9.53E-05 0.00265153 
MGP_FVBNJ_G0019204 Ush1g -1.8516976 0.0003913 0.00881937 
MGP_FVBNJ_G0032285 Dlg2 -1.8470091 9.81E-08 5.78E-06 
MGP_FVBNJ_G0028273 Dnajc6 -1.8427885 0.00035789 0.00815717 
MGP_FVBNJ_G0023989 Asxl3 -1.8421606 9.32E-05 0.00260433 
MGP_FVBNJ_G0013976 NA -1.8405395 0.00135328 0.02430771 
MGP_FVBNJ_G0035214 Fam198a -1.8389017 0.00112343 0.02100861 
MGP_FVBNJ_G0018114 Fstl4 -1.836129 0.00248449 0.03910878 
MGP_FVBNJ_G0022670 Cd96 -1.8357375 0.00322317 0.04742414 
MGP_FVBNJ_G0021270 Gata4 -1.8335093 4.27E-07 2.20E-05 
MGP_FVBNJ_G0023389 NA -1.8313825 0.0002375 0.00577317 
MGP_FVBNJ_G0023928 Mkx -1.8306479 0.00038215 0.00865693 
MGP_FVBNJ_G0029503 Cxcl1 -1.8297444 2.68E-06 0.00011519 
MGP_FVBNJ_G0021851 Tst -1.8294315 0.00010148 0.00280313 
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MGP_FVBNJ_G0017622 Avpr1a -1.8238578 0.00111014 0.02083017 
MGP_FVBNJ_G0005964 A730036I17Rik -1.8237924 0.00344312 0.04990287 
MGP_FVBNJ_G0028029 Aldh1b1 -1.8236685 4.07E-05 0.00130435 
MGP_FVBNJ_G0033695 Irx3 -1.8226376 0.00022852 0.0055978 
MGP_FVBNJ_G0034266 Ntm -1.8222603 2.59E-05 0.00088741 
MGP_FVBNJ_G0018424 Vmo1 -1.8191758 0.00324713 0.04771371 
MGP_FVBNJ_G0015512 NA -1.818257 0.00091509 0.01781504 
MGP_FVBNJ_G0028497 Col9a2 -1.8168606 0.00205213 0.0336353 
MGP_FVBNJ_G0029071 Sema3d -1.8142751 2.15E-05 0.00075658 
MGP_FVBNJ_G0021494 NA -1.8110008 0.00015858 0.00411996 
MGP_FVBNJ_G0025530 Lypd6 -1.8104122 0.00081935 0.01632184 
MGP_FVBNJ_G0030415 Gstk1 -1.8095328 0.00025301 0.00605205 
MGP_FVBNJ_G0035431 Dcaf12l1 -1.8081886 0.00130856 0.02375338 
MGP_FVBNJ_G0019869 Ppp4r4 -1.807914 0.00091376 0.01780467 
MGP_FVBNJ_G0027706 Mttp -1.8033513 0.00040557 0.00911344 
MGP_FVBNJ_G0028393 Faah -1.8028816 0.0001278 0.00339554 
MGP_FVBNJ_G0016497 Tnfsf4 -1.7975262 0.00239076 0.03803878 
MGP_FVBNJ_G0026873 Car2 -1.7970855 4.44E-06 0.00018315 
MGP_FVBNJ_G0027049 P2ry1 -1.7960484 2.45E-08 1.59E-06 
MGP_FVBNJ_G0016211 Rnf152 -1.7959153 3.09E-05 0.00102868 
MGP_FVBNJ_G0039651 NA -1.7953819 0.00051577 0.01119467 
MGP_FVBNJ_G0035669 Vsig4 -1.7945894 0.00100494 0.01926157 
MGP_FVBNJ_G0017863 Adcy1 -1.7939755 0.00111532 0.02090975 
MGP_FVBNJ_G0017468 Nr1h4 -1.7921957 0.00020803 0.00518692 
MGP_FVBNJ_G0017089 Oit3 -1.786522 0.00192933 0.03211854 
MGP_FVBNJ_G0020770 Parp8 -1.7857108 0.00034531 0.00790157 
MGP_FVBNJ_G0015402 Gm830 -1.7852085 0.0011558 0.0214701 
MGP_FVBNJ_G0025634 Rapgef4 -1.7843176 0.00025604 0.0061107 
MGP_FVBNJ_G0016673 Rgs7 -1.7843065 0.00028104 0.00661525 
MGP_FVBNJ_G0020314 Cd83 -1.7758135 0.00030723 0.00714868 
MGP_FVBNJ_G0027986 Cd72 -1.7754273 0.00158491 0.02757949 
MGP_FVBNJ_G0036783 Gm13053 -1.7741179 8.38E-05 0.00239088 
MGP_FVBNJ_G0033938 Osgin1 -1.7733614 0.00042293 0.00942757 
MGP_FVBNJ_G0020797 Acox2 -1.7714974 0.00256845 0.03995339 
MGP_FVBNJ_G0026591 Lbp -1.7693497 6.23E-07 3.09E-05 
MGP_FVBNJ_G0020393 Unc5a -1.7687893 0.00134249 0.02416136 
MGP_FVBNJ_G0039551 NA -1.7647007 0.00013889 0.00365105 
MGP_FVBNJ_G0003291 Gm15638 -1.7644315 0.00011168 0.00303588 
MGP_FVBNJ_G0024653 Tkfc -1.7640223 0.00249479 0.03916285 
MGP_FVBNJ_G0023671 Unc5cl -1.7622434 0.00023665 0.00575896 
MGP_FVBNJ_G0035980 Reps2 -1.762126 0.00018361 0.0046721 
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MGP_FVBNJ_G0016628 Kcnj10 -1.7613341 0.00049858 0.010864 
MGP_FVBNJ_G0009866 Gbp11 -1.7600106 0.00133305 0.02406074 
MGP_FVBNJ_G0032570 Olfml1 -1.7583718 0.00030514 0.00711484 
MGP_FVBNJ_G0022211 Csad -1.7559476 7.54E-05 0.002184 
MGP_FVBNJ_G0033233 1810011O10Rik -1.7550194 1.14E-08 7.85E-07 
MGP_FVBNJ_G0030589 Nap1l5 -1.7533193 0.00062746 0.0131207 
MGP_FVBNJ_G0023693 Adgre4 -1.753299 0.00076834 0.01552762 
MGP_FVBNJ_G0016564 Rgs5 -1.7531678 7.29E-05 0.00212981 
MGP_FVBNJ_G0009946 NA -1.7525208 0.00117282 0.02173179 
MGP_FVBNJ_G0018416 Alox12e -1.7472026 0.00102687 0.01954729 
MGP_FVBNJ_G0021596 Nipal2 -1.7459206 0.00012537 0.00334683 
MGP_FVBNJ_G0024839 Prkg1 -1.7440115 7.67E-11 8.72E-09 
MGP_FVBNJ_G0035152 Cmtm8 -1.7438033 0.00026105 0.00621036 
MGP_FVBNJ_G0018422 Zmynd15 -1.7426604 0.00016235 0.00420116 
MGP_FVBNJ_G0029761 Tesc -1.741811 3.53E-05 0.00115833 
MGP_FVBNJ_G0025683 Cerkl -1.7373715 0.00021531 0.00532086 
MGP_FVBNJ_G0017162 Tmem26 -1.736981 8.66E-06 0.00033384 
MGP_FVBNJ_G0016281 Cd55 -1.7348274 0.00011657 0.00314571 
MGP_FVBNJ_G0023281 Tff2 -1.730647 0.00107441 0.0202326 
MGP_FVBNJ_G0022599 Ildr1 -1.7295061 0.00078658 0.01579737 
MGP_FVBNJ_G0002946 Dnah2os -1.7287436 4.34E-05 0.00136757 
MGP_FVBNJ_G0019883 Serpina3i -1.7250691 2.18E-05 0.00076557 
MGP_FVBNJ_G0031025 NA -1.7250048 0.00041099 0.00919823 
MGP_FVBNJ_G0028625 Serinc2 -1.724446 1.02E-05 0.00038564 
MGP_FVBNJ_G0007130 1810008I18Rik -1.7229692 0.00125411 0.0229518 
MGP_FVBNJ_G0035246 Ccr3 -1.721508 0.00251073 0.03932078 
MGP_FVBNJ_G0003718 Gm15998 -1.7192833 0.00075509 0.01530146 
MGP_FVBNJ_G0031024 NA -1.7145455 1.67E-05 0.0006071 
MGP_FVBNJ_G0002064 NA -1.7125782 1.23E-07 7.15E-06 
MGP_FVBNJ_G0032865 Fgfr2 -1.7110254 1.99E-07 1.10E-05 
MGP_FVBNJ_G0029782 Oas2 -1.7087209 0.0030403 0.04530168 
MGP_FVBNJ_G0020695 Marveld2 -1.7069621 0.00012757 0.00339326 
MGP_FVBNJ_G0016342 Prelp -1.704888 0.00136218 0.02440869 
MGP_FVBNJ_G0017186 Upb1 -1.7029996 0.00055956 0.01188274 
MGP_FVBNJ_G0027723 Gbp5 -1.7024355 0.00244231 0.03858639 
MGP_FVBNJ_G0002586 Gm9947 -1.7014726 0.00088017 0.01729083 
MGP_FVBNJ_G0032213 Homer2 -1.7006077 0.00192348 0.03206904 
MGP_FVBNJ_G0028238 Hook1 -1.6993644 0.00086795 0.01712158 
MGP_FVBNJ_G0022571 NA -1.6967666 1.27E-06 5.94E-05 
MGP_FVBNJ_G0027725 NA -1.6966183 6.78E-05 0.00199364 
MGP_FVBNJ_G0033450 Hapln4 -1.6942793 1.51E-05 0.00055348 
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MGP_FVBNJ_G0019258 Cygb -1.6906266 8.05E-05 0.00231267 
MGP_FVBNJ_G0023886 Epas1 -1.6892215 1.84E-07 1.02E-05 
MGP_FVBNJ_G0026719 Fam65c -1.6883548 3.99E-05 0.00128046 
MGP_FVBNJ_G0030880 Cav3 -1.6877079 0.00169743 0.02903871 
MGP_FVBNJ_G0010771 NA -1.6870941 0.00117776 0.02180517 
MGP_FVBNJ_G0026845 Il7 -1.6848082 0.0022861 0.03658251 
MGP_FVBNJ_G0032797 Qprt -1.6839756 0.00078735 0.01579737 
MGP_FVBNJ_G0019906 Ak7 -1.6834564 0.00052354 0.01133409 
MGP_FVBNJ_G0023438 H2-Q10 -1.6832049 0.0002493 0.00602065 
MGP_FVBNJ_G0031801 Prodh2 -1.6829825 0.00024108 0.00584748 
MGP_FVBNJ_G0022574 Mylk -1.6814406 1.31E-07 7.56E-06 
MGP_FVBNJ_G0023136 Tmem204 -1.677786 1.18E-06 5.56E-05 
MGP_FVBNJ_G0032150 Fam174b -1.6770027 0.00102286 0.01950429 
MGP_FVBNJ_G0028973 NA -1.6741936 0.00191643 0.0319754 
MGP_FVBNJ_G0030331 Akr1b7 -1.6733202 0.00195531 0.03235768 
MGP_FVBNJ_G0025414 Slc25a25 -1.6674327 0.00052525 0.01134998 
MGP_FVBNJ_G0030203 Ppp1r9a -1.6639696 3.24E-05 0.00107108 
MGP_FVBNJ_G0018674 Ccl5 -1.6596691 0.00199092 0.03282517 
MGP_FVBNJ_G0020038 Chrm3 -1.6590519 0.00211395 0.0343957 
MGP_FVBNJ_G0022257 Mefv -1.6573547 0.00085855 0.01696633 
MGP_FVBNJ_G0022352 Myh11 -1.6556817 0.00123204 0.0226409 
MGP_FVBNJ_G0022099 Zfp641 -1.6546948 0.00015745 0.00410013 
MGP_FVBNJ_G0029509 Btc -1.6529537 0.00128422 0.02336865 
MGP_FVBNJ_G0016280 Cd55b -1.6512026 0.00025066 0.00602817 
MGP_FVBNJ_G0016006 Cyp27a1 -1.6506312 0.00047054 0.01034407 
MGP_FVBNJ_G0024869 Pank1 -1.6494853 0.00143943 0.02556689 
MGP_FVBNJ_G0025985 Lrrc4c -1.6491035 0.00024572 0.00594715 
MGP_FVBNJ_G0028100 Palm2 -1.6490202 0.00082271 0.01635956 
MGP_FVBNJ_G0033566 Ednra -1.6487814 1.03E-06 4.90E-05 
MGP_FVBNJ_G0026219 Slc24a5 -1.6482396 0.0015422 0.02702601 
MGP_FVBNJ_G0019888 Serpina3n -1.6480526 9.67E-05 0.00268644 
MGP_FVBNJ_G0029025 AW011738 -1.6440843 2.28E-06 0.00010041 
MGP_FVBNJ_G0028842 Tmem51 -1.6429149 1.54E-07 8.72E-06 
MGP_FVBNJ_G0035274 Magix -1.638915 0.00279631 0.04255507 
MGP_FVBNJ_G0032807 Itgal -1.6386667 0.00025873 0.00616167 
MGP_FVBNJ_G0031564 Apoe -1.6374853 0.00034603 0.00790297 
MGP_FVBNJ_G0018705 Tbx2 -1.6360162 2.68E-07 1.43E-05 
MGP_FVBNJ_G0010085 NA -1.6350113 0.00193418 0.03217515 
MGP_FVBNJ_G0033928 Bco1 -1.6336783 0.00019786 0.00498915 
MGP_FVBNJ_G0023425 Aif1 -1.6305825 0.0022823 0.03654793 
MGP_FVBNJ_G0031026 NA -1.6292302 0.00028204 0.00663178 
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MGP_FVBNJ_G0022191 Krt75 -1.6275139 0.00247724 0.0390248 
MGP_FVBNJ_G0026258 Kcnip3 -1.6269443 6.13E-05 0.00183064 
MGP_FVBNJ_G0029522 Cxcl10 -1.6249993 0.0025119 0.03932078 
MGP_FVBNJ_G0025979 NA -1.6245824 8.65E-06 0.00033384 
MGP_FVBNJ_G0026861 Slc10a5 -1.6233125 0.00304684 0.04536887 
MGP_FVBNJ_G0020993 Lrit1 -1.6231615 0.00341046 0.0494616 
MGP_FVBNJ_G0016604 Tstd1 -1.6219579 0.00048001 0.01051074 
MGP_FVBNJ_G0021614 Ncald -1.621186 2.51E-06 0.00010828 
MGP_FVBNJ_G0022495 Rtp4 -1.6202438 0.00054568 0.01167351 
MGP_FVBNJ_G0024257 Chsy3 -1.6178853 7.18E-05 0.00210699 
MGP_FVBNJ_G0017878 Ddc -1.6161244 0.00156559 0.0273286 
MGP_FVBNJ_G0018476 Itgae -1.6120126 0.00333555 0.04859652 
MGP_FVBNJ_G0015559 AV026068 -1.6099704 1.68E-08 1.12E-06 
MGP_FVBNJ_G0018972 Hap1 -1.6059518 2.94E-05 0.0009826 
MGP_FVBNJ_G0027653 Enpep -1.6030001 0.00082267 0.01635956 
MGP_FVBNJ_G0031275 Tmtc1 -1.6017668 0.0003905 0.00881026 
MGP_FVBNJ_G0030063 Tmem184a -1.6013313 0.00121059 0.02237578 
MGP_FVBNJ_G0024063 Slc23a1 -1.6004654 0.0007072 0.01448916 
MGP_FVBNJ_G0019202 Fads6 -1.5955495 0.00040795 0.0091578 
MGP_FVBNJ_G0021911 Grap2 -1.5954952 0.00083205 0.01650115 
MGP_FVBNJ_G0031223 Pde3a -1.5924138 6.05E-07 3.01E-05 
MGP_FVBNJ_G0015607 Gm17396 -1.591883 8.75E-05 0.00247847 
MGP_FVBNJ_G0017498 Plxnc1 -1.5880054 7.40E-05 0.00214957 
MGP_FVBNJ_G0021953 Cyp2d22 -1.5861422 0.00050364 0.01095282 
MGP_FVBNJ_G0019261 St6galnac2 -1.584084 6.90E-06 0.00027382 
MGP_FVBNJ_G0030467 Rarres2 -1.5836175 0.00044637 0.00989059 
MGP_FVBNJ_G0026107 Rasgrp1 -1.5816469 0.0008804 0.01729083 
MGP_FVBNJ_G0024876 Ppp1r3c -1.5786324 0.00291802 0.04403891 
MGP_FVBNJ_G0022897 Bace2 -1.5776149 3.32E-10 3.22E-08 
MGP_FVBNJ_G0027764 Adgrl2 -1.5746649 2.79E-09 2.19E-07 
MGP_FVBNJ_G0025123 Phyh -1.5734862 0.00214702 0.03478149 
MGP_FVBNJ_G0033626 Cacna1a -1.5728158 0.00025317 0.00605205 
MGP_FVBNJ_G0024268 Cd74 -1.5726831 0.00107467 0.0202326 
MGP_FVBNJ_G0025581 Grb14 -1.5721366 0.00021472 0.0053123 
MGP_FVBNJ_G0019727 Dpf3 -1.5710164 0.00309986 0.04604089 
MGP_FVBNJ_G0004681 Tsix -1.5693809 0.00055819 0.01187267 
MGP_FVBNJ_G0020447 NA -1.5689773 0.00087932 0.01729083 
MGP_FVBNJ_G0024770 Pcsk5 -1.5668194 3.71E-07 1.93E-05 
MGP_FVBNJ_G0027837 Gem -1.5655365 1.91E-05 0.00068251 
MGP_FVBNJ_G0017223 Col18a1 -1.5654378 0.00026618 0.00630549 
MGP_FVBNJ_G0034446 C1qtnf5 -1.5628168 0.00075585 0.01530302 
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MGP_FVBNJ_G0027825 Gdf6 -1.5579303 0.0025845 0.04017515 
MGP_FVBNJ_G0017883 Egfr -1.5531176 7.20E-05 0.00210763 
MGP_FVBNJ_G0017148 Dnajc12 -1.5515673 0.00048986 0.01070536 
MGP_FVBNJ_G0032571 Ppfibp2 -1.5507085 1.51E-05 0.00055348 
MGP_FVBNJ_G0002078 NA -1.5506593 0.00105737 0.01997447 
MGP_FVBNJ_G0028329 Scp2 -1.5495192 0.00052036 0.01128341 
MGP_FVBNJ_G0030080 Card11 -1.5474307 0.00280385 0.04260445 
MGP_FVBNJ_G0021515 Lifr -1.5437552 0.00011914 0.00319593 
MGP_FVBNJ_G0031240 Abcc9 -1.5408368 5.02E-06 0.00020513 
MGP_FVBNJ_G0035979 Nhs -1.539863 0.00037019 0.00841176 
MGP_FVBNJ_G0015588 Gm16551 -1.5358482 0.00069845 0.01433625 
MGP_FVBNJ_G0022968 Smoc2 -1.5354479 0.00303126 0.04519719 
MGP_FVBNJ_G0029366 Limch1 -1.5343896 2.68E-05 0.00090976 
MGP_FVBNJ_G0028802 Klhdc7a -1.5338591 0.00279719 0.04255507 
MGP_FVBNJ_G0028676 Nr0b2 -1.533525 0.00255522 0.03985893 
MGP_FVBNJ_G0024116 Pcdhb8 -1.5335079 2.19E-05 0.00076557 
MGP_FVBNJ_G0019901 D430019H16Rik -1.5312349 0.00311452 0.04619149 
MGP_FVBNJ_G0027448 Hao2 -1.5296925 0.00016015 0.00415584 
MGP_FVBNJ_G0032942 Sprn -1.5246866 0.00124864 0.02288932 
MGP_FVBNJ_G0022664 BC016579 -1.5232337 0.00054135 0.01160307 
MGP_FVBNJ_G0021973 Bik -1.5205153 0.00080321 0.01604331 
MGP_FVBNJ_G0034745 Rora -1.51997 3.63E-05 0.00118317 
MGP_FVBNJ_G0031561 Gm44805 -1.5193038 0.00219833 0.03535565 
MGP_FVBNJ_G0031644 NA -1.5170097 0.00089104 0.01740761 
MGP_FVBNJ_G0020458 Dapk1 -1.5144089 1.71E-06 7.86E-05 
MGP_FVBNJ_G0029457 Ugt2a1 -1.5115922 0.00329322 0.0481056 
MGP_FVBNJ_G0032371 Il18bp -1.5114884 0.00011611 0.00313723 
MGP_FVBNJ_G0021725 Khdrbs3 -1.5100444 0.00054897 0.01173268 
MGP_FVBNJ_G0019360 Sectm1a -1.5077392 0.00012167 0.00325187 
MGP_FVBNJ_G0027219 Muc1 -1.5044181 0.00046487 0.01023961 
MGP_FVBNJ_G0027224 Efna1 -1.5015405 0.00158954 0.02761679 
MGP_FVBNJ_G0024645 Syt7 -1.4996031 0.00286311 0.04335711 
MGP_FVBNJ_G0025060 Gucy2g -1.494459 0.00170598 0.02911785 
MGP_FVBNJ_G0021157 Lrrc16b -1.4921822 0.00021137 0.00524693 
MGP_FVBNJ_G0016256 Insig2 -1.4901132 0.00248783 0.03910878 
MGP_FVBNJ_G0034966 Acad11 -1.4886144 0.00192917 0.03211854 
MGP_FVBNJ_G0015243 Gm13415 -1.4864957 0.00336615 0.04894638 
MGP_FVBNJ_G0035335 Maob -1.4844294 0.00287411 0.04346465 
MGP_FVBNJ_G0017613 Tbc1d30 -1.4833712 2.08E-05 0.00073461 
MGP_FVBNJ_G0022168 Smagp -1.4830961 0.00031299 0.0072601 
MGP_FVBNJ_G0032178 Anpep -1.481592 4.94E-05 0.0015299 
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MGP_FVBNJ_G0036772 1700012D16Rik -1.4815819 0.00166113 0.02853563 
MGP_FVBNJ_G0022131 Dnajc22 -1.4794928 0.00160247 0.02773351 
MGP_FVBNJ_G0030537 Ggct -1.4788705 0.00105454 0.01993793 
MGP_FVBNJ_G0032750 Sbk1 -1.4733015 0.00175301 0.02982935 
MGP_FVBNJ_G0024551 Batf2 -1.472789 0.00331307 0.04830058 
MGP_FVBNJ_G0024360 Lipg -1.4666614 0.00155685 0.02723999 
MGP_FVBNJ_G0021774 Naprt -1.4659563 0.00165396 0.02849178 
MGP_FVBNJ_G0016522 Sele -1.4623807 0.00324564 0.04771371 
MGP_FVBNJ_G0033873 Marveld3 -1.4593948 0.00016476 0.00424577 
MGP_FVBNJ_G0031760 Ppp1r14a -1.4482284 0.00293961 0.04426075 
MGP_FVBNJ_G0019640 Rtn1 -1.4468227 0.00052547 0.01134998 
MGP_FVBNJ_G0030298 Kcp -1.4445265 0.00149236 0.02631819 
MGP_FVBNJ_G0015763 Hs6st1 -1.4412305 8.59E-05 0.00244061 
MGP_FVBNJ_G0002065 NA -1.4385185 6.31E-05 0.001874 
MGP_FVBNJ_G0026791 Slco4a1 -1.4384003 0.00296987 0.04455002 
MGP_FVBNJ_G0027846 Runx1t1 -1.4376416 7.34E-05 0.00213816 
MGP_FVBNJ_G0017510 Lum -1.4368986 0.00026257 0.00623326 
MGP_FVBNJ_G0019518 Agmo -1.432307 0.0018695 0.03140398 
MGP_FVBNJ_G0025687 Pde1a -1.4288873 5.11E-10 4.67E-08 
MGP_FVBNJ_G0026255 Adra2b -1.4265656 0.00294264 0.04426075 
MGP_FVBNJ_G0032732 Prkcb -1.4265172 0.00299309 0.04479223 
MGP_FVBNJ_G0017168 Slc16a9 -1.4174359 0.00048166 0.01053652 
MGP_FVBNJ_G0019419 Kcns3 -1.4174295 0.00022651 0.00556068 
MGP_FVBNJ_G0034222 Tmem205 -1.4159597 0.00176274 0.02994906 
MGP_FVBNJ_G0030002 Tfr2 -1.4155508 0.00296181 0.04445914 
MGP_FVBNJ_G0019949 Ckb -1.4112572 0.00129039 0.02344252 
MGP_FVBNJ_G0021275 Xkr6 -1.4102227 0.00025225 0.00605205 
MGP_FVBNJ_G0028493 Rims3 -1.4099487 0.00182456 0.03083493 
MGP_FVBNJ_G0031857 Kctd15 -1.4075077 0.00011833 0.00318183 
MGP_FVBNJ_G0040204 NA -1.4074453 0.00064831 0.01349336 
MGP_FVBNJ_G0030508 Hoxa1 -1.4066094 0.00016265 0.00420116 
MGP_FVBNJ_G0032806 NA -1.4051202 0.00179665 0.03040944 
MGP_FVBNJ_G0018036 NA -1.4016186 0.00255707 0.03985993 
MGP_FVBNJ_G0015801 Npas2 -1.3983215 0.00045271 0.00998162 
MGP_FVBNJ_G0034271 St14 -1.3930707 0.00068137 0.01402436 
MGP_FVBNJ_G0018061 Flt4 -1.381117 5.10E-05 0.00157506 
MGP_FVBNJ_G0003935 Tmem51os1 -1.3710638 0.0001301 0.00345258 
MGP_FVBNJ_G0022518 Hes1 -1.3668108 2.65E-07 1.42E-05 
MGP_FVBNJ_G0021156 Dhrs4 -1.3604166 0.00074574 0.01513477 
MGP_FVBNJ_G0023388 Stk19 -1.3575675 0.00264234 0.04081796 
MGP_FVBNJ_G0030197 Gng11 -1.3533608 0.00142114 0.02532268 
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MGP_FVBNJ_G0015811 Il1r1 -1.3521619 3.62E-08 2.30E-06 
MGP_FVBNJ_G0018529 Rtn4rl1 -1.3463263 0.00059878 0.01261578 
MGP_FVBNJ_G0021307 Adra1a -1.3459231 0.00328876 0.04807204 
MGP_FVBNJ_G0019425 Fam49a -1.3432648 7.06E-06 0.00027972 
MGP_FVBNJ_G0032299 Thrsp -1.3393086 0.00103915 0.01971004 
MGP_FVBNJ_G0035154 Osbpl10 -1.3385437 5.95E-05 0.00178872 
MGP_FVBNJ_G0035607 F8 -1.3366859 0.00103878 0.01971004 
MGP_FVBNJ_G0031453 Sult2a6 -1.3363547 0.00044948 0.00993976 
MGP_FVBNJ_G0021443 Slain1 -1.3341211 0.0024366 0.03857548 
MGP_FVBNJ_G0023841 Qpct -1.3330622 1.78E-06 8.11E-05 
MGP_FVBNJ_G0017443 Syn3 -1.330571 0.00032846 0.00756371 
MGP_FVBNJ_G0033323 Mtus1 -1.3246645 0.00153181 0.02688625 
MGP_FVBNJ_G0022893 Igsf5 -1.3219349 0.00249188 0.03914485 
MGP_FVBNJ_G0016310 Slc45a3 -1.317578 0.00051309 0.01114749 
MGP_FVBNJ_G0024864 NA -1.3158715 0.00205161 0.0336353 
MGP_FVBNJ_G0020653 Iqgap2 -1.3153197 0.00262802 0.04065316 
MGP_FVBNJ_G0018082 Zfp454 -1.3112292 0.00112227 0.02100861 
MGP_FVBNJ_G0033686 Sall1 -1.3109727 0.00029625 0.00692939 
MGP_FVBNJ_G0002008 NA -1.3088242 0.00224208 0.03599129 
MGP_FVBNJ_G0031246 Sox5 -1.3087336 0.00036372 0.00827306 
MGP_FVBNJ_G0018421 Cxcl16 -1.3085872 0.00259527 0.04028631 
MGP_FVBNJ_G0016344 Btg2 -1.2984997 0.00083989 0.01661223 
MGP_FVBNJ_G0023575 Rcan2 -1.2856058 0.00020858 0.00519481 
MGP_FVBNJ_G0034184 A230050P20Rik -1.2841451 0.00049547 0.0108107 
MGP_FVBNJ_G0022210 NA -1.2826036 0.00083623 0.01656928 
MGP_FVBNJ_G0016573 Nos1ap -1.2791933 0.00337646 0.04906437 
MGP_FVBNJ_G0023915 Bambi -1.2755166 0.00025795 0.00614975 
MGP_FVBNJ_G0022465 Thpo -1.2748567 0.00299405 0.04479223 
MGP_FVBNJ_G0035558 Bgn -1.2733027 0.00259941 0.04030081 
MGP_FVBNJ_G0034786 Wdr72 -1.2723003 0.00168749 0.028913 
MGP_FVBNJ_G0024685 Ms4a4d -1.2716574 0.00022693 0.00556484 
MGP_FVBNJ_G0001061 NA -1.2635702 0.00032371 0.00747749 
MGP_FVBNJ_G0024926 Pik3ap1 -1.2610638 9.28E-05 0.00259854 
MGP_FVBNJ_G0022174 Fignl2 -1.2584297 3.80E-05 0.00123605 
MGP_FVBNJ_G0028330 Echdc2 -1.2578439 0.00094013 0.01820267 
MGP_FVBNJ_G0035628 Tmem47 -1.2572104 5.54E-05 0.00168582 
MGP_FVBNJ_G0018019 Adam19 -1.2552149 0.00140324 0.0250638 
MGP_FVBNJ_G0024386 Setbp1 -1.2453994 2.52E-05 0.0008675 
MGP_FVBNJ_G0016993 Slc16a10 -1.2358277 0.00283854 0.04304349 
MGP_FVBNJ_G0023986 Garem -1.2334947 0.00020739 0.00517696 
MGP_FVBNJ_G0029758 Ksr2 -1.2330126 0.00158805 0.02761243 
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MGP_FVBNJ_G0028843 NA -1.2258015 8.77E-08 5.20E-06 
MGP_FVBNJ_G0019453 Grhl1 -1.2219368 0.0001848 0.00469322 
MGP_FVBNJ_G0021773 Mroh6 -1.2096837 0.00088247 0.01731622 
MGP_FVBNJ_G0031518 Pglyrp1 -1.209556 0.00211259 0.0343957 
MGP_FVBNJ_G0030978 Cecr2 -1.1982041 0.00202307 0.03324805 
MGP_FVBNJ_G0022640 Zdhhc23 -1.196767 0.00272463 0.04165622 
MGP_FVBNJ_G0033309 Dlc1 -1.1896313 9.44E-07 4.50E-05 
MGP_FVBNJ_G0027520 Dennd2d -1.1894526 0.00095648 0.01845971 
MGP_FVBNJ_G0029682 Adrbk2 -1.1857119 0.00148929 0.02630563 
MGP_FVBNJ_G0029527 Ccdc158 -1.1849699 0.00115481 0.0214701 
MGP_FVBNJ_G0017722 NA -1.1845985 0.00335891 0.04890491 
MGP_FVBNJ_G0019509 Tspan13 -1.1843756 0.00131764 0.02385994 
MGP_FVBNJ_G0031863 Lrp3 -1.1791323 0.00232418 0.0371385 
MGP_FVBNJ_G0023897 Epcam -1.1785766 0.00210288 0.03434086 
MGP_FVBNJ_G0030201 Sgce -1.1776347 0.00265407 0.04091411 
MGP_FVBNJ_G0028417 Zswim5 -1.1732789 0.00032548 0.00751067 
MGP_FVBNJ_G0022296 AU021092 -1.1718256 0.0033931 0.04927398 
MGP_FVBNJ_G0028280 Pde4b -1.1678472 0.00023565 0.00574088 
MGP_FVBNJ_G0021479 Gpr183 -1.1668118 0.00056746 0.01202403 
MGP_FVBNJ_G0024069 Ecscr -1.1593703 0.0032636 0.04789256 
MGP_FVBNJ_G0035158 Rbms3 -1.1588181 0.00038407 0.00868276 
MGP_FVBNJ_G0028296 Plpp3 -1.1534302 0.00081643 0.01627821 
MGP_FVBNJ_G0001436 NA -1.1467148 0.00072537 0.01479343 
MGP_FVBNJ_G0030923 Mkrn2os -1.1453764 0.00142957 0.02543216 
MGP_FVBNJ_G0025715 Serping1 -1.1429977 0.00121416 0.02240472 
MGP_FVBNJ_G0020960 Vstm4 -1.140144 0.00244196 0.03858639 
MGP_FVBNJ_G0016637 Dusp23 -1.1389709 0.00157215 0.02741279 
MGP_FVBNJ_G0001437 NA -1.1373362 0.00115847 0.02150156 
MGP_FVBNJ_G0028236 Jun -1.1359503 0.00089034 0.01740761 
MGP_FVBNJ_G0025423 Eng -1.1348209 0.00194305 0.03225287 
MGP_FVBNJ_G0017509 Dcn -1.1307339 0.00011323 0.00306317 
MGP_FVBNJ_G0028050 Tgfbr1 -1.1301687 4.82E-07 2.48E-05 
MGP_FVBNJ_G0019411 Sdc1 -1.1269809 0.00079565 0.01590648 
MGP_FVBNJ_G0035825 Armcx6 -1.1236158 0.00139285 0.02489821 
MGP_FVBNJ_G0016626 Atp1a2 -1.1132455 0.00133606 0.0240955 
MGP_FVBNJ_G0035164 Itga9 -1.105215 3.77E-06 0.00015831 
MGP_FVBNJ_G0022506 Il1rap -1.104983 0.00273885 0.04179475 
MGP_FVBNJ_G0021723 St3gal1 -1.1008851 0.00046578 0.01024957 
MGP_FVBNJ_G0030207 Asb4 -1.0990721 0.00226549 0.03633103 
MGP_FVBNJ_G0019944 Exoc3l4 -1.0925037 0.00101996 0.0194656 
MGP_FVBNJ_G0020328 Nhlrc1 -1.0867089 0.00115526 0.0214701 
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MGP_FVBNJ_G0004910 F730311O21Rik -1.0856897 0.00023253 0.00568345 
MGP_FVBNJ_G0020720 Rgs7bp -1.0781281 0.00067711 0.01397552 
MGP_FVBNJ_G0015923 Raph1 -1.0760976 2.00E-05 0.00070989 
MGP_FVBNJ_G0032310 Omp -1.0693471 0.00124733 0.02288415 
MGP_FVBNJ_G0034043 Sipa1l2 -1.0604728 0.00147261 0.02605235 
MGP_FVBNJ_G0030827 Fgd5 -1.0573112 4.41E-05 0.00138604 
MGP_FVBNJ_G0031791 Syne4 -1.0435057 6.55E-05 0.00194046 
MGP_FVBNJ_G0001574 NA -1.0434141 0.00133859 0.02412167 
MGP_FVBNJ_G0029305 Ldb2 -1.0420908 0.0007586 0.01534483 
MGP_FVBNJ_G0030832 Prickle2 -1.0317701 7.90E-05 0.00227343 
MGP_FVBNJ_G0024072 Cxxc5 -1.0181664 0.00307855 0.04581036 
MGP_FVBNJ_G0002103 NA -1.0139052 0.00302626 0.04515291 
MGP_FVBNJ_G0024132 Pcdhga1 -1.0089462 0.00087219 0.01717484 
MGP_FVBNJ_G0015908 Mpp4 -1.0079916 0.00198005 0.03267016 
MGP_FVBNJ_G0027852 Tmem64 -1.0055861 9.17E-05 0.00257106 
MGP_FVBNJ_G0018829 Hoxb4 -1.0039279 0.00017042 0.00438166 
MGP_FVBNJ_G0015658 Sox17 -1.0015202 0.00126408 0.02307753 
MGP_FVBNJ_G0011307 NA -1.0012984 0.00113063 0.02110787 
MGP_FVBNJ_G0016786 Slc30a1 -1.0008855 0.00232896 0.03718825 
MGP_FVBNJ_G0030540 Inmt -0.9942106 0.00011243 0.00304881 
MGP_FVBNJ_G0016433 Rgl1 -0.9865909 8.61E-05 0.00244306 
MGP_FVBNJ_G0019866 Ifi27 -0.9865317 0.00199838 0.03291803 
MGP_FVBNJ_G0031220 Plekha5 -0.9789148 0.001035 0.01966847 
MGP_FVBNJ_G0032483 NA -0.9747602 0.00062816 0.0131231 
MGP_FVBNJ_G0028483 Hivep3 -0.9715993 0.00024891 0.00601775 
MGP_FVBNJ_G0022688 Alcam -0.9625816 0.00070971 0.01452725 
MGP_FVBNJ_G0021346 Slc39a14 -0.9549519 0.00207088 0.03386801 
MGP_FVBNJ_G0021682 Fbxo32 -0.9528517 0.00106478 0.02008036 
MGP_FVBNJ_G0027136 Trim2 -0.9509717 2.92E-05 0.00097933 
MGP_FVBNJ_G0029721 Oasl1 -0.9494705 0.00195408 0.03235768 
MGP_FVBNJ_G0024216 Sema6a -0.9460074 0.00021661 0.00534124 
MGP_FVBNJ_G0037293 Gm22107 -0.9452824 0.00155206 0.02717755 
MGP_FVBNJ_G0030301 Tspan33 -0.9175242 0.00017067 0.0043829 
MGP_FVBNJ_G0002101 NA -0.9162361 0.00055419 0.01182145 
MGP_FVBNJ_G0023783 Ptprm -0.9158988 0.00267747 0.04124633 
MGP_FVBNJ_G0007245 E230013L22Rik -0.9099908 0.00167673 0.02877281 
MGP_FVBNJ_G0016653 NA -0.9099255 0.00288482 0.04359691 
MGP_FVBNJ_G0020174 Hfe -0.9090905 0.00052689 0.01136967 
MGP_FVBNJ_G0019945 Tnfaip2 -0.9068229 0.0021128 0.0343957 
MGP_FVBNJ_G0022560 Iqcg -0.9032907 0.00219063 0.03530821 
MGP_FVBNJ_G0028586 Trim62 -0.9027369 9.79E-06 0.00037367 
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MGP_FVBNJ_G0015927 Pard3b -0.9010212 0.00026533 0.00629194 
MGP_FVBNJ_G0022784 Adamts5 -0.8824613 0.00291038 0.04395345 
MGP_FVBNJ_G0031874 Tshz3 -0.8809177 0.00185296 0.03117308 
MGP_FVBNJ_G0002102 NA -0.8782074 0.00049565 0.0108107 
MGP_FVBNJ_G0017065 Man1a -0.8635094 0.00271115 0.04150706 
MGP_FVBNJ_G0029393 Tec -0.8573019 0.00184151 0.03107951 
MGP_FVBNJ_G0015909 Als2 -0.853987 0.00186311 0.0313202 
MGP_FVBNJ_G0022578 Pdia5 -0.8536589 0.00302222 0.04512275 
MGP_FVBNJ_G0019161 Fam20a -0.8510466 0.00285249 0.04322555 
MGP_FVBNJ_G0028162 Megf9 -0.8505881 0.00273546 0.04179304 
MGP_FVBNJ_G0030873 Itpr1 -0.8482045 0.0003031 0.00707479 
MGP_FVBNJ_G0024123 Pcdhb16 -0.8285987 0.00025049 0.00602817 
MGP_FVBNJ_G0027648 Alpk1 -0.8210548 0.00315502 0.04663703 
MGP_FVBNJ_G0024125 Pcdhb18 -0.8136162 0.00340951 0.0494616 
MGP_FVBNJ_G0022357 Snai2 -0.8102366 0.00177172 0.03005588 
MGP_FVBNJ_G0019142 Pitpnc1 -0.8090541 0.00317691 0.0468673 
MGP_FVBNJ_G0023936 Colec12 -0.8084028 0.00227286 0.03642288 
MGP_FVBNJ_G0021697 Trib1 -0.8078548 7.75E-06 0.0003041 
MGP_FVBNJ_G0016424 Ivns1abp -0.8077673 9.20E-06 0.0003528 
MGP_FVBNJ_G0016423 Hmcn1 -0.8052148 0.00298074 0.04468303 
MGP_FVBNJ_G0032619 St5 -0.8018243 8.39E-05 0.00239088 
MGP_FVBNJ_G0027902 Pnrc1 -0.7998576 0.00105914 0.01999091 
MGP_FVBNJ_G0022746 Pros1 -0.7984288 0.00251132 0.03932078 
MGP_FVBNJ_G0003760 C130013H08Rik -0.7917028 0.0031335 0.04638035 
MGP_FVBNJ_G0024875 Hectd2 -0.7865744 0.00161649 0.02793272 
MGP_FVBNJ_G0017610 Msrb3 -0.7840526 0.00029669 0.0069325 
MGP_FVBNJ_G0016266 Mgat5 -0.7811527 0.00122515 0.02255142 
MGP_FVBNJ_G0019662 Rhoj -0.7785862 0.00294195 0.04426075 
MGP_FVBNJ_G0031391 Clcn4 -0.7531059 0.00213747 0.03472739 
MGP_FVBNJ_G0020768 Pelo -0.7428328 0.00200595 0.03299976 
MGP_FVBNJ_G0020744 Il6st -0.7347553 0.00025312 0.00605205 
MGP_FVBNJ_G0033307 Lonrf1 -0.7338166 0.00070253 0.0144067 
MGP_FVBNJ_G0036682 Peg13 -0.7261337 9.33E-05 0.00260433 
MGP_FVBNJ_G0021365 Rcbtb2 -0.7208425 0.00078027 0.01571182 
MGP_FVBNJ_G0031178 Dusp16 -0.7194257 0.00028639 0.00672703 
MGP_FVBNJ_G0033310 AI429214 -0.6832435 0.00162313 0.02802571 
MGP_FVBNJ_G0031663 Cyp2a4 -0.6744147 3.87E-05 0.00125202 
MGP_FVBNJ_G0033603 Adgre5 -0.6674052 0.00315094 0.04660756 
MGP_FVBNJ_G0032154 Akap13 -0.619135 9.38E-05 0.00261488 
MGP_FVBNJ_G0031902 Zfp715 -0.5879689 0.00057396 0.01213867 
MGP_FVBNJ_G0032301 Ints4 -0.5748215 0.0009581 0.01847499 
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MGP_FVBNJ_G0021701 A1bg -0.5172678 3.53E-07 1.85E-05 
MGP_FVBNJ_G0016633 Cfap45 -0.4883653 0.00168092 0.02882262 
MGP_FVBNJ_G0019709 Susd6 -0.4551219 0.00234125 0.03733105 


















Appendix 3: Functional Enrichment of 
Differentially Expressed Genes Between Nf2-A 
and KRASG12D-Library Tumours 
 
Functional Enrichment in Downregulated Genes 
Gene Ontology: Molecular Function  
Source Term Name Term ID P(adj) 
GO:MF cofactor binding GO:0048037 2.94E-18 
GO:MF heme binding GO:0020037 1.81E-16 
GO:MF monooxygenase activity GO:0004497 5.39E-16 
GO:MF tetrapyrrole binding GO:0046906 6.62E-16 
GO:MF oxidoreductase activity GO:0016491 3.21E-15 
GO:MF steroid hydroxylase activity GO:0008395 1.46E-14 
GO:MF iron ion binding GO:0005506 7.43E-14 
GO:MF 
oxidoreductase activity, acting on paired 
donors, with incorporation or reduction 
of molecular oxygen 
GO:0016705 2.15E-13 
GO:MF carboxylic acid binding GO:0031406 5.76E-13 
GO:MF 
oxidoreductase activity, acting on paired 
donors, with incorporation or reduction 
of molecular oxygen, reduced flavin or 
flavoprotein as one donor, and 
incorporation of one atom of oxygen 
GO:0016712 1.43E-12 
GO:MF organic acid binding GO:0043177 2.17E-12 
GO:MF aromatase activity GO:0070330 8.81E-12 
GO:MF catalytic activity GO:0003824 1.21E-10 
GO:MF monocarboxylic acid transmembrane transporter activity GO:0008028 4.31E-10 
GO:MF lipid transporter activity GO:0005319 8.98E-10 
GO:MF endopeptidase inhibitor activity GO:0004866 1.38E-09 
GO:MF vitamin binding GO:0019842 2.29E-09 
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GO:MF monocarboxylic acid binding GO:0033293 2.50E-09 
GO:MF endopeptidase regulator activity GO:0061135 2.74E-09 
GO:MF transporter activity GO:0005215 3.00E-09 
GO:MF peptidase inhibitor activity GO:0030414 3.29E-09 
GO:MF arachidonic acid monooxygenase activity GO:0008391 4.47E-09 
GO:MF arachidonic acid epoxygenase activity GO:0008392 1.23E-08 
GO:MF enzyme inhibitor activity GO:0004857 1.29E-08 
GO:MF serine-type endopeptidase inhibitor activity GO:0004867 1.83E-08 
GO:MF peptidase regulator activity GO:0061134 2.26E-08 
GO:MF lipid binding GO:0008289 2.32E-08 
GO:MF active transmembrane transporter activity GO:0022804 2.72E-08 
GO:MF organic anion transmembrane transporter activity GO:0008514 6.60E-08 
GO:MF secondary active transmembrane transporter activity GO:0015291 1.17E-07 
GO:MF anion binding GO:0043168 1.62E-07 
GO:MF symporter activity GO:0015293 3.13E-07 
GO:MF transmembrane transporter activity GO:0022857 4.09E-07 
GO:MF serine hydrolase activity GO:0017171 8.82E-07 
GO:MF hydrolase activity, acting on acid phosphorus-nitrogen bonds GO:0016825 8.82E-07 
GO:MF anion transmembrane transporter activity GO:0008509 1.05331E-06 
GO:MF coenzyme binding GO:0050662 1.18006E-06 
GO:MF serine-type endopeptidase activity GO:0004252 2.21924E-06 
GO:MF serine-type peptidase activity GO:0008236 2.717E-06 
GO:MF organic acid transmembrane transporter activity GO:0005342 2.98101E-06 
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GO:MF carboxylic acid transmembrane transporter activity GO:0046943 2.98101E-06 
GO:MF small molecule binding GO:0036094 4.61853E-06 
GO:MF glycosaminoglycan binding GO:0005539 5.11169E-06 
GO:MF protein dimerization activity GO:0046983 5.8256E-06 
GO:MF heparin binding GO:0008201 6.16685E-06 
GO:MF sulfur compound binding GO:1901681 6.6822E-06 
GO:MF transition metal ion binding GO:0046914 8.83753E-06 
GO:MF oxidoreductase activity, acting on CH-OH group of donors GO:0016614 1.58614E-05 
GO:MF solute:sodium symporter activity GO:0015370 2.63422E-05 
GO:MF ion binding GO:0043167 3.85868E-05 
GO:MF protein homodimerization activity GO:0042803 4.33958E-05 
GO:MF carboxylic ester hydrolase activity GO:0052689 4.63241E-05 
GO:MF fatty acid binding GO:0005504 4.75128E-05 
GO:MF phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 6.60547E-05 
GO:MF bile acid transmembrane transporter activity GO:0015125 0.000126655 
GO:MF estrogen 16-alpha-hydroxylase activity GO:0101020 0.000184575 
GO:MF steroid binding GO:0005496 0.00019423 
GO:MF 
oxidoreductase activity, acting on the 




oxidoreductase activity, acting on CH or 
CH2 groups, quinone or similar 
compound as acceptor 
GO:0033695 0.000269812 
GO:MF caffeine oxidase activity GO:0034875 0.000269812 
GO:MF triglyceride lipase activity GO:0004806 0.000311788 
GO:MF signaling receptor binding GO:0005102 0.000426904 
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GO:MF retinol dehydrogenase activity GO:0004745 0.00045026 
GO:MF amino acid binding GO:0016597 0.000490893 
GO:MF organic acid:sodium symporter activity GO:0005343 0.000571179 
GO:MF ion transmembrane transporter activity GO:0015075 0.000787142 
GO:MF steroid dehydrogenase activity GO:0016229 0.000788132 
GO:MF pyridoxal phosphate binding GO:0030170 0.000867427 
GO:MF 
oxidoreductase activity, acting on paired 
donors, with incorporation or reduction 
of molecular oxygen, NAD(P)H as one 
donor, and incorporation of one atom of 
oxygen 
GO:0016709 0.000960714 
GO:MF vitamin B6 binding GO:0070279 0.001001487 
GO:MF organic hydroxy compound transmembrane transporter activity GO:1901618 0.001037934 
GO:MF molecular function regulator GO:0098772 0.0011261 
GO:MF enzyme regulator activity GO:0030234 0.001303035 
GO:MF identical protein binding GO:0042802 0.001350589 
GO:MF receptor ligand activity GO:0048018 0.001595523 
GO:MF protein-lipid complex binding GO:0071814 0.001746356 
GO:MF lipoprotein particle binding GO:0071813 0.001746356 
GO:MF lipase inhibitor activity GO:0055102 0.001997832 
GO:MF solute:cation symporter activity GO:0015294 0.002027229 
GO:MF signaling receptor activator activity GO:0030546 0.002061052 
GO:MF retinoic acid 4-hydroxylase activity GO:0008401 0.002659966 
GO:MF receptor regulator activity GO:0030545 0.002665111 
GO:MF quaternary ammonium group binding GO:0050997 0.003123814 
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GO:MF phosphatidylcholine binding GO:0031210 0.003123814 
GO:MF alcohol binding GO:0043178 0.003229953 
GO:MF lipoprotein particle receptor binding GO:0070325 0.003297245 
GO:MF transforming growth factor beta receptor binding GO:0005160 0.003401295 
GO:MF growth factor activity GO:0008083 0.003411676 
GO:MF extracellular matrix structural constituent GO:0005201 0.003736731 
GO:MF oxidoreductase activity, acting on CH or CH2 groups GO:0016725 0.00380783 
GO:MF sterol esterase activity GO:0004771 0.003869006 
GO:MF transferase activity, transferring sulfur-containing groups GO:0016782 0.004290363 
GO:MF calcium ion binding GO:0005509 0.004642747 
GO:MF complement binding GO:0001848 0.004709524 
GO:MF nerve growth factor binding GO:0048406 0.005153332 
GO:MF sodium ion transmembrane transporter activity GO:0015081 0.006326919 
GO:MF phospholipid binding GO:0005543 0.006579004 
GO:MF fatty acid ligase activity GO:0015645 0.006762123 
GO:MF flavin adenine dinucleotide binding GO:0050660 0.007676817 
GO:MF active ion transmembrane transporter activity GO:0022853 0.008050288 
GO:MF brain-derived neurotrophic factor binding GO:0048403 0.008120362 
GO:MF carbohydrate binding GO:0030246 0.009190421 
GO:MF glucuronosyltransferase activity GO:0015020 0.009345906 
GO:MF 
oxidoreductase activity, acting on single 
donors with incorporation of molecular 




oxidoreductase activity, acting on single 





GO:MF uracil binding GO:0002058 0.012710687 
GO:MF pyrimidine nucleobase binding GO:0002061 0.012710687 
GO:MF sulfotransferase activity GO:0008146 0.013970453 
GO:MF transferase activity, transferring acyl groups GO:0016746 0.014398355 
GO:MF bile acid binding GO:0032052 0.015598446 
GO:MF long-chain fatty acid transporter activity GO:0005324 0.016325425 
GO:MF CoA-ligase activity GO:0016405 0.017579955 
GO:MF peptide hormone binding GO:0017046 0.018523039 
GO:MF neurotrophin binding GO:0043121 0.019905723 
GO:MF fatty-acyl-CoA synthase activity GO:0004321 0.02035698 
GO:MF acyl-CoA ligase activity GO:0003996 0.021262305 
GO:MF chemoattractant activity GO:0042056 0.02218264 
GO:MF 
steroid dehydrogenase activity, acting 
on the CH-OH group of donors, NAD or 
NADP as acceptor 
GO:0033764 0.022542672 
GO:MF cell adhesion molecule binding GO:0050839 0.023313447 
GO:MF alditol:NADP+ 1-oxidoreductase activity GO:0004032 0.023947867 
GO:MF alanine-glyoxylate transaminase activity GO:0008453 0.026750493 
GO:MF monosaccharide binding GO:0048029 0.027041252 
GO:MF ketosteroid monooxygenase activity GO:0047086 0.028855505 
GO:MF lyase activity GO:0016829 0.030565167 
GO:MF inorganic molecular entity transmembrane transporter activity GO:0015318 0.033052529 
GO:MF glycine N-acyltransferase activity GO:0047961 0.033327152 
GO:MF vitamin E binding GO:0008431 0.033734534 
GO:MF cation binding GO:0043169 0.037097072 
GO:MF acid-thiol ligase activity GO:0016878 0.038551003 
GO:MF endopeptidase activity GO:0004175 0.038725896 
GO:MF high-density lipoprotein particle receptor binding GO:0070653 0.038979289 
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GO:MF hormone binding GO:0042562 0.045020138 
GO:MF amide binding GO:0033218 0.046073638 
    
Gene Ontology: Biological Process 
GO:BP organic acid metabolic process GO:0006082 2.10E-46 
GO:BP carboxylic acid metabolic process GO:0019752 6.84E-44 
GO:BP oxoacid metabolic process GO:0043436 3.42E-42 
GO:BP small molecule metabolic process GO:0044281 4.90E-37 
GO:BP monocarboxylic acid metabolic process GO:0032787 1.25E-31 
GO:BP lipid metabolic process GO:0006629 7.09E-27 
GO:BP drug metabolic process GO:0017144 3.33E-24 
GO:BP fatty acid metabolic process GO:0006631 4.19E-20 
GO:BP drug catabolic process GO:0042737 8.42E-20 
GO:BP organic hydroxy compound metabolic process GO:1901615 2.60E-19 
GO:BP cellular lipid metabolic process GO:0044255 1.19E-18 
GO:BP small molecule catabolic process GO:0044282 2.10E-18 
GO:BP steroid metabolic process GO:0008202 1.79E-17 
GO:BP oxidation-reduction process GO:0055114 9.71E-17 
GO:BP fibrinolysis GO:0042730 1.37E-16 
GO:BP blood coagulation GO:0007596 2.75E-16 
GO:BP hemostasis GO:0007599 3.44E-16 
GO:BP coagulation GO:0050817 3.85E-16 
GO:BP alpha-amino acid metabolic process GO:1901605 2.15E-15 
GO:BP organic acid catabolic process GO:0016054 5.06E-15 
GO:BP carboxylic acid catabolic process GO:0046395 5.06E-15 
GO:BP alpha-amino acid catabolic process GO:1901606 6.58E-15 
GO:BP negative regulation of blood coagulation GO:0030195 1.77E-14 
GO:BP regulation of blood coagulation GO:0030193 2.29E-14 
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GO:BP negative regulation of hemostasis GO:1900047 2.50E-14 
GO:BP organic acid biosynthetic process GO:0016053 2.60E-14 
GO:BP regulation of hemostasis GO:1900046 2.74E-14 
GO:BP negative regulation of coagulation GO:0050819 3.50E-14 
GO:BP cellular amino acid metabolic process GO:0006520 3.79E-14 
GO:BP regulation of coagulation GO:0050818 3.89E-14 
GO:BP regulation of biological quality GO:0065008 5.35E-14 
GO:BP cellular amino acid catabolic process GO:0009063 8.43E-14 
GO:BP lipid localization GO:0010876 1.17E-13 
GO:BP carboxylic acid biosynthetic process GO:0046394 1.74E-13 
GO:BP triglyceride metabolic process GO:0006641 5.54E-13 
GO:BP small molecule biosynthetic process GO:0044283 5.70E-13 
GO:BP exogenous drug catabolic process GO:0042738 6.64E-13 
GO:BP cellular ketone metabolic process GO:0042180 9.43E-13 
GO:BP organic hydroxy compound transport GO:0015850 1.09E-12 
GO:BP organic anion transport GO:0015711 1.32E-12 
GO:BP lipid transport GO:0006869 2.64E-12 
GO:BP xenobiotic metabolic process GO:0006805 3.29E-12 
GO:BP aromatic amino acid family catabolic process GO:0009074 3.56E-12 
GO:BP acylglycerol metabolic process GO:0006639 4.99E-12 
GO:BP negative regulation of wound healing GO:0061045 7.54E-12 
GO:BP neutral lipid metabolic process GO:0006638 8.21E-12 
GO:BP cofactor metabolic process GO:0051186 1.12E-11 
GO:BP wound healing GO:0042060 1.76E-11 
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GO:BP regulation of body fluid levels GO:0050878 1.83E-11 
GO:BP catabolic process GO:0009056 2.64E-11 
GO:BP response to external stimulus GO:0009605 3.21E-11 
GO:BP alcohol metabolic process GO:0006066 4.53E-11 
GO:BP plasminogen activation GO:0031639 4.56E-11 
GO:BP regulation of hormone levels GO:0010817 5.49E-11 
GO:BP cellular response to xenobiotic stimulus GO:0071466 7.63E-11 
GO:BP response to xenobiotic stimulus GO:0009410 8.87E-11 
GO:BP cellular catabolic process GO:0044248 1.07E-10 
GO:BP negative regulation of response to wounding GO:1903035 1.22E-10 
GO:BP regulation of wound healing GO:0061041 1.25E-10 
GO:BP positive regulation of lipid catabolic process GO:0050996 1.98E-10 
GO:BP long-chain fatty acid metabolic process GO:0001676 4.11E-10 
GO:BP aromatic amino acid family metabolic process GO:0009072 4.40E-10 
GO:BP regulation of fibrinolysis GO:0051917 4.50E-10 
GO:BP arachidonic acid metabolic process GO:0019369 8.12E-10 
GO:BP coenzyme metabolic process GO:0006732 8.67E-10 
GO:BP cellular response to chemical stimulus GO:0070887 8.98E-10 
GO:BP anion transport GO:0006820 1.15E-09 
GO:BP ion transport GO:0006811 1.44E-09 
GO:BP positive regulation of lipid metabolic process GO:0045834 1.51E-09 
GO:BP response to wounding GO:0009611 1.88E-09 
GO:BP unsaturated fatty acid metabolic process GO:0033559 2.10E-09 
GO:BP regulation of response to wounding GO:1903034 2.16E-09 
GO:BP response to drug GO:0042493 3.77E-09 
GO:BP purine-containing compound metabolic process GO:0072521 4.38E-09 
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GO:BP zymogen activation GO:0031638 4.44E-09 
GO:BP lipid homeostasis GO:0055088 4.81E-09 
GO:BP acute-phase response GO:0006953 4.94E-09 
GO:BP regulation of lipid metabolic process GO:0019216 5.02E-09 
GO:BP lipid biosynthetic process GO:0008610 5.10E-09 
GO:BP hormone metabolic process GO:0042445 6.40E-09 
GO:BP regulation of lipid catabolic process GO:0050994 6.50E-09 
GO:BP monocarboxylic acid biosynthetic process GO:0072330 7.73E-09 
GO:BP cholesterol metabolic process GO:0008203 8.41E-09 
GO:BP lipid catabolic process GO:0016042 1.30E-08 
GO:BP negative regulation of proteolysis GO:0045861 1.62E-08 
GO:BP icosanoid metabolic process GO:0006690 1.72E-08 
GO:BP negative regulation of endopeptidase activity GO:0010951 1.83E-08 
GO:BP epoxygenase P450 pathway GO:0019373 1.98E-08 
GO:BP negative regulation of peptidase activity GO:0010466 4.38E-08 
GO:BP acylglycerol homeostasis GO:0055090 4.71E-08 
GO:BP triglyceride homeostasis GO:0070328 4.71E-08 
GO:BP fatty acid derivative metabolic process GO:1901568 5.57E-08 
GO:BP nucleobase-containing small molecule metabolic process GO:0055086 5.92E-08 
GO:BP steroid biosynthetic process GO:0006694 7.33E-08 
GO:BP chemical homeostasis GO:0048878 9.01E-08 
GO:BP sterol metabolic process GO:0016125 1.07E-07 
GO:BP secondary alcohol metabolic process GO:1902652 1.07E-07 
GO:BP sulfur compound metabolic process GO:0006790 1.15E-07 
GO:BP defense response GO:0006952 1.23E-07 
GO:BP negative regulation of hydrolase activity GO:0051346 1.37E-07 
GO:BP negative regulation of response to external stimulus GO:0032102 1.37E-07 
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GO:BP blood coagulation, fibrin clot formation GO:0072378 1.64E-07 
GO:BP regulation of cellular ketone metabolic process GO:0010565 1.86E-07 
GO:BP acute inflammatory response GO:0002526 1.86E-07 
GO:BP regulation of lipid biosynthetic process GO:0046890 2.30E-07 
GO:BP organic substance catabolic process GO:1901575 2.53E-07 
GO:BP triglyceride catabolic process GO:0019433 3.44E-07 
GO:BP neutral lipid catabolic process GO:0046461 3.69E-07 
GO:BP acylglycerol catabolic process GO:0046464 3.69E-07 
GO:BP plasma lipoprotein particle remodeling GO:0034369 4.84E-07 
GO:BP protein-lipid complex remodeling GO:0034368 4.84E-07 
GO:BP regulation of triglyceride metabolic process GO:0090207 5.44E-07 
GO:BP protein activation cascade GO:0072376 7.88E-07 
GO:BP protein-containing complex remodeling GO:0034367 9.73E-07 
GO:BP ammonium ion metabolic process GO:0097164 9.81E-07 
GO:BP organic acid transport GO:0015849 9.91E-07 
GO:BP glycerolipid metabolic process GO:0046486 1.11035E-06 
GO:BP phosphatidylcholine metabolic process GO:0046470 1.11458E-06 
GO:BP very-low-density lipoprotein particle remodeling GO:0034372 1.11852E-06 
GO:BP plasma lipoprotein particle organization GO:0071827 1.34157E-06 
GO:BP regulation of multicellular organismal process GO:0051239 1.34631E-06 
GO:BP positive regulation of lipid biosynthetic process GO:0046889 1.46307E-06 
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GO:BP regulation of steroid metabolic process GO:0019218 2.39558E-06 
GO:BP negative regulation of fibrinolysis GO:0051918 2.39951E-06 
GO:BP glycerolipid catabolic process GO:0046503 2.48121E-06 
GO:BP carboxylic acid transport GO:0046942 2.54306E-06 
GO:BP triglyceride-rich lipoprotein particle remodeling GO:0034370 3.30946E-06 
GO:BP monocarboxylic acid transport GO:0015718 3.34284E-06 
GO:BP regulation of triglyceride catabolic process GO:0010896 3.45376E-06 
GO:BP cellular lipid catabolic process GO:0044242 3.87653E-06 
GO:BP humoral immune response GO:0006959 4.02063E-06 
GO:BP organic hydroxy compound biosynthetic process GO:1901617 4.18209E-06 
GO:BP positive regulation of cholesterol esterification GO:0010873 4.19864E-06 
GO:BP positive regulation of transport GO:0051050 4.20957E-06 
GO:BP regulation of small molecule metabolic process GO:0062012 4.3995E-06 
GO:BP cellular hormone metabolic process GO:0034754 4.61963E-06 
GO:BP sterol esterification GO:0034434 4.98705E-06 
GO:BP cholesterol esterification GO:0034435 4.98705E-06 
GO:BP steroid esterification GO:0034433 4.98705E-06 
GO:BP primary alcohol metabolic process GO:0034308 5.02236E-06 
GO:BP cellular modified amino acid metabolic process GO:0006575 5.22235E-06 
GO:BP response to metal ion GO:0010038 6.35326E-06 
GO:BP thioester metabolic process GO:0035383 6.42013E-06 
GO:BP acyl-CoA metabolic process GO:0006637 6.42013E-06 
GO:BP positive regulation of triglyceride metabolic process GO:0090208 6.49586E-06 
GO:BP regulation of endopeptidase activity GO:0052548 6.55977E-06 
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GO:BP proteolysis GO:0006508 7.05622E-06 
GO:BP protein-lipid complex subunit organization GO:0071825 7.51614E-06 
GO:BP response to inorganic substance GO:0010035 7.82436E-06 
GO:BP high-density lipoprotein particle assembly GO:0034380 8.16001E-06 
GO:BP regulation of lipase activity GO:0060191 8.81996E-06 
GO:BP regulation of neurotransmitter levels GO:0001505 1.09166E-05 
GO:BP bile acid and bile salt transport GO:0015721 1.17395E-05 
GO:BP negative regulation of catalytic activity GO:0043086 1.3588E-05 
GO:BP antibiotic metabolic process GO:0016999 1.49519E-05 
GO:BP response to glucagon GO:0033762 1.50063E-05 
GO:BP regulation of peptidase activity GO:0052547 1.51656E-05 
GO:BP protein processing GO:0016485 1.71534E-05 
GO:BP protein maturation GO:0051604 1.72423E-05 
GO:BP monosaccharide metabolic process GO:0005996 1.74292E-05 
GO:BP positive regulation of steroid metabolic process GO:0045940 1.76246E-05 
GO:BP positive regulation of triglyceride catabolic process GO:0010898 1.77055E-05 
GO:BP positive regulation of heterotypic cell-cell adhesion GO:0034116 1.81893E-05 
GO:BP urate metabolic process GO:0046415 1.93978E-05 
GO:BP positive regulation of fibrinolysis GO:0051919 1.96562E-05 
GO:BP regulation of localization GO:0032879 2.18579E-05 
GO:BP regulation of lipoprotein lipase activity GO:0051004 2.89854E-05 
GO:BP regulation of plasma lipoprotein particle levels GO:0097006 2.90203E-05 
GO:BP response to organic substance GO:0010033 3.04325E-05 
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GO:BP nucleoside bisphosphate metabolic process GO:0033865 3.14154E-05 
GO:BP purine nucleoside bisphosphate metabolic process GO:0034032 3.14154E-05 
GO:BP ribonucleoside bisphosphate metabolic process GO:0033875 3.14154E-05 
GO:BP cholesterol homeostasis GO:0042632 3.19801E-05 
GO:BP cell adhesion GO:0007155 3.31648E-05 
GO:BP bile acid metabolic process GO:0008206 3.552E-05 
GO:BP liver development GO:0001889 3.71224E-05 
GO:BP blood circulation GO:0008015 3.77545E-05 
GO:BP sterol homeostasis GO:0055092 3.84633E-05 
GO:BP cholesterol transport GO:0030301 3.87561E-05 
GO:BP system development GO:0048731 4.05585E-05 
GO:BP innate immune response GO:0045087 4.11117E-05 
GO:BP regulation of cholesterol esterification GO:0010872 4.42323E-05 
GO:BP monosaccharide biosynthetic process GO:0046364 4.67513E-05 
GO:BP hepaticobiliary system development GO:0061008 4.84173E-05 
GO:BP benzene-containing compound metabolic process GO:0042537 5.09469E-05 
GO:BP response to other organism GO:0051707 5.22829E-05 
GO:BP biological adhesion GO:0022610 5.32217E-05 
GO:BP sterol transport GO:0015918 5.49365E-05 
GO:BP plasma lipoprotein particle assembly GO:0034377 5.628E-05 
GO:BP organophosphate metabolic process GO:0019637 5.77856E-05 
GO:BP response to external biotic stimulus GO:0043207 5.88408E-05 
GO:BP inflammatory response GO:0006954 6.10617E-05 
GO:BP secretion GO:0046903 6.49589E-05 
GO:BP nucleoside phosphate metabolic process GO:0006753 6.79161E-05 
GO:BP response to stress GO:0006950 7.06252E-05 
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GO:BP complement activation, alternative pathway GO:0006957 7.32701E-05 
GO:BP response to biotic stimulus GO:0009607 8.06427E-05 
GO:BP circulatory system process GO:0003013 8.19458E-05 
GO:BP adaptive immune response GO:0002250 8.60495E-05 
GO:BP bile acid biosynthetic process GO:0006699 8.85134E-05 
GO:BP cellular response to glucagon stimulus GO:0071377 9.06236E-05 
GO:BP organonitrogen compound metabolic process GO:1901564 9.73302E-05 
GO:BP positive regulation of response to stimulus GO:0048584 9.94951E-05 
GO:BP negative regulation of protein metabolic process GO:0051248 9.95299E-05 
GO:BP terpenoid metabolic process GO:0006721 0.000108737 
GO:BP positive regulation of small molecule metabolic process GO:0062013 0.000112219 
GO:BP kynurenine metabolic process GO:0070189 0.000112498 
GO:BP nucleotide metabolic process GO:0009117 0.000122615 
GO:BP regulation of heterotypic cell-cell adhesion GO:0034114 0.000129703 
GO:BP 
negative regulation of extrinsic 
apoptotic signaling pathway via death 
domain receptors 
GO:1902042 0.000145895 
GO:BP negative regulation of endothelial cell apoptotic process GO:2000352 0.000148622 
GO:BP positive regulation of fatty acid metabolic process GO:0045923 0.000149433 
GO:BP positive regulation of fatty acid biosynthetic process GO:0045723 0.000153946 
GO:BP regulation of lipid localization GO:1905952 0.000156635 
GO:BP transmembrane transport GO:0055085 0.000168604 
GO:BP positive regulation of hemostasis GO:1900048 0.000171427 
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GO:BP positive regulation of blood coagulation GO:0030194 0.000171427 
GO:BP metal ion transport GO:0030001 0.000187967 
GO:BP complement activation GO:0006956 0.000205522 
GO:BP regulation of response to external stimulus GO:0032101 0.000229885 
GO:BP defense response to other organism GO:0098542 0.000246088 
GO:BP high-density lipoprotein particle remodeling GO:0034375 0.000253594 
GO:BP positive regulation of coagulation GO:0050820 0.000254418 
GO:BP regulation of fatty acid biosynthetic process GO:0042304 0.000272666 
GO:BP response to hormone GO:0009725 0.000334323 
GO:BP regulation of protein metabolic process GO:0051246 0.000337463 
GO:BP regulation of proteolysis GO:0030162 0.000345176 
GO:BP negative regulation of cellular protein metabolic process GO:0032269 0.000363456 
GO:BP purine nucleotide metabolic process GO:0006163 0.000377568 
GO:BP regulation of blood vessel diameter GO:0097746 0.00038488 
GO:BP regulation of tube diameter GO:0035296 0.00038488 
GO:BP animal organ development GO:0048513 0.00041361 
GO:BP protein-lipid complex assembly GO:0065005 0.000427651 
GO:BP regulation of tube size GO:0035150 0.000438147 
GO:BP anion homeostasis GO:0055081 0.000442449 
GO:BP positive regulation of lipase activity GO:0060193 0.000448665 
GO:BP organophosphate ester transport GO:0015748 0.00045832 
GO:BP response to oxygen-containing compound GO:1901700 0.000475071 
GO:BP extracellular structure organization GO:0043062 0.000485741 
GO:BP neurotransmitter metabolic process GO:0042133 0.000508551 
GO:BP regulation of cellular protein metabolic process GO:0032268 0.000527465 
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GO:BP negative regulation of molecular function GO:0044092 0.000529309 
GO:BP tube development GO:0035295 0.000550239 
GO:BP regulation of transport GO:0051049 0.000573562 
GO:BP tyrosine metabolic process GO:0006570 0.000592044 
GO:BP positive regulation of vasoconstriction GO:0045907 0.00061416 
GO:BP tryptophan catabolic process GO:0006569 0.000678605 
GO:BP indolalkylamine catabolic process GO:0046218 0.000678605 
GO:BP indole-containing compound catabolic process GO:0042436 0.000678605 
GO:BP purine ribonucleotide metabolic process GO:0009150 0.000681418 
GO:BP 
regulation of extrinsic apoptotic 
signaling pathway via death domain 
receptors 
GO:1902041 0.000705977 
GO:BP negative regulation of epithelial cell apoptotic process GO:1904036 0.000755124 
GO:BP regulation of fatty acid metabolic process GO:0019217 0.00075856 
GO:BP diterpenoid metabolic process GO:0016101 0.000774544 
GO:BP regulation of complement activation GO:0030449 0.000797811 
GO:BP platelet aggregation GO:0070527 0.000806495 
GO:BP positive regulation of multicellular organismal process GO:0051240 0.000881711 
GO:BP serine family amino acid metabolic process GO:0009069 0.000953272 
GO:BP complement activation, lectin pathway GO:0001867 0.000971476 
GO:BP cellular amino acid biosynthetic process GO:0008652 0.001013437 
GO:BP antibiotic catabolic process GO:0017001 0.001025204 
GO:BP alcohol catabolic process GO:0046164 0.001099993 
GO:BP phospholipid efflux GO:0033700 0.001121155 
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GO:BP ion homeostasis GO:0050801 0.001164272 
GO:BP isoprenoid metabolic process GO:0006720 0.001171341 
GO:BP cellular biogenic amine catabolic process GO:0042402 0.001201566 
GO:BP response to endogenous stimulus GO:0009719 0.001205194 
GO:BP regulation of endothelial cell apoptotic process GO:2000351 0.001232469 
GO:BP induction of bacterial agglutination GO:0043152 0.001273132 
GO:BP multicellular organism development GO:0007275 0.001310518 
GO:BP glucose metabolic process GO:0006006 0.001319637 
GO:BP retinoid metabolic process GO:0001523 0.001348509 
GO:BP vascular process in circulatory system GO:0003018 0.00141079 
GO:BP heterotypic cell-cell adhesion GO:0034113 0.001453262 
GO:BP ribonucleotide metabolic process GO:0009259 0.001502173 
GO:BP negative regulation of multicellular organismal process GO:0051241 0.001528684 
GO:BP endothelial cell apoptotic process GO:0072577 0.001532314 
GO:BP positive regulation of cell communication GO:0010647 0.001556855 
GO:BP gluconeogenesis GO:0006094 0.001556963 
GO:BP organic cyclic compound catabolic process GO:1901361 0.001676385 
GO:BP cation transport GO:0006812 0.001718658 
GO:BP indole-containing compound metabolic process GO:0042430 0.001839317 
GO:BP regulation of ion transport GO:0043269 0.001852735 
GO:BP glutamine family amino acid metabolic process GO:0009064 0.001913991 
GO:BP phospholipid transport GO:0015914 0.001914125 
GO:BP positive regulation of signaling GO:0023056 0.00193335 
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GO:BP response to extracellular stimulus GO:0009991 0.002040245 
GO:BP hexose metabolic process GO:0019318 0.002083928 
GO:BP hexose biosynthetic process GO:0019319 0.002156866 
GO:BP animal organ regeneration GO:0031100 0.002305934 
GO:BP thyroid hormone transport GO:0070327 0.00231767 
GO:BP dicarboxylic acid metabolic process GO:0043648 0.002361415 
GO:BP homotypic cell-cell adhesion GO:0034109 0.002375937 
GO:BP organic substance transport GO:0071702 0.002377613 
GO:BP C21-steroid hormone metabolic process GO:0008207 0.00250696 
GO:BP ribose phosphate metabolic process GO:0019693 0.002530683 
GO:BP 
positive regulation of transmembrane 
receptor protein serine/threonine 
kinase signaling pathway 
GO:0090100 0.002603301 
GO:BP humoral immune response mediated by circulating immunoglobulin GO:0002455 0.002672684 
GO:BP amine catabolic process GO:0009310 0.002859459 
GO:BP regulation of vasoconstriction GO:0019229 0.00295586 




amino acid catabolic process 
GO:1902222 0.003267641 
GO:BP L-phenylalanine catabolic process GO:0006559 0.003267641 
GO:BP vitamin transport GO:0051180 0.003384496 
GO:BP response to acid chemical GO:0001101 0.003403398 
GO:BP positive regulation of phosphate metabolic process GO:0045937 0.003419052 
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GO:BP positive regulation of phosphorus metabolic process GO:0010562 0.003419052 
GO:BP anatomical structure development GO:0048856 0.003446674 
GO:BP regulation of very-low-density lipoprotein particle remodeling GO:0010901 0.003591326 
GO:BP negative regulation of lipase activity GO:0060192 0.003721554 
GO:BP localization GO:0051179 0.003878052 
GO:BP fatty acid biosynthetic process GO:0006633 0.003922208 
GO:BP calcium ion-regulated exocytosis of neurotransmitter GO:0048791 0.004006762 
GO:BP cellular chemical homeostasis GO:0055082 0.004086435 
GO:BP platelet activation GO:0030168 0.004223212 
GO:BP immune response GO:0006955 0.004225801 
GO:BP monocarboxylic acid catabolic process GO:0072329 0.004499481 
GO:BP response to lipid GO:0033993 0.004513293 
GO:BP nucleobase metabolic process GO:0009112 0.005025523 
GO:BP drug transport GO:0015893 0.005077318 
GO:BP regulation of lipid transport GO:0032368 0.005187058 
GO:BP regulation of epithelial cell apoptotic process GO:1904035 0.005242131 
GO:BP response to lipopolysaccharide GO:0032496 0.005254181 
GO:BP histidine catabolic process to glutamate and formate GO:0019557 0.005342756 
GO:BP formamide metabolic process GO:0043606 0.005342756 
GO:BP histidine catabolic process to glutamate and formamide GO:0019556 0.005342756 
GO:BP response to steroid hormone GO:0048545 0.005432806 
GO:BP retinol metabolic process GO:0042572 0.005485616 
GO:BP cytolysis GO:0019835 0.005509245 
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GO:BP cholesterol efflux GO:0033344 0.005695002 
GO:BP regulation of blood circulation GO:1903522 0.005768126 
GO:BP positive regulation of blood circulation GO:1903524 0.006004803 
GO:BP alpha-amino acid biosynthetic process GO:1901607 0.006054047 
GO:BP response to corticosteroid GO:0031960 0.006146522 
GO:BP aspartate family amino acid metabolic process GO:0009066 0.006196265 
GO:BP negative regulation of extrinsic apoptotic signaling pathway GO:2001237 0.006206332 
GO:BP positive regulation of phosphorylation GO:0042327 0.006257498 
GO:BP drug transmembrane transport GO:0006855 0.006327604 




amino acid metabolic process 
GO:1902221 0.006460914 
GO:BP vasoconstriction GO:0042310 0.006622755 
GO:BP positive regulation of ion transport GO:0043270 0.006640075 
GO:BP response to nutrient levels GO:0031667 0.006675636 
GO:BP phosphate-containing compound metabolic process GO:0006796 0.006798671 
GO:BP hyaluronan metabolic process GO:0030212 0.006835205 
GO:BP complement activation, classical pathway GO:0006958 0.006836306 
GO:BP positive regulation of lipoprotein lipase activity GO:0051006 0.007052521 
GO:BP positive regulation of exocytosis GO:0045921 0.007057316 
GO:BP cellular response to metal ion GO:0071248 0.007107685 
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GO:BP aromatic compound catabolic process GO:0019439 0.007322062 
GO:BP carbohydrate metabolic process GO:0005975 0.00736055 
GO:BP phenol-containing compound metabolic process GO:0018958 0.007520705 
GO:BP reverse cholesterol transport GO:0043691 0.007721618 
GO:BP NAD biosynthetic process GO:0009435 0.007774349 
GO:BP plasma lipoprotein particle clearance GO:0034381 0.007987242 
GO:BP response to glucocorticoid GO:0051384 0.008281613 
GO:BP 'de novo' NAD biosynthetic process GO:0034627 0.008313926 
GO:BP 'de novo' NAD biosynthetic process from tryptophan GO:0034354 0.008313926 
GO:BP response to peptide hormone GO:0043434 0.008381551 
GO:BP negative regulation of blood vessel diameter GO:0097756 0.008473614 
GO:BP response to chemical GO:0042221 0.008484661 
GO:BP lipid modification GO:0030258 0.008710205 
GO:BP detoxification GO:0098754 0.008760818 
GO:BP indolalkylamine metabolic process GO:0006586 0.00890632 
GO:BP tryptophan metabolic process GO:0006568 0.00890632 
GO:BP response to bacterium GO:0009617 0.009034322 
GO:BP organonitrogen compound catabolic process GO:1901565 0.009209163 
GO:BP vitamin metabolic process GO:0006766 0.00927403 
GO:BP transport GO:0006810 0.009311716 
GO:BP cellular aldehyde metabolic process GO:0006081 0.00943343 
GO:BP regulation of humoral immune response GO:0002920 0.00957931 
GO:BP organic hydroxy compound catabolic process GO:1901616 0.009733872 
GO:BP regulation of hydrolase activity GO:0051336 0.009744944 
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GO:BP homeostatic process GO:0042592 0.009811179 
GO:BP intestinal lipid absorption GO:0098856 0.010031171 
GO:BP regulation of intestinal cholesterol absorption GO:0030300 0.010520931 
GO:BP positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 0.011037523 
GO:BP phosphorus metabolic process GO:0006793 0.011227765 
GO:BP regulation of secretion GO:0051046 0.011565454 
GO:BP endocrine pancreas development GO:0031018 0.011659509 
GO:BP epithelial cell apoptotic process GO:1904019 0.011847014 
GO:BP amine transport GO:0015837 0.012484108 
GO:BP positive regulation of wound healing GO:0090303 0.01270545 
GO:BP developmental process GO:0032502 0.012744989 
GO:BP second-messenger-mediated signaling GO:0019932 0.012868054 
GO:BP glutamate metabolic process GO:0006536 0.013146555 
GO:BP response to molecule of bacterial origin GO:0002237 0.013194376 
GO:BP histidine catabolic process GO:0006548 0.013273771 
GO:BP formate metabolic process GO:0015942 0.013273771 
GO:BP positive regulation of triglyceride lipase activity GO:0061365 0.013566605 
GO:BP cellular response to inorganic substance GO:0071241 0.013634911 
GO:BP positive regulation of peptide hormone secretion GO:0090277 0.013824451 
GO:BP cholesterol biosynthetic process GO:0006695 0.014210206 
GO:BP response to organic cyclic compound GO:0014070 0.01421776 
GO:BP L-lysine catabolic process GO:0019477 0.015120579 
GO:BP lysine catabolic process GO:0006554 0.015120579 
GO:BP L-lysine metabolic process GO:0046440 0.015120579 
GO:BP L-lysine catabolic process to acetyl-CoA GO:0019474 0.015120579 
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GO:BP neurotransmitter transport GO:0006836 0.015343174 
GO:BP sulfur amino acid metabolic process GO:0000096 0.016262145 
GO:BP canalicular bile acid transport GO:0015722 0.017234219 
GO:BP aspartate family amino acid catabolic process GO:0009068 0.017238471 
GO:BP export from cell GO:0140352 0.017385224 
GO:BP tissue development GO:0009888 0.017520659 
GO:BP negative regulation of lipid metabolic process GO:0045833 0.017724289 
GO:BP regulation of response to stimulus GO:0048583 0.0177968 
GO:BP L-kynurenine metabolic process GO:0097052 0.018275104 
GO:BP epithelium development GO:0060429 0.018545623 
GO:BP regulation of intestinal lipid absorption GO:1904729 0.018693804 
GO:BP regulation of secretion by cell GO:1903530 0.018757552 
GO:BP regulation of sterol transport GO:0032371 0.019950307 
GO:BP regulation of cholesterol transport GO:0032374 0.019950307 
GO:BP locomotion GO:0040011 0.020104939 
GO:BP pyruvate metabolic process GO:0006090 0.020614871 
GO:BP chylomicron remnant clearance GO:0034382 0.020713492 
GO:BP triglyceride-rich lipoprotein particle clearance GO:0071830 0.020713492 
GO:BP regulation of cellular component movement GO:0051270 0.020865025 
GO:BP defense response to fungus GO:0050832 0.023009525 
GO:BP negative regulation of small molecule metabolic process GO:0062014 0.023479906 
GO:BP fatty acid catabolic process GO:0009062 0.023701329 
GO:BP negative regulation of humoral immune response GO:0002921 0.025439936 
GO:BP anthranilate metabolic process GO:0043420 0.025703366 
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GO:BP imidazole-containing compound catabolic process GO:0052805 0.026382402 
GO:BP regulation of plasminogen activation GO:0010755 0.026445609 
GO:BP inorganic ion homeostasis GO:0098771 0.026735005 
GO:BP secondary alcohol biosynthetic process GO:1902653 0.026898346 
GO:BP acetyl-CoA metabolic process GO:0006084 0.027688718 
GO:BP regulation of extrinsic apoptotic signaling pathway GO:2001236 0.02867571 
GO:BP sodium ion transport GO:0006814 0.028804206 
GO:BP response to calcium ion GO:0051592 0.02924127 
GO:BP regulation of extracellular matrix constituent secretion GO:0003330 0.02924127 
GO:BP quinolinate metabolic process GO:0046874 0.029952568 
GO:BP positive regulation of ERK1 and ERK2 cascade GO:0070374 0.030059142 
GO:BP regeneration GO:0031099 0.031148813 
GO:BP positive regulation of hormone secretion GO:0046887 0.031577299 
GO:BP immunoglobulin mediated immune response GO:0016064 0.031902634 
GO:BP regulation of response to stress GO:0080134 0.032435475 
GO:BP cell-cell adhesion GO:0098609 0.032683374 
GO:BP hormone transport GO:0009914 0.033516364 
GO:BP B cell mediated immunity GO:0019724 0.036529112 
GO:BP cell killing GO:0001906 0.037404636 
GO:BP lysine metabolic process GO:0006553 0.037467368 
GO:BP immune system process GO:0002376 0.038758689 
GO:BP cellular response to oxygen-containing compound GO:1901701 0.040552312 
GO:BP positive regulation of response to wounding GO:1903036 0.043430956 
GO:BP carbohydrate biosynthetic process GO:0016051 0.043600137 
GO:BP positive regulation of protein phosphorylation GO:0001934 0.044390565 
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GO:BP fatty acid homeostasis GO:0055089 0.044395646 
GO:BP cellular homeostasis GO:0019725 0.04442799 
GO:BP xenobiotic transport GO:0042908 0.04448435 
GO:BP pancreas development GO:0031016 0.044846397 
GO:BP histidine metabolic process GO:0006547 0.045882118 
GO:BP activation of immune response GO:0002253 0.046213638 
GO:BP establishment of localization GO:0051234 0.047806202 
GO:BP urate catabolic process GO:0019628 0.048204113 
    
Gene Ontology: Cellular Compartment 
GO:CC extracellular region part GO:0044421 1.12E-25 
GO:CC extracellular region GO:0005576 2.79E-25 
GO:CC extracellular space GO:0005615 6.80E-25 
GO:CC high-density lipoprotein particle GO:0034364 8.84E-16 
GO:CC lipoprotein particle GO:1990777 3.13E-13 
GO:CC plasma lipoprotein particle GO:0034358 3.13E-13 
GO:CC plasma membrane region GO:0098590 6.73E-13 
GO:CC protein-lipid complex GO:0032994 8.56E-13 
GO:CC plasma membrane part GO:0044459 4.44E-12 
GO:CC apical part of cell GO:0045177 1.39E-10 
GO:CC basolateral plasma membrane GO:0016323 1.55E-10 
GO:CC collagen-containing extracellular matrix GO:0062023 3.86E-10 
GO:CC fibrinogen complex GO:0005577 1.35E-09 
GO:CC endoplasmic reticulum GO:0005783 8.82E-09 
GO:CC apical plasma membrane GO:0016324 1.01E-08 
GO:CC extracellular matrix GO:0031012 1.36E-08 
GO:CC intrinsic component of plasma membrane GO:0031226 8.00E-08 
GO:CC triglyceride-rich plasma lipoprotein particle GO:0034385 1.24E-07 
GO:CC very-low-density lipoprotein particle GO:0034361 1.24E-07 
GO:CC integral component of plasma membrane GO:0005887 2.90E-07 
GO:CC blood microparticle GO:0072562 3.22E-07 
GO:CC brush border GO:0005903 2.84682E-06 
GO:CC membrane attack complex GO:0005579 3.62223E-06 
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GO:CC platelet alpha granule GO:0031091 1.04678E-05 
GO:CC cell surface GO:0009986 1.80701E-05 
GO:CC endoplasmic reticulum part GO:0044432 2.42567E-05 
GO:CC brush border membrane GO:0031526 4.26662E-05 
GO:CC endoplasmic reticulum membrane GO:0005789 6.17105E-05 
GO:CC nuclear outer membrane-endoplasmic reticulum membrane network GO:0042175 6.67944E-05 
GO:CC spherical high-density lipoprotein particle GO:0034366 8.37536E-05 
GO:CC chylomicron GO:0042627 9.83703E-05 
GO:CC peroxisome GO:0005777 0.000179335 
GO:CC microbody GO:0042579 0.000179335 
GO:CC cluster of actin-based cell projections GO:0098862 0.000234054 
GO:CC microvillus GO:0005902 0.001777006 
GO:CC glutamatergic synapse GO:0098978 0.006212845 
GO:CC hippocampal mossy fiber to CA3 synapse GO:0098686 0.016330931 
GO:CC T-tubule GO:0030315 0.018552407 
GO:CC pore complex GO:0046930 0.019083323 
GO:CC MHC class II protein complex GO:0042613 0.024129456 
GO:CC cell projection membrane GO:0031253 0.029451908 
GO:CC discoidal high-density lipoprotein particle GO:0034365 0.030899039 
GO:CC intrinsic component of postsynaptic density membrane GO:0099146 0.034212097 
GO:CC intrinsic component of presynaptic membrane GO:0098889 0.037117626 
GO:CC presynaptic membrane GO:0042734 0.0395144 
GO:CC low-density lipoprotein particle GO:0034362 0.039767519 
    
Kyoto Encyclopedia of Genes and Genomes Pathways 
KEGG Complement and coagulation cascades KEGG:04610 1.51E-19 
KEGG Steroid hormone biosynthesis KEGG:00140 1.41E-13 
KEGG Retinol metabolism KEGG:00830 1.56E-07 
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KEGG Chemical carcinogenesis KEGG:05204 4.93E-07 
KEGG Bile secretion KEGG:04976 4.01304E-06 
KEGG Drug metabolism - other enzymes KEGG:00983 0.000179241 
KEGG Linoleic acid metabolism KEGG:00591 0.000471958 
KEGG Glycine, serine and threonine metabolism KEGG:00260 0.00064813 
KEGG Metabolism of xenobiotics by cytochrome P450 KEGG:00980 0.002500161 
KEGG Drug metabolism - cytochrome P450 KEGG:00982 0.003949089 
KEGG Arachidonic acid metabolism KEGG:00590 0.011044643 
KEGG Platelet activation KEGG:04611 0.01125404 
KEGG PPAR signaling pathway KEGG:03320 0.011850295 
KEGG Primary bile acid biosynthesis KEGG:00120 0.017092955 
KEGG Cholesterol metabolism KEGG:04979 0.019166305 
KEGG Ascorbate and aldarate metabolism KEGG:00053 0.023393723 
KEGG Tryptophan metabolism KEGG:00380 0.032295018 
    
Reactome Pathways 
REAC Formation of Fibrin Clot (Clotting Cascade) 
REAC:R-MMU-
140877 4.98E-12 
REAC Platelet degranulation  REAC:R-MMU-114608 3.10E-08 
REAC Response to elevated platelet cytosolic Ca2+ REAC:R-MMU-76005 4.44E-08 
REAC Intrinsic Pathway of Fibrin Clot Formation 
REAC:R-MMU-
140837 1.69E-07 
REAC Metabolism of amino acids and derivatives REAC:R-MMU-71291 1.26236E-06 
REAC Common Pathway of Fibrin Clot Formation 
REAC:R-MMU-
140875 1.30109E-05 
REAC Platelet activation, signaling and aggregation REAC:R-MMU-76002 1.43987E-05 
REAC Plasma lipoprotein remodeling REAC:R-MMU-8963899 2.21369E-05 





REAC GRB2:SOS provides linkage to MAPK signaling for Integrins  
REAC:R-MMU-
354194 3.861E-05 
REAC Regulation of TLR by endogenous ligand REAC:R-MMU-5686938 3.861E-05 
REAC Bile acid and bile salt metabolism REAC:R-MMU-194068 8.33825E-05 
REAC Recycling of bile acids and salts REAC:R-MMU-159418 0.000126436 
REAC Extracellular matrix organization REAC:R-MMU-1474244 0.000135513 
REAC Hemostasis REAC:R-MMU-109582 0.00015474 
REAC Complement cascade REAC:R-MMU-166658 0.00023432 
REAC Integrin signaling REAC:R-MMU-9006921 0.000274637 
REAC Integrin alphaIIb beta3 signaling REAC:R-MMU-354192 0.000274637 
REAC Plasma lipoprotein assembly, remodeling, and clearance 
REAC:R-MMU-
174824 0.000292165 
REAC Platelet Aggregation (Plug Formation) REAC:R-MMU-76009 0.000574912 
REAC MAP2K and MAPK activation REAC:R-MMU-5674135 0.000817604 
REAC Post-translational protein phosphorylation 
REAC:R-MMU-
8957275 0.001093165 
REAC Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol 
REAC:R-MMU-
193368 0.001096415 
REAC Metabolism of fat-soluble vitamins REAC:R-MMU-6806667 0.002070415 
REAC 
Regulation of Insulin-like Growth Factor 
(IGF) transport and uptake by Insulin-like 
Growth Factor Binding Proteins (IGFBPs) 
REAC:R-MMU-
381426 0.002126044 
REAC Regulation of Complement cascade REAC:R-MMU-977606 0.002423426 
REAC Integrin cell surface interactions REAC:R-MMU-216083 0.004988395 
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REAC Terminal pathway of complement REAC:R-MMU-166665 0.0082513 
REAC Retinoid metabolism and transport REAC:R-MMU-975634 0.00924114 
REAC Plasma lipoprotein assembly REAC:R-MMU-8963898 0.0100308 
REAC Tryptophan catabolism REAC:R-MMU-71240 0.017197 
REAC Toll-like Receptor Cascades REAC:R-MMU-168898 0.030901184 
REAC Metabolism of steroids REAC:R-MMU-8957322 0.036310477 
REAC Visual phototransduction REAC:R-MMU-2187338 0.040221958 
REAC HDL remodeling REAC:R-MMU-8964058 0.041581529 
REAC 
Transport of gamma-carboxylated 
protein precursors from the 




    
Transcription Factor Binding Motifs 
TF Factor: HNF-4alpha; motif: GNNCAAAGKYCANNN; match class: 0 TF:M02016_0 7.07E-07 
TF Factor: HNF-4alpha; motif: GNNCAAAGKYCANNN TF:M02016 7.07E-07 
TF Factor: Rxrb; motif: GGGGTCAAAGGTCA; match class: 1 TF:M04493_1 9.23261E-06 
TF Factor: HNF-1beta; motif: GTTAATYATTAACY; match class: 0 TF:M03872_0 2.23106E-05 
TF Factor: HNF-1beta; motif: GTTAATYATTAACY TF:M03872 2.23106E-05 
TF Factor: HNF4; motif: TGAMCTTTGNCCN; match class: 0 TF:M00764_0 0.000118373 
TF Factor: HNF4; motif: TGAMCTTTGNCCN TF:M00764 0.000118373 
TF Factor: HNF-1; motif: DGTTAATKAWTNACCAM; match class: 0 TF:M00206_0 0.000122328 
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TF Factor: HNF-1; motif: DGTTAATKAWTNACCAM TF:M00206 0.000122328 
TF Factor: PPAR,; motif: RGGNCAAAGGTCA TF:M00762 0.000626013 
TF Factor: PPAR,; motif: RGGNCAAAGGTCA; match class: 0 TF:M00762_0 0.000626013 
TF Factor: HNF-1beta; motif: GTTAATYATTAACY; match class: 1 TF:M03872_1 0.001038357 
TF Factor: PPARgamma:RXR-alpha; motif: NTRGGNCARAGGKCA; match class: 1 TF:M02262_1 0.001106799 
TF 




TF Factor: Rxrb; motif: GGGGTCAAAGGTCA TF:M04493 0.002244809 
TF Factor: Rxrb; motif: GGGGTCAAAGGTCA; match class: 0 TF:M04493_0 0.002244809 
TF Factor: PPAR; motif: TGACCTTTGNCCY; match class: 0 TF:M00763_0 0.002917992 
TF Factor: PPAR; motif: TGACCTTTGNCCY TF:M00763 0.002917992 
TF Factor: CDP; motif: NNNNWGWYMAATR TF:M04610 0.003643281 
TF Factor: CDP; motif: NNNNWGWYMAATR; match class: 0 TF:M04610_0 0.003643281 
TF Factor: HNF-1alpha; motif: GGTTAATNWTTAMCN; match class: 0 TF:M00132_0 0.004360202 
TF Factor: HNF-1alpha; motif: GGTTAATNWTTAMCN TF:M00132 0.004360202 
TF 
Factor: GR; motif: 
NNNNNNNGKACNNNNTGTTCTNNNNNN; 




TF Factor: HNF-4A; motif: NGNNCAAAGKYCAN; match class: 1 TF:M07321_1 0.006023834 
TF Factor: HNF-1; motif: WRGTTAATNATTAACNNN TF:M00790 0.007932802 
TF 
Factor: HNF-1; motif: 
WRGTTAATNATTAACNNN; match class: 
0 
TF:M00790_0 0.007932802 
TF Factor: COUP; motif: TGACCTTTGACCC; match class: 0 TF:M00765_0 0.008121556 
TF Factor: COUP; motif: TGACCTTTGACCC TF:M00765 0.008121556 
TF Factor: EAR2; motif: YGNNCTTTGNCCTK; match class: 1 TF:M01728_1 0.008705386 
TF 
Factor: HNF-1; motif: 








TF Factor: EAR2; motif: YGNNCTTTGNCCTK TF:M01728 0.014377745 
TF Factor: EAR2; motif: YGNNCTTTGNCCTK; match class: 0 TF:M01728_0 0.014377745 
TF 




TF Factor: HNF-4; motif: NNNRGGNCAAAGKTCANNN TF:M00134 0.018978606 
TF 




TF Factor: RORbeta; motif: TGACCYA; match class: 1 TF:M01722_1 0.020756116 
TF Factor: HNF-4A; motif: NGNNCAAAGKYCAN TF:M07321 0.031603367 
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TF Factor: HNF-4A; motif: NGNNCAAAGKYCAN; match class: 0 TF:M07321_0 0.031603367 
TF Factor: aMEF-2; motif: CKGDYTAAAAATAACYMM TF:M00403 0.035015042 
TF 
Factor: aMEF-2; motif: 
CKGDYTAAAAATAACYMM; match class: 
0 
TF:M00403_0 0.035015042 















Functional Enrichment in Upregulated Genes 
Gene Ontology: Molecular Function  
Source Term Name Term ID P(adj) 
GO:MF 5S rRNA binding GO:0008097 0.03772079 
    
Gene Ontology: Cellular Compartment 
GO:CC intracellular part GO:0044424 0.009999706 
GO:CC cytosolic ribosome GO:0022626 0.012747959 
GO:CC intracellular organelle part GO:0044446 0.018463811 
GO:CC intracellular GO:0005622 0.036242363 
GO:CC organelle part GO:0044422 0.039661927 
GO:CC Cul4A-RING E3 ubiquitin ligase complex GO:0031464 0.04328979 
    
Transcription Factor Binding Motifs 
TF Factor: E2F-3; motif: GGCGGGN; match class: 0 TF:M02089_0 0.000428677 
TF Factor: E2F-3; motif: GGCGGGN TF:M02089 0.000428677 
TF Factor: AP-2gamma; motif: GCCYNNGGS; match class: 1 TF:M00470_1 0.000777899 
TF Factor: AP-2alpha; motif: GCCNNNRGS; match class: 0 TF:M00469_0 0.000910247 
TF Factor: AP-2alpha; motif: GCCNNNRGS TF:M00469 0.000910247 
TF Factor: Mybl1; motif: NNNNNAACCGTTANNNN TF:M02780 0.001529094 
TF 
Factor: Mybl1; motif: 




Factor: FOXN4; motif: 
NNWANNCGWMCGCGTCNNNNMT; 
match class: 1 
TF:M04662_1 0.002181657 
TF Factor: E2F; motif: GGCGSG; match class: 1 TF:M00803_1 0.0034288 
TF Factor: Sp1; motif: NNGGGGCGGGGNN TF:M00932 0.003621403 
TF Factor: Sp1; motif: NNGGGGCGGGGNN; match class: 0 TF:M00932_0 0.003621403 
TF Factor: Sp1; motif: GGGGCGGGGC TF:M00931 0.004273116 
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TF Factor: Sp1; motif: GGGGCGGGGC; match class: 0 TF:M00931_0 0.004273116 
TF Factor: E2F; motif: TTTSGCGC; match class: 0 TF:M00050_0 0.005505702 
TF Factor: E2F; motif: TTTSGCGC TF:M00050 0.005505702 
TF Factor: SP2; motif: GNNGGGGGCGGGGSN TF:M03807 0.007444705 
TF Factor: SP2; motif: GNNGGGGGCGGGGSN; match class: 0 TF:M03807_0 0.007444705 
TF Factor: GKLF; motif: GCCMCRCCCNNN TF:M01588 0.00770919 
TF Factor: GKLF; motif: GCCMCRCCCNNN; match class: 0 TF:M01588_0 0.00770919 
TF Factor: AP-2alpha; motif: NGCCYSNNGSN TF:M01857 0.009272203 
TF Factor: AP-2alpha; motif: NGCCYSNNGSN; match class: 0 TF:M01857_0 0.009272203 
TF Factor: Sp1; motif: NGGGGGCGGGGYN TF:M00196 0.009731006 
TF Factor: Sp1; motif: NGGGGGCGGGGYN; match class: 0 TF:M00196_0 0.009731006 
TF Factor: AP-2alpha; motif: GCCNNNRGS; match class: 1 TF:M00469_1 0.009868444 
TF Factor: Sp1; motif: NGGGGCGGGGN; match class: 0 TF:M07395_0 0.01087233 
TF Factor: Sp1; motif: NGGGGCGGGGN TF:M07395 0.01087233 
TF Factor: E2F-4; motif: GCGGGAAANA; match class: 0 TF:M02090_0 0.013169512 
TF Factor: E2F-4; motif: GCGGGAAANA TF:M02090 0.013169512 
TF Factor: ZF5; motif: GSGCGCGR; match class: 0 TF:M00716_0 0.01460553 
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TF Factor: ZF5; motif: GSGCGCGR TF:M00716 0.01460553 
TF Factor: AP-2gamma; motif: GCCYNNGGS; match class: 0 TF:M00470_0 0.021976769 
TF Factor: AP-2gamma; motif: GCCYNNGGS TF:M00470 0.021976769 
TF Factor: AP-2; motif: MKCCCSCNGGCG; match class: 0 TF:M00189_0 0.026224875 
TF Factor: AP-2; motif: MKCCCSCNGGCG TF:M00189 0.026224875 
TF Factor: E2F; motif: GGCGSG TF:M00803 0.026431078 
TF Factor: E2F; motif: GGCGSG; match class: 0 TF:M00803_0 0.026431078 
TF Factor: ZF5; motif: GSGCGCGR; match class: 1 TF:M00716_1 0.027624825 
TF Factor: Sp1; motif: CCCCGCCCCN TF:M00933 0.044120426 











Appendix 4: Human Mutations Found In 
Predicted Driver Genes From The Input Cohort 
Gene Human Sample Chr Start  Tumour Allele  in vivo screen 
            
IDH1 Nakamura_BD115 2 209113113 C Yes 
IDH1 Nakamura_BD141 2 209113112 A Yes 
IDH1 Nakamura_BD167 2 209113113 A Yes 
IDH1 Nakamura_BD169 2 209110270 T Yes 
IDH1 Nakamura_BD169 2 209113113 C Yes 
IDH1 Nakamura_BD200 2 209113113 A Yes 
IDH1 Nakamura_BD212 2 209113113 A Yes 
IDH1 Nakamura_BD245 2 209113113 C Yes 
IDH1 Nakamura_BD38 2 209113113 A Yes 
IDH1 Nakamura_BD8 2 209113113 A Yes 
IDH1 Nakamura_BD81 2 209113112 A Yes 
IDH1 Nakamura_BD81 2 209113113 T Yes 
IDH1 Chan-On_p05 2 209113112 A Yes 
IDH1 Zou_p122 2 209113112 A Yes 
IDH1 Zou_p132 2 209113113 A Yes 
IDH1 Zou_p42 2 209113113 A Yes 
IDH1 Zou_p46 2 209113113 A Yes 
IDH1 Zou_p8_6 2 209113113 A Yes 
IDH1 Sia_iCC9-10  2 209113112 A Yes 
IDH1 TCGA_p04 2 209113113 A Yes 
IDH1 TCGA_p10 2 209113113 A Yes 
IDH1 TCGA_p23 2 209113049 A Yes 
IDH1 TCGA_p36 2 209113113 A Yes 
IDH1 TCGA_p46 2 209116300 A Yes 
IDH1 TCGA_p47 2 209113113 A Yes 
BAP1 Nakamura_BD105 3 52443569 - Yes 
BAP1 Nakamura_BD140 3 52441302 T Yes 
BAP1 Nakamura_BD141 3 52443599 - Yes 
BAP1 Nakamura_BD169 3 52442512 - Yes 
BAP1 Nakamura_BD197 3 52441990 - Yes 
BAP1 Nakamura_BD199 3 52441448 - Yes 
BAP1 Nakamura_BD21 3 52439913 A Yes 
BAP1 Nakamura_BD224 3 52441266 A Yes 
BAP1 Nakamura_BD224 3 52441337 A Yes 
BAP1 Nakamura_BD224 3 52441423 A Yes 
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BAP1 Nakamura_BD226 3 52441312 - Yes 
BAP1 Nakamura_BD28 3 52441252 C Yes 
BAP1 Nakamura_BD33 3 52441333 A Yes 
BAP1 Nakamura_BD50 3 52437679 T Yes 
BAP1 Nakamura_BD79 3 52441226 A Yes 
BAP1 Nakamura_BD8 3 52437557 - Yes 
BAP1 Nakamura_BD92 3 52436633 A Yes 
BAP1 Chan-On_p05 3 52439880 - Yes 
BAP1 Chan-On_p07 3 52437650 - Yes 
BAP1 Chan-On_p08 3 52437802 T Yes 
BAP1 TCGA_p02 3 52437221 - Yes 
BAP1 TCGA_p03 3 52439916 G Yes 
BAP1 TCGA_p03 3 52439930 C Yes 
BAP1 TCGA_p06 3 52438377 C Yes 
BAP1 TCGA_p21 3 52442599 G Yes 
BAP1 TCGA_p23 3 52437154 A Yes 
BAP1 TCGA_p25 3 52440307 A Yes 
BAP1 TCGA_p27 3 52439230 T Yes 
BAP1 TCGA_p32 3 52441235 A Yes 
BAP1 TCGA_p47 3 52433843 T Yes 
ARID1A Nakamura_BD101 1 27088022 G Yes 
ARID1A Nakamura_BD104 1 27094293 T Yes 
ARID1A Nakamura_BD109 1 27099285 - Yes 
ARID1A Nakamura_BD120 1 27087410 - Yes 
ARID1A Nakamura_BD130 1 27099947 T Yes 
ARID1A Nakamura_BD141 1 27101048 T Yes 
ARID1A Nakamura_BD148 1 27057916 T Yes 
ARID1A Nakamura_BD154 1 27092809 T Yes 
ARID1A Nakamura_BD167 1 27105978 - Yes 
ARID1A Nakamura_BD169 1 27089727 T Yes 
ARID1A Nakamura_BD213 1 27023717 G Yes 
ARID1A Nakamura_BD213 1 27089679 - Yes 
ARID1A Nakamura_BD234 1 27106648 A Yes 
ARID1A Nakamura_BD237 1 27102084 A Yes 
ARID1A Nakamura_BD33 1 27059264 G Yes 
ARID1A Nakamura_BD58 1 27105541 T Yes 
ARID1A Nakamura_BD69 1 27106106 - Yes 
ARID1A Nakamura_BD81 1 27101711 T Yes 
ARID1A Chan-On_p03 1 27100060 G Yes 
ARID1A Chan-On_p08 1 27089777 T Yes 
ARID1A Chan-On_p15 1 27092770 T Yes 
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ARID1A Zou_p03 1 27087458 T Yes 
ARID1A Zou_p10 1 27057766 T Yes 
ARID1A Zou_p108 1 27100082 A Yes 
ARID1A Zou_p108 1 27100292 C Yes 
ARID1A Zou_p111 1 27106504 T Yes 
ARID1A Zou_p53 1 27105550 T Yes 
ARID1A Zou_p56 1 27092812 T Yes 
ARID1A TCGA_p01 1 27101384 - Yes 
ARID1A TCGA_p03 1 27099298 - Yes 
ARID1A TCGA_p14 1 27107084 T Yes 
ARID1A TCGA_p16 1 27101387 - Yes 
ARID1A TCGA_p24 1 27105848 - Yes 
ARID1A TCGA_p27 1 27088093 C Yes 
ARID1A TCGA_p41 1 27105967 T Yes 
ARID1A TCGA_p41 1 27107951 - Yes 
ARID1A TCGA_p42 1 27107951 - Yes 
ARID1A TCGA_p45 1 27107136 A Yes 
ARID1A TCGA_p46 1 27089711 - Yes 
KRAS Nakamura_BD10 12 25398284 T Yes 
KRAS Nakamura_BD104 12 25398284 T Yes 
KRAS Nakamura_BD118 12 25380276 C Yes 
KRAS Nakamura_BD118 12 25380281 G Yes 
KRAS Nakamura_BD127 12 25398284 T Yes 
KRAS Nakamura_BD129 12 25398281 T Yes 
KRAS Nakamura_BD143 12 25380275 G Yes 
KRAS Nakamura_BD148 12 25398284 A Yes 
KRAS Nakamura_BD153 12 25398284 T Yes 
KRAS Nakamura_BD154 12 25398284 A Yes 
KRAS Nakamura_BD157 12 25398284 T Yes 
KRAS Nakamura_BD18 12 25398284 T Yes 
KRAS Nakamura_BD211 12 25398284 T Yes 
KRAS Nakamura_BD213 12 25398284 T Yes 
KRAS Nakamura_BD221 12 25398284 A Yes 
KRAS Nakamura_BD229 12 25398285 A Yes 
KRAS Nakamura_BD230 12 25398284 T Yes 
KRAS Nakamura_BD233 12 25378562 T Yes 
KRAS Nakamura_BD234 12 25398266 C Yes 
KRAS Nakamura_BD243 12 25398284 T Yes 
KRAS Nakamura_BD247 12 25398284 T Yes 
KRAS Nakamura_BD25 12 25398284 A Yes 
KRAS Nakamura_BD29 12 25398284 T Yes 
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KRAS Nakamura_BD30 12 25398284 A Yes 
KRAS Nakamura_BD47 12 25380275 G Yes 
KRAS Nakamura_BD5 12 25398284 T Yes 
KRAS Nakamura_BD66 12 25398284 T Yes 
KRAS Nakamura_BD74 12 25398284 G Yes 
KRAS Nakamura_BD86 12 25398284 A Yes 
KRAS Nakamura_BD88 12 25398284 T Yes 
KRAS Zou_p03 12 25398284 T Yes 
KRAS Zou_p07 12 25398284 T Yes 
KRAS Zou_p107 12 25398284 A Yes 
KRAS Zou_p108 12 25398284 A Yes 
KRAS Zou_p111 12 25398284 T Yes 
KRAS Zou_p120 12 25398285 A Yes 
KRAS Zou_p129 12 25398284 T Yes 
KRAS Zou_p133 12 25398285 A Yes 
KRAS Zou_p134 12 25398284 G Yes 
KRAS Zou_p137 12 25398284 A Yes 
KRAS Zou_p144 12 25398284 A Yes 
KRAS Zou_p17 12 25398284 T Yes 
KRAS Zou_p29 12 25398284 A Yes 
KRAS Zou_p33 12 25398284 A Yes 
KRAS Zou_p46 12 25398284 T Yes 
KRAS Zou_p59 12 25398284 T Yes 
KRAS Zou_p66 12 25398284 G Yes 
KRAS TCGA_p25 12 25359465 - Yes 
KRAS TCGA_p26 12 25380277 T Yes 
KRAS TCGA_p26 12 25380278 T Yes 
KRAS TCGA_p32 12 25359046 A Yes 
KRAS TCGA_p41 12 25398284 T Yes 
TP53 Nakamura_BD111 17 7577085 T Yes 
TP53 Nakamura_BD120 17 7577538 T Yes 
TP53 Nakamura_BD129 17 7577580 C Yes 
TP53 Nakamura_BD130 17 7578212 A Yes 
TP53 Nakamura_BD134 17 7577538 A Yes 
TP53 Nakamura_BD140 17 7578517 A Yes 
TP53 Nakamura_BD143 17 7578550 A Yes 
TP53 Nakamura_BD154 17 7576852 A Yes 
TP53 Nakamura_BD18 17 7577022 A Yes 
TP53 Nakamura_BD203 17 7577534 A Yes 
TP53 Nakamura_BD211 17 7578191 T Yes 
TP53 Nakamura_BD213 17 7577106 T Yes 
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TP53 Nakamura_BD214 17 7577557 C Yes 
TP53 Nakamura_BD220 17 7578550 A Yes 
TP53 Nakamura_BD227 17 7578265 T Yes 
TP53 Nakamura_BD229 17 7577539 C Yes 
TP53 Nakamura_BD23 17 7578190 C Yes 
TP53 Nakamura_BD231 17 7578271 C Yes 
TP53 Nakamura_BD234 17 7579472 G Yes 
TP53 Nakamura_BD243 17 7578234 - Yes 
TP53 Nakamura_BD244 17 7577094 A Yes 
TP53 Nakamura_BD25 17 7578406 T Yes 
TP53 Nakamura_BD29 17 7578265 G Yes 
TP53 Nakamura_BD38 17 7578369 G Yes 
TP53 Nakamura_BD74 17 7578529 C Yes 
TP53 Nakamura_BD82 17 7578177 T Yes 
TP53 Nakamura_BD86 17 7576855 A Yes 
TP53 Nakamura_BD88 17 7576926 A Yes 
TP53 Nakamura_BD88 17 7576927 A Yes 
TP53 Chan-On_p02 17 7578457 T Yes 
TP53 Zou_p05 17 7577568 A Yes 
TP53 Zou_p08 17 7578493 T Yes 
TP53 Zou_p113 17 7579406 T Yes 
TP53 Zou_p121 17 7578440 A Yes 
TP53 Zou_p127 17 7577498 A Yes 
TP53 Zou_p128 17 7573996 C Yes 
TP53 Zou_p131 17 7578239 A Yes 
TP53 Zou_p134 17 7574017 A Yes 
TP53 Zou_p135 17 7577018 A Yes 
TP53 Zou_p140 17 7579311 A Yes 
TP53 Zou_p143 17 7578530 G Yes 
TP53 Zou_p145 17 7578235 C Yes 
TP53 Zou_p16 17 7574035 A Yes 
TP53 Zou_p17 17 7578404 T Yes 
TP53 Zou_p34 17 7577509 G Yes 
TP53 Zou_p44 17 7578177 T Yes 
TP53 Zou_p58 17 7578224 A Yes 
TP53 Zou_p66 17 7578535 C Yes 
TP53 Zou_p8_4 17 7578410 A Yes 
TP53 Zou_p87 17 7578226 A Yes 
TP53 Zou_p95 17 7576927 A Yes 
TP53 Zou_p95 17 7578419 A Yes 
TP53 TCGA_p05 17 7578509 G Yes 
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TP53 TCGA_p12 17 7592560 T Yes 
TP53 TCGA_p22 17 7574005 T Yes 
PBRM1 Nakamura_BD12 3 52595944 - Yes 
PBRM1 Nakamura_BD147 3 52696293 T Yes 
PBRM1 Nakamura_BD167 3 52668672 T Yes 
PBRM1 Nakamura_BD211 3 52598156 C Yes 
PBRM1 Nakamura_BD245 3 52643728 A Yes 
PBRM1 Nakamura_BD247 3 52685758 T Yes 
PBRM1 Nakamura_BD31 3 52675988 A Yes 
PBRM1 Nakamura_BD33 3 52661291 T Yes 
PBRM1 Zou_p8_1 3 52661288 G Yes 
PBRM1 TCGA_p02 3 52643837 T Yes 
PBRM1 TCGA_p02 3 52662939 A Yes 
PBRM1 TCGA_p03 3 52592205 A Yes 
PBRM1 TCGA_p03 3 52651496 A Yes 
PBRM1 TCGA_p05 3 52621439 AAT Yes 
PBRM1 TCGA_p06 3 52661362 A Yes 
PBRM1 TCGA_p07 3 52713533 T Yes 
PBRM1 TCGA_p09 3 52682330 - Yes 
PBRM1 TCGA_p09 3 52682473 T Yes 
PBRM1 TCGA_p14 3 52651334 A Yes 
PBRM1 TCGA_p17 3 52649497 G Yes 
PBRM1 TCGA_p20 3 52621364 T Yes 
PBRM1 TCGA_p33 3 52620649 - Yes 
PBRM1 TCGA_p37 3 52592236 - Yes 
PBRM1 TCGA_p38 3 52678790 A Yes 
PBRM1 TCGA_p45 3 52668817 A Yes 
IDH2 Nakamura_BD117 15 90631838 T Yes 
IDH2 Nakamura_BD149 15 90631838 T Yes 
IDH2 Nakamura_BD219 15 90631838 T Yes 
IDH2 Chan-On_p07 15 90622990 T Yes 
IDH2 TCGA_p09 15 90631838 T Yes 
IDH2 TCGA_p23 15 90631837 A Yes 
IDH2 TCGA_p33 15 90631838 T Yes 
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